[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_response": "Acrokeratosis paraneoplastica is a rare genodermatosis that is characterized by the development of keratoses (small, scaly spots) on the skin, often in association with various types of cancer, particularly lymphoma. Here are some synonyms for Acrokeratosis paraneoplastica:\n1. Acrokeratosis paraneoplastic\n2. Paraneoplastic acrokeratosis\n3. Acrokeratosis associated with cancer\n4. Cancer-associated acrokeratosis\n5. Keratosis paraneoplastica\n6. Paraneoplastic keratosis\n7. Acrokeratosis neoplastica\n8. Neoplastic acrokeratosis\n9. Acrokeratosis with malignancy\n10. Malignancy-associated acrokeratosis\nIt is important to note that these synonyms refer to the same condition, which is characterized by the presence of keratoses on the skin in association with cancer, particularly lymphoma.",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrokeratosis paraneoplastic is a synonym for Acrokeratosis paraneoplastica.\n2. Paraneoplastic acrokeratosis is a synonym for Acrokeratosis paraneoplastica.\n3. Acrokeratosis associated with cancer is a synonym for Acrokeratosis paraneoplastica.\n4. Cancer-associated acrokeratosis is a synonym for Acrokeratosis paraneoplastica.\n5. Keratosis paraneoplastica is a synonym for Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_fact": [
      "Acrokeratosis paraneoplastic is a synonym for Acrokeratosis paraneoplastica.",
      "Paraneoplastic acrokeratosis is a synonym for Acrokeratosis paraneoplastica.",
      "Acrokeratosis associated with cancer is a synonym for Acrokeratosis paraneoplastica.",
      "Cancer-associated acrokeratosis is a synonym for Acrokeratosis paraneoplastica.",
      "Keratosis paraneoplastica is a synonym for Acrokeratosis paraneoplastica."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Keratosis paraneoplastica is not a commonly used term for Acrokeratosis paraneoplastica. Acrokeratosis paraneoplastica specifically refers to a rare skin disorder associated with underlying malignancy. Without further medical context indicating that \"Keratosis paraneoplastica\" is indeed used as a synonym for Acrokeratosis paraneoplastica in the literature, the correctness of this statement remains in question. Additionally, \"keratosis\" generally refers to a growth of keratin on the skin or on mucous membranes, which can occur in various forms and is not necessarily paraneoplastic.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-7b-chat-hf_response": "Weaver syndrome and Sotos syndrome are both rare genetic disorders that can affect physical and intellectual development. While they share some similarities, they are distinct conditions with different genetic causes and clinical features. Here are some key similarities and differences between Weaver syndrome and Sotos syndrome:\nSimilarities:\n1. Both are caused by mutations in genes involved in the regulation of gene expression: Weaver syndrome is caused by mutations in the PRC2 gene, while Sotos syndrome is caused by mutations in the NSD1 gene.\n2. Both can cause intellectual disability: Both Weaver syndrome and Sotos syndrome can result in intellectual disability, which can range from mild to severe.\n3. Both can cause growth delays: Children with Weaver syndrome and Sotos syndrome may experience delays in their growth and development, including short stature and delayed attainment of milestones.\nDifferences:\n1. Genetic cause: Weaver syndrome is caused by mutations in the PRC2 gene, which is involved in the epigenetic regulation of gene expression. Sotos syndrome, on the other hand, is caused by mutations in the NSD1 gene, which is involved in the regulation of gene expression and chromatin remodeling.\n2. Clinical features: Weaver syndrome typically presents with a distinctive facial appearance, including a flat nasal bridge, broad nose, and widely spaced eyes. Sotos syndrome can also cause facial abnormalities, but the features are less pronounced than those seen in Weaver syndrome. Other clinical features of Weaver syndrome can include developmental delays, intellectual disability, and seizures. Sotos syndrome can also cause developmental delays and intellectual disability, but may have additional features such as heart defects, growth delays, and distinctive facial features.\n3. Prevalence: Weaver syndrome is a rare disorder, with an estimated prevalence of 1 in 100,000 to 1 in 50,000 births. Sotos syndrome is also rare, with an estimated prevalence of 1 in 15,000 to 1 in 20,000 births.\n4. Treatment",
    "llama-2-7b-chat-hf_fact_raw": "1. Weaver syndrome is caused by mutations in the PRC2 gene.\n2. Sotos syndrome is caused by mutations in the NSD1 gene.\n3. Both Weaver and Sotos syndromes can cause intellectual disability.\n4. The estimated prevalence of Weaver syndrome is between 1 in 100,000 to 1 in 50,000 births.\n5. The estimated prevalence of Sotos syndrome is between 1 in 15,000 to 1 in 20,000 births.",
    "llama-2-7b-chat-hf_fact": [
      "Weaver syndrome is caused by mutations in the PRC2 gene.",
      "Sotos syndrome is caused by mutations in the NSD1 gene.",
      "Both Weaver and Sotos syndromes can cause intellectual disability.",
      "The estimated prevalence of Weaver syndrome is between 1 in 100,000 to 1 in 50,000 births.",
      "The estimated prevalence of Sotos syndrome is between 1 in 15,000 to 1 in 20,000 births."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Weaver syndrome is caused by mutations in the EZH2 gene, which is part of the PRC2 complex.\n2. TRUE\n3. TRUE\n4. UNKNOWN: The exact prevalence of Weaver syndrome is not well established; it is a rare condition, and the available data may not be precise enough to give a reliable estimate.\n5. UNKNOWN: The prevalence of Sotos syndrome varies in different reports, and without a specific reference, it is difficult to confirm the accuracy of this range.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-7b-chat-hf_response": "JASPAR (Junkunc et al., 2003) is a widely used database of transcription factor binding site (TFBS) probabilities for various organisms. Here are the releases of the JASPAR database:\n1. JASPAR Release 1 (2003): This was the first release of the JASPAR database, containing TFBS probabilities for 146 transcription factors in 10 organisms.\n2. JASPAR Release 2 (2006): This release expanded the database to include TFBS probabilities for 202 transcription factors in 14 organisms, as well as new algorithms for predicting TFBSs.\n3. JASPAR Release 3 (2010): This release added TFBS probabilities for 244 transcription factors in 18 organisms, as well as improved algorithms for predicting TFBSs.\n4. JASPAR Release 4 (2013): This release included TFBS probabilities for 320 transcription factors in 21 organisms, as well as new features such as the ability to predict TFBSs in non-coding regions.\n5. JASPAR Release 5 (2017): This release expanded the database to include TFBS probabilities for 437 transcription factors in 31 organisms, as well as improved algorithms for predicting TFBSs and new features such as the ability to predict TFBSs in alternative promoter regions.\n6. JASPAR Release 6 (2020): This is the latest release of the JASPAR database, containing TFBS probabilities for 530 transcription factors in 43 organisms. This release also includes improved algorithms for predicting TFBSs and new features such as the ability to predict TFBSs in enhancer regions.\nIt's worth noting that the JASPAR database has been continuously updated and improved over the years, with new releases adding new transcription factors, organisms, and features.",
    "llama-2-7b-chat-hf_fact_raw": "1. JASPAR Release 1 was launched in 2003 with TFBS probabilities for 146 transcription factors in 10 organisms.\n2. JASPAR Release 2, released in 2006, included TFBS probabilities for 202 transcription factors in 14 organisms.\n3. JASPAR Release 3 was added in 2010 and it contained TFBS probabilities for 244 transcription factors in 18 organisms.\n4. The 2013 update, JASPAR Release 4, included TFBS probabilities for 320 transcription factors in 21 organisms.\n5. JASPAR Release 6, the latest as of the provided information, was released in 2020 with TFBS probabilities for 530 transcription factors in 43 organisms.",
    "llama-2-7b-chat-hf_fact": [
      "JASPAR Release 1 was launched in 2003 with TFBS probabilities for 146 transcription factors in 10 organisms.",
      "JASPAR Release 2, released in 2006, included TFBS probabilities for 202 transcription factors in 14 organisms.",
      "JASPAR Release 3 was added in 2010 and it contained TFBS probabilities for 244 transcription factors in 18 organisms.",
      "The 2013 update, JASPAR Release 4, included TFBS probabilities for 320 transcription factors in 21 organisms.",
      "JASPAR Release 6, the latest as of the provided information, was released in 2020 with TFBS probabilities for 530 transcription factors in 43 organisms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-7b-chat-hf_response": "The KP4 protein is a component of the KPNA (Karyopherin-associated protein) family of proteins, which are involved in the transport of proteins and RNAs within cells. The KP4 protein is specifically associated with the transport of viral RNAs, such as those produced by the HIV virus, and plays a role in the replication of the virus.\nThe function of the KP4 protein can be broken down into several key steps:\n1. Interaction with viral RNAs: The KP4 protein binds to the viral RNAs, such as the HIV-1 RNA, and forms a complex that is involved in the replication of the virus.\n2. Nuclear import: The KP4 protein helps to import the viral RNAs into the nucleus of infected cells, where they can be used for the transcription of new viral genes.\n3. RNA unwinding: The KP4 protein can also help to unwinds RNA duplexes, which is necessary for the transcription of the viral genes.\n4. Recruitment of other proteins: The KP4 protein can recruit other proteins that are necessary for the replication of the virus, such as the viral reverse transcriptase.\n5. Inhibition of interferon signaling: The KP4 protein can also inhibit the production of interferon, a protein that is produced by cells in response to the presence of viruses, and can help to prevent the host immune system from mounting a response against the virus.\nIn summary, the KP4 protein is a key component of the HIV-1 replication machinery and plays a critical role in the transport of viral RNAs, nuclear import, RNA unwinding, recruitment of other proteins, and inhibition of interferon signaling.",
    "llama-2-7b-chat-hf_fact_raw": "1. The KP4 protein is involved in the transport of proteins and RNAs within cells.\n2. The KP4 protein interacts with viral RNAs, such as those produced by the HIV virus, and is involved in the replication of the virus.\n3. The KP4 protein facilitates the import of viral RNAs into the nucleus of infected cells.\n4. The KP4 protein can help to unwind RNA duplexes, which is necessary for the transcription of the viral genes.\n5. The KP4 protein can inhibit the production of interferon, which is part of the host immune response to viruses.",
    "llama-2-7b-chat-hf_fact": [
      "The KP4 protein is involved in the transport of proteins and RNAs within cells.",
      "The KP4 protein interacts with viral RNAs, such as those produced by the HIV virus, and is involved in the replication of the virus.",
      "The KP4 protein facilitates the import of viral RNAs into the nucleus of infected cells.",
      "The KP4 protein can help to unwind RNA duplexes, which is necessary for the transcription of the viral genes.",
      "The KP4 protein can inhibit the production of interferon, which is part of the host immune response to viruses."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: KP4 is an antifungal protein from Ustilago maydis (corn smut fungus). It does not facilitate the import of viral RNAs into the nucleus of infected cells, as this function is not associated with KP4's known antifungal properties.\n4. UNKNOWN\n5. UNKNOWN\n\nThe KP4 protein is typically referenced as an antifungal protein from Ustilago maydis, also known as corn smut fungus. Statements 2, 4, and 5 may be true for some proteins involved in viral replication or host immune response, but without more context specific to KP4 and its mechanisms of action in relation to viruses, their accuracy cannot be determined. Therefore, my responses to those are marked as UNKNOWN. Meanwhile, statement 3 is corrected based on the general knowledge of the KP4 protein's known function.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-7b-chat-hf_response": "Yes, DITPA (N-[4-(2-chloroethyl)phenyl]-1,3,5-triazin-2-amine) is a synthetic thyroid hormone analog that has been used in both experimental and clinical studies.\nExperimental Studies:\nDITPA has been used as a tool to study the mechanisms of thyroid hormone action in various tissues, including the brain, heart, and liver. It has been shown to mimic the effects of thyroid hormones in these tissues, allowing researchers to investigate the downstream effects of thyroid hormone signaling. For example, DITPA has been used to study the effects of thyroid hormone deficiency on brain development and function, as well as the role of thyroid hormones in regulating heart rate and contractility.\nClinical Studies:\nDITPA has been investigated as a potential therapeutic agent for various conditions, including:\n1. Hypothyroidism: DITPA has been used to treat hypothyroidism, a condition in which the thyroid gland does not produce enough thyroid hormones. Studies have shown that DITPA can restore normal thyroid hormone levels and improve symptoms such as fatigue, weight gain, and cold intolerance.\n2. Cancer: DITPA has been investigated as a potential anti-cancer agent, as it can inhibit the growth of cancer cells and induce apoptosis (cell death). Studies have shown that DITPA can be effective in treating certain types of cancer, including breast, lung, and prostate cancer.\n3. Neurodegenerative diseases: DITPA has been investigated as a potential treatment for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Studies have shown that DITPA can improve cognitive function and motor function in these diseases.\nIn summary, DITPA is a synthetic thyroid hormone analog that has been used in both experimental and clinical studies to investigate the mechanisms of thyroid hormone action and to treat various conditions, including hypothyroidism, cancer, and neurodegenerative diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. DITPA is a synthetic thyroid hormone analog that has been used in experimental and clinical studies.\n2. DITPA has been used to study the mechanisms of thyroid hormone action in various tissues such as the brain, heart, and liver.\n3. DITPA has been utilized to treat hypothyroidism in clinical studies.\n4. DITPA has been investigated as a potential anti-cancer agent in treating types of cancer like breast, lung, and prostate cancer.\n5. DITPA has been studied as a potential treatment for neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.",
    "llama-2-7b-chat-hf_fact": [
      "DITPA is a synthetic thyroid hormone analog that has been used in experimental and clinical studies.",
      "DITPA has been used to study the mechanisms of thyroid hormone action in various tissues such as the brain, heart, and liver.",
      "DITPA has been utilized to treat hypothyroidism in clinical studies.",
      "DITPA has been investigated as a potential anti-cancer agent in treating types of cancer like breast, lung, and prostate cancer.",
      "DITPA has been studied as a potential treatment for neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nExplanation:\nDITPA (3,5-diiodothyropropionic acid) is indeed a synthetic thyroid hormone analog that has been researched in various experimental and clinical settings, which includes the study of thyroid hormone action in different tissues and its potential use in treating hypothyroidism. However, the use of DITPA as an anti-cancer agent and its investigation in the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's is not as widely documented or established in scientific literature up to my knowledge cutoff in 2023. Therefore, without specific references to credible studies supporting statements 4 and 5, it is not possible to confirm their accuracy and they are marked as UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-7b-chat-hf_response": "COUGER (COntext-dependent Ubiquitination GEneRator) is a tool used in bioinformatics to predict the context-dependent ubiquitination patterns of proteins. Ubiquitination is the covalent attachment of a ubiquitin protein to a target protein, which can alter the target protein's function or localization. COUGER is a computational tool that uses machine learning algorithms to predict the ubiquitination patterns of a protein based on its sequence, structure, and other contextual information.\nCOUGER takes as input a protein sequence or structure, and outputs a prediction of the ubiquitination sites and patterns on the protein. The tool can also predict the type of ubiquitin molecule (e.g., monoubiquitin, polyubiquitin) and the linkage between the ubiquitin and the target protein.\nCOUGER is based on a variety of features that capture different aspects of protein structure and function, including:\n1. Sequence features: Such as hydrophobicity, charge, and secondary structure.\n2. Structure features: Such as the distance between ubiquitin and the target protein, and the orientation of the ubiquitin molecule.\n3. Post-translational modification (PTM) features: Such as the presence of other PTMs on the protein, and the distance between the PTM sites and the ubiquitin.\n4. Gene ontology (GO) features: Such as the functional categories of the target protein, and the expression level of the protein.\nCOUGER has been shown to be accurate in predicting ubiquitination sites in various protein systems, including cancer proteins and proteins involved in neurodegenerative diseases. The tool can be useful for identifying potential ubiquitination sites on a protein, which can inform experimental validation and further research into the role of ubiquitination in protein function and disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. COUGER (COntext-dependent Ubiquitination GEneRator) is a tool in bioinformatics used to predict ubiquitination patterns of proteins.\n2. COUGER uses machine learning algorithms to make predictions based on protein sequence, structure, and other contextual information.\n3. The tool can predict ubiquitination sites and patterns as well as the type of ubiquitin molecule and linkage between ubiquitin and the target protein.\n4. COUGER employs features such as hydrophobicity, charge, secondary structure, distance and orientation of ubiquitin, presence of other post-translational modifications, and gene ontology categories.\n5. COUGER has been demonstrated to accurately predict ubiquitination sites in proteins associated with cancer and neurodegenerative diseases.",
    "llama-2-7b-chat-hf_fact": [
      "COUGER (COntext-dependent Ubiquitination GEneRator) is a tool in bioinformatics used to predict ubiquitination patterns of proteins.",
      "COUGER uses machine learning algorithms to make predictions based on protein sequence, structure, and other contextual information.",
      "The tool can predict ubiquitination sites and patterns as well as the type of ubiquitin molecule and linkage between ubiquitin and the target protein.",
      "COUGER employs features such as hydrophobicity, charge, secondary structure, distance and orientation of ubiquitin, presence of other post-translational modifications, and gene ontology categories.",
      "COUGER has been demonstrated to accurately predict ubiquitination sites in proteins associated with cancer and neurodegenerative diseases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided pertain to a specific bioinformatics tool named COUGER. However, without having access to accurate and current scientific literature or databases that describe COUGER and its functionalities, it is not possible to verify the truthfulness of these claims. Therefore, all these statements are classified as UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-7b-chat-hf_response": "Yes, there are drugs available for the treatment of tick-borne encephalitis (TBE). The choice of drug and the duration of treatment depend on the severity and location of the infection, as well as the patient's overall health. Here are some of the most commonly used drugs for TBE treatment:\n1. Antiviral drugs:\nThe most commonly used antiviral drugs for TBE treatment are:\na. Ribavirin: This drug is effective against all three TBE virus serotypes and is given orally in a dosage of 10-20 mg/kg per day for 5-10 days.\nb. Oseltamivir: This drug is effective against TBE virus serotype 1 and 2, and is given orally in a dosage of 75 mg once daily for 5 days.\nc. Zanamivir: This drug is effective against TBE virus serotype 1 and 2, and is given orally in a dosage of 10 mg once daily for 5 days.\n2. Corticosteroids:\nCorticosteroids, such as prednisone, are used to reduce inflammation in the brain and can help improve neurological symptoms. They are usually given in a dosage of 1-2 mg/kg per day for 5-7 days.\n3. Immunoglobulins:\nImmunoglobulins, such as intravenous immunoglobulin (IVIG), contain antibodies that can help neutralize the virus and reduce inflammation. They are usually given in a dosage of 0.2-0.4 mg/kg once daily for 5-7 days.\n4. Supportive care:\nSupportive care, such as rest, hydration, and pain management, is important for managing symptoms and preventing complications in patients with TBE.\nIt's important to note that the best treatment approach for TBE may vary depending on the specific virus serotype, the severity of the infection, and the patient's overall health. In some cases, a combination of drugs may be used for optimal treatment. It's essential to consult a healthcare professional for proper diagnosis and treatment",
    "llama-2-7b-chat-hf_fact_raw": "1. Ribavirin is used to treat all three TBE virus serotypes and is typically given orally in a dosage of 10-20 mg/kg per day for 5-10 days.\n2. Oseltamivir is effective against TBE virus serotype 1 and 2, with a recommended oral dosage of 75 mg once daily for 5 days.\n3. Zanamivir can be used to treat TBE virus serotype 1 and 2, administered orally in a dosage of 10 mg once daily for 5 days.\n4. Corticosteroids, like prednisone, are administered to reduce inflammation in the brain at doses of 1-2 mg/kg per day for 5-7 days.\n5. Intravenous immunoglobulin (IVIG) is utilized to neutralize the virus and reduce inflammation, usually at dosages of 0.2-0.4 mg/kg once daily for 5-7 days.",
    "llama-2-7b-chat-hf_fact": [
      "Ribavirin is used to treat all three TBE virus serotypes and is typically given orally in a dosage of 10-20 mg/kg per day for 5-10 days.",
      "Oseltamivir is effective against TBE virus serotype 1 and 2, with a recommended oral dosage of 75 mg once daily for 5 days.",
      "Zanamivir can be used to treat TBE virus serotype 1 and 2, administered orally in a dosage of 10 mg once daily for 5 days.",
      "Corticosteroids, like prednisone, are administered to reduce inflammation in the brain at doses of 1-2 mg/kg per day for 5-7 days.",
      "Intravenous immunoglobulin (IVIG) is utilized to neutralize the virus and reduce inflammation, usually at dosages of 0.2-0.4 mg/kg once daily for 5-7 days."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ribavirin is not used to treat TBE (Tick-Borne Encephalitis) virus. It is an antiviral medication used for other types of viral infections but not for TBE.\n2. FALSE [correction]: Oseltamivir (commonly known as Tamiflu) is not effective against TBE virus. It is used to treat influenza and has no established effectiveness against TBE.\n3. FALSE [correction]: Zanamivir (commonly known as Relenza) is not used to treat TBE virus. Similar to oseltamivir, it is used to treat influenza virus and is not effective against TBE.\n4. TRUE [with caveat]: While corticosteroids like prednisone can be used to reduce inflammation in the brain, which can occur in cases of severe TBE, recommendations for dosage and duration of treatment can vary, and such usage should be based on specific medical indications and contraindications.\n5. FALSE [correction]: The dosage units for intravenous immunoglobulin (IVIG) are incorrect. IVIG dosages are usually prescribed in grams per kilogram, not milligrams per kilogram. The treatment dosage might be in the range of 0.2-0.4 g/kg, rather than mg/kg, and they may be given in a single dose or over several days, depending on the protocol and the disease being treated. However, it should be noted that the use of IVIG for TBE has limited evidence and is not an established standard of care.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-7b-chat-hf_response": "There are several genome browsers available that provide DNA shape annotations. Here are some of the most popular ones:\n1. UCSC Genome Browser: The University of California, Santa Cruz (UCSC) Genome Browser is a widely used tool for exploring the human genome and other organism genomes. It provides a variety of annotation layers, including DNA shape annotations, based on data from the ENCyclopedia of DNA Elements (ENCODE) project.\n2. Ensembl Genome Browser: Ensembl is another popular genome browser that provides DNA shape annotations for a wide range of organisms, including humans. Ensembl's DNA shape annotations are based on data from the ENCODE project and other sources, and include information on chromatin structure, histone modifications, and other epigenetic marks.\n3. HISAT2 Genome Browser: HISAT2 is a genome browser that provides high-resolution DNA shape annotations for a variety of organisms, including humans. It uses a combination of Hi-C data and other epigenetic marks to provide detailed information on chromatin structure and dynamics.\n4. ChromHMM Genome Browser: ChromHMM is a genome browser that provides DNA shape annotations based on chromatin conformation data. It uses a hidden Markov model (HMM) to infer the 3D structure of chromatin and predict the interactions between different regions of the genome.\n5. 4D-Nucleosome Genome Browser: 4D-Nucleosome is a genome browser that provides DNA shape annotations based on 4D nucleosome resolution data. It provides detailed information on the dynamics of chromatin structure and the interactions between nucleosomes and other chromatin-associated proteins.\nThese are just a few examples of the many genome browsers available for DNA shape annotations. Each one has its own strengths and limitations, and the choice of which one to use will depend on the specific research question and the type of data being analyzed.",
    "llama-2-7b-chat-hf_fact_raw": "1. The UCSC Genome Browser is a tool for exploring genomic data, including DNA shape annotations.\n2. The University of California, Santa Cruz (UCSC) Genome Browser provides annotation layers based on data from the ENCODE project.\n3. The Ensembl Genome Browser provides DNA shape annotations for humans and other organisms.\n4. HISAT2 Genome Browser offers high-resolution DNA shape annotations using Hi-C data and epigenetic marks.\n5. ChromHMM Genome Browser utilizes a hidden Markov model to infer chromatin 3D structure and predict genomic interactions.",
    "llama-2-7b-chat-hf_fact": [
      "The UCSC Genome Browser is a tool for exploring genomic data, including DNA shape annotations.",
      "The University of California, Santa Cruz (UCSC) Genome Browser provides annotation layers based on data from the ENCODE project.",
      "The Ensembl Genome Browser provides DNA shape annotations for humans and other organisms.",
      "HISAT2 Genome Browser offers high-resolution DNA shape annotations using Hi-C data and epigenetic marks.",
      "ChromHMM Genome Browser utilizes a hidden Markov model to infer chromatin 3D structure and predict genomic interactions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The Ensembl Genome Browser provides a comprehensive source of annotation data for a large number of organisms, but it is not focused primarily on DNA shape annotations.\n4. FALSE [correction]: HISAT2 is not a genome browser; it is an alignment program for mapping next-generation sequencing reads to a reference genome. Additionally, it does not specialize in high-resolution DNA shape annotations using Hi-C data and epigenetic marks.\n5. FALSE [correction]: ChromHMM is not a genome browser but a computational tool that uses hidden Markov models to characterize the genomic landscape of different cell types. ChromHMM uses chromatin state data derived from epigenetic marks to delineate genomic regions associated with various chromatin states but does not directly infer 3D structure or predict genomic interactions.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-7b-chat-hf_response": "The EZH2 gene encodes the enzyme enzyme histone methyltransferase 2 (EZH2), which is involved in regulating gene expression by modifying histone proteins. Mutations in the EZH2 gene have been associated with several syndromes, including:\n1. Beckwith-Wiedemann syndrome (BWS): BWS is a genetic disorder that affects the development of various organs, including the kidneys, pancreas, and brain. Mutations in the EZH2 gene are a common cause of BWS.\n2. Silver-Russell syndrome (SRS): SRS is a rare genetic disorder that affects growth and development. Mutations in the EZH2 gene have been identified in some cases of SRS.\n3. Lymphedema-distichiasis syndrome (LDS): LDS is a rare genetic disorder that affects the development of the lymphatic system and the eyes. Mutations in the EZH2 gene have been identified in some cases of LDS.\n4. Cardio-facio-cutaneous syndrome (CFCS): CFCS is a rare genetic disorder that affects the development of the heart, face, and skin. Mutations in the EZH2 gene have been identified in some cases of CFCS.\n5. Costello syndrome (CS): CS is a rare genetic disorder that affects the growth and development of various organs, including the skin, heart, and brain. Mutations in the EZH2 gene have been identified in some cases of CS.\n6. Mowat-Wilson syndrome (MWS): MWS is a rare genetic disorder that affects the development of various organs, including the brain, heart, and digestive system. Mutations in the EZH2 gene have been identified in some cases of MWS.\n7. Neurofibromatosis type 1 (NF1): NF1 is a genetic disorder that affects the growth and development of nerve tissue. Mutations in the EZH2 gene have been identified in some cases of NF1.\n8. Noonan syndrome (NS): NS is a genetic disorder that affects the growth and development of various org",
    "llama-2-7b-chat-hf_fact_raw": "1. The EZH2 gene encodes the enzyme histone methyltransferase 2, which is involved in gene expression regulation.\n2. Mutations in the EZH2 gene have been associated with Beckwith-Wiedemann syndrome, which affects organ development.\n3. Mutations in the EZH2 gene have been identified in some cases of Silver-Russell syndrome that affects growth and development.\n4. Lymphedema-distichiasis syndrome, which affects the lymphatic system and the eyes, has been associated with mutations in the EZH2 gene.\n5. Mutations in the EZH2 gene have been identified in some cases of Cardio-facio-cutaneous syndrome that affects the heart, face, and skin.",
    "llama-2-7b-chat-hf_fact": [
      "The EZH2 gene encodes the enzyme histone methyltransferase 2, which is involved in gene expression regulation.",
      "Mutations in the EZH2 gene have been associated with Beckwith-Wiedemann syndrome, which affects organ development.",
      "Mutations in the EZH2 gene have been identified in some cases of Silver-Russell syndrome that affects growth and development.",
      "Lymphedema-distichiasis syndrome, which affects the lymphatic system and the eyes, has been associated with mutations in the EZH2 gene.",
      "Mutations in the EZH2 gene have been identified in some cases of Cardio-facio-cutaneous syndrome that affects the heart, face, and skin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The EZH2 gene encodes the enzyme enhancer of zeste homolog 2, which is a histone methyltransferase that is specifically involved in tri-methylation of the lysine 27 residue on histone H3 (H3K27me3), important in gene silencing.\n2. FALSE [correction]: Mutations in the EZH2 gene have been associated with Weaver syndrome, not Beckwith-Wiedemann syndrome. Beckwith-Wiedemann syndrome is often associated with changes in the imprinting of genes on chromosome 11p15.\n3. FALSE [correction]: As of my knowledge cutoff date, mutations in EZH2 have been primarily associated with Weaver syndrome and some hematological malignancies, not Silver-Russell syndrome which is often associated with abnormalities on chromosome 7 or 11.\n4. FALSE [correction]: Lymphedema-distichiasis syndrome has been associated with mutations in the FOXC2 gene, not the EZH2 gene.\n5. FALSE [correction]: To my knowledge, Cardio-facio-cutaneous syndrome is typically associated with mutations in the genes BRAF, MAP2K1/2 (also known as MEK1/2), or KRAS and not EZH2.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_response": "There are several human proteins that are known to undergo a dimer-to-tetramer transition. Here are some examples:\n1. p53: The tumor suppressor protein p53 is a transcription factor that regulates various cellular processes, including cell cycle arrest, apoptosis, and DNA repair. p53 exists as a tetramer in its active form, and its dimerization is thought to be involved in its regulatory function.\n2. c-Myc: c-Myc is a transcription factor that regulates cellular processes such as cell growth, proliferation, and differentiation. c-Myc exists as a dimer in its inactive form and transitions to a tetramer upon phosphorylation, leading to its activation.\n3. HIF1α: HIF1α is a transcription factor that regulates the response to hypoxia and plays a role in cellular processes such as angiogenesis, metabolism, and cell survival. HIF1α exists as a dimer in its inactive form and transitions to a tetramer upon binding to oxygen, leading to its activation.\n4. FOXO1: FOXO1 is a transcription factor that regulates various cellular processes, including cellular metabolism, stress resistance, and longevity. FOXO1 exists as a dimer in its inactive form and transitions to a tetramer upon phosphorylation, leading to its activation.\n5. NF-κB: NF-κB is a transcription factor that regulates the expression of genes involved in inflammation and immune responses. NF-κB exists as a dimer in its inactive form and transitions to a tetramer upon activation, leading to its activation.\n6. STAT3: STAT3 is a transcription factor that regulates various cellular processes, including inflammation, immune responses, and cellular proliferation. STAT3 exists as a dimer in its inactive form and transitions to a tetramer upon phosphorylation, leading to its activation.\n7. CREB: CREB is a transcription factor that regulates various cellular processes, including cellular metabolism, stress resistance, and neuronal function",
    "llama-2-7b-chat-hf_fact_raw": "1. The tumor suppressor protein p53 exists as a tetramer in its active form.\n2. c-Myc exists as a dimer in its inactive form and transitions to a tetramer upon phosphorylation for activation.\n3. HIF1α exists as a dimer in its inactive form and transitions to a tetramer upon binding to oxygen for activation.\n4. FOXO1 exists as a dimer in its inactive form and transitions to a tetramer upon phosphorylation for activation.\n5. NF-κB exists as a dimer in its inactive form and transitions to a tetramer upon activation.",
    "llama-2-7b-chat-hf_fact": [
      "The tumor suppressor protein p53 exists as a tetramer in its active form.",
      "c-Myc exists as a dimer in its inactive form and transitions to a tetramer upon phosphorylation for activation.",
      "HIF1α exists as a dimer in its inactive form and transitions to a tetramer upon binding to oxygen for activation.",
      "FOXO1 exists as a dimer in its inactive form and transitions to a tetramer upon phosphorylation for activation.",
      "NF-κB exists as a dimer in its inactive form and transitions to a tetramer upon activation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The tumor suppressor protein p53 does indeed exist as a tetramer in its active form.\n\n2. FALSE [correction]: c-Myc exists as a dimer in both its active and inactive forms. Phosphorylation can regulate its activity, but it does not transition to a tetramer upon phosphorylation for activation. \n\n3. FALSE [correction]: HIF1α (Hypoxia-inducible factor 1-alpha) exists as a dimer with HIF1β. It does not become a tetramer upon binding to oxygen; instead, it is degraded under normoxic conditions (when oxygen levels are normal) and stabilized when oxygen levels are low, allowing it to act as a transcription factor when dimerized with HIF1β.\n\n4. UNKNOWN: The statement about FOXO1 transitioning to a tetramer upon phosphorylation for activation is not commonly described in biochemistry or molecular biology. FOXO1 activity is known to be regulated by various post-translational modifications including phosphorylation, but its functional state related to dimerization or tetramerization is not well-characterized in common scientific literature.\n\n5. FALSE [correction]: NF-κB typically exists as a heterodimer in its inactive form in the cytoplasm bound to an inhibitor protein (such as IκB). Upon activation, it does not transition to a tetramer but rather the inhibitor is degraded, and the active NF-κB dimer translocates to the nucleus to act as a transcription factor.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-7b-chat-hf_response": "Phospholamban (PLN) is a protein that is known to interact with and regulate the activity of the protein Bcl-2. Bcl-2 is a family of proteins that play a critical role in regulating programmed cell death (apoptosis) and are involved in a wide range of cellular processes, including cell growth, differentiation, and survival.\nBcl-2 is an anti-apoptotic protein that inhibits the activation of the caspase cascade, which is a key pathway involved in the execution of apoptosis. By inhibiting the caspase cascade, Bcl-2 prevents the activation of downstream effectors that are involved in the breakdown of cellular structures and the death of the cell.\nPhospholamban (PLN), on the other hand, is a protein that is involved in the regulation of cardiac contractility and is known to interact with and regulate the activity of the Bcl-2 protein. PLN has been shown to bind to and inhibit the activity of Bcl-2, thereby promoting the activation of the caspase cascade and the induction of apoptosis in certain cell types.\nTherefore, the answer to your question is that the protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein is Bcl-2.",
    "llama-2-7b-chat-hf_fact_raw": "1. Phospholamban (PLN) is known to interact with the protein Bcl-2.\n2. Bcl-2 is considered an anti-apoptotic protein.\n3. Bcl-2 plays a role in inhibiting the activation of the caspase cascade, a key pathway in apoptosis.\n4. Phospholamban is involved in the regulation of cardiac contractility.\n5. Phospholamban (PLN) can bind to and inhibit the activity of Bcl-2, promoting the activation of the caspase cascade in certain cell types.",
    "llama-2-7b-chat-hf_fact": [
      "Phospholamban (PLN) is known to interact with the protein Bcl-2.",
      "Bcl-2 is considered an anti-apoptotic protein.",
      "Bcl-2 plays a role in inhibiting the activation of the caspase cascade, a key pathway in apoptosis.",
      "Phospholamban is involved in the regulation of cardiac contractility.",
      "Phospholamban (PLN) can bind to and inhibit the activity of Bcl-2, promoting the activation of the caspase cascade in certain cell types."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Phospholamban (PLN) is known to interact with the sarcoplasmic reticulum Ca2+-ATPase (SERCA), not Bcl-2.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Phospholamban (PLN) does not bind to Bcl-2. Instead, it binds to SERCA and regulates calcium uptake into the sarcoplasmic reticulum, thus affecting cardiac contractility. It is not directly involved in promoting the activation of the caspase cascade.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-7b-chat-hf_response": "Yes, several clinical trials have shown that vitamin D supplementation can reduce the incidence of falls in older people. Here are some examples:\n1. A 2010 meta-analysis published in the Journal of the American Geriatrics Society pooled data from 15 randomized controlled trials involving over 13,000 older adults. The analysis found that vitamin D supplementation was associated with a significant reduction in the incidence of falls (RR = 0.77, 95% CI = 0.65-0.90).\n2. A 2014 randomized controlled trial published in the Journal of Gerontology found that vitamin D supplementation (2000 IU/day) for 12 months reduced the incidence of falls by 34% in older adults with low baseline vitamin D levels (<20 ng/mL).\n3. A 2017 systematic review and meta-analysis published in the journal Age and Ageing pooled data from 17 randomized controlled trials involving over 10,000 older adults. The analysis found that vitamin D supplementation was associated with a significant reduction in the incidence of falls (RR = 0.83, 95% CI = 0.73-0.94).\n4. A 2019 randomized controlled trial published in the Journal of the American Geriatrics Society found that vitamin D supplementation (2000 IU/day) for 12 months reduced the incidence of falls by 40% in older adults with low baseline vitamin D levels (<30 ng/mL).\nOverall, these studies suggest that vitamin D supplementation may be effective in reducing the incidence of falls in older adults, particularly those with low baseline vitamin D levels. However, it's important to note that the optimal dosage and duration of vitamin D supplementation for fall prevention are still unknown and require further research.",
    "llama-2-7b-chat-hf_fact_raw": "1. A 2010 meta-analysis found that vitamin D supplementation was associated with a significant reduction in the incidence of falls in older adults (RR = 0.77, 95% CI = 0.65-0.90).\n2. A 2014 randomized controlled trial found that vitamin D supplementation (2000 IU/day) for 12 months reduced the incidence of falls by 34% in older adults with low baseline vitamin D levels (<20 ng/mL).\n3. A 2017 systematic review and meta-analysis found that vitamin D supplementation was associated with a significant reduction in the incidence of falls in older adults (RR = 0.83, 95% CI = 0.73-0.94).\n4. A 2019 randomized controlled trial reported that vitamin D supplementation (2000 IU/day) for 12 months reduced the incidence of falls by 40% in older adults with low baseline vitamin D levels (<30 ng/mL).",
    "llama-2-7b-chat-hf_fact": [
      "A 2010 meta-analysis found that vitamin D supplementation was associated with a significant reduction in the incidence of falls in older adults (RR = 0.77, 95% CI = 0.65-0.90).",
      "A 2014 randomized controlled trial found that vitamin D supplementation (2000 IU/day) for 12 months reduced the incidence of falls by 34% in older adults with low baseline vitamin D levels (<20 ng/mL).",
      "A 2017 systematic review and meta-analysis found that vitamin D supplementation was associated with a significant reduction in the incidence of falls in older adults (RR = 0.83, 95% CI = 0.73-0.94).",
      "A 2019 randomized controlled trial reported that vitamin D supplementation (2000 IU/day) for 12 months reduced the incidence of falls by 40% in older adults with low baseline vitamin D levels (<30 ng/mL)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nThe accuracy of the specific findings, such as the reduction percentages and the baseline vitamin D levels for the study populations, cannot be verified without access to the original study reports or meta-analyses. However, the general association between vitamin D supplementation and the reduction of fall incidence in older adults has been a subject of research, so the statements are plausible but require access to the specific studies for verification.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-7b-chat-hf_response": "Yes, there is an association between Jarid2 and miR-155 in Th17 cells.\nJarid2 (Jumonji Atrophic Ring-Finger 2) is a histone-modifying enzyme that plays a critical role in regulating gene expression by modifying histone H3 lysine 27 (H3K27) and histone H3 lysine 9 (H3K9) residues.\nMicroRNA-155 (miR-155) is a small non-coding RNA molecule that plays a crucial role in the regulation of Th17 cell differentiation and function. miR-155 has been shown to target and negatively regulate the expression of genes involved in Th17 cell differentiation and cytokine production.\nStudies have shown that Jarid2 and miR-155 interact and are involved in the regulation of Th17 cell differentiation. For example:\n1. A study published in the journal Nature Communications in 2017 found that Jarid2 regulates miR-155 expression in Th17 cells by modifying H3K27ac residues in the miR-155 promoter region.\n2. Another study published in the journal Immunity in 2018 found that Jarid2 and miR-155 interact directly and that Jarid2-mediated H3K27ac modification is required for miR-155-mediated regulation of Th17 cell differentiation.\n3. A study published in the journal Cell Reports in 2019 found that Jarid2 and miR-155 are required for the maintenance of Th17 cell identity and function, and that their interaction is critical for the regulation of Th17 cell differentiation and function.\nIn summary, there is an association between Jarid2 and miR-155 in Th17 cells, and Jarid2 regulates miR-155 expression by modifying H3K27ac residues in the miR-155 promoter region, which is critical for the regulation of Th17 cell differentiation and function.",
    "llama-2-7b-chat-hf_fact_raw": "1. Jarid2 is a histone-modifying enzyme that regulates gene expression by modifying histone H3 lysine 27 (H3K27) and histone H3 lysine 9 (H3K9) residues.\n2. MicroRNA-155 (miR-155) is involved in the regulation of Th17 cell differentiation and function.\n3. A study published in Nature Communications in 2017 reported that Jarid2 regulates miR-155 expression in Th17 cells by modifying H3K27ac residues in the miR-155 promoter region.\n4. Research published in Immunity in 2018 indicated that Jarid2 and miR-155 interact directly and that Jarid2-mediated H3K27ac modification is essential for miR-155-mediated regulation of Th17 cell differentiation.\n5. A 2019 study in Cell Reports found that Jarid2 and miR-155 are necessary for maintaining Th17 cell identity and function and that their interaction is crucial for regulating Th17 cell differentiation and function.",
    "llama-2-7b-chat-hf_fact": [
      "Jarid2 is a histone-modifying enzyme that regulates gene expression by modifying histone H3 lysine 27 (H3K27) and histone H3 lysine 9 (H3K9) residues.",
      "MicroRNA-155 (miR-155) is involved in the regulation of Th17 cell differentiation and function.",
      "A study published in Nature Communications in 2017 reported that Jarid2 regulates miR-155 expression in Th17 cells by modifying H3K27ac residues in the miR-155 promoter region.",
      "Research published in Immunity in 2018 indicated that Jarid2 and miR-155 interact directly and that Jarid2-mediated H3K27ac modification is essential for miR-155-mediated regulation of Th17 cell differentiation.",
      "A 2019 study in Cell Reports found that Jarid2 and miR-155 are necessary for maintaining Th17 cell identity and function and that their interaction is crucial for regulating Th17 cell differentiation and function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Jarid2 is not a histone-modifying enzyme; it is a component of the Polycomb Repressive Complex 2 (PRC2), which regulates gene expression by modifying histone H3 lysine 27 (H3K27), but it does not directly modify histones itself.\n2. TRUE\n3. UNKNOWN: Without access to the actual study from Nature Communications, the specific findings regarding the role of Jarid2 in regulating miR-155 expression and its mechanism cannot be confirmed.\n4. UNKNOWN: Similar to statement 3, without access to the specific research published in Immunity in 2018, it's impossible to confirm the findings regarding the direct interaction between Jarid2 and miR-155 and the importance of H3K27ac modification.\n5. UNKNOWN: As with statements 3 and 4, without access to the specific study in Cell Reports in 2019, the findings mentioned cannot be confirmed. Additionally, while Jarid2 and miR-155 may play roles in the maintenance of Th17 cell identity and function, the exact nature of their interaction and its impact on Th17 cell differentiation and function would need to be verified by the study details.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-7b-chat-hf_response": "The human HoxD cluster contains 9 genes:\n1. HOXD1\n2. HOXD2\n3. HOXD3\n4. HOXD4\n5. HOXD5\n6. HOXD6\n7. HOXD7\n8. HOXD8\n9. HOXD9\nThese genes are located on chromosome 2 and play crucial roles in the development and patterning of various tissues during embryonic development, including the nervous system, limbs, and digestive system. Mutations in these genes can lead to various developmental disorders and cancers.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human HoxD cluster consists of 9 genes.\n2. The HoxD genes are located on chromosome 2.\n3. These genes are involved in the development and patterning of the nervous system, limbs, and digestive system during embryonic development.\n4. Mutations in HoxD genes can result in developmental disorders.\n5. Mutations in HoxD genes can be associated with cancers.",
    "llama-2-7b-chat-hf_fact": [
      "The human HoxD cluster consists of 9 genes.",
      "The HoxD genes are located on chromosome 2.",
      "These genes are involved in the development and patterning of the nervous system, limbs, and digestive system during embryonic development.",
      "Mutations in HoxD genes can result in developmental disorders.",
      "Mutations in HoxD genes can be associated with cancers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The human HoxD cluster consists of 9-11 genes, depending on the nomenclature used for the various paralogous groups.\n2. FALSE [correction]: The HoxD genes are located on chromosome 2 in mice, but in humans, they are located on chromosome 17.\n3. TRUE: The HoxD genes are indeed involved in the development and patterning of various structures during embryonic development, including limbs and the digestive tract, though their primary role is not in nervous system development.\n4. TRUE: Mutations in the HoxD cluster can result in developmental disorders, particularly affecting limb development.\n5. TRUE: Abnormal expression of HoxD genes has been associated with various cancers, although the direct causative role of HoxD mutations in cancer is less established compared to their role in developmental disorders.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-7b-chat-hf_response": "Casein kinase 1 (CK1) is a serine/threonine kinase that plays a crucial role in various cellular processes, including cell signaling, metabolism, and DNA repair. CK1 is known to phosphorylate a wide range of substrates, including proteins, lipids, and nucleic acids. Here are some of the consensus motifs for phosphorylation by CK1:\n1. Serine/threonine-proline (SP) motif: This is the most common consensus motif for CK1 phosphorylation, and it is characterized by the sequence -X-S-X-P-X- (where X is any amino acid except proline).\n2. Serine/threonine-glycine (SG) motif: This motif is similar to the SP motif but with a glycine residue instead of proline. The consensus sequence is -X-S-X-G-X- .\n3. Serine/threonine-arginine (SR) motif: This motif is characterized by the sequence -X-S-X-R-X- and is often found in substrates involved in protein-protein interactions.\n4. Serine/threonine-glutamine (SQ) motif: This motif is similar to the SR motif but with a glutamine residue instead of arginine. The consensus sequence is -X-S-X-Q-X- .\n5. Serine/threonine-tyrosine (ST) motif: This motif is characterized by the sequence -X-S-X-Y-X- and is often found in substrates involved in signal transduction pathways.\n6. Serine/threonine-proline-glycine (SPG) motif: This motif is similar to the SP motif but with a proline-glycine sequence in the middle. The consensus sequence is -X-S-X-P-G-X- .\n7. Serine/threonine-proline-arginine (SPR) motif: This motif is similar to the SP motif but with a proline-arginine sequence in the middle.",
    "llama-2-7b-chat-hf_fact_raw": "1. Casein kinase 1 (CK1) is a serine/threonine kinase.\n2. The Serine/threonine-proline (SP) motif is a common consensus motif for CK1 phosphorylation, with the sequence -X-S-X-P-X- (X being any amino acid except proline).\n3. Another motif for CK1 phosphorylation is the Serine/threonine-glycine (SG) motif with the consensus sequence -X-S-X-G-X-.\n4. The Serine/threonine-arginine (SR) motif has the sequence -X-S-X-R-X- and is often found in substrates involved in protein-protein interactions.\n5. The Serine/threonine-proline-glycine (SPG) motif for CK1 phosphorylation is characterized by the consensus sequence -X-S-X-P-G-X-.",
    "llama-2-7b-chat-hf_fact": [
      "Casein kinase 1 (CK1) is a serine/threonine kinase.",
      "The Serine/threonine-proline (SP) motif is a common consensus motif for CK1 phosphorylation, with the sequence -X-S-X-P-X- (X being any amino acid except proline).",
      "Another motif for CK1 phosphorylation is the Serine/threonine-glycine (SG) motif with the consensus sequence -X-S-X-G-X-.",
      "The Serine/threonine-arginine (SR) motif has the sequence -X-S-X-R-X- and is often found in substrates involved in protein-protein interactions.",
      "The Serine/threonine-proline-glycine (SPG) motif for CK1 phosphorylation is characterized by the consensus sequence -X-S-X-P-G-X-."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Casein kinase 1 (CK1) is indeed a serine/threonine kinase, which means it phosphorylates the hydroxyl group of serine or threonine amino acid residues in proteins.\n2. TRUE: The Serine/threonine-proline (SP) motif, with the sequence -S/T-P-, is indeed a common consensus motif for CK1 phosphorylation. The sequence given, -X-S-X-P-X- (X being any amino acid except proline), is an example of an SP motif where serine or threonine is followed by proline, and 'X' can be any amino acid.\n3. UNKNOWN: While CK1 does tend to phosphorylate certain consensus sequences, the Serine/threonine-glycine (SG) motif with the consensus sequence -X-S-X-G-X- is not widely recognized as a common motif for CK1 phosphorylation. Without specific literature references to this motif for CK1, its validity remains uncertain.\n4. UNKNOWN: The Serine/threonine-arginine (SR) motif with the sequence -X-S-X-R-X- is associated with kinase substrate recognition in general, but it's not clear if it is particularly relevant to CK1 without more context or specific references. CK1 does phosphorylate sites involved in protein-protein interactions, but whether the -X-S-X-R-X- sequence is a significant motif for CK1 is not well-established.\n5. FALSE [correction]: There is no widely recognized Serine/threonine-proline-glycine (SPG) motif characterized by the consensus sequence -X-S-X-P-G-X- for CK1 phosphorylation. The canonical CK1 consensus site is generally accepted as -S/T-X-X-S/T-, where 'X' can be any amino acid, and the phosphorylation usually occurs at the serine or threonine residue just before the proline. The specific SPG sequence given is not a standard motif for CK1.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-7b-chat-hf_response": "The ASPH (aspartate beta-hydroxylase) gene in humans encodes multiple isoforms of the ASPH protein, which are produced through alternative splicing. Here are the different proteins/isoforms encoded by the ASPH gene:\n1. ASPH: The full-length ASPH protein is composed of 1045 amino acids and contains an N-terminal transmembrane domain, a proline-rich region, and a C-terminal catalytic domain. This is the main isoform of ASPH and plays a critical role in the regulation of cytoskeleton organization and cell signaling.\n2. ASPH-C: A shorter isoform of ASPH that lacks the N-terminal transmembrane domain and the proline-rich region. This isoform is primarily cytoplasmic and may play a role in regulating cytoskeleton organization and cell signaling.\n3. ASPH-A: An isoform of ASPH that is produced through alternative splicing and contains a point mutation in the catalytic domain. This isoform has reduced enzymatic activity compared to full-length ASPH.\n4. ASPH-B: Another isoform of ASPH that is produced through alternative splicing and contains a different point mutation in the catalytic domain. This isoform has reduced enzymatic activity compared to full-length ASPH.\n5. ASPH-C1: A third isoform of ASPH that is produced through alternative splicing and contains a deletion of exon 4. This isoform is primarily cytoplasmic and may play a role in regulating cytoskeleton organization and cell signaling.\n6. ASPH-C2: A fourth isoform of ASPH that is produced through alternative splicing and contains a deletion of exon 5. This isoform is primarily cytoplasmic and may play a role in regulating cytoskeleton organization and cell signaling.\n7. ASPH-D: A fifth isoform of ASPH that is produced through alternative splicing and contains a point mutation in the catalytic domain. This isoform has reduced enzymatic activity compared to full-length ASPH.\n8. ASPH-E: A sixth is",
    "llama-2-7b-chat-hf_fact_raw": "1. The ASPH gene in humans encodes the full-length ASPH protein composed of 1045 amino acids.\n2. ASPH-C is an isoform of the ASPH protein lacking the N-terminal transmembrane domain and the proline-rich region.\n3. ASPH-A is an isoform produced through alternative splicing with a point mutation in the catalytic domain, resulting in reduced enzymatic activity.\n4. ASPH-B is another isoform produced through alternative splicing, which also has a point mutation in the catalytic domain leading to reduced enzymatic activity.\n5. The ASPH gene in humans can produce multiple isoforms such as ASPH-C1, ASPH-C2, ASPH-D, and ASPH-E through the process of alternative splicing.",
    "llama-2-7b-chat-hf_fact": [
      "The ASPH gene in humans encodes the full-length ASPH protein composed of 1045 amino acids.",
      "ASPH-C is an isoform of the ASPH protein lacking the N-terminal transmembrane domain and the proline-rich region.",
      "ASPH-A is an isoform produced through alternative splicing with a point mutation in the catalytic domain, resulting in reduced enzymatic activity.",
      "ASPH-B is another isoform produced through alternative splicing, which also has a point mutation in the catalytic domain leading to reduced enzymatic activity.",
      "The ASPH gene in humans can produce multiple isoforms such as ASPH-C1, ASPH-C2, ASPH-D, and ASPH-E through the process of alternative splicing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: ASPH-A is an isoform produced through alternative splicing, but there is no specific information given to validate the presence of a point mutation in the catalytic domain and the resultant reduced enzymatic activity. The details provided for ASPH-A are insufficient and possibly incorrect as they mix features that are not typically associated with isoform naming or function.\n4. FALSE [correction]: ASPH-B being an isoform produced through alternative splicing and having a point mutation in the catalytic domain leading to reduced enzymatic activity is not standard information given for isoforms named in such a manner. The statement is too specific and may not be accurate without the appropriate context or evidence.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-7b-chat-hf_response": "Empagliflozin was FDA approved on June 29, 2014, by the US Food and Drug Administration (FDA) for the treatment of type 2 diabetes. It was approved under the brand name Jardiance (empagliflozin) and is marketed by Boehringer Ingelheim and Eli Lilly and Company.",
    "llama-2-7b-chat-hf_fact_raw": "1. Empagliflozin was FDA approved on June 29, 2014.\n2. The US Food and Drug Administration approved empagliflozin for the treatment of type 2 diabetes.\n3. Empagliflozin is marketed under the brand name Jardiance.\n4. Boehringer Ingelheim and Eli Lilly and Company market Jardiance.",
    "llama-2-7b-chat-hf_fact": [
      "Empagliflozin was FDA approved on June 29, 2014.",
      "The US Food and Drug Administration approved empagliflozin for the treatment of type 2 diabetes.",
      "Empagliflozin is marketed under the brand name Jardiance.",
      "Boehringer Ingelheim and Eli Lilly and Company market Jardiance."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Empagliflozin was FDA approved on August 1, 2014.\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-7b-chat-hf_response": "Loss of the protein Lon1 in the plant Arabidopsis has been shown to have several significant effects on the plant's growth and development. Here are some of the key results of Lon1 loss-of-function mutations in Arabidopsis:\n1. Delayed Growth: Lon1 mutants exhibit delayed growth compared to wild-type plants, with reduced stem elongation and leaf expansion.\n2. Reduced Cell Division: Lon1 regulates the G1/S checkpoint in the cell cycle, and its loss leads to an increase in cell division. This results in the formation of meristematic tissues, which are characteristic of young, rapidly dividing tissues.\n3. Enhanced Hormone Sensitivity: Lon1 mutants are more sensitive to abscisic acid (ABA) and ethylene, two plant hormones that play important roles in plant growth and development.\n4. Altered Root Development: Lon1 regulates root growth and differentiation, and its loss leads to changes in root architecture, including reduced root length and increased root branching.\n5. Changes in Leaf Morphology: Lon1 mutants exhibit altered leaf morphology, including reduced leaf size and altered leaf shape.\n6. Impaired Stress Tolerance: Lon1 is involved in the response to oxidative stress, and its loss compromises the plant's ability to withstand stress conditions, leading to increased sensitivity to heat, drought, and UV radiation.\n7. Increased Susceptibility to Pathogens: Lon1 mutants are more susceptible to bacterial and fungal pathogens, which can lead to increased disease susceptibility and reduced plant survival.\n8. Altered Flowering Time: Lon1 regulates floral initiation and transition, and its loss can lead to changes in flowering time and altered floral morphology.\n9. Changes in Shoot System Architecture: Lon1 mutants exhibit altered shoot system architecture, including reduced shoot branching and altered leaf arrangement.\n10. Reduced Seed Production: Lon1 regulates seed production, and its loss can lead to reduced seed set and altered seed morphology.\nIn summary, loss of Lon1 function in Arabidopsis results in significant",
    "llama-2-7b-chat-hf_fact_raw": "1. Lon1 mutants in Arabidopsis exhibit delayed growth with reduced stem elongation and leaf expansion compared to wild-type plants.\n2. The loss of Lon1 in Arabidopsis leads to an increase in cell division and the formation of meristematic tissues.\n3. Arabidopsis plants lacking Lon1 are more sensitive to the plant hormones abscisic acid (ABA) and ethylene.\n4. Loss of the protein Lon1 in Arabidopsis results in changes in root architecture, including reduced root length and increased root branching.\n5. Lon1 mutants of Arabidopsis have an altered leaf morphology, which includes reduced leaf size and altered leaf shape.",
    "llama-2-7b-chat-hf_fact": [
      "Lon1 mutants in Arabidopsis exhibit delayed growth with reduced stem elongation and leaf expansion compared to wild-type plants.",
      "The loss of Lon1 in Arabidopsis leads to an increase in cell division and the formation of meristematic tissues.",
      "Arabidopsis plants lacking Lon1 are more sensitive to the plant hormones abscisic acid (ABA) and ethylene.",
      "Loss of the protein Lon1 in Arabidopsis results in changes in root architecture, including reduced root length and increased root branching.",
      "Lon1 mutants of Arabidopsis have an altered leaf morphology, which includes reduced leaf size and altered leaf shape."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The loss of Lon1 in Arabidopsis does not lead to an increase in cell division and formation of meristematic tissues. Typically, mutants with delayed growth and reduced stem elongation, like Lon1 mutants, would have issues with cell expansion rather than an increase in cell division.\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-7b-chat-hf_response": "Yes, a linker histone exists in the yeast genome. In fact, there are two linker histones in yeast: H3K5ac and H3K27ac.\nH3K5ac (histone H3 lysine 5 acetylation) is a linker histone that is specifically enriched at the centromeres of yeast chromosomes. It plays a crucial role in the maintenance of chromosome stability and segregation during cell division.\nH3K27ac (histone H3 lysine 27 acetylation) is a linker histone that is enriched at the telomeres of yeast chromosomes. It helps to maintain the length of telomeres, which are the repetitive DNA sequences that cap the ends of chromosomes and prevent them from degrading.\nBoth H3K5ac and H3K27ac are involved in regulating various cellular processes, including transcriptional elongation, chromatin remodeling, and DNA repair. They are also important for the proper functioning of the yeast cell cycle and are involved in the regulation of various genes involved in cell growth and division.\nIn summary, yes, linker histones do exist in the yeast genome, and they play important roles in regulating various cellular processes and maintaining chromosome stability.",
    "llama-2-7b-chat-hf_fact_raw": "1. In yeast, H3K5ac is a linker histone that is enriched at the centromeres of chromosomes.\n2. The H3K5ac histone plays a role in maintenance of chromosome stability and segregation during cell division in yeast.\n3. H3K27ac is another linker histone in yeast that is enriched at the telomeres of chromosomes. \n4. The H3K27ac histone helps maintain the length of telomeres in yeast chromosomes. \n5. Both H3K5ac and H3K27ac are involved in cellular processes such as transcriptional elongation, chromatin remodeling, and DNA repair in yeast.",
    "llama-2-7b-chat-hf_fact": [
      "In yeast, H3K5ac is a linker histone that is enriched at the centromeres of chromosomes.",
      "The H3K5ac histone plays a role in maintenance of chromosome stability and segregation during cell division in yeast.",
      "H3K27ac is another linker histone in yeast that is enriched at the telomeres of chromosomes.",
      "The H3K27ac histone helps maintain the length of telomeres in yeast chromosomes.",
      "Both H3K5ac and H3K27ac are involved in cellular processes such as transcriptional elongation, chromatin remodeling, and DNA repair in yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: In yeast, H3K5ac is not known as a linker histone but as an acetylation modification of histone H3 at lysine 5. Linker histones, like H1, are different and are involved with the packing of nucleosomes. Acetylation marks like H3K5ac are often associated with actively transcribed regions of chromatin rather than specific regions like centromeres.\n2. UNKNOWN: While histone acetylation typically affects chromosome stability and segregation, the specific role of H3K5ac in these processes in yeast cells is not sufficiently clarified without additional context.\n3. FALSE [correction]: H3K27ac is not classified as a linker histone but as an acetylation modification of histone H3 at lysine 27. It is generally associated with transcriptionally active regions and not specifically enriched at the telomeres of chromosomes.\n4. FALSE [correction]: There is no established direct link between H3K27ac and telomere length maintenance in yeast. H3K27ac is usually associated with gene expression regulation rather than telomere length regulation.\n5. FALSE [correction]: While H3K5ac and H3K27ac are involved in transcriptional regulation, chromatin remodeling, and perhaps DNA repair, stating that both are involved in all these processes for yeast may be too broad without specifying the particular roles and evidence. Also, being specific that they are involved in transcriptional elongation might not be accurate without further context. Generally, acetylation marks correlate with active transcription, but the specific processes can vary.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-7b-chat-hf_response": "Yes, there is evidence to suggest that tomato juice may help lower cholesterol levels. Here are some studies that have investigated the potential cholesterol-lowering effects of tomato juice:\n1. A 2013 study published in the Journal of Functional Foods found that drinking 200 mL of tomato juice per day for 12 weeks significantly reduced total cholesterol and LDL (bad) cholesterol levels in healthy adults.\n2. A 2011 study published in the Journal of Nutrition found that drinking 100 mL of tomato juice per day for 12 weeks lowered LDL cholesterol levels by 10% in a group of healthy male subjects.\n3. A 2009 study published in the Journal of Lipid Research found that a tomato juice extract rich in lycopene and other phytochemicals reduced LDL cholesterol levels by 13% in a group of healthy adults.\n4. A 2008 study published in the European Journal of Nutrition found that drinking 200 mL of tomato juice per day for 12 weeks lowered total cholesterol and LDL cholesterol levels in a group of healthy postmenopausal women.\nIt's worth noting that these studies were small and had limited sample sizes, so more research is needed to confirm the cholesterol-lowering effects of tomato juice in larger populations. Additionally, it's important to keep in mind that tomato juice is just one part of a healthy diet and lifestyle, and it's unlikely to have a significant impact on cholesterol levels without other dietary and lifestyle changes.\nIn summary, while there is some evidence to suggest that tomato juice may help lower cholesterol levels, more research is needed to confirm these findings and establish the optimal dosage and duration of tomato juice consumption for cholesterol-lowering effects.",
    "llama-2-7b-chat-hf_fact_raw": "1. A 2013 study published in the Journal of Functional Foods found that drinking 200 mL of tomato juice per day for 12 weeks significantly reduced total cholesterol and LDL cholesterol levels in healthy adults.\n2. A 2011 study published in the Journal of Nutrition found that drinking 100 mL of tomato juice per day for 12 weeks lowered LDL cholesterol levels by 10% in healthy male subjects.\n3. A 2009 study published in the Journal of Lipid Research discovered that a tomato juice extract rich in lycopene and other phytochemicals reduced LDL cholesterol levels by 13% in healthy adults.\n4. A 2008 study published in the European Journal of Nutrition found that drinking 200 mL of tomato juice per day for 12 weeks lowered total cholesterol and LDL cholesterol levels in healthy postmenopausal women.",
    "llama-2-7b-chat-hf_fact": [
      "A 2013 study published in the Journal of Functional Foods found that drinking 200 mL of tomato juice per day for 12 weeks significantly reduced total cholesterol and LDL cholesterol levels in healthy adults.",
      "A 2011 study published in the Journal of Nutrition found that drinking 100 mL of tomato juice per day for 12 weeks lowered LDL cholesterol levels by 10% in healthy male subjects.",
      "A 2009 study published in the Journal of Lipid Research discovered that a tomato juice extract rich in lycopene and other phytochemicals reduced LDL cholesterol levels by 13% in healthy adults.",
      "A 2008 study published in the European Journal of Nutrition found that drinking 200 mL of tomato juice per day for 12 weeks lowered total cholesterol and LDL cholesterol levels in healthy postmenopausal women."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nI cannot verify the specific findings of the studies mentioned in each statement without access to the actual content of the studies. The truthfulness of the statements depends on the accurate representation of the study findings as published in the respective journals.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-7b-chat-hf_response": "Heat shock proteins (HSPs) are a family of proteins that play a crucial role in maintaining cellular homeostasis by protecting cells against various stressors, including heat stress, oxidative stress, and protein misfolding. Two members of the HSP family that have been implicated in mRNA stability are Hsp70 and Hsp110.\nHsp70 is a well-studied protein that has been shown to play a role in mRNA stability in various cell types. Hsp70 binds to the 3' untranslated region (3' UTR) of target mRNAs and protects them from degradation by the RNA exosome, a complex of ribonucleases that degrade RNA. Hsp70 can also inhibit the activity of the RNA exosome by sequestering its components, thereby promoting the stability of target mRNAs. Hsp70 has been shown to stabilize mRNAs involved in various cellular processes, including cell proliferation, differentiation, and stress response.\nHsp110 is another HSP that has been implicated in mRNA stability. Hsp110 is a molecular chaperone that is involved in protein folding and degradation, but it has also been shown to interact with RNA and affect its stability. Hsp110 has been shown to bind to the 3' UTR of target mRNAs and prevent their degradation by the RNA exosome. Hsp110 has also been shown to regulate the translation of target mRNAs by inhibiting the activity of the ribosome.\nBoth Hsp70 and Hsp110 have been shown to play a role in regulating mRNA stability in response to stress, but they have different mechanisms of action. Hsp70 acts by protecting mRNAs from degradation by the RNA exosome, while Hsp110 acts by binding to the 3' UTR of target mRNAs and preventing their degradation.\nIn summary, Hsp70 and Hsp110 are two heat shock proteins that have been implicated in mRNA stability. Hsp70 protects mRNAs from degrad",
    "llama-2-7b-chat-hf_fact_raw": "1. Hsp70 binds to the 3' untranslated region (3' UTR) of target mRNAs.\n2. Hsp70 protects mRNAs from degradation by the RNA exosome.\n3. Hsp70 can inhibit the activity of the RNA exosome.\n4. Hsp110 has been shown to interact with RNA and affect its stability.\n5. Hsp110 can regulate the translation of target mRNAs by inhibiting the activity of the ribosome.",
    "llama-2-7b-chat-hf_fact": [
      "Hsp70 binds to the 3' untranslated region (3' UTR) of target mRNAs.",
      "Hsp70 protects mRNAs from degradation by the RNA exosome.",
      "Hsp70 can inhibit the activity of the RNA exosome.",
      "Hsp110 has been shown to interact with RNA and affect its stability.",
      "Hsp110 can regulate the translation of target mRNAs by inhibiting the activity of the ribosome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Hsp70 typically binds to nascent polypeptides or denatured proteins, not directly to the 3' untranslated region (3' UTR) of mRNAs.\n2. UNKNOWN: While it's true that Hsp70 has a protective role for proteins, the specific interaction and protective mechanism of Hsp70 for mRNAs, particularly from degradation by the RNA exosome, requires more context for verification.\n3. UNKNOWN: There is limited information on Hsp70 directly inhibiting the RNA exosome. Hsp70 is known for its role in protein folding and stabilization, not typically for inhibiting the RNA exosome. The direct interaction would depend on specific experimental evidence.\n4. UNKNOWN: Hsp110 is a nucleotide exchange factor for Hsp70 and is involved in protein folding like Hsp70. Its interaction with RNA and effect on its stability is not well-documented and would require specific evidence.\n5. UNKNOWN: While Hsp110 is primarily known for its protein chaperone activity, its regulation of translation by inhibiting ribosome activity is not a commonly recognized function. Specific evidence and context would be needed to verify this statement.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-7b-chat-hf_response": "Deiodinases are enzymes that play a crucial role in the regulation of thyroid hormone metabolism in various tissues, including skeletal muscle. There are three isoforms of deiodinases found in skeletal muscle:\n1. Deiodinase type 1 (D1): D1 is the primary deiodinase isoform in skeletal muscle, and it is responsible for converting T4 to T3. T3 is the active form of thyroid hormone that stimulates muscle contraction and metabolism.\n2. Deiodinase type 2 (D2): D2 is less abundant in skeletal muscle compared to D1, but it still plays a role in the conversion of T4 to T3.\n3. Deiodinase type 3 (D3): D3 is primarily found in the brain and pituitary gland, but it is also expressed in skeletal muscle to a lesser extent. D3 converts T3 to reverse T3 (rT3), which is an inactive form of thyroid hormone that can inhibit the activity of D1 and D2.\nIn summary, the deiodinases present in skeletal muscle are D1, D2, and D3, with D1 being the most abundant and playing a critical role in the regulation of T3 levels in muscle tissue.",
    "llama-2-7b-chat-hf_fact_raw": "1. Deiodinase type 1 (D1) is found in skeletal muscle and converts T4 to T3.\n2. Deiodinase type 2 (D2) is also present in skeletal muscle, aiding in the conversion of T4 to T3, though it is less abundant than D1.\n3. Deiodinase type 3 (D3) is expressed in skeletal muscle as well as in the brain and pituitary gland, and it converts T3 to reverse T3 (rT3).\n4. D1 is the primary deiodinase isoform in skeletal muscle and is responsible for stimulating muscle contraction and metabolism.\n5. The three isoforms of deiodinases found in skeletal muscle are D1, D2, and D3.",
    "llama-2-7b-chat-hf_fact": [
      "Deiodinase type 1 (D1) is found in skeletal muscle and converts T4 to T3.",
      "Deiodinase type 2 (D2) is also present in skeletal muscle, aiding in the conversion of T4 to T3, though it is less abundant than D1.",
      "Deiodinase type 3 (D3) is expressed in skeletal muscle as well as in the brain and pituitary gland, and it converts T3 to reverse T3 (rT3).",
      "D1 is the primary deiodinase isoform in skeletal muscle and is responsible for stimulating muscle contraction and metabolism.",
      "The three isoforms of deiodinases found in skeletal muscle are D1, D2, and D3."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Deiodinase type 1 (D1) is primarily found in the liver and kidneys, not in skeletal muscle, and it converts T4 to T3.\n2. FALSE [correction]: Deiodinase type 2 (D2) is present in skeletal muscle, but it is more abundant and important for the conversion of T4 to T3 in this tissue, not less abundant than D1.\n3. TRUE\n4. FALSE [correction]: D2, not D1, is the primary deiodinase isoform in skeletal muscle and is responsible for the local conversion of T4 to T3, which then can affect muscle contraction and metabolism.\n5. FALSE [correction]: The three isoforms of deiodinases found in the human body are D1, D2, and D3, but not all of them are primarily found in skeletal muscle. D2 is the main isoform expressed in skeletal muscle.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-7b-chat-hf_response": "Caspases are a family of enzymes that play a central role in the regulation of inflammation. Here are some inflammatory caspase proteins:\n1. Caspase-1 (also known as interleukin-1 beta (IL-1β) converter enzyme): Caspase-1 is involved in the processing and activation of pro-inflammatory cytokines, such as interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α).\n2. Caspase-3: Caspase-3 is involved in the cleavage of a variety of inflammatory proteins, including the pro-inflammatory cytokines IL-1β and TNF-α.\n3. Caspase-8 (also known as Fas-associated death domain protein 1 (FADD)): Caspase-8 is involved in the regulation of apoptosis and inflammation, particularly in the context of the Fas/FasL pathway.\n4. Caspase-9: Caspase-9 is involved in the regulation of apoptosis and inflammation, particularly in the context of the Bcl-2 family of proteins.\n5. Caspase-12: Caspase-12 is involved in the regulation of inflammation and cell death, particularly in the context of the inflammasome.\n6. Caspase-13: Caspase-13 is involved in the regulation of inflammation and cell death, particularly in the context of the inflammasome.\n7. Caspase-4 (also known as macrophage inflammatory protein-1 (MIP-1) activating protein): Caspase-4 is involved in the regulation of inflammation and cell death, particularly in the context of the inflammasome.\n8. Caspase-5: Caspase-5 is involved in the regulation of inflammation and cell death, particularly in the context of the inflammasome.\n9. Caspase-6: Caspase-6 is involved in the regulation of inflammation and cell death, particularly in the context of the inflammasome.\n10. Caspase-7:",
    "llama-2-7b-chat-hf_fact_raw": "1. Caspase-1 is involved in processing and activating pro-inflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α).\n2. Caspase-3 is implicated in the cleavage of a variety of inflammatory proteins.\n3. Caspase-8 is involved in the regulation of apoptosis and inflammation, particularly in the context of the Fas/FasL pathway.\n4. Caspase-9 is involved in the regulation of apoptosis and inflammation, particularly in the context of the Bcl-2 family of proteins.\n5. Caspase-4 is also known as macrophage inflammatory protein-1 (MIP-1) activating protein and is involved in the regulation of inflammation and cell death.",
    "llama-2-7b-chat-hf_fact": [
      "Caspase-1 is involved in processing and activating pro-inflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α).",
      "Caspase-3 is implicated in the cleavage of a variety of inflammatory proteins.",
      "Caspase-8 is involved in the regulation of apoptosis and inflammation, particularly in the context of the Fas/FasL pathway.",
      "Caspase-9 is involved in the regulation of apoptosis and inflammation, particularly in the context of the Bcl-2 family of proteins.",
      "Caspase-4 is also known as macrophage inflammatory protein-1 (MIP-1) activating protein and is involved in the regulation of inflammation and cell death."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Caspase-3 is primarily involved in the execution phase of apoptosis, not in the cleavage of a variety of inflammatory proteins. It is known for its role in the cleavage of various structural and repair proteins leading to cell death.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Caspase-4 is involved in the regulation of inflammation and cell death, but it is not known as the \"macrophage inflammatory protein-1 (MIP-1) activating protein.\" Caspase-4, along with caspase-5 in humans, is known for its role in the detection of bacterial infection and activation of inflammatory responses, particularly the inflammasome pathway.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-7b-chat-hf_response": "Yes, there is a known link between the Aurora B kinase and the Polycomb protein Ring1B. Both proteins have been implicated in various cellular processes, including chromatin remodeling, transcriptional regulation, and cell cycle progression. While they have distinct functions, they can interact and coordinate their activities to regulate gene expression and chromatin structure.\nRing1B is a Polycomb group (PcG) protein that plays a critical role in the maintenance of gene silencing and stem cell self-renewal. It is involved in the monoubiquitination of histone H2A, which is a post-translational modification that targets chromatin for repressive epigenetic marks. Ring1B also interacts with the Aurora B kinase, which is a key regulator of chromosome segregation and cell division.\nStudies have shown that Ring1B and Aurora B interact in various contexts, including during mitosis and meiosis. For example, Ring1B has been shown to be required for the proper localization and activity of Aurora B during mitosis, and Aurora B has been shown to phosphorylate and activate Ring1B. These interactions suggest that Ring1B and Aurora B may work together to regulate chromatin structure and gene expression during cell division.\nIn addition, mutations in either Ring1B or Aurora B have been implicated in various human diseases, including cancer and developmental disorders. For example, mutations in Ring1B have been associated with the development of certain types of leukemia, while mutations in Aurora B have been associated with various types of cancer, including breast and ovarian cancer.\nIn summary, there is a known link between the Aurora B kinase and the Polycomb protein Ring1B, as they interact and coordinate their activities to regulate chromatin structure and gene expression during cell division. Dysregulation of these interactions has been implicated in various human diseases, highlighting the importance of this complex interplay in maintaining proper cellular function.",
    "llama-2-7b-chat-hf_fact_raw": "1. Aurora B kinase and the Polycomb protein Ring1B are known to interact with each other.\n2. Ring1B is involved in the monoubiquitination of histone H2A.\n3. Aurora B kinase is a key regulator of chromosome segregation and cell division.\n4. Ring1B is required for the proper localization and activity of Aurora B during mitosis.\n5. Mutations in Ring1B have been associated with the development of certain types of leukemia, and mutations in Aurora B have been linked to various types of cancer, including breast and ovarian cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Aurora B kinase and the Polycomb protein Ring1B are known to interact with each other.",
      "Ring1B is involved in the monoubiquitination of histone H2A.",
      "Aurora B kinase is a key regulator of chromosome segregation and cell division.",
      "Ring1B is required for the proper localization and activity of Aurora B during mitosis.",
      "Mutations in Ring1B have been associated with the development of certain types of leukemia, and mutations in Aurora B have been linked to various types of cancer, including breast and ovarian cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE\n\nWhile statements 2 and 3 are established knowledge in molecular biology, statements 1 and 4 require specific scientific evidence that isn't provided in the context. Statement 5 is generally true, considering the roles both proteins play in cell cycle regulation, but the specific mutations would need to be referenced with scientific literature for precise verification.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-7b-chat-hf_response": "Non-canonical sequence motifs are alterations in the splice site consensus sequences that can affect the splicing process. In vertebrates, the most frequent non-canonical sequence motifs at the donor and acceptor splice sites are:\nDonor Splice Site Non-Canonical Motifs:\n1. GU-rich sequences: The consensus donor splice site sequence is GUrich, but non-canonical GU-rich sequences can also be recognized by the spliceosome. These sequences can lead to the inclusion of cryptic exons or the skipping of exons.\n2. GT-rich sequences: GT-rich sequences can act as donor splice sites and can lead to the inclusion of cryptic exons or the skipping of exons.\n3. AU-rich sequences: AU-rich sequences can act as donor splice sites and can lead to the inclusion of cryptic exons or the skipping of exons.\nAcceptor Splice Site Non-Canonical Motifs:\n1. AG-rich sequences: The consensus acceptor splice site sequence is AGrich, but non-canonical AG-rich sequences can also be recognized by the spliceosome. These sequences can lead to the inclusion of cryptic exons or the skipping of exons.\n2. GU-rich sequences: GU-rich sequences can also be found at the acceptor splice site and can lead to the inclusion of cryptic exons or the skipping of exons.\n3. GT-rich sequences: GT-rich sequences can also be found at the acceptor splice site and can lead to the inclusion of cryptic exons or the skipping of exons.\nIt's important to note that the presence of these non-canonical motifs can be context-dependent, and their effects on splicing can vary depending on the cell type, tissue, and developmental stage.",
    "llama-2-7b-chat-hf_fact_raw": "1. The consensus donor splice site sequence in vertebrates is generally GU-rich.\n2. Non-canonical GU-rich sequences can act as donor splice sites and may be recognized by the spliceosome.\n3. The consensus acceptor splice site sequence in vertebrates is generally AG-rich.\n4. Non-canonical AG-rich sequences can act as acceptor splice sites and may be recognized by the spliceosome.\n5. The effects of non-canonical sequence motifs on splicing can vary depending on the cell type, tissue, and developmental stage.",
    "llama-2-7b-chat-hf_fact": [
      "The consensus donor splice site sequence in vertebrates is generally GU-rich.",
      "Non-canonical GU-rich sequences can act as donor splice sites and may be recognized by the spliceosome.",
      "The consensus acceptor splice site sequence in vertebrates is generally AG-rich.",
      "Non-canonical AG-rich sequences can act as acceptor splice sites and may be recognized by the spliceosome.",
      "The effects of non-canonical sequence motifs on splicing can vary depending on the cell type, tissue, and developmental stage."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The consensus acceptor splice site sequence in vertebrates is generally AG at the 3' end of the intron, but it is not correct to say it is AG-rich because the rich implies a larger region, whereas the consensus sequence refers specifically to the dinucleotide at the intron-exon boundary.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-7b-chat-hf_response": "The acetylation of S6K1 (p70 S6 kinase 1) is regulated by several events, including:\n1. Phosphorylation of S6K1 on T389 by LKB1-STRAD: LKB1 (lipoate-binding kinase 1) and STRAD (sterile alpha and TIR domain-containing protein) are upstream kinases that phosphorylate S6K1 on T389, leading to its activation.\n2. Phosphorylation of S6K1 on S422 by MAPK/ERK: Mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) can phosphorylate S6K1 on S422, which can also activate the kinase.\n3. Ubiquitination of S6K1: S6K1 can be ubiquitinated by the ubiquitin-proteasome pathway, which can affect its activity and localization.\n4. Acetylation of S6K1: Acetylation of S6K1 on specific lysine residues, such as K383, K425, and K431, can also play a role in regulating its activity and localization.\n5. Interaction with other proteins: S6K1 can interact with other proteins, such as 14-3-3 proteins, which can also regulate its activity and localization.\nIn summary, the acetylation of S6K1 is regulated by multiple events, including phosphorylation, ubiquitination, and interaction with other proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. LKB1 and STRAD are upstream kinases that phosphorylate S6K1 on T389, which leads to its activation.\n2. MAPK/ERK can phosphorylate S6K1 on S422.\n3. S6K1 can be ubiquitinated by the ubiquitin-proteasome pathway.\n4. Acetylation of S6K1 on specific lysine residues such as K383, K425, and K431 can regulate its activity and localization.\n5. S6K1 can interact with proteins like 14-3-3 proteins, which can regulate its activity and localization.",
    "llama-2-7b-chat-hf_fact": [
      "LKB1 and STRAD are upstream kinases that phosphorylate S6K1 on T389, which leads to its activation.",
      "MAPK/ERK can phosphorylate S6K1 on S422.",
      "S6K1 can be ubiquitinated by the ubiquitin-proteasome pathway.",
      "Acetylation of S6K1 on specific lysine residues such as K383, K425, and K431 can regulate its activity and localization.",
      "S6K1 can interact with proteins like 14-3-3 proteins, which can regulate its activity and localization."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: LKB1 and STRAD activate the AMPK pathway, but they are not the upstream kinases that phosphorylate S6K1 on T389. T389 is phosphorylated by the mammalian target of rapamycin complex 1 (mTORC1).\n2. TRUE: The MAPK/ERK pathway can lead to the phosphorylation of S6K1, one of the target sites being S422.\n3. TRUE: S6K1 can be regulated by the ubiquitin-proteasome pathway, which includes ubiquitination leading to its degradation.\n4. UNKNOWN: While acetylation can regulate the activity and localization of certain proteins, whether S6K1 has specific lysine residues such as K383, K425, and K431 that are acetylated for its regulation is not stated. Without specific literature references, its correctness cannot be determined.\n5. TRUE: S6K1 can indeed interact with 14-3-3 proteins, and such interactions can impact its activity and cellular localization.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-7b-chat-hf_response": "Episodic ataxia type 6 (EA6) is a rare genetic disorder that is caused by mutations in the FKBP14 gene. This gene provides instructions for making a protein called FKBP14, which is involved in the regulation of protein synthesis and degradation.\nThe FKBP14 protein is a molecular chaperone that helps to regulate the folding and stability of other proteins, particularly those involved in cellular signaling pathways. In EA6, mutations in the FKBP14 gene lead to the accumulation of abnormally folded or misfolded proteins, which can disrupt normal cellular function and lead to the symptoms of the disorder.\nThe exact mechanism by which FKBP14 mutations cause the symptoms of EA6 is not fully understood, but it is thought to involve disruptions in the regulation of protein synthesis and degradation, as well as the misfolding of key proteins involved in cellular signaling pathways.\nEA6 is an autosomal dominant disorder, which means that a single copy of the mutated gene is enough to cause the condition. The disorder typically becomes apparent in adulthood, often in the third or fourth decade of life, and can be characterized by recurrent episodes of ataxia, which are often triggered by stress or other environmental factors. Other symptoms can include nystagmus, dysarthria, and cognitive decline.\nThere is currently no cure for EA6, and treatment is focused on managing the symptoms and preventing complications. Medications such as anticholinergics and benzodiazepines can help to reduce the frequency and severity of ataxia episodes, while physical therapy and occupational therapy can help to improve coordination and balance. In some cases, surgery may be necessary to relieve pressure on the brain or spinal cord caused by ataxic episodes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Episodic ataxia type 6 (EA6) is caused by mutations in the FKBP14 gene.\n2. The FKBP14 protein is involved in the regulation of protein synthesis and degradation.\n3. Mutations in the FKBP14 gene can lead to the accumulation of abnormally folded or misfolded proteins.\n4. EA6 is an autosomal dominant disorder, meaning that a single copy of the mutated gene can cause the condition.\n5. Symptoms of episodic ataxia type 6 typically become apparent in adulthood, often in the third or fourth decade of life.",
    "llama-2-7b-chat-hf_fact": [
      "Episodic ataxia type 6 (EA6) is caused by mutations in the FKBP14 gene.",
      "The FKBP14 protein is involved in the regulation of protein synthesis and degradation.",
      "Mutations in the FKBP14 gene can lead to the accumulation of abnormally folded or misfolded proteins.",
      "EA6 is an autosomal dominant disorder, meaning that a single copy of the mutated gene can cause the condition.",
      "Symptoms of episodic ataxia type 6 typically become apparent in adulthood, often in the third or fourth decade of life."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Episodic ataxia type 6 (EA6) is not caused by mutations in the FKBP14 gene, but rather by mutations in the SLC1A3 gene.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: EA6 is not an autosomal dominant disorder. It is actually autosomal recessive, meaning that two copies of the mutated gene are needed to cause the condition.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-7b-chat-hf_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are enzymes that add a methyl group to specific residues on histones or other chromatin-associated proteins, leading to changes in chromatin structure and gene expression. While the best-studied chromomethylases are found in bacteria and archaea, there is evidence that these enzymes are also present in animal genomes.\nOne of the earliest studies to identify chromomethylases in animal cells was conducted in the 1990s, when a team of researchers found that the enzyme H3K4 methyltransferase was present in mammalian cells (1). Since then, several other chromomethylases have been identified in animal species, including H3K27 methyltransferase, H3K9 methyltransferase, and H3K27 demethylase.\nFor example, studies have shown that H3K4 methyltransferase is involved in the regulation of gene expression in various animal tissues, including the brain, heart, and liver (2,3). Similarly, H3K27 methyltransferase has been implicated in the regulation of stem cell self-renewal and differentiation in mammalian cells (4,5).\nWhile the functions of chromomethylases in animal cells are not as well understood as those in bacteria and archaea, there is evidence to suggest that they play important roles in regulating chromatin structure and gene expression in a variety of organisms.\nReferences:\n1. Kim, J. et al. (1997). Mammalian histone H3-lysine 4 trimethyltransferase: a novel enzyme involved in chromatin structure and gene expression. Journal of Biological Chemistry, 272(34), 21435-21441.\n2. Wang, Z. et al. (2009). H3K4 trimethylation is mediated by a histone-lysine N-methyltransferase in mammalian cells. Nature Communications, 1, 1-9.\n3. Zhang, Y. et al.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromomethylases are enzymes that add a methyl group to specific residues on histones or chromatin-associated proteins.\n2. These enzymes are found in bacteria, archaea, and animal genomes.\n3. The enzyme H3K4 methyltransferase was identified in mammalian cells.\n4. H3K27 methyltransferase has been implicated in the regulation of stem cell self-renewal and differentiation in mammalian cells.\n5. H3K9 methyltransferase and H3K27 demethylase have been identified in animal species.",
    "llama-2-7b-chat-hf_fact": [
      "Chromomethylases are enzymes that add a methyl group to specific residues on histones or chromatin-associated proteins.",
      "These enzymes are found in bacteria, archaea, and animal genomes.",
      "The enzyme H3K4 methyltransferase was identified in mammalian cells.",
      "H3K27 methyltransferase has been implicated in the regulation of stem cell self-renewal and differentiation in mammalian cells.",
      "H3K9 methyltransferase and H3K27 demethylase have been identified in animal species."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Chromomethylases are enzymes that typically add a methyl group to DNA, not specifically to histones or chromatin-associated proteins, although histone methylation is catalyzed by histone methyltransferases.\n2. FALSE [correction]: Chromomethylases are primarily found in plants, not commonly in bacteria, archaea, or animal genomes. The reference to these enzymes in bacteria, archaea, and animal genomes is not accurate; in these organisms, similar methylation functions are carried out by other types of DNA methyltransferases or histone methyltransferases.\n3. TRUE: H3K4 methyltransferase, which catalyzes the methylation of lysine 4 on histone H3, has indeed been identified and is well-studied in mammalian cells.\n4. TRUE: H3K27 methyltransferase, such as EZH2, plays a role in regulating gene expression, and has been implicated in controlling stem cell fate through methylation of lysine 27 on histone H3 in mammalian cells.\n5. TRUE: Both H3K9 methyltransferases, which target lysine 9 on histone H3, and H3K27 demethylases, which remove methyl groups from lysine 27 on histone H3, have been characterized in animal species. These enzymes are involved in epigenetic regulation.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-7b-chat-hf_response": "There are several packages available in R/Bioconductor for the analysis of transcription factor binding sites (TFBS) data. Here are some of the most popular ones:\n1. ChIPseek: This package is specifically designed for the analysis of ChIP-seq data, which is often used to identify TFBS. ChIPseek provides a range of tools for peak calling, motif discovery, and visualization.\n2. TFBS: This package provides a comprehensive set of tools for the analysis of TFBS data, including peak calling, motif discovery, and the prediction of TF-DNA interactions.\n3. TRANSFAC: TRANSFAC is a widely used package for the analysis of TFBS data. It provides a range of tools for motif discovery, peak calling, and the prediction of TF-DNA interactions.\n4. HISAT2: HISAT2 is a spliced aligner that can be used to identify TFBS by aligning RNA-seq reads to a reference genome and identifying peak regions with high signal intensity.\n5. STAR: STAR is another spliced aligner that can be used to identify TFBS by aligning RNA-seq reads to a reference genome and identifying peak regions with high signal intensity.\n6. DeepTools: DeepTools is a package that provides a range of tools for the analysis of ChIP-seq data, including peak calling, motif discovery, and visualization.\n7. Bedtools: Bedtools is a package that provides a range of tools for the analysis of genomic data, including the identification of TFBS. It can be used to identify peak regions and predict TF-DNA interactions.\n8. GSEA: GSEA (Gene Set Enrichment Analysis) is a package that provides a range of tools for the analysis of gene expression data, including the identification of TFBS. It can be used to identify sets of genes that are co-regulated by a particular TF.\n9. DREAM: DREAM (Differential Regulatory Element Analysis Method) is a package that provides a range of tools for the analysis of TFBS data, including peak calling, motif discovery, and the prediction of TF-DNA interactions.\n10. R/Bioconductor packages for mot",
    "llama-2-7b-chat-hf_fact_raw": "1. ChIPseek is a package in R/Bioconductor designed for ChIP-seq data analysis, including peak calling, motif discovery, and visualization.\n2. The TFBS package in R/Bioconductor offers tools for the analysis of transcription factor binding sites data, including peak calling, motif discovery, and prediction of TF-DNA interactions.\n3. TRANSFAC is a package in R/Bioconductor used for the analysis of transcription factor binding sites data, providing tools for motif discovery, peak calling, and prediction of TF-DNA interactions.\n4. HISAT2 is a spliced aligner in R/Bioconductor that can identify transcription factor binding sites by aligning RNA-seq reads to a reference genome.\n5. STAR is a spliced aligner in R/Bioconductor that can identify transcription factor binding sites by aligning RNA-seq reads to a reference genome.",
    "llama-2-7b-chat-hf_fact": [
      "ChIPseek is a package in R/Bioconductor designed for ChIP-seq data analysis, including peak calling, motif discovery, and visualization.",
      "The TFBS package in R/Bioconductor offers tools for the analysis of transcription factor binding sites data, including peak calling, motif discovery, and prediction of TF-DNA interactions.",
      "TRANSFAC is a package in R/Bioconductor used for the analysis of transcription factor binding sites data, providing tools for motif discovery, peak calling, and prediction of TF-DNA interactions.",
      "HISAT2 is a spliced aligner in R/Bioconductor that can identify transcription factor binding sites by aligning RNA-seq reads to a reference genome.",
      "STAR is a spliced aligner in R/Bioconductor that can identify transcription factor binding sites by aligning RNA-seq reads to a reference genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ChIPseeker is the correct package name, not ChIPseek, and it is designed for ChIP-seq data analysis that provides functionalities such as peak annotation, visualization, and comparison.\n2. TRUE\n3. FALSE [correction]: TRANSFAC is not an R/Bioconductor package but actually a database that contains data about transcription factors, their experimentally-proven binding sites, and regulated genes.\n4. FALSE [correction]: HISAT2 is a fast and sensitive spliced aligner for aligning RNA-seq reads to a reference genome, but it is not designed for the identification of transcription factor binding sites and it is not an R/Bioconductor package; it is a standalone software tool.\n5. FALSE [correction]: STAR (Spliced Transcripts Alignment to a Reference) is indeed a spliced aligner that aligns RNA-seq reads to a reference genome and is highly efficient, but it is not specifically designed to identify transcription factor binding sites and it is not an R/Bioconductor package; it is a standalone software tool.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-7b-chat-hf_response": "Sarcopenia is the progressive loss of muscle mass and strength that occurs with aging. While there are no approved treatments for the prevention of sarcopenia, several clinical trials are currently underway to evaluate the effectiveness of various interventions in preventing or slowing the progression of sarcopenia. Here are some of the ongoing clinical trials for the prevention of sarcopenia:\n1. Resistance Training and Nutritional Interventions to Prevent Sarcopenia (RRNS): This randomized controlled trial is evaluating the effectiveness of resistance training and nutritional interventions in preventing sarcopenia in older adults.\n2. Effects of Long-Term Resistance Training on Sarcopenia in Frail Older Adults (FIT-Sarcopenia): This randomized controlled trial is examining the effects of long-term resistance training on sarcopenia in frail older adults.\n3. Nutritional Interventions to Prevent Sarcopenia in Older Adults (Nutri-Sarc): This randomized controlled trial is evaluating the effectiveness of various nutritional interventions in preventing sarcopenia in older adults.\n4. Exercise and Nutrition Interventions to Prevent Sarcopenia in Older Adults (ENSAR): This randomized controlled trial is examining the effects of exercise and nutrition interventions on sarcopenia in older adults.\n5. Sarcopenia Prevention by Nutrition and Exercise (SPRINT): This randomized controlled trial is evaluating the effectiveness of a combination of nutrition and exercise interventions in preventing sarcopenia in older adults.\n6. Effects of Progressive Resistance Exercise on Sarcopenia in Older Adults (PRES): This randomized controlled trial is examining the effects of progressive resistance exercise on sarcopenia in older adults.\n7. Nutritional Interventions to Prevent Sarcopenia and Improve Health Outcomes in Older Adults (NUTRISARC): This randomized controlled trial is evaluating the effectiveness of various nutritional interventions in preventing sarcopen",
    "llama-2-7b-chat-hf_fact_raw": "1. There are no approved treatments for the prevention of sarcopenia.\n2. The RRNS trial is evaluating the effectiveness of resistance training and nutritional interventions in preventing sarcopenia in older adults.\n3. The FIT-Sarcopenia trial is examining the effects of long-term resistance training on sarcopenia in frail older adults.\n4. The Nutri-Sarc trial is evaluating the effectiveness of various nutritional interventions in preventing sarcopenia in older adults.\n5. The SPRINT trial is evaluating the effectiveness of a combination of nutrition and exercise interventions in preventing sarcopenia in older adults.",
    "llama-2-7b-chat-hf_fact": [
      "There are no approved treatments for the prevention of sarcopenia.",
      "The RRNS trial is evaluating the effectiveness of resistance training and nutritional interventions in preventing sarcopenia in older adults.",
      "The FIT-Sarcopenia trial is examining the effects of long-term resistance training on sarcopenia in frail older adults.",
      "The Nutri-Sarc trial is evaluating the effectiveness of various nutritional interventions in preventing sarcopenia in older adults.",
      "The SPRINT trial is evaluating the effectiveness of a combination of nutrition and exercise interventions in preventing sarcopenia in older adults."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: As of my knowledge cutoff in early 2023, there were no drugs officially approved by major regulatory agencies specifically for the prevention of sarcopenia. However, it should be noted that various interventions, such as exercise and nutritional strategies, may be recommended to prevent or manage sarcopenia.\n\n2. UNKNOWN: Without specific reference to the \"RRNS trial,\" I am unable to confirm the details of this statement. Trials with different names or acronyms may evaluate the effectiveness of resistance training and nutritional interventions, but the specifics about the \"RRNS trial\" are not provided here.\n\n3. UNKNOWN: The \"FIT-Sarcopenia trial\" is not a well-known trial as of my last update, and no specifics are provided to verify this statement. It is not possible to confirm the existence or the details of this trial without additional information.\n\n4. UNKNOWN: As with statement 2 and 3, the \"Nutri-Sarc trial\" is not a trial that I have specific information on, and thus I cannot confirm the validity of this statement. Trials may exist that evaluate nutritional interventions for sarcopenia, but without more context or specific naming, it is not possible to verify this.\n\n5. UNKNOWN: Similar to the previous trials mentioned, without specific details regarding the \"SPRINT trial\" and its relation to sarcopenia prevention, the accuracy of this statement cannot be verified. While the name \"SPRINT\" has been associated with a major trial in the past (e.g., the SPRINT trial for hypertension), this does not confirm the existence or details of a trial by the same name related to sarcopenia.\n\nIt is important to note that while the area of sarcopenia prevention and treatment is an active field of research, the details of specific trials (as mentioned in statements 2-5) are not well-known without further context or reference. Therefore, more specific information would be required to determine the truth of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several databases of molecular recognition features in membrane proteins that can be used for protein structure prediction and design. Here are some of the most popular ones:\n1. Membrane Protein Databank (MPDB): This database contains a collection of membrane protein structures, including their three-dimensional structures, functional sites, and molecular recognition features.\n2. Membrane Protein Function Prediction (MPFP): This database provides a comprehensive set of functional sites and molecular recognition features for membrane proteins, which can be used for predicting protein function and design.\n3. Membrane Protein Structural Alignment (MPSA): This database provides a collection of aligned structures of membrane protein complexes, which can be used for identifying molecular recognition features and predicting protein structure and function.\n4. Membrane Protein-Ligand Interactions (MPI): This database contains a collection of membrane protein-ligand complexes, including their three-dimensional structures, binding affinities, and molecular recognition features.\n5. Membrane Protein-Protein Interactions (MPII): This database provides a collection of membrane protein-protein complexes, including their three-dimensional structures, binding affinities, and molecular recognition features.\n6. Protein Data Bank (PDB): While not exclusively focused on membrane proteins, the PDB is a comprehensive database of protein structures that can be used to identify molecular recognition features and predict protein structure and function.\nThese databases can be accessed through various web servers and software tools, and can be used for a variety of applications, including protein structure prediction, design, and engineering.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Membrane Protein Databank (MPDB) contains a collection of membrane protein structures with three-dimensional structures, functional sites, and molecular recognition features.\n2. The Membrane Protein Function Prediction (MPFP) provides a set of functional sites and molecular recognition features for membrane proteins to aid in predicting protein function and design.\n3. The Membrane Protein Structural Alignment (MPSA) offers a collection of aligned structures of membrane protein complexes for identifying molecular recognition features and predicting protein structure and function.\n4. The Membrane Protein-Ligand Interactions (MPI) database contains a collection of membrane protein-ligand complexes, including three-dimensional structures, binding affinities, and molecular recognition features.\n5. The Protein Data Bank (PDB) is a comprehensive database of protein structures that includes information useful for identifying molecular recognition features and predicting protein structure and function, even though it is not exclusively focused on membrane proteins.",
    "llama-2-7b-chat-hf_fact": [
      "The Membrane Protein Databank (MPDB) contains a collection of membrane protein structures with three-dimensional structures, functional sites, and molecular recognition features.",
      "The Membrane Protein Function Prediction (MPFP) provides a set of functional sites and molecular recognition features for membrane proteins to aid in predicting protein function and design.",
      "The Membrane Protein Structural Alignment (MPSA) offers a collection of aligned structures of membrane protein complexes for identifying molecular recognition features and predicting protein structure and function.",
      "The Membrane Protein-Ligand Interactions (MPI) database contains a collection of membrane protein-ligand complexes, including three-dimensional structures, binding affinities, and molecular recognition features.",
      "The Protein Data Bank (PDB) is a comprehensive database of protein structures that includes information useful for identifying molecular recognition features and predicting protein structure and function, even though it is not exclusively focused on membrane proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN – The statement about the Membrane Protein Function Prediction (MPFP) appears to be about a specific database or tool, but without proper context, its existence and the accuracy of its description cannot be verified.\n3. UNKNOWN – Like statement 2, the Membrane Protein Structural Alignment (MPSA) could be a specific database or tool. Without additional context about its existence and features, the truth of the statement cannot be determined.\n4. UNKNOWN – The description of the Membrane Protein-Ligand Interactions (MPI) database is plausible, but without further context, the existence and characteristics of this database cannot be confirmed.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-7b-chat-hf_response": "Yes, rivaroxaban is metabolized in the kidneys to a limited extent. Rivaroxaban is primarily metabolized by the liver, but the kidneys also play a role in its metabolism.\nRivaroxaban is converted to its active metabolite, rivaroxaban acid, primarily by the liver enzyme cytochrome P450 (CYP) 3A4. However, the kidneys also contribute to rivaroxaban metabolism to a lesser extent, particularly through the activity of other liver enzymes, such as CYP2C8 and CYP2C9.\nStudies have shown that the kidneys account for approximately 20-30% of rivaroxaban metabolism in healthy individuals, while the liver accounts for the remaining 70-80%. However, the relative contribution of the kidneys to rivaroxaban metabolism may vary depending on factors such as liver function, drug interactions, and renal function.\nGiven the role of the kidneys in rivaroxaban metabolism, it is important to monitor renal function in patients taking this drug, particularly those with pre-existing kidney disease or those who are at risk of developing acute kidney injury. Rivaroxaban has been shown to increase serum creatinine levels and reduce glomerular filtration rate (GFR) in some studies, suggesting that it may have a negative impact on renal function. Therefore, careful monitoring of renal function and dose adjustment may be necessary in certain patient populations.",
    "llama-2-7b-chat-hf_fact_raw": "1. Rivaroxaban is metabolized in the kidneys to a limited extent.\n2. Rivaroxaban is primarily metabolized by the liver.\n3. The liver enzyme cytochrome P450 (CYP) 3A4 is primarily responsible for converting rivaroxaban to its active metabolite, rivaroxaban acid.\n4. Studies suggest that kidneys account for approximately 20-30% of rivaroxaban metabolism in healthy individuals.\n5. The relative contribution of the kidneys to rivaroxaban metabolism can vary based on liver function, drug interactions, and renal function.",
    "llama-2-7b-chat-hf_fact": [
      "Rivaroxaban is metabolized in the kidneys to a limited extent.",
      "Rivaroxaban is primarily metabolized by the liver.",
      "The liver enzyme cytochrome P450 (CYP) 3A4 is primarily responsible for converting rivaroxaban to its active metabolite, rivaroxaban acid.",
      "Studies suggest that kidneys account for approximately 20-30% of rivaroxaban metabolism in healthy individuals.",
      "The relative contribution of the kidneys to rivaroxaban metabolism can vary based on liver function, drug interactions, and renal function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Rivaroxaban is primarily metabolized by the liver, but it is not extensively metabolized; the majority is eliminated unchanged.\n3. FALSE [correction]: While the liver enzyme cytochrome P450 (CYP) 3A4 is involved in the metabolism of rivaroxaban, it does not convert rivaroxaban into an active metabolite. Rivaroxaban is an active drug itself, and its metabolites are less active or inactive.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-7b-chat-hf_response": "TRalpha2 is a subtype of the thyroid hormone receptor (TR) that is primarily expressed in the heart and plays a crucial role in regulating cardiac gene expression. Studies have shown that TRalpha2 regulates a wide range of genes involved in various cardiac processes, including:\n1. Cardiac hypertrophy: TRalpha2 regulates genes involved in cardiac hypertrophy, such as the atrial natriuretic factor (ANF) and the beta-myosin heavy chain (MHC-β).\n2. Contractility: TRalpha2 regulates genes involved in cardiac contractility, such as the troponin T (TnT) and the cardiac troponin I (cTnI).\n3. Rhythm: TRalpha2 regulates genes involved in cardiac rhythm, such as the ion channels KCNQ1 and KCNH2, and the pacemaker protein (atrioventricular nodal myosin-binding protein C).\n4. Remodeling: TRalpha2 regulates genes involved in cardiac remodeling, such as the transforming growth factor-beta (TGF-β) and the connective tissue growth factor (CTGF).\n5. Autophagy: TRalpha2 regulates genes involved in autophagy, such as the autophagy-related gene 7 (ATG7) and the LC3-associated protein (LAMP2A).\n6. Energy metabolism: TRalpha2 regulates genes involved in energy metabolism, such as the pyruvate dehydrogenase kinase (PDK4) and the acetyl-CoA carboxylase (ACC).\n7. Inflammation: TRalpha2 regulates genes involved in inflammation, such as the interleukin-6 (IL-6) and the tumor necrosis factor-alpha (TNF-α).\n8. Oxidative stress: TRalpha2 regulates genes involved in oxidative stress, such as the glutathione peroxidase 1 (GPx1) and the NADPH oxidase 4 (NOX4).\n9. Cell death: TRalpha2 regulates genes involved in cell death, such as the",
    "llama-2-7b-chat-hf_fact_raw": "1. TRalpha2 is a subtype of the thyroid hormone receptor that is primarily expressed in the heart.\n2. TRalpha2 regulates genes involved in cardiac hypertrophy, including atrial natriuretic factor (ANF) and beta-myosin heavy chain (MHC-β).\n3. TRalpha2 regulates genes that affect cardiac contractility, such as troponin T (TnT) and cardiac troponin I (cTnI).\n4. TRalpha2 is involved in the regulation of genes that are responsible for cardiac rhythm, including ion channels KCNQ1 and KCNH2, as well as the pacemaker protein atrioventricular nodal myosin-binding protein C.\n5. TRalpha2 regulates genes linked to autophagy in the heart, such as the autophagy-related gene 7 (ATG7) and LC3-associated protein (LAMP2A).",
    "llama-2-7b-chat-hf_fact": [
      "TRalpha2 is a subtype of the thyroid hormone receptor that is primarily expressed in the heart.",
      "TRalpha2 regulates genes involved in cardiac hypertrophy, including atrial natriuretic factor (ANF) and beta-myosin heavy chain (MHC-β).",
      "TRalpha2 regulates genes that affect cardiac contractility, such as troponin T (TnT) and cardiac troponin I (cTnI).",
      "TRalpha2 is involved in the regulation of genes that are responsible for cardiac rhythm, including ion channels KCNQ1 and KCNH2, as well as the pacemaker protein atrioventricular nodal myosin-binding protein C.",
      "TRalpha2 regulates genes linked to autophagy in the heart, such as the autophagy-related gene 7 (ATG7) and LC3-associated protein (LAMP2A)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TRalpha2 (thyroid hormone receptor alpha 2) is not primarily expressed in the heart; it is expressed in various tissues but notably, it lacks a direct DNA-binding domain and generally does not act as a transcriptional activator. TRalpha1 is the subtype more commonly associated with heart function.\n2. FALSE [correction]: Since TRalpha2 typically does not function as a transcriptional activator due to its lack of a direct DNA-binding domain, it is unlikely that it regulates genes involved in cardiac hypertrophy in the same manner as other thyroid hormone receptors like TRalpha1 might.\n3. UNKNOWN: Although thyroid hormone receptors are involved in cardiac contractility regulation, it is unclear whether TRalpha2 specifically regulates troponin T (TnT) and cardiac troponin I (cTnI), especially because its role as a regulator of gene transcription is limited compared to other thyroid hormone receptor subtypes.\n4. UNKNOWN: The specific role of TRalpha2 in regulating genes responsible for cardiac rhythm, including the ion channels KCNQ1 and KCNH2, and the pacemaker protein atrioventricular nodal myosin-binding protein C, is not clearly established, especially given TRalpha2's distinct properties.\n5. UNKNOWN: The regulation of autophagy genes such as ATG7 and LAMP2A specifically by TRalpha2 is not well established in the scientific literature. While thyroid hormones can influence autophagy, the role of TRalpha2 in this process is not clear.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-7b-chat-hf_response": "There are several biomedical question answering systems available, including:\n1. PubMed Central's Queries: PubMed Central's Queries is a question answering system that uses natural language processing and machine learning to retrieve answers from the PubMed database.\n2. Biomedical Information Retrieval System (BIRS): BIRS is a question answering system developed at the University of California, Los Angeles (UCLA) that uses a combination of natural language processing and machine learning to retrieve answers from biomedical databases.\n3. Biomedical Question Answering System (BQAS): BQAS is a question answering system developed at the University of Texas Southwestern Medical Center that uses a combination of natural language processing and machine learning to retrieve answers from biomedical databases.\n4. BioCreative II: BioCreative II is a question answering system developed at the University of Colorado Boulder that uses natural language processing and machine learning to retrieve answers from biomedical databases.\n5. Biomedical Text Mining (BTM): BTM is a question answering system developed at the University of California, San Diego that uses natural language processing and machine learning to retrieve answers from biomedical texts.\n6. Med2Text: Med2Text is a question answering system developed at the University of California, San Francisco that uses natural language processing and machine learning to retrieve answers from biomedical texts.\n7. BioGRID: BioGRID is a question answering system developed at the University of California, San Diego that uses natural language processing and machine learning to retrieve answers from biomedical databases.\n8. Biomedical Natural Language Processing (BioNLP): BioNLP is a question answering system developed at the University of Colorado Boulder that uses natural language processing and machine learning to retrieve answers from biomedical texts.\n9. Biomedical Question Answering System using Deep Learning (BQA-Deep): BQA-Deep is a question answering system developed at the University of California, Los Angeles (UCLA) that uses deep learning techniques to retrieve answers from biomedical databases.\n10. Biomedical Text Summarization and Question Answering System (BTSQA): BTSQA is a question answering system developed at the University of California, San Diego that uses natural language processing and machine learning to retrieve answers from biomedical texts.\nThese are just a few examples of the many bi",
    "llama-2-7b-chat-hf_fact_raw": "1. PubMed Central's Queries is a question answering system that retrieves answers from the PubMed database.\n2. The Biomedical Information Retrieval System (BIRS) was developed at the University of California, Los Angeles (UCLA).\n3. The Biomedical Question Answering System (BQAS) was developed at the University of Texas Southwestern Medical Center.\n4. BioCreative II is a question answering system developed at the University of Colorado Boulder.\n5. The Biomedical Text Mining (BTM) system was developed at the University of California, San Diego.",
    "llama-2-7b-chat-hf_fact": [
      "PubMed Central's Queries is a question answering system that retrieves answers from the PubMed database.",
      "The Biomedical Information Retrieval System (BIRS) was developed at the University of California, Los Angeles (UCLA).",
      "The Biomedical Question Answering System (BQAS) was developed at the University of Texas Southwestern Medical Center.",
      "BioCreative II is a question answering system developed at the University of Colorado Boulder.",
      "The Biomedical Text Mining (BTM) system was developed at the University of California, San Diego."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: PubMed Central is a free full-text archive of biomedical and life sciences journal literature at the U.S. National Institutes of Health's National Library of Medicine. It is not a question-answering system.\n2. UNKNOWN: The statement doesn't provide enough information to verify the development of a system named the Biomedical Information Retrieval System (BIRS) at UCLA.\n3. UNKNOWN: There is no widely recognizable system known as the Biomedical Question Answering System (BQAS) that can be specifically attributed to the University of Texas Southwestern Medical Center without further context.\n4. FALSE [correction]: BioCreative (Critical Assessment for Information Extraction in Biology) is not a question answering system but a series of workshops that includes challenges for tasks such as text mining and information extraction in biology. It is not developed by a single institution such as the University of Colorado Boulder, as it is a collaborative effort involving multiple international research teams.\n5. FALSE [correction]: The University of California, San Diego, is well-known for its work in bioinformatics, but there is no specific system known as the Biomedical Text Mining (BTM) system that is recognized as being developed there. BTM refers to a field of research rather than a single system.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-7b-chat-hf_response": "The transcription factor that activates the betalain pathway is called BETAINE TRANSCRIPTION FACTOR 1 (BTF1). BTF1 is a transcriptional activator that regulates the expression of genes involved in the biosynthesis of betalains, a class of natural pigments found in plants.\nHere's a breakdown of the steps:\n1. Transcription factor BTF1: BTF1 is a transcription factor that binds to specific DNA sequences in the promoter region of betalain biosynthetic genes, thereby regulating their expression.\n2. Activation of betalain biosynthesis: BTF1 binds to the promoter region of genes involved in betalain biosynthesis, leading to their activation. This results in the production of betalains, which are then transported to the chloroplasts for accumulation.\nIn summary, BTF1 is the transcription factor that activates the betalain pathway by regulating the expression of genes involved in betalain biosynthesis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The transcription factor that activates the betalain pathway is called BETAINE TRANSCRIPTION FACTOR 1 (BTF1).\n2. BTF1 is a transcriptional activator that regulates the expression of genes involved in the biosynthesis of betalains.\n3. Betalains are a class of natural pigments found in plants.\n4. BTF1 binds to specific DNA sequences in the promoter region of betalain biosynthetic genes.\n5. The activation of betalain biosynthesis by BTF1 leads to the production of betalains, which are transported to chloroplasts for accumulation.",
    "llama-2-7b-chat-hf_fact": [
      "The transcription factor that activates the betalain pathway is called BETAINE TRANSCRIPTION FACTOR 1 (BTF1).",
      "BTF1 is a transcriptional activator that regulates the expression of genes involved in the biosynthesis of betalains.",
      "Betalains are a class of natural pigments found in plants.",
      "BTF1 binds to specific DNA sequences in the promoter region of betalain biosynthetic genes.",
      "The activation of betalain biosynthesis by BTF1 leads to the production of betalains, which are transported to chloroplasts for accumulation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The transcription factor that activates the betalain pathway is called BETAINE ALDEHYDE DEHYDROGENASE 1 (BvMYB1) or Betalain regulation factor 1 (BvMYB1), not BETAINE TRANSCRIPTION FACTOR 1 (BTF1).\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The activation of betalain biosynthesis by BTF1 leads to the production of betalains, which are not transported to chloroplasts for accumulation. Betalains accumulate in the vacuoles of plant cells.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-7b-chat-hf_response": "There are several technologies available for enriching phosphorylated peptides for global quantitative phosphoproteomic analyses. Here are some of the preferred technologies:\n1. TiO2-based enrichment: This method uses titanium dioxide (TiO2) to selectively capture phosphorylated peptides based on their higher affinity for the bead surface. TiO2-based enrichment is a widely used method for phosphoproteomics due to its high efficiency and specificity.\n2. Magnetic bead-based enrichment: This method uses magnetic beads conjugated with phosphopeptide-specific antibodies to capture phosphorylated peptides. The beads are then separated from the sample using a magnet, and the enriched phosphorylated peptides are analyzed.\n3. IMAC (Immobilized Metal Affinity Chromatography): IMAC is a widely used method for enriching phosphorylated peptides. It involves immobilizing a metal ion (e.g., iron or copper) onto a resin, which selectively binds to phosphorylated peptides. The bound peptides are then eluted and analyzed.\n4. Cation exchange chromatography: Cation exchange chromatography is a method that separates peptides based on their charge and size. It can be used to enrich phosphorylated peptides by using a cation exchange resin that selectively binds to positively charged phosphorylated peptides.\n5. Hydrophilic interaction liquid chromatography (HILIC): HILIC is a method that separates peptides based on their hydrophilicity. It can be used to enrich phosphorylated peptides by using a HILIC column that selectively binds to hydrophilic phosphorylated peptides.\n6. Reversed-phase HPLC: Reversed-phase HPLC is a method that separates peptides based on their hydrophobicity. It can be used to enrich phosphorylated peptides by using a reversed-phase column that selectively binds to hydrophobic phosphory",
    "llama-2-7b-chat-hf_fact_raw": "1. TiO2-based enrichment, which uses titanium dioxide to selectively capture phosphorylated peptides, is a widely used method in phosphoproteomics.\n2. Magnetic bead-based enrichment captures phosphorylated peptides using magnetic beads conjugated with phosphopeptide-specific antibodies.\n3. Immobilized Metal Affinity Chromatography (IMAC) enriches phosphorylated peptides by immobilizing a metal ion onto a resin, which then selectively binds to phosphorylated peptides.\n4. Cation exchange chromatography is used to enrich phosphorylated peptides, separating them based on charge and size using a cation exchange resin.\n5. Hydrophilic interaction liquid chromatography (HILIC) separates and enriches peptides based on hydrophilicity, utilizing a column that binds to hydrophilic phosphorylated peptides.",
    "llama-2-7b-chat-hf_fact": [
      "TiO2-based enrichment, which uses titanium dioxide to selectively capture phosphorylated peptides, is a widely used method in phosphoproteomics.",
      "Magnetic bead-based enrichment captures phosphorylated peptides using magnetic beads conjugated with phosphopeptide-specific antibodies.",
      "Immobilized Metal Affinity Chromatography (IMAC) enriches phosphorylated peptides by immobilizing a metal ion onto a resin, which then selectively binds to phosphorylated peptides.",
      "Cation exchange chromatography is used to enrich phosphorylated peptides, separating them based on charge and size using a cation exchange resin.",
      "Hydrophilic interaction liquid chromatography (HILIC) separates and enriches peptides based on hydrophilicity, utilizing a column that binds to hydrophilic phosphorylated peptides."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Cation exchange chromatography separates peptides based on their charge; however, it does not enrich phosphorylated peptides specifically. Rather, it can be used in conjunction with other enrichment methods to further purify the sample.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-7b-chat-hf_response": "The Palmini classification is a system used to rate the severity of intellectual disability (ID), which is also known as intellectual disability (ID), mentally retarded (MR), or cretinism. The Palmini classification system was developed by Dr. Riccardo Palmini and is used to classify individuals with ID based on their cognitive and adaptive functioning abilities.\nThe Palmini classification system uses the following categories:\n1. Level I - Mild ID: This category includes individuals with mild ID who have cognitive abilities within the normal range for most age-appropriate tasks, but may have difficulty with certain tasks or skills.\n2. Level II - Moderate ID: This category includes individuals with moderate ID who have cognitive abilities that are significantly below average, but are still within the normal range for most age-appropriate tasks.\n3. Level III - Severe ID: This category includes individuals with severe ID who have significant cognitive impairments that are below the normal range for most age-appropriate tasks.\n4. Level IV - Profound ID: This category includes individuals with profound ID who have severe cognitive impairments that are significantly below the normal range for most age-appropriate tasks.\n5. Level V - Severe Profound ID: This category includes individuals with severe profound ID who have the most significant cognitive impairments, which are significantly below the normal range for most age-appropriate tasks.\nIt's important to note that the Palmini classification system is not a diagnostic tool, but rather a way to rate the severity of intellectual disability. It's used to help healthcare professionals and educators understand the individual's cognitive and adaptive functioning abilities and to develop appropriate interventions and support strategies.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Palmini classification is used to rate the severity of intellectual disability.\n2. Dr. Riccardo Palmini developed the Palmini classification system.\n3. The system classifies individuals with intellectual disability based on cognitive and adaptive functioning abilities.\n4. The Palmini classification includes five levels of intellectual disability severity: Mild, Moderate, Severe, Profound, and Severe Profound ID.\n5. The Palmini classification system is not a diagnostic tool but is used to help understand cognitive and adaptive functioning for interventions and support strategies.",
    "llama-2-7b-chat-hf_fact": [
      "The Palmini classification is used to rate the severity of intellectual disability.",
      "Dr. Riccardo Palmini developed the Palmini classification system.",
      "The system classifies individuals with intellectual disability based on cognitive and adaptive functioning abilities.",
      "The Palmini classification includes five levels of intellectual disability severity: Mild, Moderate, Severe, Profound, and Severe Profound ID.",
      "The Palmini classification system is not a diagnostic tool but is used to help understand cognitive and adaptive functioning for interventions and support strategies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Palmeri classification, not the Palmini classification, is used to rate the severity of intellectual disability.\n2. FALSE [correction]: It would be Dr. Palmeri associated with the Palmeri classification system, not Dr. Riccardo Palmini.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-7b-chat-hf_response": "Yes, some viruses have been implicated in the etiology of human subacute thyroiditis. Here are some of the viruses that have been linked to this condition:\n1. Epstein-Barr virus (EBV): EBV is a common viral infection that can cause subacute thyroiditis. Studies have shown that EBV antigens are present in the thyroid glands of patients with subacute thyroiditis, and some studies have found that EBV infection can trigger an immune response that leads to inflammation of the thyroid gland.\n2. Herpesvirus: Herpesviruses, such as herpes simplex virus (HSV) and human herpesvirus 6 (HHV-6), have been linked to subacute thyroiditis. HSV has been shown to infect the thyroid gland and cause inflammation, while HHV-6 has been implicated in the development of autoimmune thyroid diseases, including subacute thyroiditis.\n3. Adenovirus: Adenovirus has been detected in the thyroid glands of patients with subacute thyroiditis, suggesting that it may play a role in the pathogenesis of this condition.\n4. Respiratory syncytial virus (RSV): RSV is a common respiratory virus that has been linked to subacute thyroiditis in some studies. However, the evidence is not consistent, and more research is needed to confirm this association.\n5. Influenza virus: Influenza virus has been implicated in the development of subacute thyroiditis, particularly in older adults.\nIt's worth noting that the exact role of viruses in the development of subacute thyroiditis is still not fully understood, and more research is needed to determine the extent to which viral infections contribute to the pathogenesis of this condition. However, it is clear that viruses can play a role in the inflammation and immune dysregulation that characterize subacute thyroiditis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Epstein-Barr virus (EBV) antigens are present in the thyroid glands of patients with subacute thyroiditis.\n2. Herpes simplex virus (HSV) can infect the thyroid gland and cause inflammation.\n3. Human herpesvirus 6 (HHV-6) has been implicated in the development of autoimmune thyroid diseases, including subacute thyroiditis.\n4. Adenovirus has been detected in the thyroid glands of patients with subacute thyroiditis.\n5. Influenza virus has been implicated in the development of subacute thyroiditis, particularly in older adults.",
    "llama-2-7b-chat-hf_fact": [
      "Epstein-Barr virus (EBV) antigens are present in the thyroid glands of patients with subacute thyroiditis.",
      "Herpes simplex virus (HSV) can infect the thyroid gland and cause inflammation.",
      "Human herpesvirus 6 (HHV-6) has been implicated in the development of autoimmune thyroid diseases, including subacute thyroiditis.",
      "Adenovirus has been detected in the thyroid glands of patients with subacute thyroiditis.",
      "Influenza virus has been implicated in the development of subacute thyroiditis, particularly in older adults."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without a specific reference to a study or scientific data, it is impossible to confirm the presence of Epstein-Barr virus (EBV) antigens in the thyroid glands of patients with subacute thyroiditis.\n2. FALSE [correction]: Herpes simplex virus (HSV) typically causes infections in mucous membranes and the skin and is not commonly known to infect the thyroid gland or cause thyroiditis. \n3. UNKNOWN: Human herpesvirus 6 (HHV-6) has been studied in connection with various diseases, but its direct implication in the development of autoimmune thyroid diseases, including subacute thyroiditis, requires specific reference to supporting scientific studies.\n4. UNKNOWN: Adenoviruses are known to cause a range of illnesses, but a definitive link to their presence in the thyroid glands of patients with subacute thyroiditis would require specific scientific evidence.\n5. UNKNOWN: While viruses such as influenza can trigger thyroiditis, more information or specific research would be needed to support this claim, particularly the mention that it affects predominantly older adults.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-7b-chat-hf_response": "Yes, STAT3 (Signal Transducer and Activator of Transcription 3) is involved in EIF2AK2-dependent suppression of autophagy.\nEIF2AK2 (Eukaryotic Translation Initiation Factor 2-Associated Kinase 2) is a kinase that phosphorylates and inhibits EIF2, a key regulator of protein synthesis and autophagy. Phosphorylation of EIF2 by EIF2AK2 leads to the inhibition of protein synthesis and the induction of autophagy.\nSTAT3 (Signal Transducer and Activator of Transcription 3) is a transcription factor that plays a crucial role in the regulation of inflammation and immune responses. STAT3 is activated by a variety of cytokines, including interleukin-6 (IL-6), and upon activation, it translocates to the nucleus where it regulates the expression of target genes involved in inflammation and immune responses.\nRecent studies have shown that EIF2AK2 and STAT3 interact and coordinate to regulate autophagy. EIF2AK2 phosphorylation of EIF2 inhibits protein synthesis and induces autophagy, which is then further regulated by STAT3. STAT3 can either enhance or inhibit autophagy, depending on the context. In some cases, STAT3 can promote autophagy by activating the expression of autophagy-related genes, while in other cases, it can inhibit autophagy by repressing the expression of autophagy-related genes.\nIn particular, STAT3 has been shown to repress the expression of the autophagy-related gene Atg7 in response to IL-6 signaling. IL-6 signaling activates STAT3, which then binds to the Atg7 promoter and represses its transcription, leading to the inhibition of autophagy.\nIn summary, EIF2AK2-dependent suppression of autophagy is involved in the regulation of STAT3 activity, and STAT3 can either enhance or inhibit autophagy depending on the context.",
    "llama-2-7b-chat-hf_fact_raw": "1. STAT3 is involved in EIF2AK2-dependent suppression of autophagy.\n2. EIF2AK2 phosphorylates and inhibits EIF2, leading to the inhibition of protein synthesis and the induction of autophagy.\n3. STAT3 is a transcription factor that is activated by interleukin-6 (IL-6) and other cytokines.\n4. STAT3 regulates the expression of genes involved in inflammation and immune responses.\n5. IL-6 signaling can lead to STAT3 repression of the autophagy-related gene Atg7, resulting in the inhibition of autophagy.",
    "llama-2-7b-chat-hf_fact": [
      "STAT3 is involved in EIF2AK2-dependent suppression of autophagy.",
      "EIF2AK2 phosphorylates and inhibits EIF2, leading to the inhibition of protein synthesis and the induction of autophagy.",
      "STAT3 is a transcription factor that is activated by interleukin-6 (IL-6) and other cytokines.",
      "STAT3 regulates the expression of genes involved in inflammation and immune responses.",
      "IL-6 signaling can lead to STAT3 repression of the autophagy-related gene Atg7, resulting in the inhibition of autophagy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: STAT3 is indeed involved in EIF2AK2-dependent suppression of autophagy. STAT3 can be activated and can have a role in autophagy regulation.\n2. FALSE [correction]: EIF2AK2 phosphorylates EIF2α, not EIF2, which indeed leads to inhibition of protein synthesis, but this phosphorylation is generally known to activate stress responses that can include autophagy, not to its inhibition.\n3. TRUE: STAT3 is a transcription factor and is activated by cytokines such as interleukin-6 (IL-6).\n4. TRUE: STAT3 is known to regulate genes involved in inflammation and immune responses, among other functions.\n5. TRUE: IL-6 signaling through STAT3 can lead to the repression of autophagy-related genes, such as Atg7, which would result in the inhibition of autophagy.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-7b-chat-hf_response": "Theatre is a software tool designed for genomic analysis, particularly for the analysis of ChIP-seq (Chromatin Immunoprecipitation sequencing) data. It is used to identify regions of the genome that are bound by specific proteins or DNA-binding proteins, which play a crucial role in regulating gene expression. Here are some of the key uses of Theatre software for genomic analysis:\n1. Peak calling: Theatre can be used to identify regions of the genome that are enriched with a specific protein or DNA-binding protein. These regions are called peaks, and they are typically associated with regulatory elements such as promoters, enhancers, and silencers.\n2. Peak annotation: Once peaks are identified, Theatre can be used to annotate them by predicting the type of protein or DNA-binding protein that is bound at each peak. This information can be used to understand the functional role of each peak.\n3. Motif discovery: Theatre can be used to identify specific DNA sequences (motifs) that are associated with a particular protein or DNA-binding protein. These motifs can be used to understand the binding preferences of the protein and to predict the function of the associated peaks.\n4. Chromatin structure analysis: Theatre can be used to analyze the three-dimensional structure of chromatin by integrating ChIP-seq data with other genomic data such as histone modification profiles. This can provide insights into how proteins and DNA-binding proteins interact with chromatin to regulate gene expression.\n5. Gene regulatory network analysis: Theatre can be used to infer gene regulatory networks by identifying the interactions between transcription factors and their target genes. This can provide insights into how gene expression is regulated in different cell types and under different conditions.\n6. Disease research: Theatre can be used to identify genetic variations that are associated with diseases by analyzing ChIP-seq data from diseased tissues compared to healthy tissues. This can provide insights into how genetic variations affect gene expression and how this contributes to disease.\n7. Drug discovery: Theatre can be used to identify potential drug targets by identifying proteins that are associated with specific diseases. This can provide insights into how these proteins can be targeted by drugs to treat disease.\n8. Personalized medicine: Theatre can be used",
    "llama-2-7b-chat-hf_fact_raw": "1. Theatre is a software tool used for genomic analysis, especially for analyzing ChIP-seq data.\n2. It assists in identifying genomic regions enriched with specific proteins or DNA-binding proteins, known as peaks.\n3. Theatre can annotate peaks by predicting the type of protein bound at each peak.\n4. The software is capable of identifying specific DNA sequences (motifs) that are associated with particular proteins or DNA-binding proteins.\n5. Theatre can be utilized to infer gene regulatory networks by identifying interactions between transcription factors and their target genes.",
    "llama-2-7b-chat-hf_fact": [
      "Theatre is a software tool used for genomic analysis, especially for analyzing ChIP-seq data.",
      "It assists in identifying genomic regions enriched with specific proteins or DNA-binding proteins, known as peaks.",
      "Theatre can annotate peaks by predicting the type of protein bound at each peak.",
      "The software is capable of identifying specific DNA sequences (motifs) that are associated with particular proteins or DNA-binding proteins.",
      "Theatre can be utilized to infer gene regulatory networks by identifying interactions between transcription factors and their target genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Theatre does not appear to be a recognized software tool for genomic analysis. A widely known tool for analyzing ChIP-seq data is MACS (Model-based Analysis of ChIP-Seq).\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nGiven that the existence of \"Theatre\" as a software tool for genomic analysis is not recognized in the given context, it's not possible to determine the accuracy of statements 2 through 5. They may refer to capabilities typical of genomic analysis software, but without accurate information or context about \"Theatre,\" their truth cannot be verified.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-7b-chat-hf_response": "The execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences depends on the specific implementation and the size of the sequences. However, here are some general complexity bounds for the Smith-Waterman algorithm:\n* Time complexity: O(n^2), where n is the length of the longer sequence.\n* Space complexity: O(n), where n is the length of the longer sequence.\nThe time complexity of the Smith-Waterman algorithm grows quadratically with the length of the sequences, making it computationally expensive for large sequences. However, the algorithm is still widely used in many applications due to its high accuracy and versatility.\nIt's worth noting that there are several optimizations and variations of the Smith-Waterman algorithm that can improve its performance, such as:\n* Using a sliding window approach instead of scanning the entire sequence.\n* Using a hash table to store the similarity scores for each position in the sequence, which can reduce the time complexity to O(n).\n* Using a parallel or distributed computing approach to speed up the computation.\nOverall, while the Smith-Waterman algorithm has a high time complexity, it remains a widely used and important tool in bioinformatics and computational biology.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Smith-Waterman algorithm has a time complexity of O(n^2), where n is the length of the longer sequence.\n2. The space complexity of the Smith-Waterman algorithm is O(n), where n is the length of the longer sequence.\n3. The time complexity of Smith-Waterman grows quadratically with the length of the sequences.\n4. There are optimizations and variations of the Smith-Waterman algorithm that can potentially reduce time complexity to O(n).\n5. The Smith-Waterman algorithm is used in bioinformatics and computational biology.",
    "llama-2-7b-chat-hf_fact": [
      "The Smith-Waterman algorithm has a time complexity of O(n^2), where n is the length of the longer sequence.",
      "The space complexity of the Smith-Waterman algorithm is O(n), where n is the length of the longer sequence.",
      "The time complexity of Smith-Waterman grows quadratically with the length of the sequences.",
      "There are optimizations and variations of the Smith-Waterman algorithm that can potentially reduce time complexity to O(n).",
      "The Smith-Waterman algorithm is used in bioinformatics and computational biology."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The Smith-Waterman algorithm indeed has a time complexity of O(n^2), where n is the length of the longer sequence being compared.\n2. FALSE [correction]: The space complexity of the Smith-Waterman algorithm is also O(n^2), since it requires creating a matrix where the number of cells is the product of the lengths of the two sequences being aligned.\n3. TRUE: The time complexity of the Smith-Waterman algorithm grows quadratically with the length of the sequences, which is consistent with its O(n^2) time complexity.\n4. TRUE: There are optimizations and heuristic approaches to the Smith-Waterman algorithm that can potentially reduce its time complexity for certain cases, although these optimizations do not apply to all scenarios or change the worst-case time complexity.\n5. TRUE: The Smith-Waterman algorithm is widely used in bioinformatics and computational biology, particularly for local sequence alignment.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-7b-chat-hf_response": "FLVCR1 (Flavocyclin Related Protein 1) is a member of the Solute Carrier (SLC) family of transmembrane transporters. Specifically, FLVCR1 is a member of the SLC16 subfamily, which is also known as the ATP-binding cassette (ABC) transporter superfamily.\nThe SLC16 subfamily includes a variety of membrane proteins that are involved in the transport of small molecules across cell membranes, including sugars, amino acids, and neurotransmitters. FLVCR1 is specifically classified as an SLC16A10 protein, as it is expressed primarily in the brain and is involved in the transport of the neurotransmitter GABA (gamma-aminobutyric acid).",
    "llama-2-7b-chat-hf_fact_raw": "1. FLVCR1 stands for Flavocyclin Related Protein 1.\n2. FLVCR1 is a member of the Solute Carrier (SLC) family of transmembrane transporters.\n3. FLVCR1 is part of the SLC16 subfamily.\n4. The SLC16 subfamily is also known as the ATP-binding cassette (ABC) transporter superfamily.\n5. FLVCR1 is classified as an SLC16A10 protein involved in the transport of the neurotransmitter GABA.",
    "llama-2-7b-chat-hf_fact": [
      "FLVCR1 stands for Flavocyclin Related Protein 1.",
      "FLVCR1 is a member of the Solute Carrier (SLC) family of transmembrane transporters.",
      "FLVCR1 is part of the SLC16 subfamily.",
      "The SLC16 subfamily is also known as the ATP-binding cassette (ABC) transporter superfamily.",
      "FLVCR1 is classified as an SLC16A10 protein involved in the transport of the neurotransmitter GABA."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: FLVCR1 is not a member of the Solute Carrier (SLC) family of transmembrane transporters, but rather a member of the Major Facilitator Superfamily (MFS).\n3. FALSE [correction]: FLVCR1 is part of the Major Facilitator Superfamily (MFS), not the SLC16 subfamily.\n4. FALSE [correction]: The SLC16 subfamily is not known as the ATP-binding cassette (ABC) transporter superfamily. The ABC transporter superfamily is a different class of transporters. The SLC16 subfamily is also known as the Monocarboxylate Transporter (MCT) family.\n5. FALSE [correction]: FLVCR1 is not classified as an SLC16A10 protein neither involved in the transport of the neurotransmitter GABA. FLVCR1 is known to be involved in the export of heme from cells. SLC16A10 (also known as MCT10) is involved in the transport of aromatic amino acids and unrelated to FLVCR1.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_response": "GATA-1 is a transcription factor that plays a crucial role in regulating gene expression during erythropoiesis, particularly in the development and maturation of red blood cells. The biotinylation tagging approach has been used to identify GATA-1 interacting partners, and here are some of the key partners that have been identified:\n1. Runx1: Runx1 is a transcription factor that collaborates with GATA-1 to regulate the expression of genes involved in erythropoiesis. Biotinylation tagging has shown that Runx1 interacts with GATA-1 and is required for the proper localization of GATA-1 to the nucleus.\n2. Tal1: Tal1 is another transcription factor that interacts with GATA-1 and is involved in the regulation of erythropoiesis. Biotinylation tagging has shown that Tal1 and GATA-1 form a complex and are required for the proper differentiation of red blood cells.\n3. BCL11A: BCL11A is a transcription factor that regulates the expression of genes involved in the differentiation of red blood cells. Biotinylation tagging has shown that BCL11A interacts with GATA-1 and is required for the proper differentiation of red blood cells.\n4. KLF1: KLF1 is a transcription factor that regulates the expression of genes involved in the differentiation of red blood cells. Biotinylation tagging has shown that KLF1 interacts with GATA-1 and is required for the proper differentiation of red blood cells.\n5. FOG-1: FOG-1 is a transcription factor that regulates the expression of genes involved in the differentiation of red blood cells. Biotinylation tagging has shown that FOG-1 interacts with GATA-1 and is required for the proper differentiation of red blood cells.\n6. CBFA2T1: CBFA2T1 is a transcription factor that regulates the expression of genes involved in the differentiation of red blood cells. Biotinylation tagging has shown that CBFA2T1 interacts with GATA-1 and is required for the proper differentiation of red blood cells.\n7.",
    "llama-2-7b-chat-hf_fact_raw": "1. The biotinylation tagging approach has been used to identify GATA-1 interacting partners.\n2. Runx1 is a transcription factor that interacts with GATA-1 to regulate gene expression during erythropoiesis.\n3. The biotinylation tagging approach has shown that Tal1 interacts with GATA-1.\n4. Biotinylation tagging indicates that BCL11A interacts with GATA-1.\n5. FOG-1 has been shown to interact with GATA-1 through the biotinylation tagging method.",
    "llama-2-7b-chat-hf_fact": [
      "The biotinylation tagging approach has been used to identify GATA-1 interacting partners.",
      "Runx1 is a transcription factor that interacts with GATA-1 to regulate gene expression during erythropoiesis.",
      "The biotinylation tagging approach has shown that Tal1 interacts with GATA-1.",
      "Biotinylation tagging indicates that BCL11A interacts with GATA-1.",
      "FOG-1 has been shown to interact with GATA-1 through the biotinylation tagging method."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-7b-chat-hf_response": "TAF10 (TATA box-binding protein-associated factor 10) is a subunit of the TFIID complex, which is a key transcriptional regulatory complex that recognizes and binds to the TATA box element in the promoter region of eukaryotic genes. GATA1 is a transcription factor that plays a crucial role in regulating gene expression in hematopoietic cells, particularly in the development and differentiation of blood cells.\nInterestingly, TAF10 and GATA1 have been shown to interact and regulate gene expression in a coordinated manner. When TAF10 interacts with GATA1, it enhances the ability of GATA1 to recruit other transcriptional regulators and activate gene transcription. This interaction is important for the proper regulation of hematopoiesis, as it allows GATA1 to activate the expression of genes involved in blood cell development and differentiation.\nStudies have shown that TAF10 and GATA1 interact in several ways:\n1. TAF10 binds to the GATA1 protein and enhances its ability to recruit other transcriptional regulators.\n2. TAF10 and GATA1 cooperate to activate the transcription of target genes involved in hematopoiesis.\n3. TAF10 and GATA1 regulate the expression of genes involved in the cell cycle and proliferation of hematopoietic cells.\n4. TAF10 and GATA1 are required for the maintenance of hematopoietic stem cell self-renewal and multipotency.\nIn summary, the interaction between TAF10 and GATA1 is crucial for the proper regulation of hematopoiesis, as it allows GATA1 to activate the expression of genes involved in blood cell development and differentiation, and ensures the maintenance of hematopoietic stem cell self-renewal and multipotency.",
    "llama-2-7b-chat-hf_fact_raw": "1. TAF10 is a subunit of the TFIID complex which is involved in recognizing and binding to the TATA box element in the promoter region of eukaryotic genes.\n2. GATA1 is a transcription factor that is important in regulating gene expression in hematopoietic cells, particularly in blood cell development and differentiation.\n3. TAF10 enhances GATA1's ability to recruit other transcriptional regulators when they interact.\n4. The interaction between TAF10 and GATA1 is crucial for the proper regulation of hematopoiesis.\n5. TAF10 and GATA1 are necessary for the maintenance of hematopoietic stem cell self-renewal and multipotency.",
    "llama-2-7b-chat-hf_fact": [
      "TAF10 is a subunit of the TFIID complex which is involved in recognizing and binding to the TATA box element in the promoter region of eukaryotic genes.",
      "GATA1 is a transcription factor that is important in regulating gene expression in hematopoietic cells, particularly in blood cell development and differentiation.",
      "TAF10 enhances GATA1's ability to recruit other transcriptional regulators when they interact.",
      "The interaction between TAF10 and GATA1 is crucial for the proper regulation of hematopoiesis.",
      "TAF10 and GATA1 are necessary for the maintenance of hematopoietic stem cell self-renewal and multipotency."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nRationale:\n1. TAF10 is indeed a subunit of the TFIID complex, a key component in eukaryotic transcription initiation that is involved in recognizing and binding to the TATA box element in promoter regions.\n2. GATA1 is a well-known transcription factor that plays a critical role in the regulation of gene expression during blood cell development and differentiation, especially within hematopoietic cells.\n3. While TAF10 and GATA1 are both involved in gene regulation, the specific statement about TAF10 enhancing GATA1's ability to recruit other transcriptional regulators requires more context to confirm or refute.\n4. Similarly, the claim about the criticality of TAF10 and GATA1 interaction in hematopoiesis regulation is too specific without accompanying scientific evidence provided.\n5. The necessity of TAF10 and GATA1 for hematopoietic stem cell self-renewal and multipotency is a detailed assertion that would require empirical evidence to validate, making it uncertain without further information.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-7b-chat-hf_response": "Yes, there are several decision support systems (DSS) available for chronic pain management. These systems are designed to help healthcare providers make informed decisions about the management of chronic pain, taking into account the individual needs and preferences of the patient. Some examples of DSS for chronic pain management include:\n1. Chronic Pain Management Decision Support System (CPMDSS): This DSS was developed by the University of Washington and provides a comprehensive framework for managing chronic pain. It includes clinical guidelines, treatment recommendations, and a decision-making algorithm to help healthcare providers make informed decisions about pain management.\n2. Pain Management Decision Support System (PMDSS): This DSS was developed by the University of California, Los Angeles (UCLA) and provides a comprehensive approach to chronic pain management. It includes a clinical decision support module, a patient education module, and a research module to help healthcare providers stay up-to-date on the latest research and best practices in chronic pain management.\n3. PainCare: This DSS was developed by the University of Michigan and provides a comprehensive framework for managing chronic pain. It includes clinical guidelines, treatment recommendations, and a decision-making algorithm to help healthcare providers make informed decisions about pain management.\n4. PAIN-Q: This DSS was developed by the University of California, San Francisco (UCSF) and provides a comprehensive approach to chronic pain management. It includes a clinical decision support module, a patient education module, and a research module to help healthcare providers stay up-to-date on the latest research and best practices in chronic pain management.\n5. Chronic Pain Management System (CPMS): This DSS was developed by the University of Florida and provides a comprehensive framework for managing chronic pain. It includes clinical guidelines, treatment recommendations, and a decision-making algorithm to help healthcare providers make informed decisions about pain management.\n6. Pain Management Algorithm: This DSS was developed by the University of Texas Southwestern Medical Center and provides a step-by-step approach to managing chronic pain. It includes a clinical decision support module, a patient education module, and a research module to help healthcare providers stay up-to-date on the latest research and best",
    "llama-2-7b-chat-hf_fact_raw": "1. The Chronic Pain Management Decision Support System (CPMDSS) was developed by the University of Washington.\n2. The Pain Management Decision Support System (PMDSS) was developed by the University of California, Los Angeles (UCLA).\n3. The PainCare decision support system was developed by the University of Michigan.\n4. The PAIN-Q decision support system was developed by the University of California, San Francisco (UCSF).\n5. The Chronic Pain Management System (CPMS) was developed by the University of Florida.",
    "llama-2-7b-chat-hf_fact": [
      "The Chronic Pain Management Decision Support System (CPMDSS) was developed by the University of Washington.",
      "The Pain Management Decision Support System (PMDSS) was developed by the University of California, Los Angeles (UCLA).",
      "The PainCare decision support system was developed by the University of Michigan.",
      "The PAIN-Q decision support system was developed by the University of California, San Francisco (UCSF).",
      "The Chronic Pain Management System (CPMS) was developed by the University of Florida."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information on the development origins of these decision support systems, I cannot accurately confirm or correct the statements provided. The development of such systems could be done by any number of universities, research teams, or collaborations, and without concrete data or references, their true origins remain unknown.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-7b-chat-hf_response": "Angiogenin is a protein that is primarily localized to the endoplasmic reticulum (ER) and the Golgi apparatus in various cell types, including endothelial cells, fibroblasts, and immune cells.\n1. Endoplasmic reticulum (ER): Angiogenin is primarily localized to the ER, where it plays a role in the regulation of ER-associated degradation (ERAD) and the processing of misfolded proteins.\n2. Golgi apparatus: Angiogenin is also found in the Golgi apparatus, where it may play a role in the regulation of protein transport and processing.\nIn addition to its ER and Golgi localization, angiogenin has been shown to be secreted from cells and to accumulate in the extracellular space, where it can interact with other proteins and play a role in various cellular processes, including angiogenesis and inflammation.\nIn summary, the subcellular localization of angiogenin is primarily the endoplasmic reticulum and the Golgi apparatus, but it can also be secreted and accumulate in the extracellular space.",
    "llama-2-7b-chat-hf_fact_raw": "1. Angiogenin is primarily localized to the endoplasmic reticulum (ER) in various cell types.\n2. Angiogenin is also found in the Golgi apparatus in various cell types.\n3. Angiogenin can be secreted from cells.\n4. Angiogenin can accumulate in the extracellular space.\n5. Angiogenin plays a role in angiogenesis and inflammation.",
    "llama-2-7b-chat-hf_fact": [
      "Angiogenin is primarily localized to the endoplasmic reticulum (ER) in various cell types.",
      "Angiogenin is also found in the Golgi apparatus in various cell types.",
      "Angiogenin can be secreted from cells.",
      "Angiogenin can accumulate in the extracellular space.",
      "Angiogenin plays a role in angiogenesis and inflammation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Angiogenin is primarily localized to the nucleolus and cytoplasm in various cell types, not the endoplasmic reticulum (ER).\n2. FALSE [correction]: While angiogenin may be involved in processes in the Golgi apparatus, it is not primarily localized there; instead, it's mainly found in the nucleolus and cytoplasm.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-7b-chat-hf_response": "Ranolazine is a drug that has been shown to have a direct effect on kinase signaling activation in the heart. Kinases are enzymes that play a key role in various cellular signaling pathways, including those involved in cardiac function. Ranolazine has been shown to inhibit the activity of certain kinases, including the protein kinase C (PKC) isoforms, which are involved in the regulation of cardiac contraction and relaxation.\nRanolazine's inhibition of PKC isoforms can lead to several effects on kinase signaling activation in the heart, including:\n1. Reduced phosphorylation of Akt: Akt is a key kinase that plays a critical role in cell survival and metabolism. Ranolazine has been shown to reduce the phosphorylation of Akt in the heart, which can lead to decreased cell survival and function.\n2. Increased phosphorylation of GSK-3β: Glycogen synthase kinase-3 beta (GSK-3β) is a kinase that is involved in the regulation of various cellular processes, including cell survival and metabolism. Ranolazine has been shown to increase the phosphorylation of GSK-3β in the heart, which can lead to decreased cell survival and function.\n3. Reduced phosphorylation of ERK1/2: Extracellular signal-regulated kinase 1 and 2 (ERK1/2) are kinases that are involved in the regulation of various cellular processes, including cell proliferation and differentiation. Ranolazine has been shown to reduce the phosphorylation of ERK1/2 in the heart, which can lead to decreased cell proliferation and differentiation.\n4. Increased phosphorylation of JNK: C-Jun N-terminal kinase (JNK) is a kinase that is involved in the regulation of various cellular processes, including cell survival and stress responses. Ranolazine has been shown to increase the phosphorylation of JNK in the heart, which can lead to increased cell survival and stress responses.\nOverall, ranolazine's effects on kinase signaling activation in the heart can lead to decreased cardiac function",
    "llama-2-7b-chat-hf_fact_raw": "1. Ranolazine inhibits the activity of certain kinases, including protein kinase C (PKC) isoforms.\n2. Ranolazine has been shown to reduce the phosphorylation of Akt in the heart.\n3. Ranolazine increases the phosphorylation of GSK-3β in the heart.\n4. Ranolazine reduces the phosphorylation of ERK1/2 in the heart.\n5. Ranolazine has been shown to increase the phosphorylation of JNK in the heart.",
    "llama-2-7b-chat-hf_fact": [
      "Ranolazine inhibits the activity of certain kinases, including protein kinase C (PKC) isoforms.",
      "Ranolazine has been shown to reduce the phosphorylation of Akt in the heart.",
      "Ranolazine increases the phosphorylation of GSK-3β in the heart.",
      "Ranolazine reduces the phosphorylation of ERK1/2 in the heart.",
      "Ranolazine has been shown to increase the phosphorylation of JNK in the heart."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ranolazine is primarily known for its effects on cardiac metabolism and inhibiting the late phase of the inward sodium current (INa), not for inhibiting the activity of certain kinases such as protein kinase C (PKC) isoforms.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe specific molecular effects of ranolazine on the phosphorylation states of Akt, GSK-3β, ERK1/2, or JNK in the heart are not common knowledge and would require specific scientific evidence to confirm. Without the context of a specific study or source detailing these effects, the truthfulness of these statements cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-7b-chat-hf_response": "Yes, the regulation of Vsr endonuclease is independent of the growth phase of bacteria. Vsr endonuclease is a type II toxin-antitoxin system that is regulated by the Vibrio cholerae virulence factor VipA. VipA is a small protein that inhibits the activity of Vsr endonuclease, and its expression is tightly regulated in response to changes in the environment and the host cell.\nVipA is expressed in response to several environmental cues, including changes in the availability of nutrients, pH, and temperature. When VipA levels are high, it inhibits the activity of Vsr endonuclease, preventing it from cleaving the DNA and causing lysis of the host cell. Conversely, when VipA levels are low, Vsr endonuclease is activated, and the host cell is lysed.\nThe regulation of Vsr endonuclease by VipA is independent of the growth phase of the bacteria. VipA levels are constantly regulated in response to changes in the environment, and Vsr endonuclease activity is only activated when VipA levels are low. This means that Vsr endonuclease can be activated at any time during the bacterial life cycle, regardless of the growth phase.\nIn summary, the regulation of Vsr endonuclease by VipA is independent of the growth phase of bacteria, and Vsr endonuclease can be activated at any time in response to changes in the environment and the availability of nutrients.",
    "llama-2-7b-chat-hf_fact_raw": "1. The regulation of Vsr endonuclease is independent of the growth phase of bacteria.\n2. Vsr endonuclease is regulated by the Vibrio cholerae virulence factor VipA.\n3. VipA expression is regulated in response to environmental changes such as nutrient availability, pH, and temperature.\n4. High levels of VipA inhibit the activity of Vsr endonuclease.\n5. Low levels of VipA allow Vsr endonuclease to be activated and can cause lysis of the host cell.",
    "llama-2-7b-chat-hf_fact": [
      "The regulation of Vsr endonuclease is independent of the growth phase of bacteria.",
      "Vsr endonuclease is regulated by the Vibrio cholerae virulence factor VipA.",
      "VipA expression is regulated in response to environmental changes such as nutrient availability, pH, and temperature.",
      "High levels of VipA inhibit the activity of Vsr endonuclease.",
      "Low levels of VipA allow Vsr endonuclease to be activated and can cause lysis of the host cell."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE - VipA expression is indeed regulated in response to environmental changes such as nutrient availability, pH, and temperature, which is consistent with many bacterial virulence factors.\n4. UNKNOWN\n5. UNKNOWN\n\nThe regulation of Vsr endonuclease and its relationship with VipA is specific scientific information that typically requires reference to particular scientific studies or databases. Without specific context or source material to verify these statements, it is not possible to accurately determine the truthfulness of statements 1, 2, 4, and 5.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several computational tools and methods that can be used for the prediction of beta-barrel transmembrane proteins. Here are some of the commonly used tools:\n1. TMHMM: TMHMM is a widely used tool for predicting the structure and function of transmembrane proteins. It can predict the topology of beta-barrel proteins and also identify the transmembrane helices.\n2. TopoPred: TopoPred is a tool that predicts the topology of transmembrane proteins, including beta-barrel proteins. It uses a combination of sequence and structural information to make predictions.\n3. SignalP: SignalP is a tool that predicts the signal peptides in proteins, including beta-barrel proteins. It can help identify the N-terminal region of the protein that is involved in protein targeting and transport across the membrane.\n4. PredictProtein: PredictProtein is a tool that can predict various features of transmembrane proteins, including beta-barrel proteins. It can predict the topology, secondary structure, and transmembrane helices of the protein.\n5. PRED-TMB: PRED-TMB is a tool that predicts the transmembrane helices of beta-barrel proteins. It uses a combination of sequence and structural information to make predictions.\n6. TM-Align: TM-Align is a tool that aligns multiple protein structures with each other, including beta-barrel proteins. It can help identify the transmembrane helices and their orientation in the membrane.\n7. Membrane Protein Structure Prediction (MPSP): MPSP is a tool that predicts the structure of transmembrane proteins, including beta-barrel proteins. It uses a combination of sequence and structural information to make predictions.\n8. PHBob: PHBob is a tool that predicts the transmembrane helices of beta-barrel proteins. It uses a combination of sequence and structural information to make predictions.\n9. TM-Coffee: TM-Coffee is a tool that predicts the transmembrane helices of beta-barrel proteins. It uses a combination of sequence and structural information to make predictions.\n10. TMHMM-2.",
    "llama-2-7b-chat-hf_fact_raw": "1. TMHMM is used for predicting the structure and function of transmembrane proteins, including the prediction of topology and identifying transmembrane helices of beta-barrel proteins.\n2. TopoPred predicts the topology of transmembrane proteins, utilizing sequence and structural information, and is applicable to beta-barrel proteins.\n3. SignalP predicts signal peptides in proteins and is applicable to beta-barrel proteins for identifying the N-terminal region involved in targeting and transport across membranes.\n4. PredictProtein can predict various features of transmembrane proteins, including beta-barrel proteins' topology, secondary structure, and transmembrane helices.\n5. PRED-TMB is a tool that predicts transmembrane helices in beta-barrel proteins by using sequence and structural information.",
    "llama-2-7b-chat-hf_fact": [
      "TMHMM is used for predicting the structure and function of transmembrane proteins, including the prediction of topology and identifying transmembrane helices of beta-barrel proteins.",
      "TopoPred predicts the topology of transmembrane proteins, utilizing sequence and structural information, and is applicable to beta-barrel proteins.",
      "SignalP predicts signal peptides in proteins and is applicable to beta-barrel proteins for identifying the N-terminal region involved in targeting and transport across membranes.",
      "PredictProtein can predict various features of transmembrane proteins, including beta-barrel proteins' topology, secondary structure, and transmembrane helices.",
      "PRED-TMB is a tool that predicts transmembrane helices in beta-barrel proteins by using sequence and structural information."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TMHMM is used for predicting the topology of transmembrane proteins, including identifying transmembrane helices, but it does not predict the structure and function of beta-barrel proteins, as it is designed primarily for alpha-helical transmembrane proteins.\n2. UNKNOWN: There are various tools available for the prediction of transmembrane protein topology, but without further information, the existence and workings of \"TopoPred\" for predicting the topology of beta-barrel proteins specifically cannot be confirmed or denied.\n3. TRUE: SignalP is indeed used to predict signal peptides in proteins, and such peptides often serve in targeting and transport across membranes, but whether it is applicable specifically to beta-barrel proteins may require more specific knowledge about versions and capabilities of the tool.\n4. UNKNOWN: PredictProtein is a suite of tools designed to predict multiple features of proteins, but without more specific information it's not possible to confirm whether it can predict beta-barrel proteins' topology, secondary structure, and transmembrane helices specifically.\n5. TRUE: PRED-TMBB (assuming the intended tool name was meant to be PRED-TMBB and not PRED-TMB) is a prediction tool designed specifically to identify transmembrane strands in beta-barrel transmembrane proteins using sequence data.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-7b-chat-hf_response": "Galassi classification is used to classify dissociative disorders, specifically dissociative identity disorder (DID), which was previously known as multiple personality disorder.\nThe Galassi classification system was developed by Dr. Salvatore Galassi and colleagues in 2010 as an alternative to the traditional DSM-IV criteria for diagnosing DID. The system is based on the idea that DID is characterized by the presence of two or more distinct identities or personalities, which are referred to as \"alters.\"\nThe Galassi classification system includes the following categories:\n1. Type A: Simple DID - This is the most common type of DID, where the individual has two or more distinct alters with relatively distinct personalities, but they are able to cooperate and communicate with each other.\n2. Type B: Complex DID - This type of DID is characterized by the presence of multiple alters with more complex and overlapping personalities, and the alters may have difficulty cooperating or communicating with each other.\n3. Type C: Dissociative Subtype - This subtype is characterized by the presence of a single alter that is dominant and has a distinct personality, but the individual may also experience dissociative symptoms and dissociative episodes.\n4. Type D: Trauma-related DID - This type of DID is characterized by the presence of multiple alters that are related to specific traumatic events, and the alters may have different personalities and memories related to those events.\nThe Galassi classification system is considered to be more nuanced and comprehensive than the traditional DSM-IV criteria for diagnosing DID, and it has been shown to be more accurate in identifying the specific features of DID in clinical populations. However, it is important to note that the Galassi classification system is not yet widely adopted in clinical practice, and the diagnosis of DID remains a complex and challenging task for clinicians.",
    "llama-2-7b-chat-hf_fact_raw": "1. Galassi classification is used to classify dissociative identity disorder (DID).\n2. Galassi classification system was developed by Dr. Salvatore Galassi and colleagues in 2010.\n3. The Galassi system categorizes DID into four types: Simple DID (Type A), Complex DID (Type B), Dissociative Subtype (Type C), and Trauma-related DID (Type D).\n4. The system suggests that Simple DID involves two or more distinct alters that can cooperate and communicate with each other.\n5. The Galassi classification system is not yet widely adopted in clinical practice.",
    "llama-2-7b-chat-hf_fact": [
      "Galassi classification is used to classify dissociative identity disorder (DID).",
      "Galassi classification system was developed by Dr. Salvatore Galassi and colleagues in 2010.",
      "The Galassi system categorizes DID into four types: Simple DID (Type A), Complex DID (Type B), Dissociative Subtype (Type C), and Trauma-related DID (Type D).",
      "The system suggests that Simple DID involves two or more distinct alters that can cooperate and communicate with each other.",
      "The Galassi classification system is not yet widely adopted in clinical practice."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Galassi classification is used to categorize meniscal tears in the knee, not dissociative identity disorder (DID).\n2. UNKNOWN\n3. FALSE [correction]: These categories might refer to a different classification system or concept, as the Galassi classification relates to meniscal tears, not DID.\n4. FALSE [correction]: As previously stated, the Galassi classification deals with meniscal tears, so it does not involve \"alters\" or other aspects of DID.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-7b-chat-hf_response": "Shapiro syndrome, also known as Shapiro-Omenn syndrome, is a rare genetic disorder characterized by a variety of symptoms affecting the skin, eyes, and nervous system. Here are some common features of Shapiro syndrome:\n1. Skin manifestations: People with Shapiro syndrome typically have skin that is thin and fragile, with easy bruising and bleeding. They may also experience skin blistering, ulceration, and scarring.\n2. Eye abnormalities: Shapiro syndrome can cause various eye problems, including microphthalmia (small eyes), coloboma (a hole in the iris), and cataracts.\n3. Neurological symptoms: Individuals with Shapiro syndrome may experience neurological symptoms such as seizures, developmental delays, and intellectual disability.\n4. Skeletal abnormalities: Shapiro syndrome can lead to various skeletal abnormalities, including short stature, thinning of the bones (osteoporosis), and joint deformities.\n5. Hearing loss: Some individuals with Shapiro syndrome may experience hearing loss or deafness.\n6. Vision loss: Shapiro syndrome can also cause vision loss or blindness, often due to retinal detachment or other eye problems.\n7. Respiratory issues: People with Shapiro syndrome may experience respiratory problems, such as shortness of breath or respiratory infections.\n8. Gastrointestinal problems: Shapiro syndrome can lead to gastrointestinal issues, including constipation, diarrhea, and gastroesophageal reflux disease (GERD).\n9. Cardiovascular problems: Individuals with Shapiro syndrome may be at risk for cardiovascular problems, including heart valve disease and abnormal heart rhythms.\n10. Increased risk of infections: People with Shapiro syndrome may be more susceptible to infections, particularly respiratory and sinus infections, due to their compromised immune system.\nIt's important to note that not everyone with Shapiro syndrome will experience all of these features",
    "llama-2-7b-chat-hf_fact_raw": "1. Shapiro syndrome is characterized by thin and fragile skin, with easy bruising and bleeding.\n2. Individuals with Shapiro syndrome may have eye abnormalities such as small eyes (microphthalmia), a hole in the iris (coloboma), and cataracts.\n3. Neurological symptoms of Shapiro syndrome can include seizures, developmental delays, and intellectual disability.\n4. Skeletal abnormalities associated with Shapiro syndrome may include short stature, osteoporosis, and joint deformities.\n5. Shapiro syndrome can result in hearing loss or deafness.",
    "llama-2-7b-chat-hf_fact": [
      "Shapiro syndrome is characterized by thin and fragile skin, with easy bruising and bleeding.",
      "Individuals with Shapiro syndrome may have eye abnormalities such as small eyes (microphthalmia), a hole in the iris (coloboma), and cataracts.",
      "Neurological symptoms of Shapiro syndrome can include seizures, developmental delays, and intellectual disability.",
      "Skeletal abnormalities associated with Shapiro syndrome may include short stature, osteoporosis, and joint deformities.",
      "Shapiro syndrome can result in hearing loss or deafness."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Shapiro syndrome is not characterized by thin and fragile skin, with easy bruising and bleeding. It is a rare neurologic condition characterized by the triad of recurrent hypothermia, hyperhidrosis, and agenesis of the corpus callosum.\n2. FALSE [correction]: Eye abnormalities such as small eyes (microphthalmia), a hole in the iris (coloboma), and cataracts are not typical features of Shapiro syndrome, which primarily involves the symptoms described in statement 1.\n3. TRUE: Neurological symptoms of Shapiro syndrome can include seizures and developmental delays. Although intellectual disability is not explicitly mentioned in the classic triad of symptoms, it can be associated with the condition given its effects on the central nervous system.\n4. FALSE [correction]: Skeletal abnormalities such as short stature, osteoporosis, and joint deformities are not characteristic features of Shapiro syndrome. The key features of this syndrome involve recurrent hypothermia and sometimes other neurological issues.\n5. FALSE [correction]: Hearing loss or deafness are not typical symptoms of Shapiro syndrome. The condition is primarily neurologic, with the triad mentioned in statement 1 as its characteristic features.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-7b-chat-hf_response": "BRAG1 is a gene that has been associated with several diseases, including:\n1. Neurodegenerative diseases: Mutations in the BRAG1 gene have been linked to several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These mutations are thought to disrupt the normal functioning of the BRAG1 protein, leading to the death of brain cells and the progression of these diseases.\n2. Cancer: BRAG1 mutations have also been found in various types of cancer, including breast, ovarian, and colon cancer. The BRAG1 protein plays a role in regulating cell growth and division, and mutations in this gene may contribute to the development and progression of cancer.\n3. Cardiovascular disease: Some studies have suggested that BRAG1 mutations may also be associated with an increased risk of cardiovascular disease, including heart attack and stroke.\nIt's worth noting that the specific disease associated with a given BRAG1 mutation can vary depending on the location and type of mutation. Further research is needed to fully understand the role of BRAG1 in these diseases and to develop effective treatments.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the BRAG1 gene have been linked to several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.\n2. BRAG1 mutations have been found in various types of cancer, including breast, ovarian, and colon cancer.\n3. The BRAG1 protein is involved in regulating cell growth and division.\n4. There is an association suggested between BRAG1 mutations and increased risk of cardiovascular diseases, such as heart attack and stroke.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the BRAG1 gene have been linked to several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.",
      "BRAG1 mutations have been found in various types of cancer, including breast, ovarian, and colon cancer.",
      "The BRAG1 protein is involved in regulating cell growth and division.",
      "There is an association suggested between BRAG1 mutations and increased risk of cardiovascular diseases, such as heart attack and stroke."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: It is typically mutations in the genes such as APP, PSEN1, and PSEN2 that are linked to Alzheimer's disease. Genes such as SNCA, LRRK2, and PARK genes are associated with Parkinson's disease, and HTT with Huntington's disease. The correct gene related to the context provided is uncertain without further specific information.\n2. UNKNOWN: Without specific information about the BRAG1 gene and its association with these cancer types, it is not possible to determine the accuracy of this statement. BRAG1 is not a widely recognized acronym in the context of cancer research, and it's possible there is confusion or a typo with a more established cancer-associated gene such as BRCA1.\n3. UNKNOWN: Without concrete information regarding the function of the BRAG1 protein (which is not a standard nomenclature in genetics), we cannot accurately assess the truth of this statement.\n4. UNKNOWN: Without specific peer-reviewed scientific sources highlighting an association between BRAG1 mutations and cardiovascular diseases, this statement cannot be confirmed or corrected.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-7b-chat-hf_response": "Protein phosphatase 1 (PP1) is a serine/threonine protein phosphatase that plays a crucial role in various cellular processes, including cell signaling, metabolism, and protein degradation. The main inhibitor of PP1 is the protein called PP1-binding protein 1 (PP1BP1).\nPP1BP1 is a negative regulator of PP1 activity and is known to bind to and inhibit the activity of PP1 in vitro. PP1BP1 is a 14-3-3 protein that is ubiquitously expressed in cells and is involved in various cellular processes, including cell signaling, cytoskeleton organization, and protein degradation.\nThe inhibition of PP1 by PP1BP1 is thought to play a role in regulating the activity of PP1 in response to various cellular signals, including growth factors, hormones, and nutrient availability. PP1BP1 has also been implicated in the regulation of cancer cell growth and survival, and alterations in PP1BP1 expression have been observed in various types of cancer.\nIn summary, the main inhibitor of protein phosphatase 1 (PP1) is PP1-binding protein 1 (PP1BP1), which is a negative regulator of PP1 activity and plays a crucial role in regulating PP1 activity in response to various cellular signals.",
    "llama-2-7b-chat-hf_fact_raw": "1. Protein phosphatase 1 (PP1) is a serine/threonine protein phosphatase involved in cell signaling, metabolism, and protein degradation.\n2. The main inhibitor of PP1 is the protein called PP1-binding protein 1 (PP1BP1).\n3. PP1BP1 binds to and inhibits the activity of PP1 in vitro.\n4. The protein PP1BP1 is a 14-3-3 protein that is ubiquitously expressed in cells.\n5. Alterations in the expression of PP1BP1 have been observed in various types of cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Protein phosphatase 1 (PP1) is a serine/threonine protein phosphatase involved in cell signaling, metabolism, and protein degradation.",
      "The main inhibitor of PP1 is the protein called PP1-binding protein 1 (PP1BP1).",
      "PP1BP1 binds to and inhibits the activity of PP1 in vitro.",
      "The protein PP1BP1 is a 14-3-3 protein that is ubiquitously expressed in cells.",
      "Alterations in the expression of PP1BP1 have been observed in various types of cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The main inhibitors of PP1 include proteins such as Inhibitor-1 (I-1), Inhibitor-2 (I-2), and DARPP-32, not a protein called PP1-binding protein 1 (PP1BP1).\n3. UNKNOWN (The statement is unclear as there is no widely recognized inhibitor named PP1BP1; the activity of actual known inhibitors like I-1, I-2, or DARPP-32 inhibiting PP1 in vitro is well-established.)\n4. FALSE [correction]: The 14-3-3 proteins are a family of conserved regulatory molecules but are not referred to as PP1BP1. There is no standard protein recognized as PP1BP1 that is a 14-3-3 protein.\n5. UNKNOWN (Without specific scientific literature to confirm or refute the claim about PP1BP1, given that it is not a well-established protein, the statement’s accuracy is difficult to determine.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-7b-chat-hf_response": "Adaptive mutagenesis, also known as stationary-phase mutagenesis, is a process by which bacteria increase their adaptability to changing environments by accumulating mutations in their genome during stationary phase. In Bacillus subtilis, several mechanisms underlie adaptive mutagenesis:\n1. Reactive oxygen species (ROS) production: ROS, such as hydrogen peroxide (H2O2), can damage DNA and lead to mutations. B. subtilis produces ROS during stationary phase, which can increase mutation rates and promote adaptive mutagenesis.\n2. DNA repair and mutagenesis: B. subtilis has a comprehensive DNA repair system that can repair DNA damage caused by environmental stressors, including oxidative stress. However, this repair process can also introduce mutations, promoting adaptive mutagenesis.\n3. Telomere shortening: Telomeres are repetitive DNA sequences that protect the ends of chromosomes. During stationary phase, telomeres shorten, which can lead to gene silencing and the activation of silent genes, promoting adaptive mutagenesis.\n4. Epigenetic modifications: Epigenetic modifications, such as DNA methylation and histone modifications, can affect gene expression and chromosome stability. During stationary phase, B. subtilis can undergo epigenetic changes that promote adaptive mutagenesis.\n5. Horizontal gene transfer: B. subtilis can exchange genetic material with other bacteria, leading to the acquisition of new genes and mutations, which can promote adaptive mutagenesis.\n6. Random mutagenesis: Random mutagenesis can occur due to errors during DNA replication and repair. This process can also contribute to adaptive mutagenesis in B. subtilis.\n7. Mutator phenotype: Some B. subtilis strains have a mutator phenotype, which results in an increased mutation rate due to mutations in genes involved in DNA repair and replication. These mutations can promote adaptive mutagenesis.\n8. Genomic rearrangements: Genomic rearrangements, such as gene deletions, duplications, and inversions, can also contribute to adaptive mutagenesis in B. subtilis.\nThese mechanisms work",
    "llama-2-7b-chat-hf_fact_raw": "1. Bacillus subtilis produces reactive oxygen species (ROS) like hydrogen peroxide during its stationary phase, which can lead to DNA damage and mutations.\n2. The DNA repair system in Bacillus subtilis can introduce mutations during the repair process, which promotes adaptive mutagenesis.\n3. Telomeres shorten during the stationary phase in Bacillus subtilis, which can lead to gene silencing and the activation of silent genes.\n4. Bacillus subtilis can undergo epigenetic modifications during stationary phase that promote adaptive mutagenesis.\n5. Bacillus subtilis is capable of horizontal gene transfer with other bacteria, which can lead to the acquisition of new genes and mutations.",
    "llama-2-7b-chat-hf_fact": [
      "Bacillus subtilis produces reactive oxygen species (ROS) like hydrogen peroxide during its stationary phase, which can lead to DNA damage and mutations.",
      "The DNA repair system in Bacillus subtilis can introduce mutations during the repair process, which promotes adaptive mutagenesis.",
      "Telomeres shorten during the stationary phase in Bacillus subtilis, which can lead to gene silencing and the activation of silent genes.",
      "Bacillus subtilis can undergo epigenetic modifications during stationary phase that promote adaptive mutagenesis.",
      "Bacillus subtilis is capable of horizontal gene transfer with other bacteria, which can lead to the acquisition of new genes and mutations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Bacillus subtilis can produce reactive oxygen species (ROS) such as hydrogen peroxide during its stationary phase, which can lead to oxidative stress and potentially DNA damage and mutations.\n2. TRUE: The DNA repair systems in bacteria, including Bacillus subtilis, can sometimes introduce mutations during the repair process, and this can contribute to adaptive mutagenesis.\n3. FALSE [correction]: Telomeres are a feature of linear chromosomes, typically found in eukaryotic organisms, not in bacteria like Bacillus subtilis which has a circular chromosome. The concept of telomere shortening and its associated effects are not applicable to Bacillus subtilis.\n4. TRUE: While the exact mechanisms may vary, bacteria such as Bacillus subtilis can undergo epigenetic changes that may affect gene expression and could contribute to adaptive mutagenesis, especially under stress conditions like the stationary phase.\n5. TRUE: Bacillus subtilis is known to be capable of horizontal gene transfer, which is a common way that bacteria can acquire new genes and introduce genetic variations. Horizontal gene transfer can happen through transformation, transduction, or conjugation.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-7b-chat-hf_response": "Erucism is a rare genetic disorder that affects the body's ability to break down certain fats, including erucic acid, which is found in rapeseed (also known as canola) oil and other plant-based oils. The disorder is caused by mutations in the ERU gene, which provides instructions for making an enzyme called erucase. This enzyme is responsible for breaking down erucic acid in the body.\nThere are two main types of erucism:\n1. Classic erucism: This is the most common type of erucism and is caused by mutations in the ERU gene that lead to a complete deficiency of erucase enzyme activity. This results in the accumulation of toxic levels of erucic acid in the body, which can lead to a range of serious health problems, including liver damage, muscle weakness, and heart problems.\n2. Late-onset erucism: This type of erucism is caused by mutations in the ERU gene that lead to a decrease in erucase enzyme activity, but not a complete deficiency. This can result in a milder form of the disorder, with fewer and less severe symptoms.\nErucism is inherited in an autosomal recessive pattern, which means that a person must inherit two copies of the mutated ERU gene (one from each parent) to develop the disorder. Genetic testing can help identify carriers of the disorder, who may be at risk of passing it on to their children.",
    "llama-2-7b-chat-hf_fact_raw": "1. Erucism is a genetic disorder that impairs the body's ability to break down certain fats, including erucic acid.\n2. Erucic acid is found in rapeseed (canola) oil and other plant-based oils.\n3. Mutations in the ERU gene cause erucism by affecting erucase enzyme production.\n4. Classic erucism is a type of the disorder that results from a complete deficiency of erucase enzyme activity, leading to toxic levels of erucic acid in the body.\n5. Late-onset erucism is a milder form of the disorder caused by a decreased, but not completely deficient, erucase enzyme activity.",
    "llama-2-7b-chat-hf_fact": [
      "Erucism is a genetic disorder that impairs the body's ability to break down certain fats, including erucic acid.",
      "Erucic acid is found in rapeseed (canola) oil and other plant-based oils.",
      "Mutations in the ERU gene cause erucism by affecting erucase enzyme production.",
      "Classic erucism is a type of the disorder that results from a complete deficiency of erucase enzyme activity, leading to toxic levels of erucic acid in the body.",
      "Late-onset erucism is a milder form of the disorder caused by a decreased, but not completely deficient, erucase enzyme activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Erucism is not a known genetic disorder; the term appears to be incorrect or fictional. Disorders related to fat metabolism do exist, such as lipid storage diseases, but erucism isn't a recognized term in medical literature.\n2. TRUE: Erucic acid is indeed found in rapeseed (canola) oil and some other plant-based oils.\n3. FALSE [correction]: Since erucism is not an established medical condition, there is no ERU gene associated with it or an erucase enzyme. Instead, a real condition involving the breakdown of long-chain fatty acids is caused by mutations in the gene that encodes the enzyme acyl-CoA dehydrogenase.\n4. FALSE [correction]: As erucism is not a recognized medical condition, there is no such thing as \"classic erucism.\"\n5. FALSE [correction]: Similarly, as erucism is not a recognized medical condition, there is no such thing as \"late-onset erucism.\"",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-7b-chat-hf_response": "Hydrochlorothiazide (HCTZ) is a diuretic medication that is commonly used to treat various conditions related to fluid retention and hypertension (high blood pressure). Here are some of the most common indications for hydrochlorothiazide:\n1. Hypertension: HCTZ is often used as a first-line treatment for mild to moderate hypertension, as it can help to reduce blood pressure levels and improve cardiovascular health.\n2. Heart Failure: HCTZ can help to reduce fluid retention and improve breathing in people with heart failure.\n3. Edema: HCTZ is effective in reducing swelling in the legs, ankles, and feet associated with conditions such as liver disease, kidney disease, and cancer.\n4. Nephrotic Syndrome: HCTZ can help to reduce proteinuria (excess protein in the urine) in people with nephrotic syndrome, a group of conditions that can cause excessive protein loss in the urine.\n5. Cystitis: HCTZ can help to reduce inflammation and pain associated with cystitis, a bladder infection that can cause discomfort and frequency.\n6. Glaucoma: HCTZ can help to reduce intraocular pressure in people with glaucoma, a group of conditions that can damage the optic nerve and lead to vision loss.\n7. Hyperlipidemia: HCTZ can help to reduce triglyceride levels and improve lipid profiles in people with high cholesterol or hyperlipidemia.\n8. Pregnancy-induced Hypertension (PIH): HCTZ is sometimes used to treat high blood pressure that develops during pregnancy, particularly in cases where other medications are not effective.\n9. Renal Artery Stenosis: HCTZ can help to reduce blood pressure in people with renal artery stenosis, a condition in which the arteries that supply blood to the kidneys become narrowed or blocked.\n10. Systemic Lupus Erythematosus: HCTZ can help to reduce edema and proteinuria in people with systemic lupus erythematosus, an autoimmune disease that can cause inflammation",
    "llama-2-7b-chat-hf_fact_raw": "1. Hydrochlorothiazide (HCTZ) is used as a first-line treatment for mild to moderate hypertension.\n2. HCTZ is prescribed to help reduce fluid retention in patients with heart failure.\n3. HCTZ is utilized to decrease swelling in the legs, ankles, and feet due to conditions such as liver disease, kidney disease, and cancer.\n4. HCTZ is employed to reduce proteinuria in individuals with nephrotic syndrome.\n5. HCTZ can help to lower intraocular pressure in patients with glaucoma.",
    "llama-2-7b-chat-hf_fact": [
      "Hydrochlorothiazide (HCTZ) is used as a first-line treatment for mild to moderate hypertension.",
      "HCTZ is prescribed to help reduce fluid retention in patients with heart failure.",
      "HCTZ is utilized to decrease swelling in the legs, ankles, and feet due to conditions such as liver disease, kidney disease, and cancer.",
      "HCTZ is employed to reduce proteinuria in individuals with nephrotic syndrome.",
      "HCTZ can help to lower intraocular pressure in patients with glaucoma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Hydrochlorothiazide (HCTZ) is commonly used as a first-line treatment for managing mild to moderate hypertension.\n\n2. TRUE: HCTZ is also prescribed as a diuretic to help reduce fluid retention (edema) in patients with congestive heart failure.\n\n3. TRUE: The medication is used to help decrease edema which could be caused by a variety of conditions, including liver disease and kidney disease. Although not specifically for cancer, it may indirectly help with edema associated with cancer or its treatment.\n\n4. FALSE [correction]: HCTZ is not typically employed to reduce proteinuria in individuals with nephrotic syndrome. It may actually exacerbate urinary protein loss in such patients. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) are more commonly used for reducing proteinuria in nephrotic syndrome.\n\n5. FALSE [correction]: HCTZ is not typically used to lower intraocular pressure in patients with glaucoma. Other types of diuretics, such as carbonic anhydrase inhibitors, are more commonly used for this purpose.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-7b-chat-hf_response": "Yes, silicon has been used in the treatment of incontinence. Silicon-based materials have been investigated for their potential to improve the mechanical properties of tissues and organs, including the bladder and urethra, which are affected in individuals with incontinence. Here are some ways in which silicon has been used in the treatment of incontinence:\n1. Bulking agents: Silicon-based bulking agents, such as polydimethylsiloxane (PDMS), have been used to treat urinary incontinence. These agents are injected into the bladder or urethra to increase the volume of the bladder and improve the function of the urethra, reducing the likelihood of leakage.\n2. Urinary tract implants: Silicon-based materials have been used to create implants for the urinary tract, such as urethral bulking agents, bladder neck suspensory devices, and urethral sling systems. These implants are designed to support the bladder or urethra and improve the function of the urinary system, reducing the symptoms of incontinence.\n3. Tissue engineering: Silicon-based materials have been used in tissue engineering applications to create scaffolds for the growth and repair of bladder and urethral tissues. These scaffolds can be used to repair damaged tissues or to create new tissues that can help restore normal urinary function.\n4. Electrical stimulation: Silicon-based devices have been used to deliver electrical stimulation to the bladder and urethra, which can help to improve bladder function and reduce the symptoms of incontinence.\n5. Drug delivery: Silicon-based materials have been used to create devices that can deliver drugs directly to the bladder or urethra, which can help to reduce the symptoms of incontinence by relaxing the bladder muscles or reducing inflammation.\nOverall, silicon has shown promise as a material for the treatment of incontinence, particularly in the areas of bulking agents, implants, tissue engineering, electrical stimulation, and drug delivery. However, further research is needed to fully understand the safety and efficacy of silicon-based treatments",
    "llama-2-7b-chat-hf_fact_raw": "1. Silicon-based bulking agents, such as polydimethylsiloxane (PDMS), have been used to treat urinary incontinence.\n2. Silicon-based materials have been used to create implants for the urinary tract, including urethral bulking agents, bladder neck suspensory devices, and urethral sling systems.\n3. Silicon-based materials are employed in tissue engineering applications to create scaffolds for the growth and repair of bladder and urethral tissues.\n4. Silicon-based devices have been utilized to deliver electrical stimulation to the bladder and urethra to improve bladder function.\n5. Silicon-based materials have been used in devices for drug delivery directly to the bladder or urethra to help reduce the symptoms of incontinence.",
    "llama-2-7b-chat-hf_fact": [
      "Silicon-based bulking agents, such as polydimethylsiloxane (PDMS), have been used to treat urinary incontinence.",
      "Silicon-based materials have been used to create implants for the urinary tract, including urethral bulking agents, bladder neck suspensory devices, and urethral sling systems.",
      "Silicon-based materials are employed in tissue engineering applications to create scaffolds for the growth and repair of bladder and urethral tissues.",
      "Silicon-based devices have been utilized to deliver electrical stimulation to the bladder and urethra to improve bladder function.",
      "Silicon-based materials have been used in devices for drug delivery directly to the bladder or urethra to help reduce the symptoms of incontinence."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Polydimethylsiloxane (PDMS) is a type of silicone that has been used as a bulking agent to treat urinary incontinence by injection into the urethral tissue to help provide better closure of the urethra.\n\n2. TRUE: Silicon-based materials, due to their biocompatibility and favorable mechanical properties, have indeed been used for various implants in the urinary tract, including urethral bulking agents, bladder neck suspensory devices, and urethral sling systems.\n\n3. FALSE [correction]: Silicon is a chemical element, while silicone, which is composed of silicon, oxygen, carbon, and hydrogen, is a synthetic polymer. Silicone-based materials, rather than silicon-based, are used in tissue engineering applications to create scaffolds for the growth and repair of tissues, including those in the bladder and urethra.\n\n4. UNKNOWN: The statement is unclear because while devices have been used to deliver electrical stimulation to the bladder and urethra, it is typically through electrodes rather than being inherently \"silicon-based.\" Without more context on the materials used for these devices, the accuracy of this statement cannot be confirmed.\n\n5. UNKNOWN: While drug delivery systems can involve various materials, including silicones for sustained release, it is unclear from this statement whether specific silicon-based materials are used for drug delivery devices for the bladder or urethra. Without further context or specification, this statement cannot be accurately assessed.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-7b-chat-hf_response": "There is a controversial association between the moon cycle and the rupture risk of intracranial aneurysms. Some studies have suggested that the incidence of rupture of intracranial aneurysms may increase during the full moon, while others have found no correlation.\nThe proposed mechanisms for the association between the moon cycle and aneurysm rupture include:\n1. Changes in blood pressure: Some studies have suggested that there may be changes in blood pressure during the full moon, which could increase the risk of aneurysm rupture. However, these changes are typically small and are not consistently observed.\n2. Increased flow velocity: The full moon is associated with increased blood flow in the internal carotid artery, which could potentially increase the risk of aneurysm rupture.\n3. Hormonal changes: Some studies have suggested that changes in hormone levels, such as increased levels of estrogen during the full moon, may play a role in the association between the moon cycle and aneurysm rupture.\n4. Vasospasm: Some studies have suggested that the full moon may be associated with vasospasm, which could potentially increase the risk of aneurysm rupture.\nIt is important to note that the evidence for a correlation between the moon cycle and aneurysm rupture is largely anecdotal and has not been consistently demonstrated in large, well-designed studies. Therefore, the association between the moon cycle and aneurysm rupture remains controversial and is not widely accepted as a valid predictor of aneurysm rupture.\nIn conclusion, while there is some evidence to suggest that the moon cycle may be associated with an increased risk of aneurysm rupture, the evidence is largely anecdotal and has not been consistently demonstrated in large, well-designed studies. Therefore, the association between the moon cycle and aneurysm rupture remains controversial and is not widely accepted as a valid predictor of aneurysm rupture.",
    "llama-2-7b-chat-hf_fact_raw": "1. Some studies have suggested that the incidence of rupture of intracranial aneurysms may increase during the full moon.\n2. There may be changes in blood pressure during the full moon, which could theoretically increase the risk of aneurysm rupture.\n3. The full moon is associated with increased blood flow in the internal carotid artery in some studies.\n4. Hormonal changes, such as increased levels of estrogen, have been suggested by some studies to occur during the full moon.\n5. Vasospasm may be associated with the full moon, potentially increasing the risk of aneurysm rupture according to some studies.",
    "llama-2-7b-chat-hf_fact": [
      "Some studies have suggested that the incidence of rupture of intracranial aneurysms may increase during the full moon.",
      "There may be changes in blood pressure during the full moon, which could theoretically increase the risk of aneurysm rupture.",
      "The full moon is associated with increased blood flow in the internal carotid artery in some studies.",
      "Hormonal changes, such as increased levels of estrogen, have been suggested by some studies to occur during the full moon.",
      "Vasospasm may be associated with the full moon, potentially increasing the risk of aneurysm rupture according to some studies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Explanation]:\nWithout specific and reliable sources to back up these claims, it is not possible to accurately verify the statements about the correlation between the full moon and various physiological changes or events such as rupture of intracranial aneurysms, changes in blood pressure, blood flow variations, hormonal changes, or vasospasm. The effects of the lunar cycle on human physiology are a topic of debate and research, and thus any claims require careful examination of the evidence.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-7b-chat-hf_response": "Yes, the HuR protein (also known as ELAVL1) has been shown to regulate the splicing process in various cell types. HuR is a RNA-binding protein that plays a critical role in the regulation of mRNA metabolism, including pre-mRNA splicing, transport, and stability.\nHuR has been shown to bind to the introns and exons of target mRNAs and regulate their splicing in several ways:\n1. Enhancing splicing: HuR can facilitate the recognition of the splice sites by the spliceosome, leading to increased splicing efficiency and the production of mature mRNAs with the correct splicing patterns.\n2. Inhibiting splicing: HuR can also bind to specific exons and inhibit their splicing, leading to the retention of introns and the production of alternative splice variants.\n3. Regulating splice site selection: HuR can influence the selection of the 5' or 3' splice site during splicing, leading to the production of different splice variants.\n4. Modulating the stability of mRNAs: HuR can affect the stability of mRNAs by regulating their translation or degradation, which can also impact the splicing process.\nIn summary, HuR regulates the splicing process by modulating the recognition of splice sites, inhibiting or enhancing splicing, and affecting the stability of mRNAs. These functions are crucial for the proper regulation of gene expression and cellular processes, and dysregulation of HuR has been implicated in various diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. The HuR protein, also known as ELAVL1, regulates the splicing process in various cell types.\n2. HuR is a RNA-binding protein involved in the regulation of mRNA metabolism, including pre-mRNA splicing, transport, and stability.\n3. HuR can enhance splicing by facilitating the recognition of the splice sites by the spliceosome.\n4. HuR can inhibit splicing by binding to specific exons, leading to the retention of introns and the production of alternative splice variants.\n5. Dysregulation of HuR has been implicated in various diseases, including cancer and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact": [
      "The HuR protein, also known as ELAVL1, regulates the splicing process in various cell types.",
      "HuR is a RNA-binding protein involved in the regulation of mRNA metabolism, including pre-mRNA splicing, transport, and stability.",
      "HuR can enhance splicing by facilitating the recognition of the splice sites by the spliceosome.",
      "HuR can inhibit splicing by binding to specific exons, leading to the retention of introns and the production of alternative splice variants.",
      "Dysregulation of HuR has been implicated in various diseases, including cancer and neurodegenerative disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The HuR protein, also known as ELAVL1, does not regulate the splicing process but rather is involved in mRNA stability and the regulation of translation.\n2. TRUE\n3. FALSE [correction]: HuR typically does not enhance splicing; it is more commonly associated with the regulation of mRNA stability and translation.\n4. UNKNOWN: While HuR is known to influence mRNA life cycle and function, the specific mechanisms by which it may affect splicing, including the inhibition by binding to specific exons, can vary and require more context to affirm as a general statement.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-7b-chat-hf_response": "Prothymosin alpha (ProT) is a small protein that has been implicated in various cellular processes, including cell proliferation, differentiation, and survival. The c-terminal peptide of ProT, also known as ProT-CT, has been studied for its specific functions. Here are some of the known functions of ProT-CT:\n1. Cell proliferation: ProT-CT has been shown to promote cell proliferation by stimulating the activity of key cell cycle regulators, such as cyclin-dependent kinases (CDKs) and cyclins.\n2. Apoptosis: ProT-CT has been reported to inhibit apoptosis, or programmed cell death, by suppressing the activation of pro-apoptotic proteins and increasing the expression of anti-apoptotic proteins.\n3. Cell adhesion and migration: ProT-CT has been shown to regulate cell adhesion and migration by modulating the expression of adhesion molecules and actin cytoskeleton components.\n4. Neuroprotection: ProT-CT has been investigated for its potential neuroprotective effects, particularly against excitotoxicity, which can lead to neuronal death. ProT-CT has been shown to reduce excitotoxicity by inhibiting the influx of calcium ions into neurons.\n5. Anti-inflammatory effects: ProT-CT has been reported to have anti-inflammatory properties by suppressing the production of pro-inflammatory cytokines and chemokines.\n6. Cancer: ProT-CT has been implicated in cancer development and progression. It has been shown to promote cancer cell proliferation, migration, and invasion, as well as to inhibit the activity of tumor suppressor proteins.\n7. Immune response: ProT-CT has been involved in the regulation of immune responses, particularly in the activation of immune cells and the production of cytokines.\n8. Cardiovascular health: ProT-CT has been linked to cardiovascular health, with studies suggesting that it may play a role in the regulation of blood pressure, inflammation, and cardiac function.\n9. Metabolism: ProT-CT",
    "llama-2-7b-chat-hf_fact_raw": "1. Prothymosin alpha c-terminal peptide (ProT-CT) promotes cell proliferation by stimulating the activity of cell cycle regulators like CDKs and cyclins.\n2. ProT-CT inhibits apoptosis by suppressing pro-apoptotic proteins' activation and increasing anti-apoptotic proteins' expression.\n3. ProT-CT regulates cell adhesion and migration through the modulation of adhesion molecule expression and actin cytoskeleton components.\n4. ProT-CT has potential neuroprotective effects against excitotoxicity by inhibiting calcium ion influx into neurons.\n5. ProT-CT exhibits anti-inflammatory properties by reducing the production of pro-inflammatory cytokines and chemokines.",
    "llama-2-7b-chat-hf_fact": [
      "Prothymosin alpha c-terminal peptide (ProT-CT) promotes cell proliferation by stimulating the activity of cell cycle regulators like CDKs and cyclins.",
      "ProT-CT inhibits apoptosis by suppressing pro-apoptotic proteins' activation and increasing anti-apoptotic proteins' expression.",
      "ProT-CT regulates cell adhesion and migration through the modulation of adhesion molecule expression and actin cytoskeleton components.",
      "ProT-CT has potential neuroprotective effects against excitotoxicity by inhibiting calcium ion influx into neurons.",
      "ProT-CT exhibits anti-inflammatory properties by reducing the production of pro-inflammatory cytokines and chemokines."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nPlease note that these responses assume that research to the date of the knowledge cut-off has shown Prothymosin alpha c-terminal peptide (ProT-CT) to have these properties. However, each of these statements pertains to complex biological functions that could be context-dependent and subject to additional factors not disclosed in these statements. Therefore, the responses are based on the typical understanding of ProT-CT's functions.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-7b-chat-hf_response": "Cystatin C is a protein that is involved in the regulation of protein degradation in the body. It is a cysteine protease inhibitor that is ubiquitously expressed in various tissues, including the brain. Cystatin C can form fibrils under certain conditions, which can lead to the formation of amyloid fibrils that are associated with various neurodegenerative diseases, including Alzheimer's disease.\nThe peptide that plays a pivotal role in human cystatin C fibrillization is the amino acid sequence RRARRRRRRR (residues 13-20). This sequence is located in the N-terminal region of the cystatin C protein and is responsible for the formation of fibrils. The RRARRRRRRR sequence forms a β-sheet structure that is stabilized by hydrogen bonding and ionic interactions, leading to the formation of fibrils.\nThe formation of fibrils by cystatin C is a complex process that involves several steps, including the aggregation of the protein, the formation of oligomers, and the assembly of these oligomers into fibrils. The RRARRRRRRR sequence plays a critical role in these processes, as it provides a template for the assembly of cystatin C monomers into fibrils.\nUnderstanding the mechanisms of cystatin C fibrillization is important for understanding the pathogenesis of neurodegenerative diseases, as cystatin C fibrils are a hallmark of these diseases. By studying the structure and function of the RRARRRRRRR sequence, researchers may be able to develop new therapeutic strategies for the prevention and treatment of these diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cystatin C is a cysteine protease inhibitor that is expressed in various tissues including the brain.\n2. Cystatin C fibrillization is associated with the formation of amyloid fibrils linked to neurodegenerative diseases such as Alzheimer's disease.\n3. The peptide sequence RRARRRRRRR (residues 13-20) in cystatin C plays a pivotal role in its fibrillization.\n4. The RRARRRRRRR sequence in cystatin C forms a β-sheet structure that is stabilized by hydrogen bonding and ionic interactions.\n5. Understanding the process of cystatin C fibrillization can contribute to developing new therapeutic strategies for neurodegenerative diseases.",
    "llama-2-7b-chat-hf_fact": [
      "Cystatin C is a cysteine protease inhibitor that is expressed in various tissues including the brain.",
      "Cystatin C fibrillization is associated with the formation of amyloid fibrils linked to neurodegenerative diseases such as Alzheimer's disease.",
      "The peptide sequence RRARRRRRRR (residues 13-20) in cystatin C plays a pivotal role in its fibrillization.",
      "The RRARRRRRRR sequence in cystatin C forms a β-sheet structure that is stabilized by hydrogen bonding and ionic interactions.",
      "Understanding the process of cystatin C fibrillization can contribute to developing new therapeutic strategies for neurodegenerative diseases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The sequence provided (RRARRRRRRR; residues 13-20) seems to have an incorrect numbering or composition since cystatin C typically has around 120 amino acid residues, and such a sequence with 10 arginines (R) is not known to play a role in its fibrillization. The actual sequence that is pivotal might be different or located at a different position in the protein.\n4. UNKNOWN: Without the correct peptide sequence from cystatin C that is implicated in fibrillization, we cannot accurately determine whether this statement is true or false regarding the formation of a β-sheet structure that is stabilized by hydrogen bonding and ionic interactions. Even for sequences that we do know play a role in fibrillization, the statement is vague as it doesn't specify which sequence it is referring to, and not all sequences would form the same secondary structures.\n5. TRUE\n",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-7b-chat-hf_response": "Yes, the concentration of protein HIF-1α can increase after the administration of the cytoprotective prodrug amifostine (ethyol).\nHIF-1α (Hypoxia-Inducible Factor 1-Alpha) is a transcription factor that plays a crucial role in response to hypoxia (low oxygen levels) and is involved in the regulation of various cellular processes, including angiogenesis, glucose metabolism, and cell survival.\nAmifostine, also known as ethyol, is a cytoprotective prodrug that has been shown to have antioxidant and anti-inflammatory effects, and it has been used to protect against radiation-induced damage in cancer patients.\nStudies have shown that amifostine can increase the expression of HIF-1α in various cell types, including cancer cells. For example, a study published in the journal Radiology found that amifostine increased HIF-1α expression in human glioblastoma cells exposed to hypoxia. Another study published in the journal Cancer Research found that amifostine increased HIF-1α expression in human breast cancer cells exposed to oxidative stress.\nThe increase in HIF-1α expression after amifostine administration is thought to be mediated by the activation of various signaling pathways, including the PI3K/Akt pathway, which is involved in the regulation of HIF-1α transcriptional activity.\nOverall, the increase in HIF-1α concentration after amifostine administration may play a role in the cytoprotective effects of this drug, particularly in conditions where hypoxia is present, such as in solid tumors.",
    "llama-2-7b-chat-hf_fact_raw": "1. HIF-1α (Hypoxia-Inducible Factor 1-Alpha) is involved in the regulation of various cellular processes, including angiogenesis, glucose metabolism, and cell survival.\n2. Amifostine, also known as ethyol, is a cytoprotective prodrug with antioxidant and anti-inflammatory effects.\n3. Amifostine has been used to protect against radiation-induced damage in cancer patients.\n4. A study in the journal Radiology found that amifostine increased HIF-1α expression in human glioblastoma cells exposed to hypoxia.\n5. The PI3K/Akt pathway is involved in the regulation of HIF-1α transcriptional activity.",
    "llama-2-7b-chat-hf_fact": [
      "HIF-1α (Hypoxia-Inducible Factor 1-Alpha) is involved in the regulation of various cellular processes, including angiogenesis, glucose metabolism, and cell survival.",
      "Amifostine, also known as ethyol, is a cytoprotective prodrug with antioxidant and anti-inflammatory effects.",
      "Amifostine has been used to protect against radiation-induced damage in cancer patients.",
      "A study in the journal Radiology found that amifostine increased HIF-1α expression in human glioblastoma cells exposed to hypoxia.",
      "The PI3K/Akt pathway is involved in the regulation of HIF-1α transcriptional activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: HIF-1α is indeed involved in the regulation of various cellular processes, including angiogenesis, glucose metabolism, and cell survival.\n2. TRUE: Amifostine, known by the brand name Ethyol among others, is a cytoprotective drug with antioxidant and anti-inflammatory properties.\n3. TRUE: Amifostine is used to decrease the risk of kidney damage in patients receiving cisplatin for the treatment of cancer, and can also be used to reduce dryness in the mouth caused by radiation therapy after treatment for cancer of the head and neck. It works by protecting normal tissue from harmful effects of radiation (radioprotectant).\n4. UNKNOWN: Without access to the specific journal article mentioned, it is impossible to verify the accuracy of this statement. This would require direct access to that study to confirm if amifostine increased HIF-1α expression in the context given.\n5. TRUE: The PI3K/Akt pathway is one of the pathways that regulate HIF-1α, specifically its transcriptional activity, through various mechanisms like influencing the translation and degradation of the HIF-1α protein.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-7b-chat-hf_response": "Set7 is a histone methyltransferase that deposits histone marks involved in various epigenetic processes, including chromatin remodeling and transcriptional regulation. Set7 specifically methylates histone H3 at lysine 7 (H3K7), leading to the recruitment of chromatin-modifying complexes and the alteration of chromatin structure.\nHere are some of the key histone marks deposited by Set7:\n1. H3K7 tri-methylation (H3K7me3): Set7 is the primary enzyme responsible for the tri-methylation of histone H3 at lysine 7 (H3K7me3). H3K7me3 is a repressive mark that is involved in the silencing of gene expression, particularly in the context of facultative heterochromatin.\n2. H3K27ac: Set7 can also methylate histone H3 at lysine 27 (H3K27), leading to the deposition of the activating mark H3K27ac. H3K27ac is involved in the regulation of active gene transcription and is often associated with the elongating phases of transcription.\n3. H3K36me3: Set7 has been shown to methylate histone H3 at lysine 36 (H3K36), leading to the deposition of the repressive mark H3K36me3. H3K36me3 is involved in the silencing of gene expression, particularly in the context of facultative heterochromatin.\nIn summary, Set7 is a key player in the deposition of various histone marks involved in chromatin regulation, including H3K7me3, H3K27ac, and H3K36me3. These marks play important roles in the regulation of gene expression, chromatin structure, and cellular differentiation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Set7 specifically methylates histone H3 at lysine 7 (H3K7).\n2. H3K7 tri-methylation (H3K7me3) is a histone mark deposited by Set7.\n3. H3K27ac, an activating mark involved in active gene transcription, can be deposited by Set7 through methylation at histone H3 at lysine 27.\n4. Set7 is responsible for the deposition of H3K36me3, a repressive mark, through methylation at histone H3 at lysine 36.\n5. The histone marks deposited by Set7, such as H3K7me3, H3K27ac, and H3K36me3, are involved in the regulation of gene expression and chromatin structure.",
    "llama-2-7b-chat-hf_fact": [
      "Set7 specifically methylates histone H3 at lysine 7 (H3K7).",
      "H3K7 tri-methylation (H3K7me3) is a histone mark deposited by Set7.",
      "H3K27ac, an activating mark involved in active gene transcription, can be deposited by Set7 through methylation at histone H3 at lysine 27.",
      "Set7 is responsible for the deposition of H3K36me3, a repressive mark, through methylation at histone H3 at lysine 36.",
      "The histone marks deposited by Set7, such as H3K7me3, H3K27ac, and H3K36me3, are involved in the regulation of gene expression and chromatin structure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Set7 specifically methylates histone H3 at lysine 4 (H3K4), not lysine 7 (H3K7).\n2. FALSE [correction]: H3K7 tri-methylation (H3K7me3) is not a histone mark deposited by Set7, as Set7 is responsible for methylation at lysine 4 (H3K4).\n3. FALSE [correction]: H3K27ac is an acetylation mark, not a methylation mark, and it is not deposited by Set7. Set7 does not have acetyltransferase activity and specifically methylates lysine 4 of histone H3.\n4. FALSE [correction]: Set7 is not responsible for the deposition of H3K36me3, as its methylation activity is specific to H3K4. H3K36me3 is catalyzed by other methyltransferases such as Set2.\n5. TRUE (with caveats): The histone marks deposited by Set7 are involved in the regulation of gene expression and chromatin structure. However, as noted in the corrections above, the specific histone marks mentioned in the statement (H3K7me3, H3K27ac, and H3K36me3) are not deposited by Set7. The statement is true to the extent that histone marks such as H3K4 methylation, which is deposited by Set7, are involved in these regulatory processes.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-7b-chat-hf_response": "Hepcidin, the antimicrobial peptide, has 4 disulfide bridges.\n1. Hepcidin has 2 intra-molecular disulfide bonds (between Cys17-Cys34 and Cys51-Cys67) and 2 inter-molecular disulfide bonds (between Cys17-Cys34 and Cys51-Cys67, and between Cys34-Cys51).\nThese disulfide bonds play a crucial role in the folding and stability of hepcidin, as well as in its ability to interact with its target proteins, such as ferroportin, and regulate iron homeostasis in the body.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hepcidin has 4 disulfide bridges.\n2. The protein hepcidin contains intra-molecular disulfide bonds between Cys17-Cys34 and Cys51-Cys67.\n3. There are inter-molecular disulfide bonds present in hepcidin between Cys17-Cys34 and Cys51-Cys67, and between Cys34-Cys51.",
    "llama-2-7b-chat-hf_fact": [
      "Hepcidin has 4 disulfide bridges.",
      "The protein hepcidin contains intra-molecular disulfide bonds between Cys17-Cys34 and Cys51-Cys67.",
      "There are inter-molecular disulfide bonds present in hepcidin between Cys17-Cys34 and Cys51-Cys67, and between Cys34-Cys51."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The disulfide bonds mentioned (Cys17-Cys34 and Cys51-Cys67) are intra-molecular within hepcidin, not inter-molecular. There is no mention of a Cys34-Cys51 bond in hepcidin; the known bonds within hepcidin are Cys7-Cys23, Cys10-Cys13, Cys17-Cys34, and Cys51-Cys67.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-7b-chat-hf_response": "The protein encoded by the gene DNAJC11 (also known as DNAJC11 or HSPA8L1) is a member of the heat shock protein 80 (HSP80) family and is primarily localized to the cytoplasm. However, it can also be found in the nucleus under certain conditions.\nDNAJC11 is a chaperone protein that plays a crucial role in protein folding and degradation, particularly in the context of cellular stress. It is involved in the regulation of protein homeostasis and is thought to help maintain cellular proteostasis by promoting the proper folding and degradation of misfolded proteins.\nStudies have shown that DNAJC11 is predominantly cytoplasmic in its localization, although it can also be found in the nucleus under conditions of cellular stress, such as exposure to heat shock, oxidative stress, or protein misfolding. In the nucleus, DNAJC11 appears to play a role in regulating the expression of genes involved in the heat shock response and other cellular stress pathways.\nIn summary, the localization of the protein encoded by the gene DNAJC11 is primarily cytoplasmic, but it can also be found in the nucleus under certain conditions of cellular stress.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein encoded by the gene DNAJC11 is primarily localized to the cytoplasm.\n2. The DNAJC11 protein can also be found in the nucleus under certain conditions.\n3. DNAJC11 is a member of the heat shock protein 80 (HSP80) family.\n4. DNAJC11 plays a crucial role in protein folding and degradation.\n5. The protein is involved in the regulation of protein homeostasis and the maintenance of cellular proteostasis.",
    "llama-2-7b-chat-hf_fact": [
      "The protein encoded by the gene DNAJC11 is primarily localized to the cytoplasm.",
      "The DNAJC11 protein can also be found in the nucleus under certain conditions.",
      "DNAJC11 is a member of the heat shock protein 80 (HSP80) family.",
      "DNAJC11 plays a crucial role in protein folding and degradation.",
      "The protein is involved in the regulation of protein homeostasis and the maintenance of cellular proteostasis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: DNAJC11 is a member of the DNAJ/HSP40 (heat shock protein 40) family, not the HSP80 family.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-7b-chat-hf_response": "Yes, ultraconserved elements (UEs) are depleted among copy number variants (CNVs). UEs are short, highly conserved sequences that are found throughout the genome, and they are often associated with important regulatory elements, such as promoters and enhancers. CNVs, on the other hand, are genomic regions that contain one or more copies of a segment of DNA, resulting in changes in the copy number of the genome.\nStudies have shown that UEs are overrepresented in non-CNV genomic regions, but they are underrepresented in CNVs. For example, a study by Zhang et al. (2010) found that UEs were more abundant in regions of the genome that were not affected by CNVs, while another study by Chudova et al. (2010) found that UEs were significantly less common in CNVs than in non-CNV regions.\nThe reason for this difference in distribution is not fully understood, but it is thought to be related to the role of UEs in regulating gene expression. UEs are often found in regions of the genome that are important for regulating gene expression, such as promoters and enhancers, and they are thought to play a role in the regulation of gene expression by acting as binding sites for transcription factors and other regulatory proteins. CNVs, on the other hand, are more likely to disrupt the normal functioning of the genome by altering the copy number of genes and regulatory elements, which can lead to changes in gene expression and cellular function. Therefore, UEs are less likely to be found in regions of the genome that are affected by CNVs.\nIn summary, UEs are depleted among CNVs due to their important role in regulating gene expression and their tendency to be located in non-CNV regions of the genome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ultraconserved elements (UEs) are short, highly conserved sequences found throughout the genome.\n2. Copy number variants (CNVs) are genomic regions that can have a variable number of copies of a DNA segment.\n3. Studies indicate that UEs are underrepresented in CNVs but overrepresented in non-CNV regions of the genome.\n4. Zhang et al. (2010) found that UEs were more common in genomic regions not affected by CNVs.\n5. Chudova et al. (2010) found UEs to be significantly less common in CNVs compared to non-CNV regions.",
    "llama-2-7b-chat-hf_fact": [
      "Ultraconserved elements (UEs) are short, highly conserved sequences found throughout the genome.",
      "Copy number variants (CNVs) are genomic regions that can have a variable number of copies of a DNA segment.",
      "Studies indicate that UEs are underrepresented in CNVs but overrepresented in non-CNV regions of the genome.",
      "Zhang et al. (2010) found that UEs were more common in genomic regions not affected by CNVs.",
      "Chudova et al. (2010) found UEs to be significantly less common in CNVs compared to non-CNV regions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Ultraconserved elements (UEs) are indeed short, highly conserved sequences that are found throughout the genome. They are typically 200 base pairs or more in length and are identical in humans, rats, and mice.\n2. TRUE: Copy number variants (CNVs) are genomic regions where the number of copies of a particular DNA segment can vary between individuals in the human population.\n3. TRUE: Research suggests that ultraconserved elements are less likely to be a part of regions with CNVs and are more likely found in regions of the genome not affected by copy number variation.\n4. TRUE: Zhang et al. (2010) did find that ultraconserved elements were more common in genomic regions not affected by CNVs, which is consistent with the notion that these elements are highly conserved and less prone to genomic structural variation.\n5. TRUE: Based on the given statements, if Chudova et al. (2010) found UEs to be significantly less common in CNVs compared to non-CNV regions, it aligns with the previous research mentioned. It suggests that there is consistency in findings across different studies regarding the distribution of UEs in relation to CNVs.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-7b-chat-hf_response": "Has2 (Haspin) is a protein kinase that plays a crucial role in regulating the progression of mitosis. It is a key regulator of the spindle assembly checkpoint, which ensures that sister chromatids are properly separated during cell division.\nThe substrate of Has2 (Haspin) during mitosis is primarily the protein tubulin. Has2 phosphorylates tubulin on specific residues, which alter its conformation and affect its interaction with other proteins, leading to the formation of stable microtubules. This process is essential for the proper organization of the mitotic spindle and the separation of chromosomes during cell division.\nIn addition to tubulin, Has2 has been shown to phosphorylate and regulate other proteins involved in mitosis, including the aurora kinases, which are important for the proper formation of the spindle, and the polo-like kinase 1 (PLK1), which is involved in the regulation of chromosome alignment and separation.\nOverall, the substrate specificity of Has2 during mitosis is focused on regulating the structure and function of microtubules, which are critical for the proper progression of mitosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Has2 (Haspin) is a protein kinase that participates in regulating the progression of mitosis.\n2. Has2 is a key regulator of the spindle assembly checkpoint during cell division.\n3. The primary substrate of Has2 during mitosis is the protein tubulin.\n4. Has2 phosphorylates tubulin on specific residues that are involved in the formation of stable microtubules.\n5. Has2 also phosphorylates and regulates proteins such as aurora kinases and polo-like kinase 1 (PLK1) during mitosis.",
    "llama-2-7b-chat-hf_fact": [
      "Has2 (Haspin) is a protein kinase that participates in regulating the progression of mitosis.",
      "Has2 is a key regulator of the spindle assembly checkpoint during cell division.",
      "The primary substrate of Has2 during mitosis is the protein tubulin.",
      "Has2 phosphorylates tubulin on specific residues that are involved in the formation of stable microtubules.",
      "Has2 also phosphorylates and regulates proteins such as aurora kinases and polo-like kinase 1 (PLK1) during mitosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Haspin, not Has2, is a key regulator of the spindle assembly checkpoint during cell division.\n3. FALSE [correction]: The primary substrate of Haspin during mitosis is histone H3, not tubulin. Haspin particularly phosphorylates threonine 3 of histone H3 (H3T3ph).\n4. FALSE [correction]: Haspin does not phosphorylate tubulin but phosphorylates threonine 3 on histone H3 during mitosis. Formation of stable microtubules is not directly related to the role of Haspin.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-7b-chat-hf_response": "Viroids are small, single-stranded RNA molecules that replicate through a unique mechanism that does not involve the standard cellular machinery for protein synthesis and genome replication. Here's a simplified overview of the mechanism of viroid replication:\n1. Attachment: Viroids attach to the host cell membrane through specific sequences in their RNA molecule.\n2. Endosomal sorting: Once attached, viroids are endocytosed and sorted into endosomes, where they interact with cellular machinery.\n3. Release from endosomes: Viroids are released from the endosomes and enter the cytosol, where they can interact with host cell factors.\n4. Replication: In the cytosol, viroids replicate their RNA molecules through a mechanism that involves the host cell's RNA-dependent RNA polymerase. This enzyme is responsible for synthesizing new RNA molecules from existing ones.\n5. Formation of new viroid particles: Once replicated, the new RNA molecules are assembled into new viroid particles through a process that involves the host cell's ribosomes and other cytosolic factors.\n6. Maturation: The new viroid particles are then matured through a process that involves the removal of the RNA template, leaving behind the mature viroid molecule.\n7. Release: The mature viroids are then released from the host cell through a variety of mechanisms, including exocytosis, lysis, or budding.\nIt's worth noting that the exact mechanisms of viroid replication are still not fully understood and are the subject of ongoing research. However, the general outline provided above provides a general understanding of how viroids replicate and spread within host cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viroids are small, single-stranded RNA molecules.\n2. Viroids replicate without the standard cellular machinery for protein synthesis and genome replication.\n3. Viroids attach to the host cell membrane through specific sequences within their RNA molecule.\n4. Viroid replication in the cytosol involves the host cell's RNA-dependent RNA polymerase.\n5. New viroid particles are assembled with the involvement of the host cell's ribosomes and other cytosolic factors.",
    "llama-2-7b-chat-hf_fact": [
      "Viroids are small, single-stranded RNA molecules.",
      "Viroids replicate without the standard cellular machinery for protein synthesis and genome replication.",
      "Viroids attach to the host cell membrane through specific sequences within their RNA molecule.",
      "Viroid replication in the cytosol involves the host cell's RNA-dependent RNA polymerase.",
      "New viroid particles are assembled with the involvement of the host cell's ribosomes and other cytosolic factors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Viroids do not attach to the host cell membrane; they typically interact with the host cell's nucleic acids or proteins.\n4. TRUE\n5. FALSE [correction]: Viroids do not form particles and thus do not require assembly by ribosomes or other cytosolic factors; they are naked RNA molecules that self-replicate within the host cell.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-7b-chat-hf_response": "Fibronectin is a protein that has been suggested as a potential biomarker for Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle weakness and degeneration.\nResearch has shown that the levels of fibronectin in the blood or cerebrospinal fluid (CSF) of individuals with DMD are altered compared to those in healthy individuals. For example:\n1. Elevated fibronectin levels: Studies have consistently shown that the levels of fibronectin are elevated in the blood or CSF of individuals with DMD, particularly during the early stages of the disease.\n2. Reduced fibronectin stability: Fibronectin is known to be unstable in the bloodstream, and its levels can fluctuate over time. Studies have shown that the stability of fibronectin is reduced in the blood of individuals with DMD, which may contribute to the elevated levels observed.\n3. Abnormal fibronectin distribution: Fibronectin is typically found in the basement membrane of muscle tissue, where it plays a role in maintaining muscle structure and function. In DMD, fibronectin is altered and can be found in the bloodstream, which may indicate muscle degeneration.\nWhile elevated fibronectin levels have been associated with DMD, it is important to note that the sensitivity and specificity of this biomarker for DMD are still being studied and refined. Therefore, further research is needed to fully understand the potential of fibronectin as a serum biomarker for DMD.\nIn summary, fibronectin has been suggested as a potential biomarker for DMD, but its use for diagnosis and monitoring of the disease is still in the early stages of investigation. Further research is needed to fully understand the potential of fibronectin as a biomarker for DMD.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fibronectin has been suggested as a potential biomarker for Duchenne muscular dystrophy (DMD).\n2. Studies have shown that levels of fibronectin are elevated in the blood or cerebrospinal fluid (CSF) of individuals with DMD, especially during early stages of the disease.\n3. Research indicates that the stability of fibronectin is reduced in the blood of individuals with DMD.\n4. In individuals with DMD, fibronectin distribution is abnormal, often found in the bloodstream instead of its typical location in the basement membrane of muscle tissue.\n5. The sensitivity and specificity of fibronectin as a biomarker for DMD are still under investigation.",
    "llama-2-7b-chat-hf_fact": [
      "Fibronectin has been suggested as a potential biomarker for Duchenne muscular dystrophy (DMD).",
      "Studies have shown that levels of fibronectin are elevated in the blood or cerebrospinal fluid (CSF) of individuals with DMD, especially during early stages of the disease.",
      "Research indicates that the stability of fibronectin is reduced in the blood of individuals with DMD.",
      "In individuals with DMD, fibronectin distribution is abnormal, often found in the bloodstream instead of its typical location in the basement membrane of muscle tissue.",
      "The sensitivity and specificity of fibronectin as a biomarker for DMD are still under investigation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Research indicates that the stability of fibronectin is not the primary focus regarding DMD; rather, changes in the levels and distribution are of concern.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-7b-chat-hf_response": "DeepBlue is a comprehensive epigenomic data server that contains data from various epigenome projects. Here are some of the major epigenome projects whose data are contained in the DeepBlue server:\n1. ENCODE (Encyclopedia of DNA Elements): The ENCODE project is a large-scale effort to map all the functional elements in the human genome. The project has generated a wealth of epigenetic data, including histone modification profiles, DNA methylation profiles, and chromatin accessibility profiles.\n2. Roadmap Epigenomics Project: The Roadmap Epigenomics Project is a collaborative effort to map the epigenetic landscape of multiple organisms, including humans, mice, and yeast. The project has generated extensive epigenetic data, including histone modification profiles, DNA methylation profiles, and chromatin structure data.\n3. NIH Roadmap Epigenomics Mapping Center (MEMC): The MEMC is a consortium of researchers who are working to generate high-resolution epigenetic maps of various organisms, including humans. The center has generated a large amount of epigenetic data, including histone modification profiles, DNA methylation profiles, and chromatin structure data.\n4. The Cancer Genome Atlas (TCGA): TCGA is a collaborative effort to catalogue the genomic and epigenetic changes that occur in various types of cancer. The project has generated a wealth of epigenetic data, including histone modification profiles, DNA methylation profiles, and chromatin structure data.\n5. The Human Epigenome Atlas (HEA): The HEA is a comprehensive effort to map the epigenetic landscape of human tissues and cells. The project has generated a large amount of epigenetic data, including histone modification profiles, DNA methylation profiles, and chromatin structure data.\n6. The Mouse Epigenome Project (MEP): The MEP is a large-scale effort to map the epigenetic landscape of the mouse genome. The project has generated a wealth of epigenetic data, including histone modification profiles, DNA methylation profiles, and chromatin structure data.\n7. The Yeast Epigenome Project (YEP): The YEP is a comprehensive effort to map the epigenetic landscape of the yeast genome. The project has generated",
    "llama-2-7b-chat-hf_fact_raw": "1. The DeepBlue epigenomic data server contains data from the ENCODE project.\n2. The Roadmap Epigenomics Project's data, including histone modification profiles, DNA methylation profiles, and chromatin structure data, is included in DeepBlue.\n3. NIH Roadmap Epigenomics Mapping Center (MEMC) has generated high-resolution epigenetic maps, and this data is stored on the DeepBlue server.\n4. The Cancer Genome Atlas (TCGA) project's epigenetic data is part of the DeepBlue epigenomic data server.\n5. The Human Epigenome Atlas (HEA) provides histone modification profiles, DNA methylation profiles, and chromatin structure data that are accessible through the DeepBlue server.",
    "llama-2-7b-chat-hf_fact": [
      "The DeepBlue epigenomic data server contains data from the ENCODE project.",
      "The Roadmap Epigenomics Project's data, including histone modification profiles, DNA methylation profiles, and chromatin structure data, is included in DeepBlue.",
      "NIH Roadmap Epigenomics Mapping Center (MEMC) has generated high-resolution epigenetic maps, and this data is stored on the DeepBlue server.",
      "The Cancer Genome Atlas (TCGA) project's epigenetic data is part of the DeepBlue epigenomic data server.",
      "The Human Epigenome Atlas (HEA) provides histone modification profiles, DNA methylation profiles, and chromatin structure data that are accessible through the DeepBlue server."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The Cancer Genome Atlas (TCGA) project's primary focus is on genomic data, not specifically epigenetic data, and while it may contain some epigenetic information, it is known for its genomic and transcriptomic data. Therefore, it cannot be definitively stated that TCGA's epigenetic data is part of the DeepBlue epigenomic data server without specific evidence.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-7b-chat-hf_response": "One tool that employs self-organizing maps (SOMs) for analyzing synonymous codon usage is the \"CodonUsage tool\" in the \"GLIMMER\" suite of bioinformatics tools.\nThe GLIMMER suite is a collection of tools for the analysis of non-coding RNA genes, including microRNAs (miRNAs), lncRNAs, and circRNAs. The codonusage tool in GLIMMER uses SOMs to analyze the codon usage of a given gene or transcript, and to identify patterns and trends in codon usage that may be associated with specific functional or evolutionary mechanisms.\nThe tool works by mapping the codons in a given sequence to a lower-dimensional representation, called a \"map,\" using a SOM algorithm. The map is then analyzed to identify clusters of codons that are co-used in the same context, which can indicate the presence of functional or evolutionary patterns.\nSome of the key features of the codonusage tool include:\n1. Codon usage analysis: The tool can analyze the codon usage of a given gene or transcript, and identify patterns and trends in codon usage that may be associated with specific functional or evolutionary mechanisms.\n2. Identification of functional or evolutionary patterns: The tool can identify clusters of codons that are co-used in the same context, which can indicate the presence of functional or evolutionary patterns.\n3. Visualization of codon usage: The tool can visualize the codon usage of a given sequence, making it easier to identify patterns and trends in codon usage.\n4. Identification of potential functional or evolutionary mechanisms: The tool can identify potential functional or evolutionary mechanisms that may be associated with specific codon usage patterns.\nOverall, the codonusage tool in GLIMMER is a useful tool for analyzing synonymous codon usage and identifying patterns and trends in codon usage that may be associated with specific functional or evolutionary mechanisms.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"CodonUsage tool\" in the \"GLIMMER\" suite uses self-organizing maps (SOMs) to analyze synonymous codon usage.\n2. The GLIMMER suite is a collection of tools for the analysis of non-coding RNA genes, such as microRNAs (miRNAs), lncRNAs, and circRNAs.\n3. The codonusage tool can visualize the codon usage of a given sequence to help identify patterns and trends.\n4. Clusters of codons identified by the codonusage tool can potentially indicate the presence of functional or evolutionary patterns.\n5. The codonusage tool maps codons to a lower-dimensional space to identify codon usage patterns associated with specific functional or evolutionary mechanisms.",
    "llama-2-7b-chat-hf_fact": [
      "The \"CodonUsage tool\" in the \"GLIMMER\" suite uses self-organizing maps (SOMs) to analyze synonymous codon usage.",
      "The GLIMMER suite is a collection of tools for the analysis of non-coding RNA genes, such as microRNAs (miRNAs), lncRNAs, and circRNAs.",
      "The codonusage tool can visualize the codon usage of a given sequence to help identify patterns and trends.",
      "Clusters of codons identified by the codonusage tool can potentially indicate the presence of functional or evolutionary patterns.",
      "The codonusage tool maps codons to a lower-dimensional space to identify codon usage patterns associated with specific functional or evolutionary mechanisms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The \"CodonUsage tool\" in the \"GLIMMER\" suite does not use self-organizing maps (SOMs) to analyze synonymous codon usage. GLIMMER (Gene Locator and Interpolated Markov ModelER) primarily uses interpolated Markov models to identify microbial genes.\n2. FALSE [correction]: The GLIMMER suite is not specifically for the analysis of non-coding RNA genes. It is designed for the identification of protein-coding genes in prokaryotic genomes and metagenomes.\n3. TRUE: The CodonUsage tool can indeed be used to visualize codon usage of a given sequence, which helps researchers identify patterns and trends in codon usage.\n4. TRUE: Clusters of codons identified by tools like CodonUsage can indicate the presence of functional or evolutionary patterns such as codon bias.\n5. UNKNOWN: The statement is vague regarding the specific functionality of the \"codonusage tool\" within GLIMMER. While such tools can map codons to a lower-dimensional space for analysis, it is not clear whether this is a feature of the specific \"codonusage tool\" referred to in the GLIMMER suite.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-7b-chat-hf_response": "MINDY-1 (Mammary Interaction Network Downstream of EGFR 1) is a protein that plays a crucial role in the regulation of cellular processes such as cell proliferation, differentiation, and survival. It is a key component of the PI3K/Akt signaling pathway, which is involved in various cellular processes, including cell survival, growth, and migration.\nMINDY-1 is a downstream target of the epidermal growth factor receptor (EGFR), which is a key regulator of cellular signaling pathways. Upon activation of the EGFR, MINDY-1 is phosphorylated and activated, leading to the activation of the PI3K/Akt signaling pathway. Activation of this pathway can promote cell survival, proliferation, and migration, and is often implicated in cancer development and progression.\nMINDY-1 has been shown to play a role in various types of cancer, including breast, lung, and colon cancer, and is often overexpressed in these tumors. Overexpression of MINDY-1 has been linked to increased cancer cell proliferation, migration, and invasion, and is thought to contribute to the development and progression of cancer.\nIn summary, MINDY-1 is a key regulator of cellular signaling pathways, particularly the PI3K/Akt pathway, and plays a crucial role in the regulation of cellular processes such as cell proliferation, differentiation, and survival. Its overexpression is often associated with cancer development and progression, and it is a promising target for cancer therapy.",
    "llama-2-7b-chat-hf_fact_raw": "1. MINDY-1 (Mammary Interaction Network Downstream of EGFR 1) is a protein involved in cell proliferation, differentiation, and survival.\n2. MINDY-1 is a component of the PI3K/Akt signaling pathway.\n3. The protein is a downstream target of the epidermal growth factor receptor (EGFR).\n4. Overexpression of MINDY-1 has been linked to various types of cancer, including breast, lung, and colon cancer.\n5. MINDY-1 is considered a promising target for cancer therapy due to its role in cancer development and progression.",
    "llama-2-7b-chat-hf_fact": [
      "MINDY-1 (Mammary Interaction Network Downstream of EGFR 1) is a protein involved in cell proliferation, differentiation, and survival.",
      "MINDY-1 is a component of the PI3K/Akt signaling pathway.",
      "The protein is a downstream target of the epidermal growth factor receptor (EGFR).",
      "Overexpression of MINDY-1 has been linked to various types of cancer, including breast, lung, and colon cancer.",
      "MINDY-1 is considered a promising target for cancer therapy due to its role in cancer development and progression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific scientific literature or data to confirm or refute these detailed statements about the MINDY-1 protein, its pathways, and associations with cancer, I cannot accurately determine their truthfulness. Information about specific proteins and their roles in cellular processes is highly specialized, and would require access to up-to-date scientific research to verify these claims.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-7b-chat-hf_response": "There are several software packages available for the analysis of conserved genomic loci, including:\n1. PhyloBayes: PhyloBayes is a software package for inferring the evolutionary history of a set of genomic loci, including conserved regions. It uses a Bayesian approach and can incorporate multiple types of data, including DNA sequence, gene expression, and functional annotation.\n2. HYPHEN-GA: HYPHEN-GA is a software package for identifying and annotating conserved genomic regions. It uses a hidden Markov model to infer the evolutionary history of a set of genomic loci and can incorporate multiple types of data, including DNA sequence, gene expression, and functional annotation.\n3. GERP: GERP (Genomic Evolutionary Rate Profiling) is a software package for identifying and analyzing conserved genomic regions. It uses a Bayesian approach and can incorporate multiple types of data, including DNA sequence, gene expression, and functional annotation.\n4. ConServe: ConServe is a software package for identifying and annotating conserved genomic regions. It uses a hidden Markov model to infer the evolutionary history of a set of genomic loci and can incorporate multiple types of data, including DNA sequence, gene expression, and functional annotation.\n5. Prodigal: Prodigal is a software package for identifying and annotating conserved genomic regions. It uses a Bayesian approach and can incorporate multiple types of data, including DNA sequence, gene expression, and functional annotation.\n6. ABySS: ABySS (Assembler of Biological Sequences) is a software package for assembling genomic DNA sequences, including conserved regions. It uses a de novo assembly approach and can incorporate multiple types of data, including DNA sequence, gene expression, and functional annotation.\n7. SPAdes: SPAdes (Assembler of Spaced Reads) is a software package for assembling genomic DNA sequences, including conserved regions. It uses a de novo assembly approach and can incorporate multiple types of data, including DNA sequence, gene expression, and functional annotation.\n8. Canu: Canu (Comprehensive Annotation of Novel genomes) is a software package for annotating and analyzing conserved genomic regions. It",
    "llama-2-7b-chat-hf_fact_raw": "1. PhyloBayes is a software package that can be used to infer the evolutionary history of conserved genomic loci.\n2. HYPHEN-GA is a software package for identifying and annotating conserved genomic regions using hidden Markov models.\n3. GERP (Genomic Evolutionary Rate Profiling) is a software package for identifying and analyzing conserved genomic regions.\n4. ConServe is a software package that uses hidden Markov models to infer the evolutionary history of conserved genomic loci.\n5. ABySS (Assembler of Biological Sequences) is a software package for assembling genomic DNA sequences, including conserved regions.",
    "llama-2-7b-chat-hf_fact": [
      "PhyloBayes is a software package that can be used to infer the evolutionary history of conserved genomic loci.",
      "HYPHEN-GA is a software package for identifying and annotating conserved genomic regions using hidden Markov models.",
      "GERP (Genomic Evolutionary Rate Profiling) is a software package for identifying and analyzing conserved genomic regions.",
      "ConServe is a software package that uses hidden Markov models to infer the evolutionary history of conserved genomic loci.",
      "ABySS (Assembler of Biological Sequences) is a software package for assembling genomic DNA sequences, including conserved regions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: PhyloBayes is indeed a software package for phylogenetic reconstruction using Bayesian inference, which can be applied to study the evolutionary history of conserved genomic loci.\n   \n2. UNKNOWN: HYPHEN-GA does not appear to be a widely recognized or standard software package in genomic analysis, and without additional context or information, it is not possible to verify the accuracy of this statement.\n\n3. TRUE: GERP (Genomic Evolutionary Rate Profiling) is indeed a program designed to identify and analyze conserved elements in multiple genome alignments.\n\n4. UNKNOWN: ConServe is not a well-known software package in genomic conservation analysis. Without additional context, it is not possible to determine the accuracy of this statement.\n\n5. TRUE: ABySS (Assembler of Biological Sequences) is a de novo sequence assembler designed for assembling large genomic DNA sequences, which can include conserved regions as part of larger genomic projects.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_response": "The PIEZO2 gene encodes a protein called PIEZO2, which is a mechanosensitive ion channel that plays a crucial role in sensing and responding to mechanical stimuli in various tissues, including the nervous system, muscles, and inner ear. Mutations in the PIEZO2 gene have been associated with several human diseases, including:\n1. PIEZO2-related disorders: These are a group of rare genetic disorders caused by mutations in the PIEZO2 gene. The main symptoms of these disorders include hearing loss, balance problems, and muscle weakness.\n2. Usher syndrome type II: This is a rare genetic disorder that affects the inner ear and causes hearing loss, balance problems, and muscle weakness. Mutations in the PIEZO2 gene are a common cause of Usher syndrome type II.\n3. Charcot-Marie-Tooth disease type 2B: This is a rare genetic disorder that affects the peripheral nervous system and causes muscle weakness and wasting, primarily in the hands and feet. Mutations in the PIEZO2 gene have been identified in some cases of Charcot-Marie-Tooth disease type 2B.\nIt is important to note that these are just a few examples of diseases associated with the PIEZO2 gene, and that other diseases may also be related to this gene.",
    "llama-2-7b-chat-hf_fact_raw": "1. PIEZO2-related disorders can involve hearing loss, balance problems, and muscle weakness and are caused by mutations in the PIEZO2 gene.\n2. Usher syndrome type II, which is characterized by hearing loss and balance issues, can be caused by mutations in the PIEZO2 gene.\n3. Some cases of Charcot-Marie-Tooth disease type 2B, which causes muscle weakness and wasting primarily in the hands and feet, are associated with mutations in the PIEZO2 gene.",
    "llama-2-7b-chat-hf_fact": [
      "PIEZO2-related disorders can involve hearing loss, balance problems, and muscle weakness and are caused by mutations in the PIEZO2 gene.",
      "Usher syndrome type II, which is characterized by hearing loss and balance issues, can be caused by mutations in the PIEZO2 gene.",
      "Some cases of Charcot-Marie-Tooth disease type 2B, which causes muscle weakness and wasting primarily in the hands and feet, are associated with mutations in the PIEZO2 gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Usher syndrome type II, which is characterized by hearing loss and balance issues, is typically not caused by mutations in the PIEZO2 gene. It is usually associated with mutations in other genes such as USH2A, GPR98, and DFNB31.\n3. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-7b-chat-hf_response": "ERAP1-ERAP2 dimerization promotes the editing of RNA by the RNA editing complex. The editing complex is responsible for the conversion of adenosine (A) to inosine (I) in pre-mRNA, which can result in the alteration of the protein sequence. This process is important for the regulation of gene expression and can also affect the stability and localization of mRNAs.\nIn the context of gene expression, ERAP1-ERAP2 dimerization promotes the editing of RNA by:\n1. Recruiting the RNA editing complex: ERAP1-ERAP2 dimerization brings the RNA editing complex to the target RNA, which is necessary for the editing reaction to occur.\n2. Positioning the RNA editing complex: Once the editing complex is recruited, ERAP1-ERAP2 dimerization helps to position the complex in the correct location on the RNA molecule.\n3. Activating the editing reaction: The dimerization of ERAP1 and ERAP2 activates the editing reaction by bringing the active sites of the editing enzymes into close proximity, allowing them to interact and catalyze the editing reaction.\nIn summary, ERAP1-ERAP2 dimerization promotes the editing of RNA by recruiting the RNA editing complex, positioning it correctly on the RNA molecule, and activating the editing reaction.",
    "llama-2-7b-chat-hf_fact_raw": "1. ERAP1-ERAP2 dimerization promotes the editing of RNA by the RNA editing complex.\n2. The RNA editing process involves the conversion of adenosine (A) to inosine (I) in pre-mRNA.\n3. This RNA editing process can result in the alteration of the protein sequence that is produced.\n4. RNA editing is important for the regulation of gene expression.\n5. RNA editing can also affect the stability and localization of mRNAs.",
    "llama-2-7b-chat-hf_fact": [
      "ERAP1-ERAP2 dimerization promotes the editing of RNA by the RNA editing complex.",
      "The RNA editing process involves the conversion of adenosine (A) to inosine (I) in pre-mRNA.",
      "This RNA editing process can result in the alteration of the protein sequence that is produced.",
      "RNA editing is important for the regulation of gene expression.",
      "RNA editing can also affect the stability and localization of mRNAs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ERAP1-ERAP2 dimerization is related to trimming of peptides for MHC class I presentation and does not directly promote the editing of RNA by the RNA editing complex.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-7b-chat-hf_response": "R-spondin 1 and Noggin are two proteins that have been implicated in the regulation of gallbladder development and function. Here is a brief overview of their functions in non-damaged gallbladders:\nR-spondin 1:\n* R-spondin 1 is a secreted protein that is produced by the liver and pancreas and is also expressed in the gallbladder.\n* In non-damaged gallbladders, R-spondin 1 plays a role in regulating the proliferation and differentiation of gallbladder epithelial cells.\n* R-spondin 1 has been shown to inhibit the proliferation of gallbladder epithelial cells and promote their differentiation into mature epithelial cells.\n* R-spondin 1 also regulates the expression of genes involved in bile acid synthesis and transport in the gallbladder.\nNoggin:\n* Noggin is a secreted protein that is produced by the liver and is also expressed in the gallbladder.\n* In non-damaged gallbladders, Noggin regulates the proliferation and differentiation of gallbladder epithelial cells.\n* Noggin has been shown to inhibit the proliferation of gallbladder epithelial cells and promote their differentiation into mature epithelial cells.\n* Noggin also regulates the expression of genes involved in bile acid synthesis and transport in the gallbladder.\nIn summary, R-spondin 1 and Noggin are both important regulators of gallbladder development and function in non-damaged gallbladders. They play a role in regulating the proliferation and differentiation of gallbladder epithelial cells and the expression of genes involved in bile acid synthesis and transport. Dysregulation of these proteins has been implicated in the development of gallbladder diseases such as gallbladder cancer and cholestasis.",
    "llama-2-7b-chat-hf_fact_raw": "1. R-spondin 1 is a secreted protein produced by the liver and pancreas and expressed in the gallbladder.\n2. R-spondin 1 regulates the proliferation and differentiation of gallbladder epithelial cells in non-damaged gallbladders.\n3. Noggin is a secreted protein produced by the liver and expressed in the gallbladder.\n4. Noggin regulates the proliferation and differentiation of gallbladder epithelial cells in non-damaged gallbladders.\n5. Both R-spondin 1 and Noggin regulate the expression of genes involved in bile acid synthesis and transport in the gallbladder.",
    "llama-2-7b-chat-hf_fact": [
      "R-spondin 1 is a secreted protein produced by the liver and pancreas and expressed in the gallbladder.",
      "R-spondin 1 regulates the proliferation and differentiation of gallbladder epithelial cells in non-damaged gallbladders.",
      "Noggin is a secreted protein produced by the liver and expressed in the gallbladder.",
      "Noggin regulates the proliferation and differentiation of gallbladder epithelial cells in non-damaged gallbladders.",
      "Both R-spondin 1 and Noggin regulate the expression of genes involved in bile acid synthesis and transport in the gallbladder."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe provided statements require specific biological knowledge about the functions of R-spondin 1 and Noggin and their expression patterns and roles in the liver, pancreas, and gallbladder. This information is not commonly known outside of specialized fields of biology or medicine. Without access to appropriate scientific literature or current databases to confirm these statements, their truthfulness cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-7b-chat-hf_response": "Yes, NADPH oxidase 5 (NOX5) is a heterotetrameric enzyme that consists of four subunits: NOX5A, NOX5B, NOX5C, and NOX5D. These subunits work together to form the active enzyme complex.\nThe specific subunits that make up the NOX5 complex can vary depending on the cell type and the specific isoform of the enzyme. However, in general, the core subunits of NOX5 are:\n1. NOX5A: This subunit is the catalytic subunit that contains the NADPH oxidase domain and is responsible for the transfer of electrons from NADPH to oxygen to produce superoxide.\n2. NOX5B: This subunit is involved in the transfer of electrons from the substrate to the catalytic subunit and is also important for the stability of the enzyme complex.\n3. NOX5C: This subunit is involved in the regulation of the enzyme's activity and is important for the cellular localization of the enzyme.\n4. NOX5D: This subunit is involved in the interaction with other proteins and regulatory factors that modulate the activity of the enzyme.\nThe specific composition of the NOX5 complex can vary depending on the cell type and the specific isoform of the enzyme. For example, in the brain, NOX5 is a heterotetramer of NOX5A, NOX5B, NOX5C, and NOX5D, while in the liver, it is a heterotetramer of NOX5A, NOX5B, NOX5C, and NOX5E.\nIn summary, NADPH oxidase 5 requires at least four subunits (NOX5A, NOX5B, NOX5C, and NOX5D) to function as a heterotetrameric enzyme complex. The specific composition of the complex can vary depending on the cell type and the specific isoform of the enzyme.",
    "llama-2-7b-chat-hf_fact_raw": "1. NADPH oxidase 5 (NOX5) is a heterotetrameric enzyme that consists of four subunits.\n2. The four core subunits of the NOX5 complex are NOX5A, NOX5B, NOX5C, and NOX5D.\n3. The catalytic subunit NOX5A contains the NADPH oxidase domain and is responsible for transferring electrons from NADPH to oxygen.\n4. NOX5B assists with electron transfer to the catalytic subunit and contributes to the stability of the enzyme complex.\n5. NOX5C plays a role in the regulation of the enzyme's activity and in cellular localization.",
    "llama-2-7b-chat-hf_fact": [
      "NADPH oxidase 5 (NOX5) is a heterotetrameric enzyme that consists of four subunits.",
      "The four core subunits of the NOX5 complex are NOX5A, NOX5B, NOX5C, and NOX5D.",
      "The catalytic subunit NOX5A contains the NADPH oxidase domain and is responsible for transferring electrons from NADPH to oxygen.",
      "NOX5B assists with electron transfer to the catalytic subunit and contributes to the stability of the enzyme complex.",
      "NOX5C plays a role in the regulation of the enzyme's activity and in cellular localization."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: NADPH oxidase 5 (NOX5) is not a heterotetrameric enzyme. It is a single polypeptide enzyme with no subunits.\n2. FALSE [correction]: Since NOX5 does not have subunits, there are no such core subunits named NOX5A, NOX5B, NOX5C, and NOX5D.\n3. UNKNOWN: The statement might reference an incorrect model of NOX5, but in reality, NOX5 as a single enzyme contains a NADPH oxidase domain.\n4. FALSE [correction]: There is no NOX5B subunit as NOX5 functions as a single polypeptide enzyme.\n5. FALSE [correction]: Given that NOX5C does not exist as a part of the NOX5 complex (which does not have subunits), it cannot play a role in regulation or localization of the enzyme.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-7b-chat-hf_response": "Furin and hepcidin are two proteins that are connected through their roles in regulating iron metabolism. Here's how they are related:\n1. Furin: Furin is a protease enzyme that is involved in the processing and activation of various proteins in the cell. It is particularly important in the regulation of iron metabolism, as it is involved in the processing of the iron-regulatory protein hepcidin.\n2. Hepcidin: Hepcidin is a hormone that regulates iron absorption and distribution in the body. It is produced in the liver in response to iron levels and binds to ferroportin, a protein that regulates iron export from cells, leading to its degradation. This results in the reduction of iron release from cells and the maintenance of iron homeostasis.\n3. Interaction between furin and hepcidin: Furin is involved in the processing and activation of hepcidin, particularly in the cleavage of hepcidin into its active form. This processing is important for the proper regulation of iron metabolism, as the active form of hepcidin is more potent in inhibiting iron export from cells.\n4. Regulation of iron metabolism: The interaction between furin and hepcidin is critical for regulating iron metabolism in the body. Furin's processing of hepcidin allows for the proper activation of hepcidin, which in turn regulates iron export from cells and maintains iron homeostasis.\nIn summary, furin and hepcidin are connected through their roles in regulating iron metabolism. Furin is involved in the processing and activation of hepcidin, which is essential for the proper regulation of iron metabolism in the body.",
    "llama-2-7b-chat-hf_fact_raw": "1. Furin is a protease enzyme that is involved in the regulation of iron metabolism.\n2. Hepcidin is a hormone that regulates iron absorption and distribution in the body.\n3. Hepcidin is produced in the liver in response to iron levels.\n4. Furin is involved in the activation of hepcidin by processing it into its active form.\n5. Active hepcidin inhibits iron export from cells by binding to and leading to the degradation of ferroportin.",
    "llama-2-7b-chat-hf_fact": [
      "Furin is a protease enzyme that is involved in the regulation of iron metabolism.",
      "Hepcidin is a hormone that regulates iron absorption and distribution in the body.",
      "Hepcidin is produced in the liver in response to iron levels.",
      "Furin is involved in the activation of hepcidin by processing it into its active form.",
      "Active hepcidin inhibits iron export from cells by binding to and leading to the degradation of ferroportin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Furin is a protease enzyme that is involved in the activation of various precursor proteins, including hormones, growth factors, and receptors, rather than in the regulation of iron metabolism directly.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Furin is involved in the maturation/activation of various proteins by cleaving their precursors, but there is no direct evidence that furin is responsible for the activation of hepcidin. It is proprotein convertases like matriptase-2 that may be more directly involved in hepcidin regulation.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-7b-chat-hf_response": "The largest metabolic gene cluster in yeast is the glycolysis/gluconeogenesis gene cluster, also known as the \"Hxk\" or \"Hxt\" gene cluster. This gene cluster contains a group of genes involved in the breakdown and synthesis of glucose, which is the primary source of energy for yeast. The cluster includes the following genes:\n* HXK1 (Phosphoglucose isomerase)\n* HXK2 (Glucose-6-phosphatase)\n* HXT1 (Glucose transporter)\n* HXT2 (Glucose transporter)\n* HXT3 (Glucose transporter)\n* HXT4 (Glucose transporter)\n* HXT5 (Glucose transporter)\n* GNP1 (Glyceraldehyde-3-phosphate dehydrogenase)\n* GNP2 (Glyceraldehyde-3-phosphate dehydrogenase)\n* GNP3 (Glyceraldehyde-3-phosphate dehydrogenase)\n* PFK1 (Phosphofructokinase)\n* PFK2 (Phosphofructokinase)\n* PKM1 (Phosphoenolpyruvate kinase)\n* PKM2 (Phosphoenolpyruvate kinase)\n* TPI1 (Triosephosphate isomerase)\n* TPI2 (Triosephosphate isomerase)\nThis gene cluster is responsible for the breakdown of glucose to pyruvate, which can then be used to produce ATP through the electron transport chain. The genes in this cluster are highly co-regulated and work together to ensure the efficient breakdown and synthesis of glucose in yeast.",
    "llama-2-7b-chat-hf_fact_raw": "1. The largest metabolic gene cluster in yeast is the glycolysis/gluconeogenesis gene cluster.\n2. This gene cluster is also known as the \"Hxk\" or \"Hxt\" gene cluster.\n3. The glycolysis/gluconeogenesis gene cluster contains genes involved in the breakdown and synthesis of glucose.\n4. The genes in the glycolysis/gluconeogenesis gene cluster are highly co-regulated.\n5. This gene cluster is responsible for the breakdown of glucose to pyruvate in yeast.",
    "llama-2-7b-chat-hf_fact": [
      "The largest metabolic gene cluster in yeast is the glycolysis/gluconeogenesis gene cluster.",
      "This gene cluster is also known as the \"Hxk\" or \"Hxt\" gene cluster.",
      "The glycolysis/gluconeogenesis gene cluster contains genes involved in the breakdown and synthesis of glucose.",
      "The genes in the glycolysis/gluconeogenesis gene cluster are highly co-regulated.",
      "This gene cluster is responsible for the breakdown of glucose to pyruvate in yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: It is not accurate to refer to glycolysis/gluconeogenesis pathway-related genes as a \"cluster\" because, in yeast genomic organization, the genes involved in these pathways are not necessarily clustered together as they can be scattered throughout the genome.\n\n2. FALSE [correction]: \"Hxk\" refers to hexokinase, an enzyme involved in glycolysis, and \"Hxt\" refers to a family of hexose transporters in yeast. Neither of these designations is typically used to describe a gene cluster for glycolysis/gluconeogenesis.\n\n3. TRUE: The glycolysis/gluconeogenesis pathway does involve genes responsible for both the breakdown (glycolysis) and synthesis (gluconeogenesis) of glucose.\n\n4. TRUE: Genes involved in metabolic pathways like glycolysis and gluconeogenesis are often co-regulated to respond to the cell's metabolic needs.\n\n5 TRUE: In glycolysis, glucose is indeed broken down to pyruvate in yeast cells, which is a central pathway in their metabolism.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-7b-chat-hf_response": "LIMT (Long Non-Coding RNA in Testis) is a long non-coding RNA (lncRNA) that is specifically expressed in the testis and plays a crucial role in the regulation of male fertility. Here are some of the key functions of LIMT lncRNA:\n1. Regulation of spermatogenesis: LIMT lncRNA regulates the process of spermatogenesis, which is the development of sperm cells, by modulating the expression of genes involved in this process.\n2. Maintenance of spermatid viability: LIMT lncRNA helps to maintain the viability of spermatids, which are immature sperm cells, by regulating the expression of genes involved in cell survival and proliferation.\n3. Inhibition of apoptosis: LIMT lncRNA has been shown to inhibit apoptosis, or programmed cell death, in spermatids, which is important for maintaining the health and function of the male reproductive system.\n4. Regulation of gene expression: LIMT lncRNA can regulate the expression of genes involved in various cellular processes, including cell proliferation, differentiation, and survival.\n5. Epigenetic modification: LIMT lncRNA can also regulate gene expression by modifying chromatin structure and recruiting histone-modifying enzymes, which can alter the activity of genes involved in spermatogenesis.\n6. Male fertility: Dysregulation of LIMT lncRNA has been implicated in male infertility, and studies have shown that altered expression of LIMT lncRNA can lead to abnormal spermatogenesis and reduced fertility.\n7. Cancer: LIMT lncRNA has also been implicated in the development and progression of testicular cancer, and studies have shown that altered expression of LIMT lncRNA can lead to the development of cancer in the testis.\nIn summary, LIMT lncRNA plays a crucial role in the regulation of male fertility and testicular cancer by modulating the expression of genes involved in spermatogenesis, maintaining spermatid viability, inhibiting apoptosis, regulating gene expression, and",
    "llama-2-7b-chat-hf_fact_raw": "1. LIMT (Long Non-Coding RNA in Testis) lncRNA is specifically expressed in the testis.\n2. LIMT lncRNA regulates the process of spermatogenesis by modulating gene expression involved in this process.\n3. LIMT lncRNA plays a role in maintaining the viability of spermatids by regulating gene expression related to cell survival and proliferation.\n4. LIMT lncRNA inhibits apoptosis in spermatids, which is important for the health of the male reproductive system.\n5. Dysregulation of LIMT lncRNA has been implicated in male infertility and can lead to abnormal spermatogenesis and reduced fertility.",
    "llama-2-7b-chat-hf_fact": [
      "LIMT (Long Non-Coding RNA in Testis) lncRNA is specifically expressed in the testis.",
      "LIMT lncRNA regulates the process of spermatogenesis by modulating gene expression involved in this process.",
      "LIMT lncRNA plays a role in maintaining the viability of spermatids by regulating gene expression related to cell survival and proliferation.",
      "LIMT lncRNA inhibits apoptosis in spermatids, which is important for the health of the male reproductive system.",
      "Dysregulation of LIMT lncRNA has been implicated in male infertility and can lead to abnormal spermatogenesis and reduced fertility."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nEach statement revolves around the potential functions and importance of the LIMT (Long Non-Coding RNA in Testis) lncRNA. These statements reflect current understandings of the role of lncRNAs in testis-specific processes such as spermatogenesis. LIMT lncRNA has been studied for its expression and function in the testis, and the statements above are consistent with scientific findings that suggest its role in spermatogenesis, cell survival, and proliferation, particularly regarding spermatids. Dysregulation of such lncRNAs has been linked to reproductive issues such as male infertility, implying an association between LIMT lncRNA levels and fertility outcomes. However, the specificity of these statements to LIMT would depend on the most recent research available as of my knowledge cutoff date in 2023.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-7b-chat-hf_response": "There are several R packages and bioconductor packages that can be used for performing SNP enrichment analysis. Some of the popular ones include:\n1. 'SNPset': This package provides a comprehensive set of tools for SNP set analysis, including enrichment analysis for various types of genomic features.\n2. 'GSEA': Gene Set Enrichment Analysis (GSEA) is a popular bioconductor package that can be used for performing enrichment analysis of SNPs in various genomic features, such as gene ontology (GO) terms, pathways, and networks.\n3. 'SNPsnp': This package provides a collection of tools for SNP analysis, including enrichment analysis for SNPs in various genomic features.\n4. 'Enrichr': This package provides a comprehensive set of tools for enrichment analysis of genomic features, including SNPs, in various types of data, such as gene expression, mRNA sequencing, and genome-wide association studies (GWAS).\n5. 'MAS5': The Matrix Accessible Space (MAS) is a bioconductor package that can be used for performing enrichment analysis of SNPs in various genomic features, such as gene ontology (GO) terms, pathways, and networks.\n6. 'GCTA': The Genome-Wide Complex Trait Analysis (GCTA) package can be used for performing enrichment analysis of SNPs in various genomic features, such as gene ontology (GO) terms, pathways, and networks.\n7. 'Plink': This package can be used for performing enrichment analysis of SNPs in various genomic features, such as gene ontology (GO) terms, pathways, and networks.\n8. 'SnpSift': This package provides a comprehensive set of tools for SNP analysis, including enrichment analysis for SNPs in various genomic features.\n9. 'SnpEff': This package provides a comprehensive set of tools for SNP analysis, including enrichment analysis for SNPs in various genomic features.\n10. 'snpeff-db': This package provides a comprehensive set of tools for SNP analysis, including enrichment analysis for SNPs in various genomic features.\nIt's worth",
    "llama-2-7b-chat-hf_fact_raw": "1. The 'SNPset' package includes tools for SNP enrichment analysis.\n2. Gene Set Enrichment Analysis (GSEA) is a package available through bioconductor for SNP enrichment analysis.\n3. 'Enrichr' is a package designed for enrichment analysis of various genomic features including SNPs.\n4. 'GCTA', the Genome-Wide Complex Trait Analysis package, can be used for SNP enrichment analysis.\n5. 'Plink' is a package that offers functionality for SNP enrichment analysis.",
    "llama-2-7b-chat-hf_fact": [
      "The 'SNPset' package includes tools for SNP enrichment analysis.",
      "Gene Set Enrichment Analysis (GSEA) is a package available through bioconductor for SNP enrichment analysis.",
      "'Enrichr' is a package designed for enrichment analysis of various genomic features including SNPs.",
      "'GCTA', the Genome-Wide Complex Trait Analysis package, can be used for SNP enrichment analysis.",
      "'Plink' is a package that offers functionality for SNP enrichment analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [corjection]: Gene Set Enrichment Analysis (GSEA) is a method, rather than a package, for analyzing gene sets in expression profiling data. It is not designed exclusively for SNP enrichment analysis.\n3. UNKNOWN\n4. FALSE [correction]: 'GCTA' (Genome-Wide Complex Trait Analysis) is a tool for the analysis of complex traits in genetic association studies, particularly for estimating the genetic variance explained by all SNPs for a particular trait. It is not specifically for SNP enrichment analysis.\n5. FALSE [correction]: 'Plink' is a tool designed for the analysis of genotypic and phenotypic data, with a primary focus on genome-wide association studies (GWAS) and population-based linkage analyses, not enrichment analysis.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-7b-chat-hf_response": "Radial glial cells are a type of glial cell that are found in the neural tube and play a crucial role in the development and maintenance of the central nervous system (CNS). Ependymal cells are a type of glial cell that line the ventricles of the CNS and are involved in the production and circulation of cerebrospinal fluid (CSF). The specification of radial glial cells to ependymal cells is a complex process that involves the interaction of multiple key players. Here are some of the key players involved in radial glial specification to ependymal cells:\n1. Notch signaling pathway: The Notch signaling pathway is a critical regulator of radial glial cell fate specification. Notch ligands, such as Delta-like 1 (Dll1) and Delta-like 4 (Dll4), are expressed on the surface of nearby cells and bind to the Notch receptor on radial glial cells, triggering a cascade of downstream signaling events that promote the specification of radial glial cells to ependymal cells.\n2. Wnt signaling pathway: The Wnt signaling pathway is also involved in the regulation of radial glial cell fate specification. Wnt ligands, such as Wnt3a, promote the proliferation and maintenance of radial glial cells and inhibit their specification to ependymal cells.\n3. Shh signaling pathway: The Shh signaling pathway is another important regulator of radial glial cell fate specification. Shh ligands, such as Sonic hedgehog (Shh), promote the specification of radial glial cells to ependymal cells by activating the expression of genes involved in ependymal cell fate.\n4. Bone morphogenetic protein (BMP) signaling pathway: BMP ligands, such as BMP4, also play a role in the regulation of radial glial cell fate specification. BMP4 promotes the specification of radial glial cells to ependymal cells by activating the expression of genes involved in ependymal cell fate.\n5. Glial cell line-derived neurotrophic factor (GDNF): GDNF is a neurotrophin that is expressed in the neural tube and plays a role in the",
    "llama-2-7b-chat-hf_fact_raw": "1. Radial glial cells develop and maintain the central nervous system (CNS).\n2. Ependymal cells line the ventricles of the CNS and are involved in the production and circulation of cerebrospinal fluid (CSF).\n3. The Notch signaling pathway is a critical regulator of radial glial cell fate specification to ependymal cells.\n4. The Wnt signaling pathway influences the proliferation and maintenance of radial glial cells and can inhibit their specification to ependymal cells.\n5. The Shh signaling pathway promotes the specification of radial glial cells to ependymal cells by activating genes involved in ependymal cell fate.",
    "llama-2-7b-chat-hf_fact": [
      "Radial glial cells develop and maintain the central nervous system (CNS).",
      "Ependymal cells line the ventricles of the CNS and are involved in the production and circulation of cerebrospinal fluid (CSF).",
      "The Notch signaling pathway is a critical regulator of radial glial cell fate specification to ependymal cells.",
      "The Wnt signaling pathway influences the proliferation and maintenance of radial glial cells and can inhibit their specification to ependymal cells.",
      "The Shh signaling pathway promotes the specification of radial glial cells to ependymal cells by activating genes involved in ependymal cell fate."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Radial glial cells are indeed known to develop and maintain the structure of the central nervous system by serving as progenitor cells and guiding neurons during migration.\n\n2. TRUE: Ependymal cells do line the ventricles of the central nervous system and play a role in the production, circulation, and possibly the filtration of cerebrospinal fluid.\n\n3. TRUE: The Notch signaling pathway is indeed a critical regulator of neural cell fate, including the fate specification of radial glial cells to ependymal cells. It is heavily involved in the maintenance of neural progenitor characteristics and the decision of these cells to differentiate.\n\n4. TRUE: The Wnt signaling pathway is involved in the regulation of proliferation and the maintenance of radial glial cells, among other roles in CNS development. It can also influence cell fate decisions, but I cannot confirm the specific interaction about Wnt inhibiting the specification of radial glial cells to ependymal cells without context; cell fate regulation is complex and context-dependent, so this statement could potentially vary based on the specific conditions or model system.\n\n5. TRUE: The Sonic Hedgehog (Shh) signaling pathway is known to play a critical role in the differentiation of various cell types in the CNS. It influences the promotion of certain cell fates, including the specification of radial glial cells to different cell types, such as ependymal cells, by regulating the transcription of genes necessary for these lineages. However, the mechanisms can be quite nuanced and context-dependent.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-7b-chat-hf_response": "Triple negative gliomas are a type of glioma, which is a brain tumor that originates from glial cells. These tumors are characterized by the lack of expression of certain markers, including:\n1. Tumor suppressor proteins: Triple negative gliomas typically lack the expression of tumor suppressor proteins such as p53, p21, and p27.\n2. Estrogen receptors: These tumors usually do not express estrogen receptors (ERα and ERβ).\n3. Progesterone receptors: Triple negative gliomas also lack the expression of progesterone receptors (PR).\n4. Epidermal growth factor receptor (EGFR): These tumors often have low levels of EGFR expression.\n5. Cyclin D1: Triple negative gliomas typically have low levels of cyclin D1 expression.\n6. Methylation status: Triple negative gliomas are often characterized by a specific methylation profile, with hypermethylation of the O6-methylguanine DNA methyltransferase (MGMT) gene and hypomethylation of the p16INK4a gene.\n7. Genetic alterations: Triple negative gliomas often have genetic alterations in genes such as TP53, CDKN2A, and STK11.\n8. Immunophenotype: Triple negative gliomas typically have a distinct immunophenotype, with expression of markers such as CD45, CD13, and CD34, but lack of expression of markers such as MART-1 and HLA-DR.\n9. Clinical features: Triple negative gliomas tend to have a more aggressive clinical course than other types of gliomas, with a higher risk of recurrence and poorer overall survival.\n10. Prognosis: The prognosis for patients with triple negative gliomas is generally poorer than for those with other types of gliomas, with a median survival time of around 10-15 months.\nIt's important to note that the exact criteria for diagnosing triple negative gliomas can vary depending on the specific study or institution, and some studies may use different criteria or combinations of markers to",
    "llama-2-7b-chat-hf_fact_raw": "1. Triple negative gliomas lack the expression of tumor suppressor proteins p53, p21, and p27.\n2. Estrogen receptors (ERα and ERβ) are typically not expressed in triple negative gliomas.\n3. Triple negative gliomas do not express progesterone receptors (PR).\n4. Triple negative gliomas often have a specific methylation profile, including hypermethylation of the MGMT gene and hypomethylation of the p16INK4a gene.\n5. The median survival time for patients with triple negative gliomas is generally around 10-15 months.",
    "llama-2-7b-chat-hf_fact": [
      "Triple negative gliomas lack the expression of tumor suppressor proteins p53, p21, and p27.",
      "Estrogen receptors (ERα and ERβ) are typically not expressed in triple negative gliomas.",
      "Triple negative gliomas do not express progesterone receptors (PR).",
      "Triple negative gliomas often have a specific methylation profile, including hypermethylation of the MGMT gene and hypomethylation of the p16INK4a gene.",
      "The median survival time for patients with triple negative gliomas is generally around 10-15 months."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Triple negative gliomas lack the expression of tumor suppressor proteins such as p53, but there is no standard definition indicating they lack p21 and p27 specifically.\n2. TRUE: Triple-negative usually refers to the absence of the three common receptors, including estrogen receptors.\n3. TRUE: Triple negative gliomas typically do not express hormone receptors such as progesterone receptors.\n4. TRUE: Gliomas can indeed have a specific methylation profile, but this should be interpreted with caution without specific context since the definition of \"triple negative\" varies across studies and could refer to multiple characteristics.\n5. UNKNOWN: Without specific context or a reference for this statistic, the median survival time for patients with triple negative gliomas is not certain and can vary widely depending on many factors, such as treatment and tumor stage at diagnosis.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-7b-chat-hf_response": "TOPAZ1 (Topoisomerase II-associated protein A1) is a protein that plays a crucial role in the regulation of DNA topology and gene expression. It is a histone-fold protein that is involved in the regulation of chromatin structure and gene expression, particularly during DNA replication and repair.\nTOPAZ1 is a member of the topoisomerase II family of proteins, which are involved in the relaxation of DNA supercoils. Topoisomerase II is a enzyme that relaxes DNA supercoils by cutting and ligating the DNA strands, allowing the DNA to contract or expand. TOPAZ1 is a regulatory protein that is recruited to the DNA damage site after repair is complete, where it helps to stabilize the repaired DNA structure.\nTOPAZ1 has been shown to be involved in a variety of cellular processes, including DNA repair, gene expression, and cell cycle regulation. It is also a tumor suppressor, and its loss of function has been implicated in the development of certain types of cancer.\nIn summary, TOPAZ1 is a protein that plays a crucial role in the regulation of DNA topology and gene expression, particularly during DNA replication and repair. It is a member of the topoisomerase II family of proteins and is involved in the stabilization of repaired DNA structures.",
    "llama-2-7b-chat-hf_fact_raw": "1. TOPAZ1 is involved in the regulation of DNA topology and gene expression.\n2. It is a member of the topoisomerase II family of proteins.\n3. Topoisomerase II enzymes relax DNA supercoils through cutting and ligating DNA strands.\n4. TOPAZ1 is recruited to DNA damage sites after repair to help stabilize the repaired DNA structure.\n5. Loss of function of TOPAZ1 has been implicated in the development of certain types of cancer.",
    "llama-2-7b-chat-hf_fact": [
      "TOPAZ1 is involved in the regulation of DNA topology and gene expression.",
      "It is a member of the topoisomerase II family of proteins.",
      "Topoisomerase II enzymes relax DNA supercoils through cutting and ligating DNA strands.",
      "TOPAZ1 is recruited to DNA damage sites after repair to help stabilize the repaired DNA structure.",
      "Loss of function of TOPAZ1 has been implicated in the development of certain types of cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: TOPAZ1 is likely not a correct designation for any known protein involved in DNA topology regulation. However, Topo II α (Topoisomerase II alpha) is a member of the topoisomerase II family of proteins.\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nPlease note that TOPAZ1 may have been a typo or an incorrect term used instead of a known protein like Topoisomerase II. Corrections and responses have been provided with this assumption in mind.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-7b-chat-hf_response": "The expression of GATA-1 isoforms is controlled by multiple genes and factors, including:\n1. GATA-1 gene: The GATA-1 gene encodes the transcription factor GATA-1, which is essential for the expression of genes involved in erythropoiesis and the development of red blood cells. The GATA-1 gene contains multiple exons that are spliced together to produce different isoforms of the protein.\n2. Splicing factors: The splicing of GATA-1 mRNA is regulated by a variety of splicing factors, including SRPK1, SRPK2, and SC35. These factors recognize specific sequences in the pre-mRNA and facilitate the removal of introns and the joining of exons, leading to the production of different isoforms of GATA-1.\n3. MicroRNAs (miRNAs): MiRNAs are small non-coding RNAs that bind to messenger RNAs (mRNAs) and prevent their translation into protein. Certain miRNAs, such as miR-15a and miR-16, have been shown to regulate the expression of GATA-1 isoforms by binding to the 3' untranslated region (UTR) of the GATA-1 mRNA.\n4. Transcription factors: Other transcription factors, such as NF-κB and AP-1, can also regulate the expression of GATA-1 isoforms by binding to specific DNA sequences in the GATA-1 promoter region.\nIn summary, the expression of GATA-1 isoforms is controlled by a complex interplay of genetic and epigenetic factors, including the GATA-1 gene, splicing factors, miRNAs, and transcription factors.",
    "llama-2-7b-chat-hf_fact_raw": "1. The GATA-1 gene encodes the transcription factor GATA-1, which plays a role in erythropoiesis and the development of red blood cells.\n2. Splicing of GATA-1 mRNA is regulated by splicing factors including SRPK1, SRPK2, and SC35.\n3. MicroRNAs such as miR-15a and miR-16 can regulate the expression of GATA-1 isoforms by binding to the 3' UTR of the GATA-1 mRNA.\n4. Transcription factors like NF-κB and AP-1 can regulate the expression of GATA-1 isoforms by binding to specific sequences in the GATA-1 promoter region.",
    "llama-2-7b-chat-hf_fact": [
      "The GATA-1 gene encodes the transcription factor GATA-1, which plays a role in erythropoiesis and the development of red blood cells.",
      "Splicing of GATA-1 mRNA is regulated by splicing factors including SRPK1, SRPK2, and SC35.",
      "MicroRNAs such as miR-15a and miR-16 can regulate the expression of GATA-1 isoforms by binding to the 3' UTR of the GATA-1 mRNA.",
      "Transcription factors like NF-κB and AP-1 can regulate the expression of GATA-1 isoforms by binding to specific sequences in the GATA-1 promoter region."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE - MicroRNAs can regulate the expression of various genes, including those encoding transcription factors, by binding to the 3' UTR of mRNA, though the specific miRNAs listed may not have been experimentally validated for GATA-1 at the time of my last update.\n4. TRUE - Transcription factors such as NF-κB and AP-1 are known to regulate gene expression by binding to specific promoter regions, and while they could potentially regulate the expression of GATA-1, precise regulatory interactions for NF-κB and AP-1 with GATA-1 would require direct experimental evidence to confirm.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-7b-chat-hf_response": "MIRA-seq is a next-generation sequencing (NGS) technology that enables the simultaneous analysis of multiple RNA molecules (miRNAs) in a single sequencing run. It is a powerful tool for understanding the complex regulatory networks involved in various biological processes, including development, cell differentiation, and disease progression.\nIn MIRA-seq, RNA molecules are first enriched using molecular inversion probes (MIPs), which are designed to bind specifically to the 3' untranslated regions (UTRs) of target miRNAs. The MIPs are then sequenced using Next-Generation Sequencing (NGS) technologies, such as Illumina or PacBio.\nThe resulting data are then analyzed using computational methods to identify the enriched miRNAs and to quantify their expression levels. MIRA-seq can be used to analyze the expression of multiple miRNAs in a single sample, allowing researchers to identify changes in miRNA expression patterns that may be associated with specific biological processes or diseases.\nMIRA-seq has several advantages over other methods for analyzing miRNA expression, including:\n1. High resolution: MIRA-seq can resolve miRNAs with high resolution, allowing researchers to detect even lowly expressed miRNAs.\n2. Sensitivity: MIRA-seq is highly sensitive, allowing researchers to detect small changes in miRNA expression levels.\n3. Specificity: MIRA-seq can specifically detect miRNAs without amplifying or altering their expression levels, which can lead to false positives or negatives.\n4. Cost-effective: MIRA-seq is relatively cost-effective compared to other methods for analyzing miRNA expression, such as microarray analysis.\n5. Flexibility: MIRA-seq can be used to analyze miRNAs from a wide range of samples, including cells, tissues, and biofluids.\nIn summary, MIRA-seq is a powerful tool for analyzing miRNA expression and has the potential to reveal new insights into the complex regulatory networks involved in various biological processes and diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. MIRA-seq is a next-generation sequencing technology used for analyzing multiple RNA molecules (miRNAs).\n2. Molecular inversion probes (MIPs) are used in MIRA-seq to enrich RNA molecules by binding to the 3' untranslated regions (UTRs) of target miRNAs.\n3. Technologies such as Illumina and PacBio are employed for sequencing in the MIRA-seq process.\n4. MIRA-seq allows researchers to analyze the expression of multiple miRNAs in a single sample.\n5. MIRA-seq holds advantages such as high resolution, sensitivity, specificity, cost-effectiveness, and flexibility for analyzing miRNAs from various sample types.",
    "llama-2-7b-chat-hf_fact": [
      "MIRA-seq is a next-generation sequencing technology used for analyzing multiple RNA molecules (miRNAs).",
      "Molecular inversion probes (MIPs) are used in MIRA-seq to enrich RNA molecules by binding to the 3' untranslated regions (UTRs) of target miRNAs.",
      "Technologies such as Illumina and PacBio are employed for sequencing in the MIRA-seq process.",
      "MIRA-seq allows researchers to analyze the expression of multiple miRNAs in a single sample.",
      "MIRA-seq holds advantages such as high resolution, sensitivity, specificity, cost-effectiveness, and flexibility for analyzing miRNAs from various sample types."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MIRA-seq is a next-generation sequencing technology used for analyzing DNA methylation, not RNA molecules (miRNAs).\n2. FALSE [correction]: While molecular inversion probes (MIPs) can be used to enrich specific nucleic acid sequences, they are not specifically associated with MIRA-seq; and MIRA-seq is not used for miRNA analysis, but rather for DNA methylation.\n3. TRUE: Technologies such as Illumina (short-read sequencing) and PacBio (long-read sequencing) can be employed for sequencing in various next-generation sequencing processes, including those analyzing DNA methylation.\n4. FALSE [correction]: Since MIRA-seq is used for DNA methylation analysis and not for miRNA, it does not allow researchers to analyze the expression of multiple miRNAs in a single sample. MIRA-seq is for analyzing the methylation status of DNA.\n5. UNKNOWN: Without direct evidence or context verifying these specific advantages for MIRA-seq, we can't confirm or deny the advantages attributed to MIRA-seq in this statement. However, it is worth noting that the advantages listed are typically characteristics sought in next-generation sequencing technologies in general.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-7b-chat-hf_response": "ARCALYST (rilonacept) is a prescription medication that is FDA-approved for the treatment of cryopyrin-associated periodic syndromes (CAPS), which are a group of rare genetic disorders characterized by recurring episodes of fever, pain, and inflammation.\nSpecifically, ARCALYST is indicated for the treatment of the following CAPS:\n1. Cryopyrin-associated periodic syndrome (CAPS): This includes three subtypes: familial cold autoinflammatory syndrome (FCAS), Membranous nephropathy-associated autoinflammatory syndrome (MN-AIS), and NOMID (neonatal-onset multisystem inflammatory disease).\n2. Juvenile idiopathic arthritis (JIA): ARCALYST can be used in patients with JIA who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumor necrosis factor (TNF) blockers.\nIt is important to note that ARCALYST is not recommended for the treatment of other conditions, such as rheumatoid arthritis or psoriasis, as it has not been studied for these uses.",
    "llama-2-7b-chat-hf_fact_raw": "1. ARCALYST (rilonacept) is a prescription medication FDA-approved for the treatment of cryopyrin-associated periodic syndromes (CAPS).\n2. Cryopyrin-associated periodic syndromes (CAPS) are characterized by recurring episodes of fever, pain, and inflammation.\n3. ARCALYST is specifically indicated for familial cold autoinflammatory syndrome (FCAS), Membranous nephropathy-associated autoinflammatory syndrome (MN-AIS), and NOMID (neonatal-onset multisystem inflammatory disease).\n4. ARCALYST can be used for juvenile idiopathic arthritis (JIA) in patients with an inadequate response to DMARDs or TNF blockers.\n5. ARCALYST is not recommended for the treatment of conditions such as rheumatoid arthritis or psoriasis.",
    "llama-2-7b-chat-hf_fact": [
      "ARCALYST (rilonacept) is a prescription medication FDA-approved for the treatment of cryopyrin-associated periodic syndromes (CAPS).",
      "Cryopyrin-associated periodic syndromes (CAPS) are characterized by recurring episodes of fever, pain, and inflammation.",
      "ARCALYST is specifically indicated for familial cold autoinflammatory syndrome (FCAS), Membranous nephropathy-associated autoinflammatory syndrome (MN-AIS), and NOMID (neonatal-onset multisystem inflammatory disease).",
      "ARCALYST can be used for juvenile idiopathic arthritis (JIA) in patients with an inadequate response to DMARDs or TNF blockers.",
      "ARCALYST is not recommended for the treatment of conditions such as rheumatoid arthritis or psoriasis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: ARCALYST is specifically indicated for familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS), which are subtypes of CAPS, as well as NOMID (neonatal-onset multisystem inflammatory disease). There is no condition known as \"Membranous nephropathy-associated autoinflammatory syndrome (MN-AIS)\" associated with the use of ARCALYST.\n4. FALSE [correction]: ARCALYST is not indicated for treating juvenile idiopathic arthritis (JIA). It's approved for the treatment of CAPS, including FCAS and MWS, as well as NOMID.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-7b-chat-hf_response": "Robertsonian translocations are a type of chromosomal abnormality that involve the exchange of genetic material between two acrocentric chromosomes (chromosomes 1, 9, 10, 13, 15, 16, 21, and 22). These chromosomes are characterized by their short arm (p) and long arm (q), and are named based on their size and position in the human karyotype.\nOf the human acrocentric chromosomes, the following are involved in Robertsonian translocations:\n1. Chromosome 13: Translocations involving chromosome 13 are the most common type of Robertsonian translocation, accounting for approximately 70% of all cases.\n2. Chromosome 14: Translocations involving chromosome 14 are less common than those involving chromosome 13, but still occur with some frequency.\n3. Chromosome 15: Translocations involving chromosome 15 are relatively rare, but can occur in some cases of Robertsonian translocation.\n4. Chromosome 16: Translocations involving chromosome 16 are also rare, but can occur in some cases of Robertsonian translocation.\n5. Chromosome 21: Translocations involving chromosome 21 (also known as trisomy 21) are the least common type of Robertsonian translocation, but can occur in some cases.\nIt's worth noting that the specific chromosomes involved in Robertsonian translocations can vary depending on the individual and the specific genetic material that is involved in the translocation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Robertsonian translocations involve the exchange of genetic material between two acrocentric chromosomes.\n2. The human acrocentric chromosomes are chromosomes 13, 14, 15, 16, 21, and 22.\n3. Chromosome 13 is the most common chromosome involved in Robertsonian translocations, accounting for approximately 70% of all cases.\n4. Translocations involving chromosomes 14 and 15 occur with some frequency, but are less common than those involving chromosome 13.\n5. Chromosome 21, also known as trisomy 21, is involved in the least common type of Robertsonian translocation.",
    "llama-2-7b-chat-hf_fact": [
      "Robertsonian translocations involve the exchange of genetic material between two acrocentric chromosomes.",
      "The human acrocentric chromosomes are chromosomes 13, 14, 15, 16, 21, and 22.",
      "Chromosome 13 is the most common chromosome involved in Robertsonian translocations, accounting for approximately 70% of all cases.",
      "Translocations involving chromosomes 14 and 15 occur with some frequency, but are less common than those involving chromosome 13.",
      "Chromosome 21, also known as trisomy 21, is involved in the least common type of Robertsonian translocation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Chromosome 13 is not the most common chromosome involved in Robertsonian translocations; instead, translocations often involve chromosomes 13 and 14.\n4. TRUE\n5. FALSE [correction]: Chromosome 21 is not known as trisomy 21; rather, trisomy 21 refers to a genetic condition where there are three copies of chromosome 21, known as Down syndrome. Additionally, the Robertsonian translocation involving chromosome 21 is not the least common, as translocations involving chromosome 21 can lead to inherited forms of Down syndrome and occur relatively frequently.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-7b-chat-hf_response": "There are several R packages that can be used for the identification of pediatric brain tumors, depending on the specific task and the type of data available. Here are some popular R packages that can be used for this purpose:\n1. `pediatricbraintumor`: This package provides a set of functions for analyzing pediatric brain tumor data, including data cleaning, visualization, and statistical analysis. It can be used to identify patterns and trends in the data that may be indicative of brain tumors.\n2. `brainTumor`: This package provides a set of functions for analyzing brain tumor data, including data preprocessing, feature extraction, and classification. It can be used to identify potential brain tumor markers in genomic data.\n3. `rstan`: This package provides a set of functions for Bayesian statistical analysis, including modeling of complex data structures such as those encountered in genomic analysis. It can be used to identify genetic variants associated with increased risk of pediatric brain tumors.\n4. `ggplot2`: This package provides a set of functions for data visualization, including the creation of heatmaps, scatter plots, and other visualizations. It can be used to visualize the expression of genes in different brain regions and to identify potential biomarkers for pediatric brain tumors.\n5. `limma`: This package provides a set of functions for the analysis of gene expression data, including the calculation of fold changes, dispersion estimates, and statistical testing. It can be used to identify genes that are differentially expressed between tumor and non-tumor samples.\n6. `sva`: This package provides a set of functions for the analysis of single-nucleotide variation (SNV) data, including the calculation of genotype frequencies, haplotype frequencies, and statistical testing. It can be used to identify genetic variants associated with increased risk of pediatric brain tumors.\n7. `gcta`: This package provides a set of functions for the analysis of genome-wide association study (GWAS) data, including the calculation of genotype frequencies, test statistics, and statistical testing. It can be used to identify genetic variants associated with increased risk of pediatric brain tumors.\n8. `plink`: This package provides a set of functions for the analysis of genetic data",
    "llama-2-7b-chat-hf_fact_raw": "1. The R package `pediatricbraintumor` provides functions for analyzing pediatric brain tumor data.\n2. The R package `brainTumor` is used for analyzing brain tumor data, including preprocessing and classification.\n3. The R package `rstan` is used for Bayesian statistical analysis and can help in identifying genetic variants associated with pediatric brain tumors.\n4. The R package `ggplot2` is used for data visualization, including gene expression in different brain regions.\n5. The R package `limma` is designed for analysis of gene expression data to identify differentially expressed genes.",
    "llama-2-7b-chat-hf_fact": [
      "The R package `pediatricbraintumor` provides functions for analyzing pediatric brain tumor data.",
      "The R package `brainTumor` is used for analyzing brain tumor data, including preprocessing and classification.",
      "The R package `rstan` is used for Bayesian statistical analysis and can help in identifying genetic variants associated with pediatric brain tumors.",
      "The R package `ggplot2` is used for data visualization, including gene expression in different brain regions.",
      "The R package `limma` is designed for analysis of gene expression data to identify differentially expressed genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE - While `rstan` is indeed a package for Bayesian statistical analysis, without specific context indicating its use for identifying genetic variants associated with pediatric brain tumors, this statement can't be fully verified. However, in principle, `rstan` could be used for such a purpose, so the statement is generally true.\n4. TRUE - The `ggplot2` package is a data visualization package and could be used to visualize gene expression in different brain regions, among many other data visualization tasks.\n5. TRUE - The `limma` package is commonly used for the analysis of gene expression data, particularly in the context of microarrays and RNA-sequencing, for identifying differentially expressed genes.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-7b-chat-hf_response": "Yes, NEMO (Nuclear Envelope-Associated Matrix-Organizing) is a zinc finger protein. NEMO is a key component of the NF-κB (nuclear factor kappa B) signaling pathway, which plays a crucial role in regulating inflammation and immune responses.\nNEMO contains multiple zinc fingers, which are sequence-specific DNA-binding domains that are responsible for recognizing and binding to specific DNA sequences. The zinc fingers in NEMO are involved in the regulation of gene expression by interacting with the NF-κB transcription factor.\nNEMO is a large protein consisting of multiple domains, including a zinc finger domain, a death domain, and a proline-rich region. The zinc finger domain is responsible for the DNA-binding activity of NEMO, while the death domain is involved in the regulation of protein-protein interactions.\nOverall, the zinc finger domain of NEMO is a critical component of the NF-κB signaling pathway, as it plays a central role in the regulation of gene expression by interacting with specific DNA sequences.",
    "llama-2-7b-chat-hf_fact_raw": "1. NEMO (Nuclear Envelope-Associated Matrix-Organizing) is a zinc finger protein.\n2. NEMO is a component of the NF-κB (nuclear factor kappa B) signaling pathway.\n3. The zinc fingers in NEMO are involved in regulating gene expression by interacting with the NF-κB transcription factor.\n4. NEMO contains a zinc finger domain, which is responsible for DNA-binding activity.\n5. NEMO also contains a death domain and a proline-rich region.",
    "llama-2-7b-chat-hf_fact": [
      "NEMO (Nuclear Envelope-Associated Matrix-Organizing) is a zinc finger protein.",
      "NEMO is a component of the NF-κB (nuclear factor kappa B) signaling pathway.",
      "The zinc fingers in NEMO are involved in regulating gene expression by interacting with the NF-κB transcription factor.",
      "NEMO contains a zinc finger domain, which is responsible for DNA-binding activity.",
      "NEMO also contains a death domain and a proline-rich region."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: NEMO (NF-kappa-B essential modulator) is not a zinc finger protein, it is an essential regulatory protein involved in the NF-κB signaling pathway.\n2. TRUE\n3. FALSE [correction]: NEMO does not contain zinc fingers as it is not a zinc finger protein. It is involved in regulating the NF-κB pathway but its function does not include interacting with NF-κB as a zinc finger protein would with DNA.\n4. FALSE [correction]: NEMO does not have a zinc finger domain responsible for DNA-binding activity because it is not a zinc finger protein.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-7b-chat-hf_response": "Yes, TFIIS (Transcription Factor IIIS) can affect nucleosome positioning. TFIIS is a transcriptional elongation factor that plays a crucial role in the regulation of transcriptional elongation and termination. It has been shown to interact with nucleosomes and influence their positioning along the DNA template.\nHere's how TFIIS affects nucleosome positioning:\n1. Nucleosome sliding: TFIIS can facilitate the sliding of nucleosomes along the DNA template during transcriptional elongation. This process involves the unwinding of the DNA double helix around the nucleosome, allowing the RNA polymerase complex to move along the DNA template without encountering significant resistance.\n2. Nucleosome spacing: TFIIS can also influence the spacing between nucleosomes along the DNA template. By regulating the sliding of nucleosomes, TFIIS can affect the distance between them, which in turn can impact the regulation of transcriptional elongation.\n3. Chromatin structure: TFIIS can also affect the overall structure of chromatin, which can impact the positioning of nucleosomes. Chromatin structure is dynamic and can be influenced by various factors, including the binding of transcription factors and the activity of chromatin-modifying enzymes. TFIIS can contribute to the regulation of chromatin structure by interacting with other chromatin-modifying enzymes and transcription factors.\nIn summary, TFIIS plays a crucial role in regulating nucleosome positioning by facilitating nucleosome sliding, influencing nucleosome spacing, and contributing to the overall structure of chromatin. These processes are important for the regulation of transcriptional elongation and the maintenance of genome stability.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFIIS (Transcription Factor IIIS) can influence nucleosome positioning along the DNA template.\n2. TFIIS facilitates the sliding of nucleosomes during transcriptional elongation.\n3. The regulation of transcriptional elongation by TFIIS can affect the spacing between nucleosomes.\n4. TFIIS interacts with chromatin-modifying enzymes and transcription factors to affect the overall structure of chromatin.\n5. The activity of TFIIS is important for maintaining genome stability.",
    "llama-2-7b-chat-hf_fact": [
      "TFIIS (Transcription Factor IIIS) can influence nucleosome positioning along the DNA template.",
      "TFIIS facilitates the sliding of nucleosomes during transcriptional elongation.",
      "The regulation of transcriptional elongation by TFIIS can affect the spacing between nucleosomes.",
      "TFIIS interacts with chromatin-modifying enzymes and transcription factors to affect the overall structure of chromatin.",
      "The activity of TFIIS is important for maintaining genome stability."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The function of TFIIS as described is not a typical characteristic associated with this transcription factor. TFIIS is known to stimulate the cleavage of nascent RNA in the transcription elongation complex when RNA polymerase II encounters a blockage.\n2. FALSE [correction]: TFIIS does not facilitate the sliding of nucleosomes during transcriptional elongation. Instead, it is involved in the process of transcript cleavage that helps RNA polymerase II to overcome backtracking during transcriptional elongation.\n3. UNKNOWN: While TFIIS influences transcriptional elongation, which could indirectly affect nucleosome spacing, there is no direct evidence that TFIIS regulates the spacing between nucleosomes.\n4. UNKNOWN: While TFIIS does interact with RNA polymerase II, its interactions with chromatin-modifying enzymes and transcription factors to affect the overall structure of chromatin are not well described in the literature.\n5. TRUE: The activity of TFIIS in helping RNA polymerase II to overcome transcriptional blockages can be important for maintaining genome stability as it ensures proper transcription elongation and prevention of potential DNA damage that may occur from stalled polymerase.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-7b-chat-hf_response": "Origins of replication near yeast centromeres typically fire late in the cell cycle. This is because the centromere region is rich in highly repetitive DNA sequences, known as satellite DNA, which can create a barrier to the initiation of DNA replication.\nIn yeast, the origin of replication called \"Lys2\" is located near the centromere and fires late in the cell cycle, around the G2 phase. Similarly, the \"HMR\" origin of replication, which is located near the other centromere, also fires late in the cell cycle.\nThe late firing of origins of replication near centromeres is thought to be due to the presence of the centromere-bound protein, Cbf1, which binds to the satellite DNA repeats and inhibits the activity of the origin recognition complex (ORC), a protein complex that initiates DNA replication. The binding of Cbf1 to the satellite DNA repeats creates a barrier to the initiation of DNA replication, causing the origins of replication to fire later in the cell cycle.\nIn addition, the late firing of origins of replication near centromeres may also be due to the presence of a specialized chromatin structure in the centromere region, which can make it more difficult for the ORC to access the origin of replication.\nOverall, the late firing of origins of replication near yeast centromeres is a complex process that involves the interaction of multiple proteins and chromatin structures, and is an important factor in the regulation of the cell cycle.",
    "llama-2-7b-chat-hf_fact_raw": "1. Origins of replication near yeast centromeres typically fire late in the cell cycle.\n2. The centromere region in yeast is rich in highly repetitive DNA sequences known as satellite DNA.\n3. The origin of replication \"Lys2\" is located near a centromere in yeast and fires in the G2 phase.\n4. The \"HMR\" origin of replication is situated close to another centromere in yeast and also fires late in the cell cycle.\n5. The protein Cbf1 binds to satellite DNA repeats near centromeres and inhibits the activity of the origin recognition complex (ORC), contributing to the late firing of origins of replication.",
    "llama-2-7b-chat-hf_fact": [
      "Origins of replication near yeast centromeres typically fire late in the cell cycle.",
      "The centromere region in yeast is rich in highly repetitive DNA sequences known as satellite DNA.",
      "The origin of replication \"Lys2\" is located near a centromere in yeast and fires in the G2 phase.",
      "The \"HMR\" origin of replication is situated close to another centromere in yeast and also fires late in the cell cycle.",
      "The protein Cbf1 binds to satellite DNA repeats near centromeres and inhibits the activity of the origin recognition complex (ORC), contributing to the late firing of origins of replication."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The centromere region in yeast is not characterized by highly repetitive satellite DNA, unlike centromeres in many other eukaryotes. Instead, yeast centromeres are relatively small and composed of unique DNA sequences that are sufficient for their function.\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: While it's true that certain proteins can affect the timing of origin of replication firing, Cbf1 is known to be a centromere-binding factor that plays a role in chromosome segregation. There is no direct evidence provided in the statement that Cbf1 binds specifically to satellite DNA repeats or that it inhibits the origin recognition complex (ORC) activity, thus contributing to the late firing of origins of replication. In yeast, the role of Cbf1 is primarily associated with centromere function and gene expression.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-7b-chat-hf_response": "Mammalian GA-sequences, also known as GAGAs or glycosylated arginine-glycine-arginine (R-G-R) sequences, are a type of RNA sequence found in the 3' untranslated regions (UTRs) of mammalian messenger RNAs (mRNAs). These sequences are known for their unique properties and functions in the cell. Here are some of the key properties of mammalian GA-sequences:\n1. Glycosylation: Mammalian GA-sequences are characterized by the presence of a conserved sequence motif, R-G-R, which is followed by a glycosylation site. The glycosylation of these sequences is important for their function in the cell.\n2. Stability: GA-sequences are known to enhance the stability of mRNAs by protecting them from degradation by the 5' exonuclease of the ribosome. This is achieved through the formation of a stable stem-loop structure that is resistant to degradation.\n3. Transport: GA-sequences can also influence the transport of mRNAs within the cell. They can act as a signal for the transport of mRNAs from the nucleus to the cytoplasm, and can also modulate the efficiency of mRNA transport.\n4. Localization: GA-sequences can also influence the localization of mRNAs within the cell. They can act as a signal for the localization of mRNAs to specific subcellular regions, such as the cytoplasm or nucleus.\n5. Translation: GA-sequences can also affect the translation of mRNAs. They can act as a signal for the recruitment of ribosomes to the mRNA, and can also modulate the efficiency of translation.\n6. miRNA binding: GA-sequences can also interact with microRNAs (miRNAs) and influence their binding to mRNAs. This can affect the stability or translation of the target mRNA.\n7. Splicing: GA-sequences can also affect the splicing of mRNAs. They can act as a signal for the recognition of the m",
    "llama-2-7b-chat-hf_fact_raw": "1. Mammalian GA-sequences are characterized by a conserved sequence motif, R-G-R, and a glycosylation site that is important for their function.\n2. GA-sequences enhance the stability of mRNAs by protecting them from degradation by the 5' exonuclease of the ribosome.\n3. GA-sequences can influence the transport of mRNAs from the nucleus to the cytoplasm within the cell.\n4. GA-sequences can affect the localization of mRNAs to specific subcellular regions, such as the cytoplasm or nucleus.\n5. GA-sequences can modulate the efficiency of mRNA translation.",
    "llama-2-7b-chat-hf_fact": [
      "Mammalian GA-sequences are characterized by a conserved sequence motif, R-G-R, and a glycosylation site that is important for their function.",
      "GA-sequences enhance the stability of mRNAs by protecting them from degradation by the 5' exonuclease of the ribosome.",
      "GA-sequences can influence the transport of mRNAs from the nucleus to the cytoplasm within the cell.",
      "GA-sequences can affect the localization of mRNAs to specific subcellular regions, such as the cytoplasm or nucleus.",
      "GA-sequences can modulate the efficiency of mRNA translation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: GA-sequences often enhance the stability of mRNAs, but they do not protect them from degradation by the 5' exonuclease of the ribosome. They typically prevent degradation by exonucleases from the 5' end in the cytoplasm or by shielding the RNA from endonucleases.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-7b-chat-hf_response": "Groucho-related genes (GRG) are a family of transcriptional regulators that are named after the Groucho protein, which was the first member of this family to be identified. In mammals, there are four Groucho-related genes (Grg1-4) that are encoded by separate genes. These genes are located on different chromosomes in the mouse genome:\n1. Grg1 (also known as Groucho-1): located on chromosome 12\n2. Grg2 (also known as Groucho-2): located on chromosome 16\n3. Grg3 (also known as Groucho-3): located on chromosome 17\n4. Grg4 (also known as Groucho-4): located on chromosome 19\nIn total, there are four Groucho-related genes in the mouse genome.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are four Groucho-related genes (GRG) in the mouse genome.\n2. The Groucho-related gene Grg1 is located on chromosome 12 of the mouse genome.\n3. The Groucho-related gene Grg2 is located on chromosome 16 of the mouse genome.\n4. The Groucho-related gene Grg3 is located on chromosome 17 of the mouse genome.\n5. The Groucho-related gene Grg4 is located on chromosome 19 of the mouse genome.",
    "llama-2-7b-chat-hf_fact": [
      "There are four Groucho-related genes (GRG) in the mouse genome.",
      "The Groucho-related gene Grg1 is located on chromosome 12 of the mouse genome.",
      "The Groucho-related gene Grg2 is located on chromosome 16 of the mouse genome.",
      "The Groucho-related gene Grg3 is located on chromosome 17 of the mouse genome.",
      "The Groucho-related gene Grg4 is located on chromosome 19 of the mouse genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The Groucho-related gene Grg1 is located on chromosome 18 of the mouse genome.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-7b-chat-hf_response": "RNA polymerase II (RNA Pol II) is the enzyme that transcribes DNA into RNA in eukaryotic cells. RNA Pol II is a complex of several subunits, and among these subunits, the largest subunit (RPB1) carries the RNA cleavage activity.\nRPB1, also known as the largest subunit of RNA Pol II, is responsible for the processivity of transcription, meaning it can synthesize long RNA molecules by continuously adding nucleotides to the growing RNA chain. During transcription, RPB1 recognizes the DNA template and recruits other subunits of RNA Pol II to initiate transcription. Once the transcription bubble is formed, RPB1 continues to move along the DNA template, synthesizing RNA by adding nucleotides to the growing chain.\nIn addition to its processivity, RPB1 also carries the RNA cleavage activity. During transcription, RPB1 can recognize specific sequences in the RNA transcript and cleave the RNA, leading to the formation of mature RNA molecules. This process is important for the maturation of some RNA molecules, such as pre-mRNA, and for the regulation of gene expression.\nIn summary, the RNA polymerase II subunit that carries RNA cleavage activity is the largest subunit (RPB1).",
    "llama-2-7b-chat-hf_fact_raw": "1. RNA polymerase II (RNA Pol II) transcribes DNA into RNA in eukaryotic cells.\n2. The largest subunit of RNA Pol II, RPB1, carries the RNA cleavage activity.\n3. RPB1 is responsible for the processivity of transcription in RNA Pol II.\n4. RPB1 recognizes the DNA template and recruits other subunits to initiate transcription.\n5. RPB1 can recognize specific sequences in the RNA transcript and cleave the RNA during transcription.",
    "llama-2-7b-chat-hf_fact": [
      "RNA polymerase II (RNA Pol II) transcribes DNA into RNA in eukaryotic cells.",
      "The largest subunit of RNA Pol II, RPB1, carries the RNA cleavage activity.",
      "RPB1 is responsible for the processivity of transcription in RNA Pol II.",
      "RPB1 recognizes the DNA template and recruits other subunits to initiate transcription.",
      "RPB1 can recognize specific sequences in the RNA transcript and cleave the RNA during transcription."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The largest subunit of RNA Pol II, RPB1, does not carry the RNA cleavage activity. The RNA cleavage function is associated with different proteins involved in RNA processing, such as cleavage and polyadenylation factors.\n3. TRUE\n4. FALSE [correction]: The specific recognition of the DNA template is not solely the function of RPB1. It involves multiple subunits of RNA Pol II and several other transcription factors that work together to initiate transcription.\n5. FALSE [correction]: RPB1 does not have an intrinsic capacity to recognize specific sequences in the RNA transcript and cleave the RNA during transcription. RNA cleavage during transcription is typically mediated by separate enzymatic activities, such as those from the RNA processing machinery.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-7b-chat-hf_response": "Ohdo syndrome is a rare genetic disorder caused by mutations in the PTPN11 gene. The PTPN11 gene provides instructions for making a protein called SHP-2, which is a tyrosine phosphatase that plays a crucial role in signaling pathways involved in the development and function of various tissues, including the brain, heart, and skeletal system.\nMutations in the PTPN11 gene can lead to the loss of SHP-2 function, which can disrupt normal cellular signaling pathways and contribute to the development of the characteristic features of Ohdo syndrome. These mutations can occur spontaneously or be inherited from one or both parents.\nThe genetic basis of Ohdo syndrome is summarized below:\n* Mutations in the PTPN11 gene (also known as SHP-2): These mutations are the primary cause of Ohdo syndrome. The PTPN11 gene is located on chromosome 12q24.1 and consists of 17 exons. Mutations can occur in any of these exons, leading to the production of a dysfunctional SHP-2 protein.\n* Types of mutations: There are several types of mutations that can occur in the PTPN11 gene, including missense, nonsense, and frameshift mutations. Missense mutations result in a different amino acid being substituted for the normal amino acid at a specific position in the SHP-2 protein. Nonsense mutations result in premature termination of protein synthesis, leading to a truncated protein. Frameshift mutations result in the insertion or deletion of one or more nucleotides in the PTPN11 gene, leading to a changed reading frame in the protein sequence.\n* Penetrance: The penetrance of Ohdo syndrome is incomplete, meaning that not all individuals with a mutated PTPN11 gene will develop the full range of symptoms. The age of onset and severity of the disease can vary widely between individuals.\n* Expression: The PTPN11 gene is expressed in many tissues throughout the body, including the brain, heart, and skeletal system. The severity of the disease can vary depending on the tissues affected.\nIn summary, the",
    "llama-2-7b-chat-hf_fact_raw": "1. Ohdo syndrome is a rare genetic disorder caused by mutations in the PTPN11 gene.\n2. The PTPN11 gene provides instructions for making the SHP-2 protein, which is involved in signaling pathways for the development and function of the brain, heart, and skeletal system.\n3. Mutations in the PTPN11 gene can be missense, nonsense, or frameshift mutations.\n4. The penetrance of Ohdo syndrome is incomplete, meaning not all individuals with a mutated PTPN11 gene will exhibit the full range of symptoms.\n5. The PTPN11 gene is located on chromosome 12q24.1 and consists of 17 exons.",
    "llama-2-7b-chat-hf_fact": [
      "Ohdo syndrome is a rare genetic disorder caused by mutations in the PTPN11 gene.",
      "The PTPN11 gene provides instructions for making the SHP-2 protein, which is involved in signaling pathways for the development and function of the brain, heart, and skeletal system.",
      "Mutations in the PTPN11 gene can be missense, nonsense, or frameshift mutations.",
      "The penetrance of Ohdo syndrome is incomplete, meaning not all individuals with a mutated PTPN11 gene will exhibit the full range of symptoms.",
      "The PTPN11 gene is located on chromosome 12q24.1 and consists of 17 exons."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ohdo syndrome is a rare genetic disorder, but it is not typically caused by mutations in the PTPN11 gene. Ohdo syndrome, Maat-Kievit-Brunner type, is associated with mutations in the MED12 gene, while other forms of Ohdo syndrome may be associated with other genetic changes.\n2. TRUE: The PTPN11 gene does provide instructions for making the SHP-2 protein, which is indeed involved in several signaling pathways that are essential for the development and function of various tissues and organs, including the brain, heart, and skeletal system.\n3. TRUE: Mutations in the PTPN11 gene can be of several types, including missense, nonsense, or frameshift mutations. These categories of mutations can alter the function of the encoded SHP-2 protein in different ways.\n4. UNKNOWN: The specific penetrance of Ohdo syndrome is not provided in the statement, and penetrance can vary depending on the genetic disorder. In general, incomplete penetrance means that not everyone with a genetic mutation will express the phenotype associated with that mutation, but there is no specific information given for Ohdo syndrome's penetrance related to the PTPN11 gene.\n5. TRUE: The PTPN11 gene is indeed located on chromosome 12q24.13 (which is close enough to 12q24.1 to be considered a correct statement unless precision down to the sub-band level is required) and consists of 15 coding exons plus 2 non-coding exons, which can be rounded to 17 exons in total.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-7b-chat-hf_response": "There are several R/Bioconductor packages that have been developed for the analysis of psychiatric disease genes. Here are a few examples:\n1. psygen: This package provides a comprehensive set of tools for the analysis of genetic data in psychiatric disorders. It includes functions for genome-wide association study (GWAS) analysis, gene-set enrichment analysis, and pathway analysis.\n2. psychiatricGenomics: This package provides a collection of tools for the analysis of genetic data in psychiatric disorders, including GWAS, gene-set enrichment analysis, and functional enrichment analysis.\n3. PsychGWAS: This package provides a set of tools for GWAS analysis in psychiatric disorders, including functions for imputation, association mapping, and gene-set enrichment analysis.\n4. PsychiatricGenetics: This package provides a collection of tools for the analysis of genetic data in psychiatric disorders, including GWAS, gene-set enrichment analysis, and functional enrichment analysis.\n5. PsychiatricGenome: This package provides a comprehensive set of tools for the analysis of genetic data in psychiatric disorders, including GWAS, gene-set enrichment analysis, and pathway analysis.\nThese packages can be used to analyze genetic data from large-scale genetic studies of psychiatric disorders, such as the Psychiatric Genomics Consortium (PGC) and the Genome-Wide Association Study (GWAS) of Psychiatric Disorders. They can also be used to identify novel genetic variants associated with psychiatric disorders, and to investigate the genetic architecture of these disorders.\nIt's worth noting that these packages are constantly being updated and improved, so be sure to check the latest documentation for the most up-to-date information.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R/Bioconductor package \"psygen\" provides tools for the analysis of genetic data in psychiatric disorders, including GWAS analysis, gene-set enrichment analysis, and pathway analysis.\n\n2. \"psychiatricGenomics\" is an R/Bioconductor package that offers tools for GWAS, gene-set enrichment analysis, and functional enrichment analysis in psychiatric genetic data.\n\n3. The R/Bioconductor package \"PsychGWAS\" includes functions for imputation, association mapping, and gene-set enrichment analysis for psychiatric disorder GWAS.\n\n4. \"PsychiatricGenetics\" is a package in R/Bioconductor that provides tools for analyzing genetic data, including GWAS and gene-set enrichment analysis, related to psychiatric disorders.\n\n5. The \"PsychiatricGenome\" package in R/Bioconductor offers a comprehensive set of tools for psychiatric disorder genetic data analysis and includes GWAS, gene-set enrichment analysis, and pathway analysis capabilities.",
    "llama-2-7b-chat-hf_fact": [
      "The R/Bioconductor package \"psygen\" provides tools for the analysis of genetic data in psychiatric disorders, including GWAS analysis, gene-set enrichment analysis, and pathway analysis.",
      "\"psychiatricGenomics\" is an R/Bioconductor package that offers tools for GWAS, gene-set enrichment analysis, and functional enrichment analysis in psychiatric genetic data.",
      "The R/Bioconductor package \"PsychGWAS\" includes functions for imputation, association mapping, and gene-set enrichment analysis for psychiatric disorder GWAS.",
      "\"PsychiatricGenetics\" is a package in R/Bioconductor that provides tools for analyzing genetic data, including GWAS and gene-set enrichment analysis, related to psychiatric disorders.",
      "The \"PsychiatricGenome\" package in R/Bioconductor offers a comprehensive set of tools for psychiatric disorder genetic data analysis and includes GWAS, gene-set enrichment analysis, and pathway analysis capabilities."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There is no R/Bioconductor package named \"psygen\" specifically for the analysis of genetic data in psychiatric disorders. A package with tools for psychiatric genetics could exist, but not with that name.\n2. UNKNOWN: While there could be R/Bioconductor packages aimed at psychiatric genetics, the package name \"psychiatricGenomics\" does not appear to be a standard package. Without more information, the existence and features of this package cannot be confirmed.\n3. UNKNOWN: There is no widely known R/Bioconductor package by the name of \"PsychGWAS\"; therefore, without additional context, it's difficult to verify the statement regarding its functions.\n4. UNKNOWN: The package \"PsychiatricGenetics\" is not a standard R/Bioconductor package based on the information available up to my knowledge cutoff date. The existence and contents of the package cannot be verified without additional context.\n5. FALSE [correction]: To the best of my knowledge, there is no R/Bioconductor package with the name \"PsychiatricGenome\" that provides a comprehensive set of tools for psychiatric disorder genetic data analysis, including GWAS, gene-set enrichment analysis, and pathway analysis capabilities. \n\nIn the realm of Bioinformatics and specifically with R/Bioconductor, package names and their functionalities change and evolve. New packages are created, and existing ones are updated or become obsolete. As of my last update, there was no information about these specific packages. However, packages aimed at psychiatric genetic data analysis might exist under different names or perhaps those names could exist in newer, post-2021 R/Bioconductor releases or as private, non-standard packages.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_response": "Swirl sign is a radiological sign that is commonly observed in intracerebral hemorrhage (ICH), which is a type of stroke that occurs when blood bleeds into the brain tissue. The sign is characterized by a swirling or spiral pattern of blood in the affected brain area on a computed tomography (CT) or magnetic resonance imaging (MRI) scan.\nThe swirl sign is thought to be caused by the movement of blood within the brain due to the hemorrhage. As the blood flows through the affected area, it can create a spiral or swirling pattern that is visible on the imaging scan. The sign can be seen in various locations within the brain, including the cerebral hemispheres, basal ganglia, and cerebellum.\nThe swirl sign can be an important diagnostic marker for ICH, as it can help to identify the location and extent of the hemorrhage. It can also be used to monitor the progression of the hemorrhage over time and to assess the response to treatment.\nHowever, it is important to note that the swirl sign is not specific to ICH and can also be seen in other conditions, such as cerebral edema or tumors. Therefore, it is important to interpret the sign in conjunction with other clinical and radiological findings to make an accurate diagnosis.\nIn summary, the swirl sign is a radiological sign that is commonly observed in intracerebral hemorrhage and represents a spiral or swirling pattern of blood in the affected brain area. It can be an important diagnostic marker for ICH and can help to identify the location and extent of the hemorrhage, as well as monitor its progression over time.",
    "llama-2-7b-chat-hf_fact_raw": "1. Swirl sign is a radiological sign that is observed in intracerebral hemorrhage (ICH).\n2. The sign is characterized by a swirling or spiral pattern of blood visible on imaging scans.\n3. Swirl sign can be detected using computed tomography (CT) or magnetic resonance imaging (MRI) scans.\n4. The swirl sign can be an important diagnostic marker for identifying the location and extent of an intracerebral hemorrhage.\n5. The swirl sign is not specific to ICH and can also be observed in conditions such as cerebral edema or tumors.",
    "llama-2-7b-chat-hf_fact": [
      "Swirl sign is a radiological sign that is observed in intracerebral hemorrhage (ICH).",
      "The sign is characterized by a swirling or spiral pattern of blood visible on imaging scans.",
      "Swirl sign can be detected using computed tomography (CT) or magnetic resonance imaging (MRI) scans.",
      "The swirl sign can be an important diagnostic marker for identifying the location and extent of an intracerebral hemorrhage.",
      "The swirl sign is not specific to ICH and can also be observed in conditions such as cerebral edema or tumors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The swirl sign is specific to ICH and is characterized by the presence of a low-attenuation area within a hyperattenuated area seen on CT scans, which may not be seen in other conditions like cerebral edema or tumors. While other conditions may have their own specific signs on imaging scans, the swirl sign is particularly associated with ICH.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-7b-chat-hf_response": "Arabidopsis ROF1 (RNA binding protein 1) is a transcription factor that plays a crucial role in regulating gene expression in response to various environmental and developmental cues. The expression of ROF1 is induced by a variety of stimuli, including:\n1. Light: ROF1 expression is light-responsive and is induced by blue light, particularly in the blue light region of the electromagnetic spectrum (430-450 nm).\n2. Temperature: ROF1 expression is temperature-sensitive, with the highest levels of expression observed at temperatures between 15-25°C.\n3. Water availability: ROF1 expression is induced in response to drought stress, suggesting that it plays a role in the plant's response to water availability.\n4. Hormones: ROF1 expression is regulated by various plant hormones, including abscisic acid (ABA), ethylene (ET), and cytokinin (CK).\n5. Defense against pathogens: ROF1 expression is induced in response to bacterial infection, suggesting that it plays a role in the plant's defense against pathogens.\n6. Developmental cues: ROF1 expression is also regulated by developmental cues, such as the onset of flowering and the formation of seeds.\n7. Transcription factors: ROF1 expression can be induced by other transcription factors, such as ABARA (ABA-responsive element binding protein), which is a transcriptional activator of ROF1.\n8. Epigenetic modifications: ROF1 expression can also be influenced by epigenetic modifications, such as DNA methylation and histone modifications.\nIn summary, ROF1 expression in Arabidopsis is induced by a variety of environmental and developmental cues, including light, temperature, water availability, hormones, defense against pathogens, developmental cues, transcription factors, and epigenetic modifications.",
    "llama-2-7b-chat-hf_fact_raw": "1. Arabidopsis ROF1 expression is induced by blue light, particularly in the blue light region of the electromagnetic spectrum (430-450 nm).\n2. The highest levels of Arabidopsis ROF1 expression are observed at temperatures between 15-25°C.\n3. Arabidopsis ROF1 expression is induced in response to drought stress.\n4. Various plant hormones, including abscisic acid (ABA), ethylene (ET), and cytokinin (CK), regulate Arabidopsis ROF1 expression.\n5. Arabidopsis ROF1 expression is induced in response to bacterial infection.",
    "llama-2-7b-chat-hf_fact": [
      "Arabidopsis ROF1 expression is induced by blue light, particularly in the blue light region of the electromagnetic spectrum (430-450 nm).",
      "The highest levels of Arabidopsis ROF1 expression are observed at temperatures between 15-25°C.",
      "Arabidopsis ROF1 expression is induced in response to drought stress.",
      "Various plant hormones, including abscisic acid (ABA), ethylene (ET), and cytokinin (CK), regulate Arabidopsis ROF1 expression.",
      "Arabidopsis ROF1 expression is induced in response to bacterial infection."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The induction of Arabidopsis ROF1 expression by blue light is specific, but without the context or specific research findings, we cannot confirm or refute the specificity to the 430-450 nm range.\n2. UNKNOWN: The precise temperature range for the highest levels of Arabidopsis ROF1 expression isn't common knowledge and would require specific empirical data to confirm.\n3. TRUE: Arabidopsis ROF1 (also known as AtFKBP62) has been reported to be induced under drought stress conditions.\n4. TRUE: Arabidopsis ROF1 expression is known to be regulated by various plant hormones, including abscisic acid (ABA) and ethylene (ET), which play roles in stress responses. However, the influence of cytokinin (CK) on ROF1 expression would require specific scientific evidence to confirm.\n5. UNKNOWN: While plant responses to bacterial infection often involve changes in expression of a wide array of genes, whether Arabidopsis ROF1 expression is specifically induced in response to bacterial infection would require direct evidence from scientific studies.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-7b-chat-hf_response": "The most common cause of hereditary renal amyloidosis is the protein alpha-2-macroglobulin (A2M). Hereditary renal amyloidosis, also known as familial amyloid nephropathy (FAN), is a rare genetic disorder that leads to the accumulation of abnormal protein aggregates, known as amyloid fibrils, in the kidneys. These amyloid fibrils are composed of various proteins, including A2M, which is the most common component.\nThe A2M gene, located on chromosome 11, encodes for the A2M protein, which is a large glycoprotein that is produced in the liver and secreted into the bloodstream. The A2M protein plays a role in the immune system and has been implicated in various diseases, including multiple myeloma and Alzheimer's disease.\nIn hereditary renal amyloidosis, mutations in the A2M gene lead to the production of abnormal A2M proteins that are unable to be properly processed and folded, resulting in their accumulation in the kidneys and the formation of amyloid fibrils. Over time, these fibrils can cause progressive damage to the kidneys, leading to chronic kidney disease and eventually renal failure.\nOther proteins, such as apolipoprotein A-I and transthyretin, can also form amyloid fibrils in the kidneys, but A2M is the most common cause of hereditary renal amyloidosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Alpha-2-macroglobulin (A2M) is the most common cause of hereditary renal amyloidosis.\n2. The A2M gene, associated with hereditary renal amyloidosis, is located on chromosome 11.\n3. The A2M protein is produced in the liver and secreted into the bloodstream.\n4. Mutations in the A2M gene can lead to the production of abnormal A2M proteins that accumulate in the kidneys.\n5. Chronic kidney disease and eventually renal failure can result from the accumulation of amyloid fibrils in the kidneys caused by abnormal A2M proteins.",
    "llama-2-7b-chat-hf_fact": [
      "Alpha-2-macroglobulin (A2M) is the most common cause of hereditary renal amyloidosis.",
      "The A2M gene, associated with hereditary renal amyloidosis, is located on chromosome 11.",
      "The A2M protein is produced in the liver and secreted into the bloodstream.",
      "Mutations in the A2M gene can lead to the production of abnormal A2M proteins that accumulate in the kidneys.",
      "Chronic kidney disease and eventually renal failure can result from the accumulation of amyloid fibrils in the kidneys caused by abnormal A2M proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Alpha-2-macroglobulin (A2M) is not the most common cause of hereditary renal amyloidosis. The most common form of hereditary renal amyloidosis is caused by mutations in the genes encoding for transthyretin (TTR), fibrinogen A alpha-chain (AFib), apolipoprotein A-I (ApoA-I), or lysozyme.\n2. UNKNOWN: Without specific genetic information regarding the A2M gene and its location in the context of hereditary renal amyloidosis, it's difficult to verify the chromosome location for A2M. However, generally, the A2M gene resides on chromosome 12.\n3. TRUE: The A2M protein is indeed produced in the liver and secreted into the bloodstream.\n4. UNKNOWN: While mutations in certain genes can lead to amyloidosis and the production of abnormal proteins that can accumulate in organs including the kidneys, it is not clear if mutations in the A2M gene specifically are a common cause of such accumulations leading to hereditary renal amyloidosis.\n5. TRUE: Chronic kidney disease and eventually renal failure can be a result of the accumulation of amyloid fibrils in the kidneys, which may occur due to abnormal proteins, but whether this is specifically due to abnormal A2M proteins would depend on verifying the accuracy of previous statements about the role of A2M in hereditary renal amyloidosis.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-7b-chat-hf_response": "Yes, the proteome of the mouse hippocampus has been extensively analyzed using various proteomics techniques. The hippocampus is a complex brain structure involved in memory formation, spatial navigation, and emotion regulation, and its proteome is known to be involved in these processes. Here are some examples of proteome studies conducted in the mouse hippocampus:\n1. Protein identification: In a study published in the journal Nature in 2014, researchers used a combination of mass spectrometry and protein microarray analysis to identify more than 10,000 proteins in the mouse hippocampus. They found that the hippocampus contains a unique set of proteins that are involved in synaptic plasticity, neurotransmission, and inflammation.\n2. Protein expression analysis: A study published in the journal Science in 2017 used RNA sequencing (RNA-seq) to analyze the expression of genes and proteins in the mouse hippocampus. They found that the expression of genes involved in synaptic plasticity and neurotransmission was altered in the hippocampus of mice with Alzheimer's disease, and that these changes were associated with cognitive decline.\n3. Post-translational modification analysis: A study published in the journal Nature Communications in 2018 used mass spectrometry-based techniques to analyze the post-translational modifications (PTMs) of proteins in the mouse hippocampus. They found that the PTMs of proteins involved in synaptic plasticity and neurotransmission were altered in the hippocampus of mice with Alzheimer's disease, and that these changes were associated with cognitive decline.\n4. Protein-protein interaction analysis: A study published in the journal Cell in 2019 used a combination of mass spectrometry and protein microarray analysis to analyze the protein-protein interactions in the mouse hippocampus. They found that the protein-protein interactions involved in synaptic plasticity and neurotransmission were altered in the hippocampus of mice with Alzheimer's disease, and that these changes were associated with cognitive decline.\nOverall",
    "llama-2-7b-chat-hf_fact_raw": "1. A study published in Nature in 2014 identified more than 10,000 proteins in the mouse hippocampus through a combination of mass spectrometry and protein microarray analysis.\n2. A study published in Science in 2017 used RNA sequencing to analyze gene and protein expression in the mouse hippocampus, identifying changes in Alzheimer's disease mice that were associated with cognitive decline.\n3. A study detailed in Nature Communications in 2018 reported on the analysis of post-translational modifications of proteins in the mouse hippocampus, noting alterations in mice with Alzheimer's disease that were linked to cognitive decline.\n4. Research findings published in Cell in 2019 described the analysis of protein-protein interactions in the mouse hippocampus and how these interactions were altered in mice with Alzheimer's disease, correlating with cognitive decline.",
    "llama-2-7b-chat-hf_fact": [
      "A study published in Nature in 2014 identified more than 10,000 proteins in the mouse hippocampus through a combination of mass spectrometry and protein microarray analysis.",
      "A study published in Science in 2017 used RNA sequencing to analyze gene and protein expression in the mouse hippocampus, identifying changes in Alzheimer's disease mice that were associated with cognitive decline.",
      "A study detailed in Nature Communications in 2018 reported on the analysis of post-translational modifications of proteins in the mouse hippocampus, noting alterations in mice with Alzheimer's disease that were linked to cognitive decline.",
      "Research findings published in Cell in 2019 described the analysis of protein-protein interactions in the mouse hippocampus and how these interactions were altered in mice with Alzheimer's disease, correlating with cognitive decline."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement provides specific details about the publication and methods but without access to the actual study from Nature in 2014, the truthfulness of the statement cannot be verified.\n2. UNKNOWN: Similar to the previous statement, this statement includes specific details regarding the publication date and methods used. However, without access to the study from Science in 2017, it's not possible to verify the claim.\n3. UNKNOWN: The truth of this statement would depend on the ability to verify the contents of the specific article in Nature Communications in 2018, which is not possible without additional information.\n4. UNKNOWN: As with the other statements, this one also mentions detailed specifics regarding the publication and findings. Verification would require access to the Cell article from 2019.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-7b-chat-hf_response": "No, mouse chromosomes are not acrocentric.\nAcrocentric chromosomes are characterized by a centromere that is located near the center of the chromosome, with the majority of the chromosome consisting of repetitive DNA elements. In contrast, mouse chromosomes are polyploid, meaning they have more than two copies of each chromosome, and they do not have acrocentric centromeres. Instead, the centromere is located near the telomere of the chromosome, and the chromosome arm is characterized by a combination of repetitive DNA elements and gene-rich regions.\nIn mice, each chromosome is composed of multiple subchromosomes, each of which contains a centromere and a telomere. The centromere is the point where the chromosome attaches to the spindle fibers during cell division, while the telomere is the repetitive DNA sequence that caps the end of the chromosome and helps to maintain its length.\nSo, while acrocentric chromosomes are found in some other organisms, such as humans and other primates, mouse chromosomes are not acrocentric.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mouse chromosomes are not acrocentric.\n2. Mouse chromosomes are polyploid, which means they have more than two copies of each chromosome.\n3. In mouse chromosomes, the centromere is located near the telomere.\n4. Mouse chromosomes include a combination of repetitive DNA elements and gene-rich regions.\n5. Acrocentric chromosomes are found in some other organisms, including humans and other primates.",
    "llama-2-7b-chat-hf_fact": [
      "Mouse chromosomes are not acrocentric.",
      "Mouse chromosomes are polyploid, which means they have more than two copies of each chromosome.",
      "In mouse chromosomes, the centromere is located near the telomere.",
      "Mouse chromosomes include a combination of repetitive DNA elements and gene-rich regions.",
      "Acrocentric chromosomes are found in some other organisms, including humans and other primates."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mouse chromosomes are acrocentric, meaning the centromere is located near one end, not centrally.\n2. FALSE [correction]: Mouse chromosomes are not polyploid in their normal state. They are diploid, with two copies of each chromosome like most mammals.\n3. TRUE: In acrocentric chromosomes, the centromere is located near the telomere, which is consistent with the definition of acrocentric.\n4. TRUE: Mouse chromosomes, like those of other eukaryotes, include both repetitive DNA elements and gene-rich regions.\n5. TRUE: Acrocentric chromosomes are found in some other organisms, including humans and other primates, which possess them in some of their chromosomes.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-7b-chat-hf_response": "There are several siRNA-based drugs that are currently in clinical trials for the treatment of pancreatic cancer. Some of the most notable ones include:\n1. ONC201: ONC201 is a small molecule that selectively targets and silences the expression of the Wnt/β-catenin pathway, which is often overactive in pancreatic cancer. ONC201 is being developed by OncoGenex Pharmaceuticals and is currently in Phase 2 clinical trials for the treatment of pancreatic cancer.\n2. RX-0201: RX-0201 is a small interfering RNA (siRNA) that targets the mRNA of the pancreatic cancer-associated gene, PD-L1 (programmed death-ligand 1). RX-0201 is being developed by Rexahn Pharmaceuticals and is currently in Phase 2 clinical trials for the treatment of pancreatic cancer.\n3. BMS-986205: BMS-986205 is an investigational siRNA drug that targets the mRNA of the pancreatic cancer-associated gene, KRAS (Kirsten rat sarcoma viral oncogene homolog). BMS-986205 is being developed by Bristol-Myers Squibb and is currently in Phase 1 clinical trials for the treatment of pancreatic cancer.\n4. ALN-P001: ALN-P001 is an investigational siRNA drug that targets the mRNA of the pancreatic cancer-associated gene, P53 (tumor suppressor protein 53). ALN-P001 is being developed by Alnylam Pharmaceuticals and is currently in Phase 1 clinical trials for the treatment of pancreatic cancer.\nIt's important to note that these drugs are still in the experimental stage and have not yet been approved by the FDA for the treatment of pancreatic cancer. More research is needed to determine their safety and efficacy in humans.",
    "llama-2-7b-chat-hf_fact_raw": "1. ONC201 is a drug that targets the Wnt/β-catenin pathway, currently in Phase 2 clinical trials for pancreatic cancer.\n2. RX-0201 targets the mRNA of PD-L1 and is being developed by Rexahn Pharmaceuticals for pancreatic cancer, currently in Phase 2 clinical trials.\n3. BMS-986205 is an investigational siRNA drug targeting the mRNA of KRAS, under development by Bristol-Myers Squibb, and in Phase 1 clinical trials for pancreatic cancer.\n4. ALN-P001 targets the mRNA of P53, is being developed by Alnylam Pharmaceuticals, and is in Phase 1 clinical trials for pancreatic cancer.\n5. These siRNA-based drugs have not yet been approved by the FDA for the treatment of pancreatic cancer.",
    "llama-2-7b-chat-hf_fact": [
      "ONC201 is a drug that targets the Wnt/β-catenin pathway, currently in Phase 2 clinical trials for pancreatic cancer.",
      "RX-0201 targets the mRNA of PD-L1 and is being developed by Rexahn Pharmaceuticals for pancreatic cancer, currently in Phase 2 clinical trials.",
      "BMS-986205 is an investigational siRNA drug targeting the mRNA of KRAS, under development by Bristol-Myers Squibb, and in Phase 1 clinical trials for pancreatic cancer.",
      "ALN-P001 targets the mRNA of P53, is being developed by Alnylam Pharmaceuticals, and is in Phase 1 clinical trials for pancreatic cancer.",
      "These siRNA-based drugs have not yet been approved by the FDA for the treatment of pancreatic cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: BMS-986205 is not an investigational siRNA drug but is identified as an investigational small molecule being developed by Bristol-Myers Squibb which targets an enzyme called IDO1, and my available information may not be current regarding its phase of trials or specific cancer types being targeted.\n4. FALSE [correction]: As of my last update, ALN-P001 does not correspond to a documented drug code used by Alnylam Pharmaceuticals. Alnylam focuses on RNA interference (RNAi) therapies but the specific drug code, target mRNA, and phase of the trial should be verified as they may not be accurate or updated.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-7b-chat-hf_response": "The HPG pore (also known as the H+/Pi-dependent glucose transport pore) is a transmembrane protein complex that facilitates the transport of glucose across cell membranes in a coordinated and regulated manner. It is found in the plasma membrane of various cells, including those in the pancreas, liver, and muscles, and plays a crucial role in glucose homeostasis.\nThe HPG pore is composed of several subunits, including the H+/Pi-ATPase subunit (also known as ATP2B1) and the glucose transporter subunit (GLUT1). The complex is embedded in the plasma membrane and spans the cell membrane bilayer, with the H+/Pi-ATPase subunit facing the cytosolic side of the membrane and the glucose transporter subunit facing the extracellular side.\nThe HPG pore functions as a proton-coupled ATPase, meaning that the transport of glucose across the membrane is energized by the hydrolysis of ATP. The process involves the following steps:\n1. Glucose binding: Glucose molecules bind to the glucose transporter subunit of the HPG pore.\n2. Proton pumping: The H+/Pi-ATPase subunit of the HPG pore pumps protons (hydrogen ions) across the membrane, creating a proton gradient.\n3. ATP hydrolysis: The energy from the proton gradient is used to hydrolyze ATP, which drives the transport of glucose across the membrane.\n4. Glucose release: The glucose molecules are released into the cytosol on the other side of the membrane.\nThe HPG pore plays a crucial role in regulating glucose homeostasis in the body by controlling the amount of glucose that enters cells. It is also involved in the regulation of insulin signaling and glucose metabolism, and dysfunction of the HPG pore has been implicated in various diseases, including diabetes and metabolic disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. The HPG pore is a transmembrane protein complex that facilitates the transport of glucose across cell membranes.\n2. The HPG pore is found in the plasma membrane of various cells, including those in the pancreas, liver, and muscles.\n3. The HPG pore complex includes the H+/Pi-ATPase subunit and the glucose transporter subunit (GLUT1).\n4. The transport of glucose across the membrane by the HPG pore is energized by the hydrolysis of ATP.\n5. Dysfunction of the HPG pore has been implicated in diseases such as diabetes and metabolic disorders.",
    "llama-2-7b-chat-hf_fact": [
      "The HPG pore is a transmembrane protein complex that facilitates the transport of glucose across cell membranes.",
      "The HPG pore is found in the plasma membrane of various cells, including those in the pancreas, liver, and muscles.",
      "The HPG pore complex includes the H+/Pi-ATPase subunit and the glucose transporter subunit (GLUT1).",
      "The transport of glucose across the membrane by the HPG pore is energized by the hydrolysis of ATP.",
      "Dysfunction of the HPG pore has been implicated in diseases such as diabetes and metabolic disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There is no known transmembrane protein complex referred to as the \"HPG pore\" that facilitates the transport of glucose across cell membranes. The GLUT (glucose transporter) proteins, such as GLUT1, GLUT2, and others, are responsible for the facilitation of glucose transport across cell membranes.\n2. FALSE [correction]: Since there is no transmembrane complex known as the \"HPG pore,\" this statement cannot be true. However, GLUT proteins can be found in the plasma membrane of various cells, including those in the pancreas, liver, and muscles.\n3. FALSE [correction]: The H+/Pi-ATPase subunit is a component of proton-pump complexes, not specifically associated with glucose transport. GLUT1 is a glucose transporter subunit, but it is not part of an HPG pore complex because an HPG pore complex does not exist.\n4. FALSE [correction]: The transport of glucose across the membrane by GLUT transporters does not require ATP hydrolysis. GLUT transporters typically facilitate passive transport through facilitated diffusion, not active transport that would require energy from ATP hydrolysis.\n5. FALSE [correction]: Since the HPG pore does not exist, it cannot be implicated in diseases. However, dysfunctions in glucose transporters such as GLUT proteins have been implicated in diseases such as diabetes and metabolic disorders.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-7b-chat-hf_response": "The 959 Nematode Genomes (959NG) initiative is a collaborative research project that aims to sequence the genomes of 959 species of nematodes, which are a group of microscopic worms that are found in almost every environment on Earth. Nematodes are important organisms in many ecosystems, and they play key roles in decomposing organic matter, mediating plant-soil interactions, and serving as vectors of plant diseases.\nThe 959NG initiative was launched in 2017 by a group of researchers from the University of California, Davis, and it is supported by the National Science Foundation (NSF) and the University of California. The project's goal is to generate high-quality genomic data for as many nematode species as possible, with the long-term goal of improving our understanding of nematode evolution, ecology, and behavior.\nThe 959NG initiative is using a variety of cutting-edge sequencing technologies, including single-molecule real-time sequencing and nanopore sequencing, to generate genomic data for nematodes at an unprecedented scale. The project has already generated draft genomes for over 300 nematode species, and it is expected to continue generating new genomic data for many years to come.\nThe 959NG initiative is not only focused on generating genomic data, but also on developing new computational tools and methods for analyzing and interpreting the large amounts of data generated by the project. The project's researchers are also working to develop new applications of nematode genomics, such as using nematodes as model organisms for studying plant-soil interactions and developing new pest management strategies.\nOverall, the 959 Nematode Genomes initiative is an exciting and ambitious project that is shedding new light on the biology and evolution of these fascinating organisms, and it has the potential to lead to important breakthroughs in many areas of biology and agriculture.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence the genomes of 959 species of nematodes.\n2. The project was launched in 2017 by researchers from the University of California, Davis.\n3. The National Science Foundation and the University of California support the 959NG initiative.\n4. Over 300 draft genomes for nematode species have been generated by the project as of the knowledge cutoff date.\n5. The initiative employs single-molecule real-time sequencing and nanopore sequencing technologies.",
    "llama-2-7b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative aims to sequence the genomes of 959 species of nematodes.",
      "The project was launched in 2017 by researchers from the University of California, Davis.",
      "The National Science Foundation and the University of California support the 959NG initiative.",
      "Over 300 draft genomes for nematode species have been generated by the project as of the knowledge cutoff date.",
      "The initiative employs single-molecule real-time sequencing and nanopore sequencing technologies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The 959 Nematode Genomes initiative was launched by an international group of researchers, and there's no specific indication that it was spearheaded solely by researchers from the University of California, Davis.\n3. TRUE\n4. UNKNOWN (since the exact number of draft genomes generated by the project as of the knowledge cutoff date is not provided and requires up-to-date data to confirm)\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed for analyzing Non-invasive prenatal testing (NIPT) data. Some of the popular ones include:\n1. NIPTtools: This package provides a set of functions for analyzing NIPT data, including data cleaning, filtering, and visualization. It also includes tools for estimating the probability of the fetus having a particular genetic disorder based on the NIPT results.\n2. Prenatix: This package provides a comprehensive set of tools for NIPT data analysis, including data cleaning, filtering, and visualization. It also includes functions for estimating the probability of the fetus having a particular genetic disorder based on the NIPT results, as well as for calculating the false discovery rate (FDR) of the test results.\n3. PrenatalGenetics: This package provides a set of functions for analyzing NIPT data, including data cleaning, filtering, and visualization. It also includes tools for estimating the probability of the fetus having a particular genetic disorder based on the NIPT results, as well as for calculating the FDR of the test results.\n4. NIPTAnalysis: This package provides a set of functions for analyzing NIPT data, including data cleaning, filtering, and visualization. It also includes tools for estimating the probability of the fetus having a particular genetic disorder based on the NIPT results, as well as for calculating the FDR of the test results.\n5. GenNIPT: This package provides a set of functions for analyzing NIPT data, including data cleaning, filtering, and visualization. It also includes tools for estimating the probability of the fetus having a particular genetic disorder based on the NIPT results, as well as for calculating the FDR of the test results.\n6. NIPTworkflow: This package provides a workflow for analyzing NIPT data, including data cleaning, filtering, and visualization. It also includes tools for estimating the probability of the fetus having a particular genetic disorder based on the NIPT results, as well as for calculating the FDR of the test results.\nThese are some of the popular R packages for analyzing NIPT data, and the choice of which package to use will depend on the specific",
    "llama-2-7b-chat-hf_fact_raw": "1. NIPTtools is an R package developed for analyzing NIPT data.\n2. Prenatix is an R package that includes functions for calculating the false discovery rate (FDR) of NIPT test results.\n3. PrenatalGenetics is an R package designed for analyzing NIPT data and includes tools for calculating the FDR of test results.\n4. NIPTAnalysis is an R package developed to provide a set of functions for NIPT data analysis.\n5. GenNIPT is an R package that provides functions for estimating the probability of a fetus having a particular genetic disorder from NIPT results.",
    "llama-2-7b-chat-hf_fact": [
      "NIPTtools is an R package developed for analyzing NIPT data.",
      "Prenatix is an R package that includes functions for calculating the false discovery rate (FDR) of NIPT test results.",
      "PrenatalGenetics is an R package designed for analyzing NIPT data and includes tools for calculating the FDR of test results.",
      "NIPTAnalysis is an R package developed to provide a set of functions for NIPT data analysis.",
      "GenNIPT is an R package that provides functions for estimating the probability of a fetus having a particular genetic disorder from NIPT results."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - NIPTtools is indeed an R package developed for the analysis of Non-Invasive Prenatal Testing (NIPT) data.\n2. UNKNOWN - There is no widely recognized R package named Prenatix, and the statement about its functions is too precise to confirm without specific knowledge of such a package.\n3. UNKNOWN - Similar to statement 2, the existence and features of an R package named PrenatalGenetics cannot be verified without more information or significant recognition in the field.\n4. UNKNOWN - While NIPTAnalysis seems like a plausible name for an R package that would deal with NIPT data analysis, without specific knowledge or sufficient context, we cannot confirm the existence or features of such a package.\n5. UNKNOWN - GenNIPT could be a plausible name for an R package designed for genetic disorder probability estimation from NIPT results. However, as with the previous statements, the existence and functionality of the package cannot be verified without additional information.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbach’s syndrome.",
    "llama-2-7b-chat-hf_response": "Achenbach's syndrome, also known as Achenbach-Honderich syndrome or AH syndrome, is a rare genetic disorder that affects the brain and nervous system. It is characterized by a variety of symptoms, including:\n1. Delayed development and intellectual disability: Children with Achenbach's syndrome typically experience delays in reaching developmental milestones, such as sitting, standing, and walking. They may also have intellectual disability, which can range from mild to severe.\n2. Seizures: Achenbach's syndrome is often associated with seizures, which can be caused by abnormal electrical activity in the brain.\n3. Vision problems: People with Achenbach's syndrome may experience vision problems, including blurred vision, double vision, or loss of vision in one or both eyes.\n4. Hearing loss: Hearing loss is a common feature of Achenbach's syndrome, and can range from mild to severe.\n5. Sleep disturbances: Achenbach's syndrome can cause sleep disturbances, including insomnia, sleep apnea, and other sleep disorders.\n6. Autism-like symptoms: Some individuals with Achenbach's syndrome may exhibit autism-like symptoms, such as social isolation, communication difficulties, and repetitive behaviors.\n7. Other features: Achenbach's syndrome can also cause a range of other symptoms, including delayed speech and language development, coordination problems, and a higher risk of infections.\nThe exact cause of Achenbach's syndrome is not fully understood, but it is thought to be related to genetic mutations that affect the development of the brain and nervous system. There is currently no cure for the syndrome, but treatment can help manage the symptoms and improve quality of life.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-7b-chat-hf_response": "There are several algorithms used for the detection of long repeat expansions in genomic DNA, including:\n1. RepeatMasker: This is a widely used algorithm that uses a combination of sequence similarity and k-mer analysis to identify repetitive elements in a genome. RepeatMasker can be used to identify both short and long repeat expansions.\n2. GAGA: GAGA is a hidden Markov model (HMM) based algorithm that uses a probabilistic approach to identify repeat elements in a genome. GAGA can be used to identify both short and long repeat expansions, and it is particularly useful for identifying repeat elements that are difficult to detect using other methods.\n3. RepeatFinder: RepeatFinder is a software tool that uses a combination of k-mer analysis and HMMs to identify repeat elements in a genome. RepeatFinder can be used to identify both short and long repeat expansions, and it is particularly useful for identifying repeat elements that are found in non-coding regions of the genome.\n4. LRE-Cutter: LRE-Cutter is a tool that uses a combination of k-mer analysis and HMMs to identify long repeat expansions in a genome. LRE-Cutter can be used to identify repeat elements that are longer than 200 base pairs in length.\n5. RNA-seq-based methods: RNA-seq is a powerful tool for transcriptome analysis that can be used to identify long repeat expansions by sequencing the RNA molecules in a sample. RNA-seq-based methods can be used to identify both spliced and unspliced transcripts, and they can be particularly useful for identifying repeat elements that are not detected by other methods.\n6. DeepSEA: DeepSEA is a deep learning-based method that uses a convolutional neural network (CNN) to identify repeat elements in a genome. DeepSEA can be used to identify both short and long repeat expansions, and it is particularly useful for identifying repeat elements that are found in complex or highly repetitive regions of the genome.\n7. RAVEN: RAVEN is a tool that uses a combination of k-mer analysis and HMMs to identify repeat elements in a genome. RAVEN can be used to identify both short and",
    "llama-2-7b-chat-hf_fact_raw": "1. RepeatMasker uses sequence similarity and k-mer analysis to identify repetitive elements in genomic DNA.\n2. GAGA is a hidden Markov model-based algorithm that can identify repeat elements in a genome.\n3. RepeatFinder uses k-mer analysis and HMMs to identify repeat elements in genomic DNA.\n4. LRE-Cutter is designed to identify long repeat expansions longer than 200 base pairs in length.\n5. RNA-seq-based methods can be used to identify long repeat expansions by sequencing the RNA molecules in a sample.",
    "llama-2-7b-chat-hf_fact": [
      "RepeatMasker uses sequence similarity and k-mer analysis to identify repetitive elements in genomic DNA.",
      "GAGA is a hidden Markov model-based algorithm that can identify repeat elements in a genome.",
      "RepeatFinder uses k-mer analysis and HMMs to identify repeat elements in genomic DNA.",
      "LRE-Cutter is designed to identify long repeat expansions longer than 200 base pairs in length.",
      "RNA-seq-based methods can be used to identify long repeat expansions by sequencing the RNA molecules in a sample."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: GAGA is not a known standard algorithm for identifying repeat elements in a genome based on hidden Markov models (HMMs). GAGA typically refers to a transcription factor binding motif. A known HMM-based algorithm for identifying repeat elements in genomic DNA is RepeatModeler.\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-7b-chat-hf_response": "Neuroligin-3 has been implicated in the development and progression of several types of brain tumors, including:\n1. Glioblastoma: Neuroligin-3 has been shown to be overexpressed in glioblastoma, the most common and aggressive form of primary brain cancer. Overexpression of neuroligin-3 has been linked to poor prognosis and treatment resistance in glioblastoma patients.\n2. Medulloblastoma: Neuroligin-3 is also overexpressed in medulloblastoma, a type of pediatric brain cancer that originates in the cerebellum.\n3. Pontine glioma: Neuroligin-3 has been found to be overexpressed in pontine gliomas, which are tumors that originate in the pons, a part of the brainstem.\n4. Meningioma: Neuroligin-3 has been shown to be overexpressed in meningioma, a type of benign brain tumor that arises from the meninges, the protective coverings of the brain and spinal cord.\n5. Pineal parenchymal tumors: Neuroligin-3 has been found to be overexpressed in pineal parenchymal tumors, which are rare tumors that originate in the pineal gland.\nIn summary, neuroligin-3 has been implicated in the development and progression of several types of brain tumors, including glioblastoma, medulloblastoma, pontine glioma, meningioma, and pineal parenchymal tumors.",
    "llama-2-7b-chat-hf_fact_raw": "1. Neuroligin-3 has been shown to be overexpressed in glioblastoma, a form of primary brain cancer.\n2. Neuroligin-3 overexpression has been linked to poor prognosis and treatment resistance in glioblastoma patients.\n3. Neuroligin-3 is overexpressed in medulloblastoma, which is a pediatric brain cancer originating in the cerebellum.\n4. Neuroligin-3 overexpression is found in pontine gliomas, which are tumors originating in the pons of the brainstem.\n5. Neuroligin-3 is overexpressed in meningiomas, which arise from the meninges of the brain and spinal cord.",
    "llama-2-7b-chat-hf_fact": [
      "Neuroligin-3 has been shown to be overexpressed in glioblastoma, a form of primary brain cancer.",
      "Neuroligin-3 overexpression has been linked to poor prognosis and treatment resistance in glioblastoma patients.",
      "Neuroligin-3 is overexpressed in medulloblastoma, which is a pediatric brain cancer originating in the cerebellum.",
      "Neuroligin-3 overexpression is found in pontine gliomas, which are tumors originating in the pons of the brainstem.",
      "Neuroligin-3 is overexpressed in meningiomas, which arise from the meninges of the brain and spinal cord."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nNote: Statements 1 through 4 are specific and suggest a level of scientific consensus or research findings. Without specific data on neuroligin-3 expression in meningiomas as of my last update, I can't confirm or deny statement 5, thus it is UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-7b-chat-hf_response": "The size of gas vesicles in Halobacterium salinarum can vary, but they are generally around 10-20 nanometers (nm) in diameter. However, some gas vesicles can be as small as 5 nm or as large as 50 nm in diameter. The size of the gas vesicles is determined by the size of the protein subunits that make up the vesicle membrane, and can be influenced by factors such as the concentration of the gas inside the vesicle and the osmotic pressure of the surrounding environment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gas vesicles in Halobacterium salinarum generally range from 10-20 nanometers in diameter.\n2. Some gas vesicles can be as small as 5 nanometers in diameter.\n3. Others can be as large as 50 nanometers in diameter.\n4. The size of the gas vesicles is determined by the size of the protein subunits that make up the vesicle membrane.\n5. Factors such as the concentration of the gas inside the vesicle and the osmotic pressure of the surrounding environment can influence the size of gas vesicles.",
    "llama-2-7b-chat-hf_fact": [
      "Gas vesicles in Halobacterium salinarum generally range from 10-20 nanometers in diameter.",
      "Some gas vesicles can be as small as 5 nanometers in diameter.",
      "Others can be as large as 50 nanometers in diameter.",
      "The size of the gas vesicles is determined by the size of the protein subunits that make up the vesicle membrane.",
      "Factors such as the concentration of the gas inside the vesicle and the osmotic pressure of the surrounding environment can influence the size of gas vesicles."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gas vesicles in Halobacterium salinarum generally range from 45-200 nanometers in length and 100-250 nanometers in diameter.\n2. TRUE (Assuming the range provided in statement 1 was supposed to be lengths rather than diameters)\n3. TRUE (Assuming the range provided in statement 1 was supposed to be lengths rather than diameters)\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-7b-chat-hf_response": "BET (Bromodomain and Extra-Terminal) proteins are a family of proteins that play a crucial role in regulating gene expression by modulating chromatin structure. Here are the four BET proteins:\n1. BET1 (Bromodomain-Containing Protein 1): Also known as BRD1, this protein is the founding member of the BET family and plays a key role in regulating gene expression, cell proliferation, and differentiation.\n2. BET2 (Bromodomain-Containing Protein 2): BRD2 is another member of the BET family that is involved in regulating gene expression, cell proliferation, and differentiation. It is also known to play a role in the development and progression of cancer.\n3. BET3 (Bromodomain-Containing Protein 3): BRD3 is a BET protein that is involved in regulating gene expression, cell proliferation, and differentiation. It is also known to play a role in the development and progression of cancer.\n4. BET4 (Bromodomain-Containing Protein 4): BRD4 is the most recently identified member of the BET family, and it is involved in regulating gene expression, cell proliferation, and differentiation. It is also known to play a role in the development and progression of cancer.\nEach of these proteins has a bromodomain, a specific structural motif that is responsible for recognizing and binding to acetylated lysine residues on histone proteins, which in turn regulates chromatin structure and gene expression. Dysregulation of BET proteins has been implicated in various diseases, including cancer, and they are being explored as potential therapeutic targets for cancer treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Bromodomain-Containing Protein 1 (BRD1) is a member of the BET protein family and plays a role in regulating gene expression, cell proliferation, and differentiation.\n2. BRD2 is a BET protein that is involved in the regulation of gene expression and has been linked to the development and progression of cancer.\n3. BRD3 is a member of the BET protein family that is involved in gene expression regulation and has implications in cancer development.\n4. BRD4 is the most recently identified BET protein and is involved in gene expression regulation and has associations with cancer progression.\n5. BET proteins contain a bromodomain which is a structural motif that binds to acetylated lysine residues on histone proteins.",
    "llama-2-7b-chat-hf_fact": [
      "Bromodomain-Containing Protein 1 (BRD1) is a member of the BET protein family and plays a role in regulating gene expression, cell proliferation, and differentiation.",
      "BRD2 is a BET protein that is involved in the regulation of gene expression and has been linked to the development and progression of cancer.",
      "BRD3 is a member of the BET protein family that is involved in gene expression regulation and has implications in cancer development.",
      "BRD4 is the most recently identified BET protein and is involved in gene expression regulation and has associations with cancer progression.",
      "BET proteins contain a bromodomain which is a structural motif that binds to acetylated lysine residues on histone proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: BRD4 is not the most recently identified BET protein but has been known for a while to be involved in regulating gene expression and associated with cancer progression.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-7b-chat-hf_response": "There have been several deep learning algorithms developed for predicting protein subcellular localization. Some of the notable ones include:\n1. DeepLoc: Developed by Zhang et al. in 2015, DeepLoc is a deep learning-based method for predicting protein subcellular localization. It uses a combination of sequence-based features and structural information to predict the localization of proteins.\n2. LocNet: LocNet is another deep learning-based method for protein subcellular localization prediction, developed by Xu et al. in 2018. It uses a hierarchical architecture to integrate both sequence-based and structural information.\n3. PredictProteinLoc: PredictProteinLoc is a deep learning-based method developed by Li et al. in 2019 for predicting protein subcellular localization. It uses a combination of sequence-based features and graph-based features to predict the localization of proteins.\n4. PLOC: PLOC is a deep learning-based method developed by Li et al. in 2020 for predicting protein subcellular localization. It uses a multi-task learning framework to predict both the localization and function of proteins.\n5. DSSR: DSSR (Deep Subcellular Site Prediction using Recurrent Neural Networks) is a deep learning-based method developed by Zhang et al. in 2020 for predicting protein subcellular localization. It uses a recurrent neural network (RNN) architecture to predict the localization of proteins.\nThese are just a few examples of the deep learning algorithms that have been developed for predicting protein subcellular localization. Each algorithm has its strengths and limitations, and the choice of algorithm will depend on the specific needs and goals of the research project.",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepLoc is a deep learning-based algorithm developed by Zhang et al. in 2015 for predicting protein subcellular localization.\n2. LocNet, developed by Xu et al. in 2018, is a deep learning-based method for protein subcellular localization prediction that uses a hierarchical architecture.\n3. PredictProteinLoc is a deep learning-based method developed by Li et al. in 2019 for predicting protein subcellular localization.\n4. PLOC, developed by Li et al. in 2020, is a deep learning-based method for predicting protein subcellular localization using a multi-task learning framework.\n5. DSSR (Deep Subcellular Site Prediction using Recurrent Neural Networks) is a deep learning-based algorithm developed by Zhang et al. in 2020 to predict protein subcellular localization.",
    "llama-2-7b-chat-hf_fact": [
      "DeepLoc is a deep learning-based algorithm developed by Zhang et al. in 2015 for predicting protein subcellular localization.",
      "LocNet, developed by Xu et al. in 2018, is a deep learning-based method for protein subcellular localization prediction that uses a hierarchical architecture.",
      "PredictProteinLoc is a deep learning-based method developed by Li et al. in 2019 for predicting protein subcellular localization.",
      "PLOC, developed by Li et al. in 2020, is a deep learning-based method for predicting protein subcellular localization using a multi-task learning framework.",
      "DSSR (Deep Subcellular Site Prediction using Recurrent Neural Networks) is a deep learning-based algorithm developed by Zhang et al. in 2020 to predict protein subcellular localization."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without access to a specific scientific database or a specific publication from Zhang et al. in 2015, I cannot confirm nor deny the development of DeepLoc in that year.\n2. UNKNOWN: Without a reference to the specific work of Xu et al. in 2018, I cannot verify the correct details about LocNet and its hierarchical architecture for protein subcellular localization prediction.\n3. UNKNOWN: The information about PredictProteinLoc and its development by Li et al. in 2019 is very specific, but without access to records or databases, I cannot determine its accuracy.\n4. UNKNOWN: As with the previous statements, without specific reference material, I cannot verify the existence of PLOC, its developers, or the details of its methodology.\n5. UNKNOWN: The claim regarding the development of DSSR (Deep Subcellular Site Prediction using Recurrent Neural Networks) by Zhang et al. in 2020 is very precise but the veracity of the statement cannot be established without more information or a corresponding publication reference.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-7b-chat-hf_response": "I apologize, but I'm not familiar with the term \"MULTOVL.\" It could be a misspelling or a term that is not widely used. Can you please provide more context or information about where you encountered this term? This will help me better understand and provide a more accurate answer.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-7b-chat-hf_response": "Yes, Growth Differentiation Factor 15 (GDF15) has been identified as a potential biomarker for metformin treatment. Metformin is a commonly used medication for type 2 diabetes, and it has been shown to have a variety of effects on the body beyond its glucose-lowering effects.\nStudies have shown that GDF15 levels are altered in response to metformin treatment in both humans and animal models. For example, one study found that GDF15 levels were significantly increased in patients with type 2 diabetes who were treated with metformin compared to those who were not treated with metformin. Another study found that GDF15 levels were increased in mice with type 2 diabetes that were treated with metformin.\nGDF15 has been shown to have a variety of biological functions, including the regulation of glucose and lipid metabolism, the modulation of inflammation, and the promotion of cell survival and proliferation. Therefore, changes in GDF15 levels in response to metformin treatment may reflect the drug's broader effects on the body beyond its glucose-lowering effects.\nAs a potential biomarker for metformin treatment, GDF15 could be used to monitor the effectiveness of treatment, identify patients who are unlikely to respond to metformin, or detect the development of metformin-related adverse effects. However, further research is needed to confirm the clinical utility of GDF15 as a biomarker for metformin treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Growth Differentiation Factor 15 (GDF15) has been identified as a potential biomarker for metformin treatment.\n2. Metformin is a medication commonly used for treating type 2 diabetes.\n3. Studies indicate that GDF15 levels change in response to metformin treatment in both humans and animal models.\n4. A study found that GDF15 levels were significantly increased in patients with type 2 diabetes who were treated with metformin.\n5. Another study observed increased levels of GDF15 in mice with type 2 diabetes treated with metformin.",
    "llama-2-7b-chat-hf_fact": [
      "Growth Differentiation Factor 15 (GDF15) has been identified as a potential biomarker for metformin treatment.",
      "Metformin is a medication commonly used for treating type 2 diabetes.",
      "Studies indicate that GDF15 levels change in response to metformin treatment in both humans and animal models.",
      "A study found that GDF15 levels were significantly increased in patients with type 2 diabetes who were treated with metformin.",
      "Another study observed increased levels of GDF15 in mice with type 2 diabetes treated with metformin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nEach statement regarding GDF15 and metformin is consistent with current scientific understanding, as GDF15 has been studied as a biomarker that responds to metformin treatment in patients with type 2 diabetes, and these findings have been observed in both human and animal studies.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-7b-chat-hf_response": "Yes, recursive splicing is more common in short introns.\nRecursive splicing, also known as intron-within-intron splicing, occurs when a splicing event occurs within an intron, resulting in the removal of a smaller intron and the formation of a new exon. This type of splicing is more common in short introns, which are typically 100-200 nucleotides in length.\nThere are several reasons why recursive splicing is more common in short introns:\n1. Proximity: Short introns are closer together, making it easier for the splicing machinery to recognize and access the intron-exon boundaries.\n2. Conserved splicing signals: Short introns often have conserved splicing signals, which are critical for the recognition and splicing of the intron. These signals are more easily recognized when the intron is shorter.\n3. Reduced splicing complexity: Short introns have fewer nucleotides to be spliced, reducing the complexity of the splicing reaction. This can make it easier for the splicing machinery to recognize and process the intron.\n4. Increased stability: Short introns may be more stable than longer introns, which can make them more likely to be retained in the final mRNA transcript.\nIn summary, recursive splicing is more common in short introns due to their proximity, conserved splicing signals, reduced splicing complexity, and increased stability.",
    "llama-2-7b-chat-hf_fact_raw": "1. Recursive splicing is more common in short introns.\n2. Short introns are typically 100-200 nucleotides in length.\n3. Proximity facilitates the splicing machinery's ability to recognize and access intron-exon boundaries in short introns.\n4. Short introns often have conserved splicing signals.\n5. Short introns may be more stable than longer introns, increasing their likelihood of retention in the final mRNA transcript.",
    "llama-2-7b-chat-hf_fact": [
      "Recursive splicing is more common in short introns.",
      "Short introns are typically 100-200 nucleotides in length.",
      "Proximity facilitates the splicing machinery's ability to recognize and access intron-exon boundaries in short introns.",
      "Short introns often have conserved splicing signals.",
      "Short introns may be more stable than longer introns, increasing their likelihood of retention in the final mRNA transcript."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Recursive splicing is more commonly associated with longer introns.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The stability of introns does not typically affect their retention in mRNA transcripts as introns are generally removed during RNA splicing, irrespective of their length. Short introns may be spliced more efficiently, but this efficiency does not necessarily equate to stability or retention in mRNA.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-7b-chat-hf_response": "TALE-iD is a method used for identifying the regulatory elements in the genome, particularly the enhancers, that control the expression of specific genes. Enhancers are specific DNA sequences that can increase the rate at which a gene is expressed, but they are located far away from the promoter and gene they regulate. TALE-iD uses a technique called CRISPR-Cas9-based genomic engineering to identify these enhancers by exploiting the sequence specificity of the CRISPR-Cas9 system.\nThe TALE-iD method works by using a TALE (transcriptional activator-like effector) protein as a guide to find the specific DNA sequences that are responsible for regulating a particular gene. The TALE protein is programmed to recognize a specific DNA sequence, and when it finds a match, it induces a double-stranded break in the DNA. This break can be used to introduce a specific mutation or to activate a reporter gene, allowing researchers to identify the regulatory elements that are responsible for controlling gene expression.\nThe TALE-iD method has several advantages over other methods for identifying regulatory elements. It is highly specific and can identify enhancers with high accuracy, and it can be used to study the regulation of any gene in the genome. Additionally, the TALE-iD method can be used to study the regulation of gene expression in a wide range of organisms, including humans.\nOverall, the TALE-iD method is a powerful tool for understanding the complex regulatory networks that control gene expression, and it has the potential to lead to new insights into the causes of a wide range of diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. TALE-iD is a method used for identifying regulatory elements, such as enhancers, in the genome.\n2. Enhancers increase the rate of gene expression and are located far from the promoter and gene they regulate.\n3. TALE-iD employs CRISPR-Cas9-based genomic engineering to identify enhancers by utilizing the sequence specificity of the CRISPR-Cas9 system.\n4. TALE-iD uses TALE proteins to locate specific DNA sequences responsible for regulating a particular gene.\n5. TALE-iD is capable of introducing mutations or activating reporter genes to identify regulatory elements controlling gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "TALE-iD is a method used for identifying regulatory elements, such as enhancers, in the genome.",
      "Enhancers increase the rate of gene expression and are located far from the promoter and gene they regulate.",
      "TALE-iD employs CRISPR-Cas9-based genomic engineering to identify enhancers by utilizing the sequence specificity of the CRISPR-Cas9 system.",
      "TALE-iD uses TALE proteins to locate specific DNA sequences responsible for regulating a particular gene.",
      "TALE-iD is capable of introducing mutations or activating reporter genes to identify regulatory elements controlling gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TALE-iD (Transcription Activator-Like Effector nuclease-mediated chromatin immunoprecipitation (ChIP)-derived) is a method for determining DNA binding sites of transcription factors, not specifically for identifying regulatory elements, such as enhancers.\n2. TRUE\n3. FALSE [correction]: TALE-iD does not employ CRISPR-Cas9, but rather uses TALE (Transcription Activator-Like Effector) technology for its sequence-specific DNA binding.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-7b-chat-hf_response": "There are several Lisp frameworks that have been developed for image processing, including:\n1. CL-Image: CL-Image is a Lisp library for image processing that provides a wide range of functions for image manipulation, analysis, and processing. It includes functions for image filtering, resizing, and thresholding, as well as more advanced techniques such as edge detection and morphological operations.\n2. Lisp-Image: Lisp-Image is another Lisp library for image processing that provides a variety of functions for image manipulation and analysis. It includes functions for image filtering, resizing, and thresholding, as well as support for image formats such as JPEG and PNG.\n3. ImageTk: ImageTk is a Lisp library that provides a simple and easy-to-use interface for image processing. It includes functions for image filtering, resizing, and thresholding, as well as support for image formats such as JPEG and PNG.\n4. Lisppix: Lisppix is a Lisp library for image processing that provides a wide range of functions for image manipulation, analysis, and processing. It includes functions for image filtering, resizing, and thresholding, as well as support for image formats such as JPEG and PNG.\n5. Araneida: Araneida is a Lisp library for image processing that provides a variety of functions for image manipulation and analysis. It includes functions for image filtering, resizing, and thresholding, as well as support for image formats such as JPEG and PNG.\nThese are some of the popular Lisp frameworks for image processing, and there are many other smaller libraries and tools available as well.",
    "llama-2-7b-chat-hf_fact_raw": "1. CL-Image is a Lisp library for image processing that includes functions for image filtering, resizing, thresholding, edge detection, and morphological operations.\n2. Lisp-Image is a Lisp library for image processing that supports image formats such as JPEG and PNG.\n3. ImageTk is a Lisp library that offers an interface for image processing with support for JPEG and PNG image formats.\n4. Lisppix is a Lisp library for image processing that includes functions for image filtering, resizing, thresholding, and supports JPEG and PNG image formats.\n5. Araneida is a Lisp library for image processing that provides functions for image manipulation and analysis, and supports image formats such as JPEG and PNG.",
    "llama-2-7b-chat-hf_fact": [
      "CL-Image is a Lisp library for image processing that includes functions for image filtering, resizing, thresholding, edge detection, and morphological operations.",
      "Lisp-Image is a Lisp library for image processing that supports image formats such as JPEG and PNG.",
      "ImageTk is a Lisp library that offers an interface for image processing with support for JPEG and PNG image formats.",
      "Lisppix is a Lisp library for image processing that includes functions for image filtering, resizing, thresholding, and supports JPEG and PNG image formats.",
      "Araneida is a Lisp library for image processing that provides functions for image manipulation and analysis, and supports image formats such as JPEG and PNG."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: There is no standard Lisp library known as Lisp-Image for image processing. However, CL-Image may support various image formats, including JPEG and PNG.\n3. FALSE [correction]: ImageTk is not a Lisp library. It is a part of the Tk toolkit used in the Python programming language for the Tkinter GUI interface which supports image formats such as JPEG and PNG.\n4. UNKNOWN\n5. FALSE [correction]: Araneida is not a library for image processing. It is actually a web server written in Common Lisp and does not provide functions for image manipulation and analysis.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-7b-chat-hf_response": "The yeast species Saccharomyces cerevisiae (baker's yeast) underwent a whole genome duplication (WGD) event around 1,000 million years ago, resulting in the duplication of approximately 80% of its genes. This event is known as the \"S. cerevisiae genome duplication\" or \"ScGD.\"\nAccording to a study published in the journal Nature in 2019, the ScGD event resulted in the duplication of around 1,000 gene families in S. cerevisiae. Of these, around 700 gene families contain two copies of the same gene, while the remaining 300 gene families contain multiple copies of genes that are related to each other but not identical.\nIt's worth noting that the ScGD event was not a single, instantaneous event, but rather a gradual process that occurred over millions of years. Additionally, the duplication of genes was not uniform throughout the genome, with some regions experiencing more extensive duplication than others.\nOverall, the ScGD event had a significant impact on the evolution of S. cerevisiae, leading to the expansion of gene families involved in various cellular processes and the development of new functions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Saccharomyces cerevisiae (baker's yeast) experienced a whole genome duplication event around 1,000 million years ago.\n2. Approximately 80% of the genes in S. cerevisiae were duplicated as a result of this whole genome duplication event.\n3. The whole genome duplication event in S. cerevisiae resulted in the duplication of around 1,000 gene families.\n4. About 700 of these gene families contain two copies of the same gene post-duplication.\n5. Another 300 gene families from the duplication event contain multiple copies of genes that are related but not identical.",
    "llama-2-7b-chat-hf_fact": [
      "Saccharomyces cerevisiae (baker's yeast) experienced a whole genome duplication event around 1,000 million years ago.",
      "Approximately 80% of the genes in S. cerevisiae were duplicated as a result of this whole genome duplication event.",
      "The whole genome duplication event in S. cerevisiae resulted in the duplication of around 1,000 gene families.",
      "About 700 of these gene families contain two copies of the same gene post-duplication.",
      "Another 300 gene families from the duplication event contain multiple copies of genes that are related but not identical."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Saccharomyces cerevisiae (baker's yeast) experienced a whole genome duplication event around 100 million years ago, not 1,000 million years ago.\n2. UNKNOWN: The percentage of genes duplicated due to the genome duplication event is subject to scientific investigation and can vary based on the methodologies and criteria used in different studies.\n3. UNKNOWN: The exact number of gene families that were duplicated is, again, subject to research and could differ based on the study or definition of a gene family used by researchers.\n4. UNKNOWN: We cannot confirm the number of gene families that contain two copies of the same gene post-duplication without specific research findings or data to support the statement.\n5. UNKNOWN: Likewise, the details about how many gene families contain multiple but not identical copies of genes after the duplication event are unclear without specific references to scientific studies or evidence.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-2-7b-chat-hf_response": "Estrogen-related receptor β (Esrrb) is a nuclear receptor that is bound by several ligands, including:\n1. Estrogen: Estrogen is the most well-known ligand for Esrrb, and it binds to the receptor with high affinity.\n2. Phytoestrogens: Phytoestrogens are plant-derived compounds that can mimic the action of estrogen in the body. Some common phytoestrogens that bind to Esrrb include isoflavones (found in soybeans and other legumes), lignans (found in flaxseed and other grains), and coumestans (found in alfalfa and other legumes).\n3. Retinoids: Retinoids are derivatives of vitamin A that can also bind to Esrrb. Retinoids include all-trans retinoic acid (ATRA) and 9-cis retinoic acid (9-cis RA).\n4. Other ligands: Other ligands that have been reported to bind to Esrrb include bile acids, farnesoid X receptor (FXR) agonists, and peroxisome proliferator-activated receptor (PPAR) agonists.\nIn summary, Esrrb is bound by a variety of ligands, including estrogen, phytoestrogens, retinoids, and other compounds.",
    "llama-2-7b-chat-hf_fact_raw": "1. Estrogen binds to estrogen-related receptor β (Esrrb) with high affinity.\n2. Phytoestrogens, including isoflavones from soybeans and other legumes, can bind to Esrrb.\n3. Lignans, found in flaxseed and other grains, are phytoestrogens that bind to Esrrb.\n4. Retinoids such as all-trans retinoic acid (ATRA) and 9-cis retinoic acid (9-cis RA) can bind to Esrrb.\n5. Bile acids and agonists for farnesoid X receptor (FXR) and peroxisome proliferator-activated receptor (PPAR) are reported to bind to Esrrb.",
    "llama-2-7b-chat-hf_fact": [
      "Estrogen binds to estrogen-related receptor β (Esrrb) with high affinity.",
      "Phytoestrogens, including isoflavones from soybeans and other legumes, can bind to Esrrb.",
      "Lignans, found in flaxseed and other grains, are phytoestrogens that bind to Esrrb.",
      "Retinoids such as all-trans retinoic acid (ATRA) and 9-cis retinoic acid (9-cis RA) can bind to Esrrb.",
      "Bile acids and agonists for farnesoid X receptor (FXR) and peroxisome proliferator-activated receptor (PPAR) are reported to bind to Esrrb."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Estrogen binds with high affinity to estrogen receptors, typically referred to as ERα (estrogen receptor alpha) and ERβ (estrogen receptor beta), rather than estrogen-related receptor β (Esrrb), which does not directly bind estrogens.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Retinoids such as all-trans retinoic acid (ATRA) and 9-cis retinoic acid (9-cis RA) are known to bind to retinoic acid receptors (RARs), not to estrogen-related receptor β (Esrrb).\n5. FALSE [correction]: Bile acids and agonists for farnesoid X receptor (FXR) and peroxisome proliferator-activated receptor (PPAR) are not reported to bind to Esrrb. FXR and PPAR have their own distinct ligands and are not associated with Esrrb binding.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-7b-chat-hf_response": "ZCCHC17 is a gene that encodes for a protein called zinc finger CCHC-type histone triad-containing protein 17. This protein is involved in various cellular processes, including:\n1. Transcriptional regulation: ZCCHC17 can bind to DNA and regulate the expression of target genes by blocking or activating the recruitment of transcription factors.\n2. Chromatin remodeling: ZCCHC17 can interact with chromatin-remodeling complexes and help to alter the chromatin structure, leading to changes in gene expression.\n3. Nuclear organization: ZCCHC17 can be involved in the organization of the nuclear landscape, influencing the positioning and interaction of different nuclear structures.\n4. Cell cycle progression: ZCCHC17 has been implicated in the regulation of the cell cycle, with altered expression levels linked to various cancer types.\n5. Apoptosis: ZCCHC17 can promote or inhibit apoptosis, depending on the context, highlighting its complexity in cellular processes.\n6. Stem cell maintenance: ZCCHC17 has been implicated in the regulation of stem cell self-renewal and differentiation.\n7. Neurodegeneration: ZCCHC17 has been linked to neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.\n8. Cancer: ZCCHC17 has been implicated in various types of cancer, including breast, lung, and colon cancer, where it can promote tumor growth and progression.\n9. Immune response: ZCCHC17 can interact with immune cells and influence their function, potentially contributing to immune-related diseases.\n10. Cardiovascular health: ZCCHC17 has been linked to cardiovascular disease, with altered expression levels associated with hypertension and atherosclerosis.\nIn summary, ZCCHC17 is a multifunctional protein involved in a wide range of cellular processes, including transcriptional regulation, chromatin remodeling, nuclear organization, cell cycle progression, apoptosis,",
    "llama-2-7b-chat-hf_fact_raw": "1. ZCCHC17 encodes for a protein called zinc finger CCHC-type histone triad-containing protein 17.\n2. ZCCHC17 can bind to DNA and regulate the expression of target genes.\n3. ZCCHC17 is involved in chromatin remodeling which leads to changes in gene expression.\n4. Altered expression levels of ZCCHC17 have been linked to various types of cancer.\n5. ZCCHC17 has been associated with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.",
    "llama-2-7b-chat-hf_fact": [
      "ZCCHC17 encodes for a protein called zinc finger CCHC-type histone triad-containing protein 17.",
      "ZCCHC17 can bind to DNA and regulate the expression of target genes.",
      "ZCCHC17 is involved in chromatin remodeling which leads to changes in gene expression.",
      "Altered expression levels of ZCCHC17 have been linked to various types of cancer.",
      "ZCCHC17 has been associated with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE - While the specific statement that ZCCHC17 \"can bind to DNA and regulate the expression of target genes\" is not detailed in terms of how the binding and regulation occur, proteins with zinc finger domains (as implied by the name) commonly interact with DNA and can play roles in gene regulation.\n3. UNKNOWN - Without specific information, it is unclear if ZCCHC17 is directly involved in chromatin remodeling; zinc finger proteins can be involved in various cellular processes including but not limited to chromatin remodeling.\n4. UNKNOWN - Without specific references, it is not possible to verify the claim that altered expression levels of ZCCHC17 have been linked to various types of cancer.\n5. UNKNOWN - Similar to statement 4, without specific references or literature supporting this statement, it is not possible to verify the association between ZCCHC17 and neurodegenerative diseases.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-7b-chat-hf_response": "The nuclear pore basket, also known as the nuclear pore complex (NPC), is a large protein structure that spans the nuclear envelope in eukaryotic cells, connecting the nucleus to the cytoplasm. The NPC is composed of several proteins that work together to regulate the transport of molecules between the nucleus and cytoplasm. The main proteins that form the nuclear pore basket in human cells are:\n1. Nucleoporin 1 (Nup1): Nup1 is the most abundant protein in the NPC and forms the central channel through which molecules pass.\n2. Nucleoporin 2 (Nup2): Nup2 is a highly glycosylated protein that forms a ring-like structure around the central channel.\n3. Nucleoporin 3 (Nup3): Nup3 is a small protein that forms a beta-barrel structure in the NPC and helps to regulate the transport of molecules.\n4. Nucleoporin 4 (Nup4): Nup4 is a highly glycosylated protein that forms a ring-like structure around the central channel and helps to regulate the transport of molecules.\n5. Nucleoporin 5 (Nup5): Nup5 is a small protein that forms a beta-barrel structure in the NPC and helps to regulate the transport of molecules.\n6. Nucleoporin 6 (Nup6): Nup6 is a small protein that forms a beta-barrel structure in the NPC and helps to regulate the transport of molecules.\n7. Nucleoporin 7 (Nup7): Nup7 is a small protein that forms a beta-barrel structure in the NPC and helps to regulate the transport of molecules.\n8. Nucleoporin 8 (Nup8): Nup8 is a small protein that forms a beta-barrel structure in the NPC and helps to regulate the transport of molecules.\n9. Nucleoporin 9 (Nup9): Nup9 is a small protein that forms a beta-barrel structure in the NPC and helps to regulate the transport of molecules.\n10. Nucleoporin",
    "llama-2-7b-chat-hf_fact_raw": "1. The nuclear pore complex (NPC) connects the nucleus to the cytoplasm in eukaryotic cells.\n2. Nucleoporin 1 (Nup1) forms the central channel through which molecules pass in the NPC.\n3. Nucleoporin 2 (Nup2) is a highly glycosylated protein that forms a ring-like structure around the NPC's central channel.\n4. The NPC is composed of several proteins, including ones that form beta-barrel structures to help regulate the transport of molecules.\n5. The NPC is responsible for regulating the transport of molecules between the nucleus and cytoplasm in eukaryotic cells.",
    "llama-2-7b-chat-hf_fact": [
      "The nuclear pore complex (NPC) connects the nucleus to the cytoplasm in eukaryotic cells.",
      "Nucleoporin 1 (Nup1) forms the central channel through which molecules pass in the NPC.",
      "Nucleoporin 2 (Nup2) is a highly glycosylated protein that forms a ring-like structure around the NPC's central channel.",
      "The NPC is composed of several proteins, including ones that form beta-barrel structures to help regulate the transport of molecules.",
      "The NPC is responsible for regulating the transport of molecules between the nucleus and cytoplasm in eukaryotic cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The name Nucleoporin 1 (Nup1) does not correspond to the standardized nomenclature for nuclear pore complex components. The central channel of the NPC is formed by multiple nucleoporins, but not specifically one called Nup1.\n3. UNKNOWN: Without adherence to the standardized nomenclature it's difficult to validate the function of \"Nucleoporin 2 (Nup2)\" as it's not clearly specified. There are nucleoporins with glycosylated components, but it's unclear which specific one is called Nup2 here.\n4. TRUE: The nuclear pore complex is indeed composed of several proteins, some of which form beta-barrel structures that are important for their function in transport regulation.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-7b-chat-hf_response": "Gepotidacin is a topoisomerase II inhibitor. Specifically, it is a topoisomerase II alpha (Topo IIα) inhibitor.\nTopo IIα is a type of topoisomerase that is involved in the religation of DNA during transcription and replication. It is overexpressed in many cancer cells, and its overexpression has been linked to cancer development and progression. Gepotidacin works by binding to the active site of Topo IIα and preventing it from religating DNA, leading to DNA damage and ultimately cell death.\nGepotidacin has been shown to have antitumor activity in various cancer cell lines and is being investigated as a potential anti-cancer drug.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gepotidacin is a topoisomerase II inhibitor.\n2. It specifically inhibits topoisomerase II alpha (Topo IIα).\n3. Topo IIα is involved in the religation of DNA during transcription and replication.\n4. Overexpression of Topo IIα has been linked to cancer development and progression.\n5. Gepotidacin is being investigated as a potential anti-cancer drug.",
    "llama-2-7b-chat-hf_fact": [
      "Gepotidacin is a topoisomerase II inhibitor.",
      "It specifically inhibits topoisomerase II alpha (Topo IIα).",
      "Topo IIα is involved in the religation of DNA during transcription and replication.",
      "Overexpression of Topo IIα has been linked to cancer development and progression.",
      "Gepotidacin is being investigated as a potential anti-cancer drug."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gepotidacin is not a topoisomerase II inhibitor; it is a bacterial topoisomerase inhibitor that works against topoisomerase II (DNA gyrase) and IV, which are distinctly different from the human topoisomerase II (topoisomerase II alpha and beta).\n2. FALSE [correction]: Gepotidacin does not specifically inhibit topoisomerase II alpha (Topo IIα), as it targets bacterial topoisomerases, not the human version which is referred to by Topo IIα.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Gepotidacin is being investigated as a potential antibiotic and not as an anti-cancer drug. It targets bacterial enzymes rather than human topoisomerase II alpha, which is involved in cancer development.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-7b-chat-hf_response": "Canvas SPW (Student Performance Widget) is a tool in Canvas that allows instructors to create and display customizable performance widgets for their students. These widgets provide real-time feedback to students on their progress in a course, based on their performance on assignments, quizzes, and other assessments.\nHere are some key features of Canvas SPW:\n1. Customizable: Instructors can create custom widgets that reflect the specific needs of their course and students. They can choose from a variety of pre-built widgets or create their own using a drag-and-drop interface.\n2. Real-time feedback: SPW provides real-time feedback to students on their performance, allowing them to track their progress and identify areas for improvement.\n3. Personalized learning: By providing students with real-time feedback, SPW enables personalized learning experiences tailored to their individual needs.\n4. Improved engagement: The ability to track progress and see real-time feedback can increase student engagement and motivation.\n5. Easy to use: SPW is designed to be user-friendly and easy to use, even for those without technical expertise.\n6. Integration with Canvas: SPW is fully integrated with Canvas, allowing instructors to access and manage all of their course content and assessments in one place.\n7. Mobile-friendly: SPW is mobile-friendly, allowing students to access their performance feedback on their mobile devices.\n8. Analytics: SPW provides instructors with detailed analytics and insights on student performance, allowing them to identify trends and areas for improvement.\n9. Collaboration: SPW enables instructors to collaborate with students and other instructors, promoting a sense of community and collaboration in the classroom.\n10. Accessibility: SPW is designed to be accessible to all students, including those with disabilities, and provides features such as alt text for images and keyboard navigation.\nBy leveraging these features, Canvas SPW enables instructors to create a more engaging, personalized, and effective learning experience for their students.",
    "llama-2-7b-chat-hf_fact_raw": "1. Canvas SPW allows instructors to create and display customizable performance widgets for their students.\n2. Canvas SPW provides real-time feedback to students based on their performance on assignments, quizzes, and other assessments.\n3. Canvas SPW is fully integrated with the Canvas learning management system.\n4. The Student Performance Widget is mobile-friendly.\n5. Canvas SPW offers detailed analytics and insights on student performance for instructors.",
    "llama-2-7b-chat-hf_fact": [
      "Canvas SPW allows instructors to create and display customizable performance widgets for their students.",
      "Canvas SPW provides real-time feedback to students based on their performance on assignments, quizzes, and other assessments.",
      "Canvas SPW is fully integrated with the Canvas learning management system.",
      "The Student Performance Widget is mobile-friendly.",
      "Canvas SPW offers detailed analytics and insights on student performance for instructors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information regarding \"Canvas SPW\" or the \"Student Performance Widget\" in the provided context, it is not possible to determine the accuracy of these statements. If these features exist and these statements accurately describe their functionalities, then they may be true, but there isn't enough information given here to confirm or correct the statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-7b-chat-hf_response": "STING (Stimulator of Interferon Genes) is a protein that plays a crucial role in the innate immune response to viral infections. STING agonists are molecules that activate the STING protein and trigger an immune response. Here are some examples of STING agonists:\n1. CpG DNA: CpG DNA is a type of bacterial DNA that contains the dinucleotide sequence CpG, which is highly conserved in bacterial genomes. CpG DNA is a potent STING agonist and is commonly used as a vaccine adjuvant to enhance the immune response to viral antigens.\n2. Poly(dA:dT): Poly(dA:dT) is a synthetic oligonucleotide that contains repeating sequences of adenine and thymine. It is also a potent STING agonist and is used as a vaccine adjuvant to enhance the immune response to viral antigens.\n3. MMK-015: MMK-015 is a small molecule STING agonist that is being developed as a potential therapy for cancer and infectious diseases.\n4. Vantictumab: Vantictumab is a monoclonal antibody that targets the STING protein and activates it, leading to the activation of the innate immune response.\n5. BMS-986177: BMS-986177 is a small molecule STING agonist that is being developed as a potential therapy for cancer and infectious diseases.\n6. RX-0201: RX-0201 is a small molecule STING agonist that is being developed as a potential therapy for cancer and infectious diseases.\n7. TGN-020: TGN-020 is a small molecule STING agonist that is being developed as a potential therapy for cancer and infectious diseases.\n8. TP-10: TP-10 is a small molecule STING agonist that is being developed as a potential therapy for cancer and infectious diseases.\n9",
    "llama-2-7b-chat-hf_fact_raw": "1. CpG DNA contains the dinucleotide sequence CpG and is used as a STING agonist and vaccine adjuvant.\n2. Poly(dA:dT) is a synthetic oligonucleotide that acts as a STING agonist and vaccine adjuvant.\n3. MMK-015 is a small molecule STING agonist under development for potential cancer and infectious disease therapy.\n4. Vantictumab is a monoclonal antibody that targets and activates the STING protein.\n5. BMS-986177 is a small molecule STING agonist under development for potential cancer and infectious disease therapy.",
    "llama-2-7b-chat-hf_fact": [
      "CpG DNA contains the dinucleotide sequence CpG and is used as a STING agonist and vaccine adjuvant.",
      "Poly(dA:dT) is a synthetic oligonucleotide that acts as a STING agonist and vaccine adjuvant.",
      "MMK-015 is a small molecule STING agonist under development for potential cancer and infectious disease therapy.",
      "Vantictumab is a monoclonal antibody that targets and activates the STING protein.",
      "BMS-986177 is a small molecule STING agonist under development for potential cancer and infectious disease therapy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Poly(dA:dT) is a synthetic oligonucleotide that is recognized by the intracellular DNA sensor known as cGAS, leading to the activation of STING; however, it is not itself a STING agonist.\n3. UNKNOWN\n4. FALSE [correction]: Vantictumab is a monoclonal antibody that targets the Wnt pathway by binding to frizzled receptors; it does not target or activate the STING protein.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-7b-chat-hf_response": "SLIC-CAGE (Slicing-based Combinatorial Assay for Genome Engineering) is a genome engineering technology that allows for the simultaneous editing of multiple genes or loci in a single step. It is a versatile and efficient approach for making targeted changes to the genome of an organism, and it has the potential to revolutionize the field of genetic engineering.\nPrinciple:\nSLIC-CAGE works by using a combination of CRISPR-Cas9 and homing endonucleases to create a series of DNA double-strand breaks (DSBs) at specific locations in the genome. These DSBs are then repaired by the cell's own repair machinery, which can result in the introduction of specific genetic changes. The process is similar to the CRISPR-Cas9 system, but it allows for the simultaneous editing of multiple locations in the genome.\nProcedure:\nThe SLIC-CAGE process involves several steps:\n1. Design of the guide RNAs (gRNAs): The gRNAs are designed to target the specific locations in the genome where the desired changes are to be introduced.\n2. Preparation of the homing endonuclease: The homing endonuclease is a enzyme that is programmed to recognize a specific DNA sequence and introduce a DSB at that location.\n3. Introduction of the CRISPR-Cas9 system: The CRISPR-Cas9 system is introduced into the cell, along with the homing endonuclease.\n4. Induction of DSBs: The CRISPR-Cas9 system creates DSBs at the targeted locations in the genome.\n5. Repair of DSBs: The cell's own repair machinery is activated, and the DSBs are repaired through either non-homologous end joining (NHEJ) or homologous recombination (HR).\n6. Verification and validation: The introduced genetic changes are verified and validated through molecular biology techniques such as PCR, sequencing, or bioinformatics analysis.\nAdvantages:\nSLIC-CAGE has several advantages over other genome engineering technologies, including:\n1. Simultaneous editing of multiple loci: SLIC",
    "llama-2-7b-chat-hf_fact_raw": "1. SLIC-CAGE is a genome engineering technology that allows for the simultaneous editing of multiple genes or loci in a single step.\n2. It uses a combination of CRISPR-Cas9 and homing endonucleases to create DNA double-strand breaks at specific locations in the genome.\n3. The gRNAs used in SLIC-CAGE are designed to target the specific locations in the genome where changes are desired.\n4. The homing endonuclease used in SLIC-CAGE is programmed to recognize a specific DNA sequence and introduce a double-strand break at that location.\n5. After the creation of double-strand breaks, repair of these breaks can be done by the cell's own repair machinery through non-homologous end joining (NHEJ) or homologous recombination (HR).",
    "llama-2-7b-chat-hf_fact": [
      "SLIC-CAGE is a genome engineering technology that allows for the simultaneous editing of multiple genes or loci in a single step.",
      "It uses a combination of CRISPR-Cas9 and homing endonucleases to create DNA double-strand breaks at specific locations in the genome.",
      "The gRNAs used in SLIC-CAGE are designed to target the specific locations in the genome where changes are desired.",
      "The homing endonuclease used in SLIC-CAGE is programmed to recognize a specific DNA sequence and introduce a double-strand break at that location.",
      "After the creation of double-strand breaks, repair of these breaks can be done by the cell's own repair machinery through non-homologous end joining (NHEJ) or homologous recombination (HR)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: SLIC-CAGE (Saturation editing via Lentivirus-driven Iterative Cassette Exchange), if accurately represented, is indeed a genome engineering technology designed for multiplex gene editing.\n2. UNKNOWN: Without specific scientific literature or reference describing SLIC-CAGE as utilizing both CRISPR-Cas9 and homing endonucleases, the details of the technology cannot be confirmed. CRISPR-Cas9 by itself is a commonly known genome-editing tool that creates double-strand breaks but whether SLIC-CAGE combines this with homing endonucleases is not specified in the provided context.\n3. TRUE: Generally, guide RNAs (gRNAs) in CRISPR-based genome editing systems are designed to target specific locations in the genome for edits, and it is reasonable to assume this is also true for SLIC-CAGE.\n4. UNKNOWN: Similar to the second statement, without specific reference to the SLIC-CAGE system using a homing endonuclease, the accuracy of this statement cannot be confirmed. While homing endonucleases do recognize specific DNA sequences to introduce double-strand breaks, its usage in the context of SLIC-CAGE is not verifiable from the provided information.\n5. TRUE: In genome editing, after the introduction of DNA double-strand breaks, the cell typically repairs the break using its own repair machinery. The two primary pathways for this are non-homologous end joining (NHEJ) and homologous recombination (HR). This is a common aspect of CRISPR technology and broadly applies to engineered nucleases, although the specifics can vary depending on the editing strategy being employed.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-7b-chat-hf_response": "LEM-3 (Lymphoid Enhancer Factor 3) is a protein that plays a crucial role in various cellular processes, including:\n1. Transcriptional regulation: LEM-3 is a transcriptional coactivator that works with other proteins to regulate gene expression. It binds to specific DNA sequences and enhances the recruitment of RNA polymerase to promoters, leading to increased transcriptional activity.\n2. Chromatin remodeling: LEM-3 can also remodel chromatin structure by altering the positioning of nucleosomes and other chromatin-associated proteins, which can affect gene expression.\n3. Cell cycle progression: LEM-3 has been shown to regulate the G1/S checkpoint and cell cycle progression by interacting with the retinoblastoma protein (Rb) and other cell cycle regulators.\n4. Apoptosis: LEM-3 has been implicated in the regulation of programmed cell death (apoptosis), particularly in the context of cancer. It can inhibit or promote apoptosis depending on the cellular context and the presence of other proteins.\n5. Nuclear organization: LEM-3 is involved in the organization of the nucleus and the maintenance of nuclear structure. It interacts with various nuclear proteins and helps to regulate the distribution of these proteins within the nucleus.\n6. RNA metabolism: LEM-3 has been shown to play a role in the metabolism of RNA, particularly in the processing and transport of RNA molecules.\n7. Cell adhesion and migration: LEM-3 has been implicated in cell adhesion and migration, particularly in the context of cancer metastasis. It can regulate the adhesion of cells to the extracellular matrix and promote cell migration.\n8. Immune response: LEM-3 has been shown to play a role in the immune response, particularly in the regulation of T cell activation and differentiation.\nIn summary, LEM-3 is a multifunctional protein that plays a crucial role in various cellular processes, including transcriptional regulation, chromatin remodeling, cell cycle progression, apoptosis, nuclear organization, RNA metabolism, cell ad",
    "llama-2-7b-chat-hf_fact_raw": "1. LEM-3 (Lymphoid Enhancer Factor 3) is a transcriptional coactivator that regulates gene expression.\n2. LEM-3 plays a role in the regulation of the G1/S checkpoint and cell cycle progression.\n3. LEM-3 is implicated in the regulation of programmed cell death (apoptosis).\n4. LEM-3 is involved in the organization of the nucleus and the maintenance of nuclear structure.\n5. LEM-3 has a role in the immune response, particularly in the regulation of T cell activation and differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "LEM-3 (Lymphoid Enhancer Factor 3) is a transcriptional coactivator that regulates gene expression.",
      "LEM-3 plays a role in the regulation of the G1/S checkpoint and cell cycle progression.",
      "LEM-3 is implicated in the regulation of programmed cell death (apoptosis).",
      "LEM-3 is involved in the organization of the nucleus and the maintenance of nuclear structure.",
      "LEM-3 has a role in the immune response, particularly in the regulation of T cell activation and differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: LEM domain-containing protein 3 (LEM-3) is not a transcriptional coactivator. LEM-3 is actually a nuclear protein known for its role in DNA damage response and repair mechanisms.\n2. UNKNOWN: Without specific scientific research to reference, it's difficult to confirm whether LEM-3 directly plays a role in the regulation of the G1/S checkpoint and cell cycle progression. LEM-3 is more generally known for its involvement in DNA damage repair which can influence the cell cycle, but the exact nature of its role in G1/S checkpoint regulation is not clear from this statement alone.\n3. FALSE [correction]: LEM-3's primary known function is in DNA repair, particularly in response to DNA damage. While DNA repair processes can influence apoptosis, there is not enough information provided here to directly link LEM-3 to the regulation of programmed cell death (apoptosis).\n4. TRUE: LEM-3 is part of the LEM domain family of proteins, which are known to be involved with the organization of the nucleus and the maintenance of nuclear structure, particularly through the interplay with the nuclear envelope.\n5. UNKNOWN: The role of LEM-3 in the immune response is not well-established or widely recognized in the context of T cell activation and differentiation, which generally involves other types of signaling pathways and transcription factors. This claim would require more specific supporting evidence to verify.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-7b-chat-hf_response": "TmVar is a software tool for the analysis of transcriptome data, specifically for the detection of alternative splicing events. Here are some of the releases of TmVar:\n1. TmVar v1.0: This was the initial release of TmVar, which provided basic functionality for the analysis of transcriptome data.\n2. TmVar v2.0: In this release, TmVar added several new features, including improved splicing event detection and visualization tools.\n3. TmVar v3.0: This release introduced a new algorithm for splicing event detection, which improved the accuracy of the results.\n4. TmVar v4.0: In this release, TmVar added support for new sequencing technologies and improved the performance of the software.\n5. TmVar v5.0: This release included several new features, including the ability to perform splicing event prediction and the integration of a new database of known splicing events.\n6. TmVar v6.0: In this release, TmVar improved the visualization tools and added support for more advanced analysis techniques, such as the use of Bayesian statistics.\n7. TmVar v7.0: This release included several new features, including the ability to perform splicing event prediction and the integration of a new database of known splicing events.\n8. TmVar v8.0: In this release, TmVar improved the visualization tools and added support for more advanced analysis techniques, such as the use of Bayesian statistics.\n9. TmVar v9.0: This release included several new features, including the ability to perform splicing event prediction and the integration of a new database of known splicing events.\n10. TmVar v10.0: In this release, TmVar improved the visualization tools and added support for more advanced analysis techniques, such as the use of Bayesian statistics.\nNote that the exact release dates and features of each version of TmVar may vary depending on the source.",
    "llama-2-7b-chat-hf_fact_raw": "1. TmVar is a software tool used for the analysis of transcriptome data.\n2. TmVar v1.0 was the initial release of the TmVar software.\n3. TmVar v2.0 added new features such as improved splicing event detection and visualization tools.\n4. TmVar v3.0 introduced a new algorithm for splicing event detection.\n5. TmVar v4.0 added support for new sequencing technologies and improved software performance.",
    "llama-2-7b-chat-hf_fact": [
      "TmVar is a software tool used for the analysis of transcriptome data.",
      "TmVar v1.0 was the initial release of the TmVar software.",
      "TmVar v2.0 added new features such as improved splicing event detection and visualization tools.",
      "TmVar v3.0 introduced a new algorithm for splicing event detection.",
      "TmVar v4.0 added support for new sequencing technologies and improved software performance."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TmVar is a software tool used for the identification and annotation of sequence variations in annotated mammalian transmembrane genes from text.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-7b-chat-hf_response": "There are several databases that contain information on somatic mutations in normal cells. Here are a few examples:\n1. The Cancer Genome Atlas (TCGA): TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) that aims to catalogue the genomic changes in various types of cancer. TCGA includes data on both tumor and normal tissue samples, and the database contains information on somatic mutations in normal cells.\n2. The ExAC (Exome Aggregation Consortium) database: ExAC is a large-scale dataset of exome data from thousands of individuals, including both cancer cases and normal controls. The database contains information on somatic mutations in normal cells, as well as genetic variation in the general population.\n3. The GTEx (Genotype-Tissue Expression) database: GTEx is a dataset of genome-wide genotype and mRNA expression data from over 1,000 tissue samples from different human tissues, including normal tissues. The database contains information on somatic mutations in normal cells, as well as information on the expression levels of genes in different tissues.\n4. The CIViC (Cancer Intervention and Vaccine Development) database: CIViC is a database of cancer genomics data, including information on somatic mutations in normal cells. The database contains data from both tumor and normal tissue samples, and includes information on the functional impact of somatic mutations.\n5. The Somatic Mutation in Normal Tissues (SMIT) database: SMIT is a database of somatic mutations identified in normal tissues, including data from the TCGA and other studies. The database contains information on the frequency, distribution, and functional impact of somatic mutations in normal tissues.\nThese are just a few examples of the many databases available that contain information on somatic mutations in normal cells. Each database has its own strengths and limitations, and researchers may find it useful to consult multiple databases to gain a more comprehensive understanding of the somatic mutations present in normal cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).\n2. The ExAC (Exome Aggregation Consortium) database includes exome data from thousands of individuals, with information on somatic mutations in normal cells.\n3. The GTEx (Genotype-Tissue Expression) database contains genome-wide genotype and mRNA expression data from over 1,000 tissue samples from different human tissues.\n4. The CIViC (Cancer Intervention and Vaccine Development) database is focused on cancer genomics data and contains information on somatic mutations in normal cells.\n5. The Somatic Mutation in Normal Tissues (SMIT) database provides data on somatic mutations identified in normal tissues, including the frequency, distribution, and functional impact.",
    "llama-2-7b-chat-hf_fact": [
      "The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).",
      "The ExAC (Exome Aggregation Consortium) database includes exome data from thousands of individuals, with information on somatic mutations in normal cells.",
      "The GTEx (Genotype-Tissue Expression) database contains genome-wide genotype and mRNA expression data from over 1,000 tissue samples from different human tissues.",
      "The CIViC (Cancer Intervention and Vaccine Development) database is focused on cancer genomics data and contains information on somatic mutations in normal cells.",
      "The Somatic Mutation in Normal Tissues (SMIT) database provides data on somatic mutations identified in normal tissues, including the frequency, distribution, and functional impact."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The ExAC (Exome Aggregation Consortium) database includes exome data from tens of thousands of unrelated individuals, primarily providing information on variation in human genes, but it does not specifically focus on somatic mutations in normal cells.\n3. TRUE\n4. FALSE [correction]: The CIViC (Clinical Interpretations of Variants in Cancer) database is focused on the clinical interpretation of genetic variants in cancer, not solely on cancer genomics data, and it does not contain information on somatic mutations in normal cells.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-7b-chat-hf_response": "Yes, there are several graph kernel libraries available that have been implemented in Java. Here are some of them:\n1. GraphKite: GraphKite is a Java library for graph kernel methods, including graph neural networks, graph autoencoders, and graph generative models. It provides a simple and efficient way to implement graph kernel methods in Java.\n2. GraphSAGE: GraphSAGE is a Java library for graph neural networks that provides an efficient implementation of the GraphSAGE algorithm. It supports various graph kernel methods, including the original GraphSAGE algorithm and its variants.\n3. DGL: DGL (Deep Graph Library) is a Python library for graph neural networks, but it also provides a Java interface for implementing graph kernel methods. DGL supports various graph kernel methods, including Graph Attention Networks (GATs), Graph Isomorphism Networks (GINs), and Graph Autoencoders (GAEs).\n4. JGraphT: JGraphT is a Java library for graph theory and graph algorithms. It provides a simple and efficient way to implement graph kernel methods, including graph neural networks and graph autoencoders.\n5. GraphBLAS: GraphBLAS is a Java library for graph computing that provides an efficient implementation of graph kernel methods. It supports various graph kernel methods, including graph neural networks, graph autoencoders, and graph clustering algorithms.\n6. JAIR: JAIR (Java Algorithm for Intelligent Research) is a Java library for graph kernel methods, including graph neural networks and graph autoencoders. It provides a simple and efficient way to implement graph kernel methods in Java.\nThese libraries can be used to implement various graph kernel methods in Java, including graph neural networks, graph autoencoders, and graph generative models. They provide a simple and efficient way to perform graph kernel computations and can be used for a wide range of applications, including social network analysis, recommendation systems, and natural language processing.",
    "llama-2-7b-chat-hf_fact_raw": "1. GraphKite is a Java library for graph kernel methods.\n2. GraphSAGE is a Java library that provides an efficient implementation of the GraphSAGE algorithm.\n3. DGL (Deep Graph Library) is a Python library which provides a Java interface for graph kernel methods.\n4. JGraphT is a Java library for graph theory and graph algorithms that supports graph kernel methods.\n5. GraphBLAS is a Java library for graph computing that supports various graph kernel methods.",
    "llama-2-7b-chat-hf_fact": [
      "GraphKite is a Java library for graph kernel methods.",
      "GraphSAGE is a Java library that provides an efficient implementation of the GraphSAGE algorithm.",
      "DGL (Deep Graph Library) is a Python library which provides a Java interface for graph kernel methods.",
      "JGraphT is a Java library for graph theory and graph algorithms that supports graph kernel methods.",
      "GraphBLAS is a Java library for graph computing that supports various graph kernel methods."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: DGL (Deep Graph Library) is a Python library for graph neural networks and does not provide a Java interface.\n4. TRUE\n5. FALSE [correction]: GraphBLAS is a specification for building graph algorithms in the language of linear algebra, and it is not specifically a Java library. Implementations of GraphBLAS are available in multiple languages, which might include Java, but it is not inherently a Java library.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_response": "The SHERLOCKv2 platform is an advanced diagnostic tool that integrates several advances in molecular biology to enable fast, sensitive, and cost-effective detection of viral pathogens. Here are the four advances integrated into the SHERLOCKv2 platform:\n1. CRISPR-Cas13-based nucleic acid detection: SHERLOCKv2 uses the CRISPR-Cas13 system to detect nucleic acids, which is a powerful tool for detecting viral pathogens. CRISPR-Cas13 is a small RNA molecule that can be programmed to recognize specific DNA or RNA sequences and cleave them, leading to the degradation of the targeted molecule. By using CRISPR-Cas13 as a detection probe, SHERLOCKv2 can detect very small amounts of viral nucleic acids in a sample.\n2. High-throughput sequencing: SHERLOCKv2 uses high-throughput sequencing to detect the cleaved DNA fragments produced by the CRISPR-Cas13 reaction. This allows for the simultaneous detection of multiple viral pathogens in a single reaction, making it a highly efficient and cost-effective diagnostic tool.\n3. Machine learning-based analysis: SHERLOCKv2 uses machine learning algorithms to analyze the sequencing data and identify the specific viral pathogen in a sample. This allows for rapid and accurate identification of the pathogen, without the need for complex and time-consuming laboratory techniques.\n4. Portable and low-resource settings: SHERLOCKv2 is designed to be portable and easy to use in low-resource settings, such as in field settings or in areas with limited access to laboratory facilities. This makes it an ideal tool for rapid detection of viral pathogens in emergency situations or in areas where access to medical care is limited.",
    "llama-2-7b-chat-hf_fact_raw": "1. SHERLOCKv2 uses the CRISPR-Cas13 system to detect nucleic acids.\n2. CRISPR-Cas13 can be programmed to recognize and cleave specific DNA or RNA sequences.\n3. High-throughput sequencing is used in SHERLOCKv2 to detect cleaved DNA fragments produced by the CRISPR-Cas13 reaction.\n4. Machine learning algorithms are employed by SHERLOCKv2 to analyze sequencing data for pathogen identification.\n5. SHERLOCKv2 is designed to be portable for use in low-resource settings.",
    "llama-2-7b-chat-hf_fact": [
      "SHERLOCKv2 uses the CRISPR-Cas13 system to detect nucleic acids.",
      "CRISPR-Cas13 can be programmed to recognize and cleave specific DNA or RNA sequences.",
      "High-throughput sequencing is used in SHERLOCKv2 to detect cleaved DNA fragments produced by the CRISPR-Cas13 reaction.",
      "Machine learning algorithms are employed by SHERLOCKv2 to analyze sequencing data for pathogen identification.",
      "SHERLOCKv2 is designed to be portable for use in low-resource settings."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: CRISPR-Cas13 is employed to specifically target and cleave RNA, not DNA.\n3. FALSE [correction]: SHERLOCKv2 does not use high-throughput sequencing to detect cleaved fragments; it uses a lateral flow assay or a similar detection method.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-7b-chat-hf_response": "The Bartender algorithm is a simple heuristic algorithm used to find the shortest path between two nodes in a graph. It is called the Bartender algorithm because it works by \"bartending\" the graph, or folding it in half, to find the shortest path between two nodes.\nHere is how the Bartender algorithm works:\n1. Start at a random node in the graph.\n2. Find the closest node to the current node that is not yet visited. This node is called the \"bartender.\"\n3. Mark the bartender node as visited.\n4. Find the shortest path between the current node and the bartender node. This path is the \"bartender path.\"\n5. Repeat steps 2-4 until the destination node is reached.\n6. The bartender path is the shortest path between the starting node and the destination node.\nHere is a simple example of how the Bartender algorithm works:\nSuppose we have a graph with the following nodes and edges:\nA - B - C\nD - E - F\nG - H - I\nThe Bartender algorithm starts at node A. In step 2, it finds the closest node to A that is not yet visited, which is node B. It marks node B as visited and finds the shortest path between node A and node B, which is the edge AB. In step 4, it repeats this process for node B, finding the closest node to B that is not yet visited (node C), marking it as visited, and finding the shortest path between node B and node C (the edge BC). It repeats this process for each node until it reaches the destination node I. The shortest path between nodes A and I is ABCDEFI, which is the path found by the Bartender algorithm.\nThe Bartender algorithm is simple to implement and has a time complexity of O(n), where n is the number of nodes in the graph. However, it is not always the most efficient algorithm for finding the shortest path in a graph, and it may not work well for very large graphs. Other algorithms, such as Dijkstra's algorithm or Bellman-Ford algorithm, may be more suitable for finding the shortest path in some cases.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Bartender algorithm is a heuristic algorithm used to find the shortest path between two nodes in a graph.\n2. The Bartender algorithm involves \"bartending\" the graph, or folding it in half, to find the shortest path.\n3. The Bartender algorithm has a time complexity of O(n), where n is the number of nodes in the graph.\n4. The algorithm starts at a random node and proceeds by finding the closest unvisited node called the \"bartender\".\n5. Dijkstra's algorithm and Bellman-Ford algorithm may be more suitable than the Bartender algorithm for finding the shortest path in some graphs.",
    "llama-2-7b-chat-hf_fact": [
      "The Bartender algorithm is a heuristic algorithm used to find the shortest path between two nodes in a graph.",
      "The Bartender algorithm involves \"bartending\" the graph, or folding it in half, to find the shortest path.",
      "The Bartender algorithm has a time complexity of O(n), where n is the number of nodes in the graph.",
      "The algorithm starts at a random node and proceeds by finding the closest unvisited node called the \"bartender\".",
      "Dijkstra's algorithm and Bellman-Ford algorithm may be more suitable than the Bartender algorithm for finding the shortest path in some graphs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There is no well-known heuristic algorithm for finding the shortest path between two nodes in a graph known as the Bartender algorithm.\n2. FALSE [correction]: Since the Bartender algorithm does not exist as described, the concept of \"bartending\" the graph or folding it in half is also false.\n3. FALSE [correction]: As the Bartender algorithm does not exist, it does not have a defined time complexity. However, common algorithms for shortest path problems like Dijkstra's algorithm can have a time complexity of O(n^2) for dense graphs, or O(n log n) with a min-priority queue, where n is the number of nodes.\n4. FALSE [correction]: This statement is based on the non-existent Bartender algorithm, so the process of starting at a random node and finding the closest unvisited node called the \"bartender\" is also incorrect. In reality, Dijkstra's algorithm starts with the source node and explores the graph usually with a priority queue to maintain a record of the shortest paths found so far.\n5. TRUE: Though the Bartender algorithm was falsely described, it is generally true that Dijkstra's algorithm and the Bellman-Ford algorithm could be more suitable for finding the shortest path in graphs, depending on the graph and the presence of negative weight edges (Dijkstra's algorithm cannot handle negative weight edges, while the Bellman-Ford algorithm can).",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-7b-chat-hf_response": "There are several web-based pedigree editors available, some of which are:\n1. Pedigree Online: This is a popular web-based platform that provides a range of tools for creating, editing, and sharing family trees. It offers features such as automatic merging of data, customizable templates, and the ability to collaborate with others.\n2. Family Tree Builder: This is another well-known web-based platform that allows users to create and edit their family trees. It offers features such as automatic source citations, ancestry research, and the ability to connect with other users.\n3. MyHeritage: MyHeritage is a genealogy platform that provides a range of tools for creating, editing, and sharing family trees. It offers features such as automatic matching of DNA relatives, historical records, and the ability to connect with other users.\n4. GenoPro: GenoPro is a web-based platform that allows users to create and edit their family trees. It offers features such as customizable templates, automatic merging of data, and the ability to collaborate with others.\n5. FamilySearch: FamilySearch is a free genealogy platform provided by The Church of Jesus Christ of Latter-day Saints. It offers a range of tools for creating, editing, and sharing family trees, including automatic source citations and the ability to connect with other users.\n6. WikiTree: WikiTree is a collaborative genealogy platform that allows users to create and edit their family trees. It offers features such as automatic merging of data, customizable templates, and the ability to connect with other users.\n7. WeRelate: WeRelate is a collaborative genealogy platform that allows users to create and edit their family trees. It offers features such as automatic merging of data, customizable templates, and the ability to connect with other users.\n8. Gramps: Gramps is a free and open-source genealogy platform that allows users to create and edit their family trees. It offers features such as customizable templates, automatic merging of data, and the ability to connect with other users.\n9. Legacy Family Tree: Legacy Family Tree is a genealogy platform that provides a range of tools for creating, editing, and sharing family trees. It offers features such as automatic source citations, ancestry research, and the ability to connect with other users.\n10",
    "llama-2-7b-chat-hf_fact_raw": "1. Pedigree Online is a web-based platform for creating, editing, and sharing family trees.\n2. Family Tree Builder is a web-based platform that includes automatic source citations and ancestry research tools.\n3. MyHeritage is a genealogy platform that offers automatic DNA relative matching and historical records access.\n4. FamilySearch is a free genealogy platform provided by The Church of Jesus Christ of Latter-day Saints.\n5. Gramps is a free and open-source genealogy platform for creating and editing family trees.",
    "llama-2-7b-chat-hf_fact": [
      "Pedigree Online is a web-based platform for creating, editing, and sharing family trees.",
      "Family Tree Builder is a web-based platform that includes automatic source citations and ancestry research tools.",
      "MyHeritage is a genealogy platform that offers automatic DNA relative matching and historical records access.",
      "FamilySearch is a free genealogy platform provided by The Church of Jesus Christ of Latter-day Saints.",
      "Gramps is a free and open-source genealogy platform for creating and editing family trees."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement is vague because \"Pedigree Online\" could refer to any number of services, and without specific context or having knowledge of a service with that exact name, its features cannot be confirmed.\n2. TRUE: Family Tree Builder is indeed a software provided by MyHeritage that includes automatic source citations and ancestry research tools.\n3. TRUE: MyHeritage is a genealogy platform known for offering services like DNA relative matching and access to a vast database of historical records.\n4. TRUE: FamilySearch is a free genealogy platform operated by The Church of Jesus Christ of Latter-day Saints (LDS Church), and it offers a variety of genealogical records.\n5. TRUE: Gramps, which stands for Genealogical Research and Analysis Management Programming System, is a free and open-source project for genealogy, allowing users to build and edit family trees.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-7b-chat-hf_response": "There are several curated databases that contain information on spider-venom toxins, including:\n1. Toxinology: This database contains information on toxins from various sources, including spiders. It provides structural information, as well as bioactivity data for many of the toxins.\n2. Spider Toxin Database (STD): This database is specifically focused on spider toxins and contains information on the structural and functional properties of these toxins, as well as their biological activities.\n3. Natural Products Dictionary (NPD): This database contains information on natural products, including spider-venom toxins. It provides structural information, as well as bioactivity data and references to literature.\n4. Toxinology Database (ToxDB): This database contains information on a wide range of toxins, including spider-venom toxins. It provides structural information, as well as bioactivity data and references to literature.\n5. Venom-DB: This database contains information on venom peptides and proteins from various organisms, including spiders. It provides structural information, as well as bioactivity data and references to literature.\n6. Spider Venom Toxin Database (SVTD): This database contains information on spider venom toxins, including their structure, function, and bioactivity. It also provides information on the species of spiders from which the toxins were isolated.\n7. The Toxinology Resource (ToxR): This database contains information on toxins from various sources, including spider venom. It provides structural information, as well as bioactivity data and references to literature.\n8. The Venomics Database (VenomDB): This database contains information on venom peptides and proteins from various organisms, including spiders. It provides structural information, as well as bioactivity data and references to literature.\n9. The Spider Venom Toxin Collection (SVTC): This database contains information on spider venom toxins, including their structure, function, and bioactivity. It also provides information on the species of spiders from which the toxins were isolated.\n10. The Toxinology and Venomics Database (TVD): This database contains information on toxins from various sources, including spider venom. It provides",
    "llama-2-7b-chat-hf_fact_raw": "1. Toxinology is a database that contains information on toxins from various sources, including spiders, and provides structural and bioactivity data.\n2. The Spider Toxin Database (STD) focuses specifically on spider toxins, including information on structural and functional properties as well as biological activities.\n3. The Natural Products Dictionary (NPD) contains information on natural products such as spider-venom toxins, including structural information, bioactivity data, and literature references.\n4. Venom-DB provides information on venom peptides and proteins from various organisms, including spiders, along with structural information, bioactivity data, and references.\n5. The Venomics Database (VenomDB) offers structural and bioactivity information on venom peptides and proteins from various organisms, including spiders.",
    "llama-2-7b-chat-hf_fact": [
      "Toxinology is a database that contains information on toxins from various sources, including spiders, and provides structural and bioactivity data.",
      "The Spider Toxin Database (STD) focuses specifically on spider toxins, including information on structural and functional properties as well as biological activities.",
      "The Natural Products Dictionary (NPD) contains information on natural products such as spider-venom toxins, including structural information, bioactivity data, and literature references.",
      "Venom-DB provides information on venom peptides and proteins from various organisms, including spiders, along with structural information, bioactivity data, and references.",
      "The Venomics Database (VenomDB) offers structural and bioactivity information on venom peptides and proteins from various organisms, including spiders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Toxinology is not a database; it is the scientific study of toxins and their effects on living organisms.\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-7b-chat-hf_response": "Axitinib is a tyrosine kinase inhibitor that has been investigated as a potential treatment for various types of cancer, including pancreatic cancer. While there is some evidence to suggest that axitinib may have antitumor activity in pancreatic cancer, the current evidence does not support a conclusion that it prolongs survival in these patients.\nA phase Ib/II trial published in 2018 investigated the safety and efficacy of axitinib in patients with advanced pancreatic cancer. The trial found that axitinib was associated with a objective response rate (ORR) of 11.4% and a disease control rate (DCR) of 42.9%, with a median duration of response of 4.8 months. However, the trial also showed that axitinib did not meet the primary endpoint of overall survival (OS), with a hazard ratio of 1.27 (95% CI: 0.85-1.90) compared to best supportive care (BSC).\nAn updated analysis of the same trial, published in 2020, found that the median overall survival (OS) for patients treated with axitinib was 10.6 months, compared to 7.4 months for those receiving BSC. However, the difference in OS between the two groups was not statistically significant (HR: 0.86; 95% CI: 0.69-1.07).\nA more recent phase II trial, published in 2022, also found that axitinib did not meet the primary endpoint of OS in patients with metastatic pancreatic cancer. The trial showed that the median OS for patients treated with axitinib was 11.3 months, compared to 9.3 months for those receiving BSC.\nOverall, while axitinib has shown some antitumor activity in pancreatic cancer, the current evidence does not support a conclusion that it prolongs survival in these patients. Further research is needed to determine the efficacy and safety of axitinib in this patient population.",
    "llama-2-7b-chat-hf_fact_raw": "1. Axitinib is a tyrosine kinase inhibitor that has been investigated for treatment in various types of cancer, including pancreatic cancer.\n2. A phase Ib/II trial published in 2018 found that axitinib was associated with an objective response rate (ORR) of 11.4% in patients with advanced pancreatic cancer.\n3. The same phase Ib/II trial from 2018 showed a median duration of response to axitinib of 4.8 months for advanced pancreatic cancer.\n4. An updated analysis of the same trial in 2020 reported a median overall survival (OS) for patients treated with axitinib as 10.6 months, versus 7.4 months for those receiving best supportive care (BSC).\n5. A phase II trial published in 2022 showed that axitinib did not meet the primary endpoint of OS in patients with metastatic pancreatic cancer, with a median OS for patients treated with axitinib at 11.3 months compared to 9.3 months for those receiving BSC.",
    "llama-2-7b-chat-hf_fact": [
      "Axitinib is a tyrosine kinase inhibitor that has been investigated for treatment in various types of cancer, including pancreatic cancer.",
      "A phase Ib/II trial published in 2018 found that axitinib was associated with an objective response rate (ORR) of 11.4% in patients with advanced pancreatic cancer.",
      "The same phase Ib/II trial from 2018 showed a median duration of response to axitinib of 4.8 months for advanced pancreatic cancer.",
      "An updated analysis of the same trial in 2020 reported a median overall survival (OS) for patients treated with axitinib as 10.6 months, versus 7.4 months for those receiving best supportive care (BSC).",
      "A phase II trial published in 2022 showed that axitinib did not meet the primary endpoint of OS in patients with metastatic pancreatic cancer, with a median OS for patients treated with axitinib at 11.3 months compared to 9.3 months for those receiving BSC."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout access to the specific clinical trial publications mentioned, it's impossible to verify the results of the trials and the associated data regarding axitinib's effectiveness in treating advanced or metastatic pancreatic cancer. Therefore, the responses to statements 2 through 5 must remain UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-7b-chat-hf_response": "MLP (Microtubule-associated protein) regulates F-actin dynamics through protein interactions with the following components of the cytoskeleton:\n1. F-actin: MLP directly binds to F-actin and modulates its dynamics by altering the interactions between F-actin and other cytoskeletal proteins.\n2. Dynamin: MLP interacts with dynamin, a GTPase that regulates the formation and stability of membrane vesicles. MLP-dynamin interaction affects the recruitment of F-actin to the plasma membrane, thereby modulating F-actin dynamics.\n3. Caveolin-1: MLP binds to caveolin-1, a protein that is involved in regulating the organization of the cytoskeleton. The MLP-caveolin-1 interaction affects the localization and dynamics of F-actin.\n4. G alpha subunits: MLP interacts with G alpha subunits, which are involved in signal transduction pathways that regulate F-actin dynamics. The MLP-G alpha interaction modulates the activity of these pathways and affects F-actin dynamics.\n5. Rho GTPases: MLP interacts with Rho GTPases, which are key regulators of F-actin dynamics. The MLP-Rho GTPase interaction affects the activity of these GTPases and modulates F-actin dynamics.\nIn summary, MLP regulates F-actin dynamics through protein interactions with multiple components of the cytoskeleton, including F-actin, dynamin, caveolin-1, G alpha subunits, and Rho GTPases. These interactions modulate the organization and dynamics of the actin cytoskeleton, which is essential for cellular processes such as cell migration, adhesion, and signaling.",
    "llama-2-7b-chat-hf_fact_raw": "1. MLP directly binds to F-actin to modulate its dynamics.\n2. MLP interacts with dynamin, affecting the recruitment of F-actin to the plasma membrane.\n3. MLP binds to caveolin-1, which influences the localization and dynamics of F-actin.\n4. MLP interacts with G alpha subunits involved in signal transduction pathways that regulate F-actin dynamics.\n5. MLP interacts with Rho GTPases, key regulators of F-actin dynamics.",
    "llama-2-7b-chat-hf_fact": [
      "MLP directly binds to F-actin to modulate its dynamics.",
      "MLP interacts with dynamin, affecting the recruitment of F-actin to the plasma membrane.",
      "MLP binds to caveolin-1, which influences the localization and dynamics of F-actin.",
      "MLP interacts with G alpha subunits involved in signal transduction pathways that regulate F-actin dynamics.",
      "MLP interacts with Rho GTPases, key regulators of F-actin dynamics."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MLP (Muscle LIM protein), also known as CRP3, does not directly bind to F-actin. MLP is known to be involved in the mechanosensor system of the sarcomere in muscle cells and influences muscle differentiation, but there is no established direct interaction with F-actin to modulate its dynamics.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific context or a detailed passage, the interaction of Muscle LIM protein (MLP) with various proteins like dynamin, caveolin-1, G alpha subunits, and Rho GTPases, in relation to F-actin dynamics is not well-established in the generalized scientific literature. Therefore, it's not possible to accurately confirm or refute these statements without more information.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-7b-chat-hf_response": "The number of pseudokinases in the human kinome is not a well-defined or universally agreed upon value, as the definition of a pseudokinase can vary depending on the source and the method used to identify them. However, here are some estimates based on different studies:\n* According to the Human Protein Atlas, there are approximately 100-150 pseudokinases in the human kinome (1).\n* A study published in the journal Nature Communications in 2018 identified 136 pseudokinases in the human kinome (2).\n* Another study published in the journal PLOS Biology in 2019 identified 161 pseudokinases in the human kinome using a machine learning-based approach (3).\n* A review article published in the journal Biochimica et Biophysica Acta in 2019 estimated that there are around 200-250 pseudokinases in the human kinome (4).\nIt's worth noting that the number of pseudokinases can vary depending on the criteria used to define them, and different studies may identify different sets of pseudokinases. Additionally, some studies have suggested that pseudokinases may not be as rare as previously thought, and may play more important roles in cellular signaling pathways than was previously appreciated.\nReferences:\n(1) The Human Protein Atlas (2017). Pseudokinases in the human kinome. Retrieved from <https://www.proteinatlas.org/about/pseudokinases-in-the-human-kinome/>\n(2) Li et al. (2018). Identification of pseudokinases in the human kinome. Nature Communications, 9(1), 4989. doi: 10.1038/s41467-018-07301-w\n(3) Liu et al. (2019). Identification of novel pseudokinases in the human kinome using a machine learning approach. PLOS Biology, 17(11), e3007386. doi: 10.1371/journal.pbio.3007386\n(4) Z",
    "llama-2-7b-chat-hf_fact_raw": "1. The Human Protein Atlas estimates there are approximately 100-150 pseudokinases in the human kinome.\n2. A study published in Nature Communications in 2018 identified 136 pseudokinases in the human kinome.\n3. A 2019 study in the journal PLOS Biology identified 161 pseudokinases in the human kinome using a machine learning-based approach.\n4. A review article in Biochimica et Biophysica Acta in 2019 estimated about 200-250 pseudokinases in the human kinome.",
    "llama-2-7b-chat-hf_fact": [
      "The Human Protein Atlas estimates there are approximately 100-150 pseudokinases in the human kinome.",
      "A study published in Nature Communications in 2018 identified 136 pseudokinases in the human kinome.",
      "A 2019 study in the journal PLOS Biology identified 161 pseudokinases in the human kinome using a machine learning-based approach.",
      "A review article in Biochimica et Biophysica Acta in 2019 estimated about 200-250 pseudokinases in the human kinome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The mentioned study attributes a machine learning-based approach to identifying pseudokinases; this specific approach or the exact number cannot be verified without access to the source.\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-7b-chat-hf_response": "ApoE mimetics are compounds that mimic the structure and function of apolipoprotein E (apoE), a protein that plays a crucial role in lipid metabolism and inflammation. Here are three examples of apoE mimetics:\n1. ApoEMime-1: This is a small molecule apoE mimetic that was developed to target the brain and nervous system. It has been shown to reduce inflammation and improve cognitive function in animal models of Alzheimer's disease.\n2. ApoE-mimetic peptides: These are short peptides that mimic the structure of apoE and have been shown to have anti-inflammatory and neuroprotective effects in animal models of Alzheimer's disease.\n3. Anti-inflammatory peptide (AIP): This is a peptide that mimics the anti-inflammatory activity of apoE and has been shown to reduce inflammation in animal models of Alzheimer's disease.\nIt's worth noting that these are just a few examples of apoE mimetics, and there are many other compounds that have been developed to target the apoE pathway for the treatment of various diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. ApoEMime-1 is an apoE mimetic targeting the brain and nervous system, used in the context of reducing inflammation and improving cognitive function in animal models of Alzheimer's disease.\n2. ApoE-mimetic peptides are designed to mimic the structure of apolipoprotein E and have shown anti-inflammatory and neuroprotective effects in animal models of Alzheimer's disease.\n3. Anti-inflammatory peptide (AIP) is an apoE mimetic that has demonstrated the ability to reduce inflammation in animal models of Alzheimer's disease.",
    "llama-2-7b-chat-hf_fact": [
      "ApoEMime-1 is an apoE mimetic targeting the brain and nervous system, used in the context of reducing inflammation and improving cognitive function in animal models of Alzheimer's disease.",
      "ApoE-mimetic peptides are designed to mimic the structure of apolipoprotein E and have shown anti-inflammatory and neuroprotective effects in animal models of Alzheimer's disease.",
      "Anti-inflammatory peptide (AIP) is an apoE mimetic that has demonstrated the ability to reduce inflammation in animal models of Alzheimer's disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n\nFor statement 3, without specific evidence or context about \"Anti-inflammatory peptide (AIP)\" and its relation to apoE mimetics, the accuracy of the claim cannot be confirmed. If AIP is an acronym for a peptide that is specifically designed as an apoE mimetic and has been studied demonstrating the ability to reduce inflammation in animal models of Alzheimer's disease, the statement would be true. However, without additional information, its truthfulness is unknown.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-7b-chat-hf_response": "SAMHD1 is an enzyme that plays a crucial role in regulating the innate immune response to viral infections, particularly in the context of HIV. While SAMHD1 is expressed in both males and females, there are sex differences in its activity and function. Here are some of the known sex differences in SAMHD1 activity:\n1. Basal activity: Studies have shown that SAMHD1 has higher basal activity in female peripheral blood mononuclear cells (PBMCs) compared to male PBMCs.\n2. Viral sensitivity: Female PBMCs are more susceptible to HIV infection than male PBMCs, and this difference is in part due to the higher basal activity of SAMHD1 in females.\n3. Regulation by estrogen: Estrogen has been shown to regulate SAMHD1 activity in a sex-specific manner. Estrogen treatment can increase SAMHD1 activity in female cells, while it has the opposite effect in male cells.\n4. HIV-1 restriction: SAMHD1 restricts HIV-1 infection in both males and females, but the efficiency of restriction varies between the sexes. Female cells are more efficient at restricting HIV-1 infection than male cells, and this difference is thought to be due in part to sex differences in SAMHD1 activity.\n5. Sexual dimorphism: There is a sexual dimorphism in the expression of SAMHD1 in different tissues. For example, SAMHD1 is more highly expressed in the brain and bone marrow of females than in males.\n6. Disease susceptibility: Sex differences in SAMHD1 activity have been implicated in the susceptibility of males and females to certain diseases. For example, females are more susceptible to HIV-1 infection and disease, and this difference is in part due to the lower basal activity of SAMHD1 in males.\n7. Pregnancy: SAMHD1 activity has been shown to be altered during pregnancy, with higher activity in placental cells compared to peripheral blood cells. This may play a role in the immune tolerance that occurs during pregnancy.\nIn summary, sex differences in SAMHD1 activity have been observed in",
    "llama-2-7b-chat-hf_fact_raw": "1. SAMHD1 has higher basal activity in female peripheral blood mononuclear cells (PBMCs) compared to male PBMCs.\n2. Female PBMCs are more susceptible to HIV infection than male PBMCs, partially due to higher basal activity of SAMHD1 in females.\n3. Estrogen treatment can increase SAMHD1 activity in female cells and decrease it in male cells.\n4. Female cells are more efficient at restricting HIV-1 infection than male cells, which is thought to be due to sex differences in SAMHD1 activity.\n5. SAMHD1 is more highly expressed in the brain and bone marrow of females than in males.",
    "llama-2-7b-chat-hf_fact": [
      "SAMHD1 has higher basal activity in female peripheral blood mononuclear cells (PBMCs) compared to male PBMCs.",
      "Female PBMCs are more susceptible to HIV infection than male PBMCs, partially due to higher basal activity of SAMHD1 in females.",
      "Estrogen treatment can increase SAMHD1 activity in female cells and decrease it in male cells.",
      "Female cells are more efficient at restricting HIV-1 infection than male cells, which is thought to be due to sex differences in SAMHD1 activity.",
      "SAMHD1 is more highly expressed in the brain and bone marrow of females than in males."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Female PBMCs are less susceptible to HIV infection than male PBMCs, partially due to higher basal activity of SAMHD1 in females.\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN\n\nMy knowledge is current up to early 2023, and without specific and current scientific research data, it's not possible to confirm or correct the statements regarding the effects of estrogen treatment on SAMHD1 or the levels of SAMHD1 expression in the brain and bone marrow of females compared to males.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-7b-chat-hf_response": "Yes, RUNX2 (Runt-related transcription factor 2) has been shown to inhibit astrocyte differentiation.\nRUNX2 is a transcription factor that plays a crucial role in the regulation of cellular differentiation, particularly in the context of hematopoiesis and bone metabolism. However, recent studies have also implicated RUNX2 in the regulation of astrocyte differentiation.\nStudies have shown that RUNX2 can directly inhibit the expression of genes involved in astrocyte differentiation, such as GFAP (glial fibrillary acidic protein) and A2B5 (amyloid beta-peptide 2B5). This inhibition of astrocyte differentiation is thought to occur through the repression of transcriptional activation of astrocyte-specific genes.\nFurthermore, RUNX2 has been shown to be upregulated in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. This upregulation of RUNX2 has been linked to the inhibition of astrocyte differentiation and the disruption of the blood-brain barrier, which can contribute to the progression of these diseases.\nIn summary, RUNX2 inhibits astrocyte differentiation, which can contribute to the progression of neurodegenerative diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. RUNX2 (Runt-related transcription factor 2) inhibits astrocyte differentiation.\n2. RUNX2 plays a significant role in the regulation of cellular differentiation in both hematopoiesis and bone metabolism.\n3. RUNX2 can inhibit the expression of genes involved in astrocyte differentiation, such as GFAP (glial fibrillary acidic protein) and A2B5 (amyloid beta-peptide 2B5).\n4. RUNX2 is upregulated in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.\n5. The upregulation of RUNX2 has been linked to the disruption of the blood-brain barrier.",
    "llama-2-7b-chat-hf_fact": [
      "RUNX2 (Runt-related transcription factor 2) inhibits astrocyte differentiation.",
      "RUNX2 plays a significant role in the regulation of cellular differentiation in both hematopoiesis and bone metabolism.",
      "RUNX2 can inhibit the expression of genes involved in astrocyte differentiation, such as GFAP (glial fibrillary acidic protein) and A2B5 (amyloid beta-peptide 2B5).",
      "RUNX2 is upregulated in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.",
      "The upregulation of RUNX2 has been linked to the disruption of the blood-brain barrier."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: RUNX2 (Runt-related transcription factor 2) is known to promote osteoblast differentiation and bone formation, not inhibit astrocyte differentiation.\n2. TRUE\n3. FALSE [correction]: While RUNX2 is involved in osteogenesis and is known to regulate gene expression related to bone metabolism, its role in inhibiting astrocyte differentiation-specific genes, such as GFAP and A2B5, is not well-established or recognized within its primary functions.\n4. UNKNOWN: While there may be research investigating the role of RUNX2 in neurodegenerative diseases, the statement about its general upregulation in various diseases such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis is not clearly accepted or established without specific references to scientific studies.\n5. UNKNOWN: The link between the upregulation of RUNX2 and the disruption of the blood-brain barrier is a specific claim that would require scientific evidence from research studies to confirm its validity. Without context or references, this statement cannot be verified.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-7b-chat-hf_response": "The Cobb-Stansby excision arthroplasty is a surgical procedure that is typically performed in the knee joint. It is a procedure that involves removing a portion of the bone in the knee joint, called the medial femoral condyle, in order to treat certain types of knee pain and disability. The procedure is typically performed through a surgical incision on the front of the knee, and the bone is removed using a specialized instrument called a bone cutter. The goal of the procedure is to relieve pressure on the surrounding soft tissue, such as ligaments and tendons, and to improve the overall function of the knee joint.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is a surgical procedure performed in the knee joint.\n2. This procedure involves the removal of the medial femoral condyle in the knee.\n3. The Cobb-Stainsby procedure is used to treat certain types of knee pain and disability.\n4. The procedure typically requires a surgical incision on the front of the knee.\n5. The procedure aims to relieve pressure on surrounding soft tissue, such as ligaments and tendons, and improve knee joint function.",
    "llama-2-7b-chat-hf_fact": [
      "The Cobb-Stainsby excision arthroplasty is a surgical procedure performed in the knee joint.",
      "This procedure involves the removal of the medial femoral condyle in the knee.",
      "The Cobb-Stainsby procedure is used to treat certain types of knee pain and disability.",
      "The procedure typically requires a surgical incision on the front of the knee.",
      "The procedure aims to relieve pressure on surrounding soft tissue, such as ligaments and tendons, and improve knee joint function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is a surgical procedure performed in the toe joint, specifically the metatarsophalangeal joint, not the knee joint.\n2. FALSE [correction]: Given that the Cobb-Stainsby excision arthroplasty is performed on the toe joint, it does not involve the removal of the medial femoral condyle which is in the knee.\n3. TRUE\n4. UNKNOWN: Without specific details about the surgical technique for the Cobb-Stainsby excision arthroplasty, we cannot confirm the location of the incision.\n5. TRUE: Arthroplasty procedures generally aim to relieve pain and improve joint function, though the statement about relieving pressure on surrounding soft tissue is more generic and may not specifically apply to the intricacies of the Cobb-Stainsby procedure.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-7b-chat-hf_response": "Yes, over-expression of GRHL2 has been shown to promote epithelial-to-mesenchymal transition (EMT) in various cell types, including cancer cells. EMT is a process by which epithelial cells lose their cell-cell adhesion and gain mesenchymal characteristics, such as increased motility and invasiveness.\nStudies have shown that GRHL2 over-expression can lead to EMT by modulating the expression of genes involved in these processes. For example, GRHL2 has been shown to upregulate the expression of the EMT transcription factor snail and downregulate the expression of the epithelial marker E-cadherin, leading to the loss of epithelial characteristics and the acquisition of mesenchymal properties.\nAdditionally, GRHL2 over-expression has been shown to promote the migration and invasion of cancer cells by activating the PI3K/Akt signaling pathway and inhibiting the tumor suppressor gene TWIST1. These findings suggest that GRHL2 may play a role in the progression of cancer by promoting EMT and enhancing the migratory and invasive properties of cancer cells.\nIn summary, over-expression of GRHL2 leads to EMT by modulating the expression of genes involved in these processes, including snail, E-cadherin, and TWIST1, and by activating the PI3K/Akt signaling pathway.",
    "llama-2-7b-chat-hf_fact_raw": "1. Over-expression of GRHL2 promotes epithelial-to-mesenchymal transition (EMT) in various cell types, including cancer cells.\n2. GRHL2 over-expression can modulate the expression of EMT-related genes.\n3. When over-expressed, GRHL2 upregulates the expression of the EMT transcription factor snail.\n4. GRHL2 over-expression results in downregulation of the epithelial marker E-cadherin.\n5. Over-expressed GRHL2 can promote the migration and invasion of cancer cells by activating the PI3K/Akt signaling pathway and inhibiting the tumor suppressor gene TWIST1.",
    "llama-2-7b-chat-hf_fact": [
      "Over-expression of GRHL2 promotes epithelial-to-mesenchymal transition (EMT) in various cell types, including cancer cells.",
      "GRHL2 over-expression can modulate the expression of EMT-related genes.",
      "When over-expressed, GRHL2 upregulates the expression of the EMT transcription factor snail.",
      "GRHL2 over-expression results in downregulation of the epithelial marker E-cadherin.",
      "Over-expressed GRHL2 can promote the migration and invasion of cancer cells by activating the PI3K/Akt signaling pathway and inhibiting the tumor suppressor gene TWIST1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Over-expression of GRHL2 typically suppresses epithelial-to-mesenchymal transition (EMT) in various cell types, including cancer cells.\n2. TRUE\n3. FALSE [correction]: When over-expressed, GRHL2 typically downregulates the expression of EMT transcription factors like snail.\n4. FALSE [correction]: GRHL2 over-expression usually results in upregulation of the epithelial marker E-cadherin.\n5. FALSE [correction]: Over-expressed GRHL2 can inhibit the migration and invasion of cancer cells by suppressing EMT-promoting pathways like the PI3K/Akt signaling pathway and it is associated with an upregulation of the tumor suppressor gene TWIST1, not inhibition.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-7b-chat-hf_response": "T-bet, Eomesodermin (Eomes), and T-box transcription factor 1 (Tbfa1) are three T-UCRs that have been implicated in lung cancer.\n1. T-bet: T-bet is a transcription factor that plays a critical role in the differentiation of T cells and the regulation of immune responses. In lung cancer, T-bet has been shown to be downregulated in many cases, leading to the inhibition of anti-tumor immune responses. Overexpression of T-bet has been associated with better prognosis in lung cancer patients.\n2. Eomes: Eomes is a transcription factor that regulates the expression of genes involved in cell proliferation, differentiation, and survival. In lung cancer, Eomes has been shown to be overexpressed in many cases, leading to the promotion of tumor growth and metastasis.\n3. Tbfa1: Tbfa1 is a transcription factor that regulates the expression of genes involved in cell proliferation, differentiation, and survival. In lung cancer, Tbfa1 has been shown to be overexpressed in many cases, leading to the promotion of tumor growth and metastasis.\nOverall, the dysregulation of these T-UCRs has been implicated in the development and progression of lung cancer, and their expression levels have been shown to be prognostic markers for patient outcomes.",
    "llama-2-7b-chat-hf_fact_raw": "1. T-bet has been implicated in lung cancer and is often downregulated, affecting the anti-tumor immune response.\n2. Overexpression of T-bet in lung cancer patients has been associated with better prognosis.\n3. Eomes has been implicated in lung cancer and is often overexpressed, contributing to tumor growth and metastasis.\n4. Tbfa1, like Eomes, has been implicated in lung cancer and is frequently overexpressed, aiding in tumor growth and metastasis.\n5. The expression levels of T-bet, Eomes, and Tbfa1 are considered prognostic markers for patient outcomes in lung cancer.",
    "llama-2-7b-chat-hf_fact": [
      "T-bet has been implicated in lung cancer and is often downregulated, affecting the anti-tumor immune response.",
      "Overexpression of T-bet in lung cancer patients has been associated with better prognosis.",
      "Eomes has been implicated in lung cancer and is often overexpressed, contributing to tumor growth and metastasis.",
      "Tbfa1, like Eomes, has been implicated in lung cancer and is frequently overexpressed, aiding in tumor growth and metastasis.",
      "The expression levels of T-bet, Eomes, and Tbfa1 are considered prognostic markers for patient outcomes in lung cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: T-bet, a transcription factor also known as TBX21, has been implicated in various forms of cancer, including lung cancer. T-bet is known to have an important role in the immune system and can be downregulated in some cases, which could indeed affect the anti-tumor immune response.\n\n2. TRUE: Typically, higher expression levels of T-bet are associated with enhanced immune responses against tumors. Therefore, overexpression of T-bet in lung cancer patients has been associated with a better prognosis, considering its role in promoting immune-mediated tumor suppression.\n\n3. TRUE: Eomes, another transcription factor that is related to T-bet and also known as eomesodermin, has been implicated in cancer. While the statement that it is often overexpressed in lung cancer and contributes to tumor growth and metastasis can be true, the role of Eomes in cancer is complex and can vary depending on the context and type of cancer.\n\n4. UNKNOWN: The statement mentions \"Tbfa1,\" which does not appear to be an established transcription factor or gene associated with lung cancer based on current scientific literature as of my knowledge cutoff in 2023. It could be a typographical error or a less-known factor not widely recognized in cancer research. Without further context or clarification, the involvement of \"Tbfa1\" in lung cancer cannot be confirmed.\n\n5. TRUE to UNKNOWN: While T-bet and Eomes expression levels may be considered prognostic markers for patient outcomes, the inclusion of \"Tbfa1\" makes this statement difficult to validate due to the previously mentioned issue with this factor. Overall, various transcription factors and genes, including T-bet and Eomes, might be considered as potential prognostic markers in lung cancer, with the caveat being dependent on the specific context of each case and additional research studies confirming such roles.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-7b-chat-hf_response": "GPR151 (G protein-coupled receptor 151) is an orphan G protein-coupled receptor, meaning that it does not have a well-defined endogenous ligand or a clear physiological function. Despite its designation as an orphan receptor, GPR151 has been implicated in a variety of biological processes, including:\n1. Inflammation: GPR151 has been shown to play a role in the regulation of inflammation, with studies suggesting that it may modulate the production of pro-inflammatory cytokines and chemokines.\n2. Immune response: GPR151 has been implicated in the regulation of immune cell function, including the activation of T cells and the modulation of immune responses.\n3. Neurotransmission: GPR151 has been shown to be involved in the regulation of neurotransmission, with studies suggesting that it may play a role in the modulation of synaptic plasticity and learning and memory.\n4. Metabolism: GPR151 has been implicated in the regulation of glucose and lipid metabolism, with studies suggesting that it may play a role in the regulation of insulin sensitivity and glucose uptake.\n5. Cancer: GPR151 has been shown to be overexpressed in a variety of cancer types, including breast, lung, and colon cancer, and it has been implicated in the regulation of cancer cell proliferation and survival.\n6. Cardiovascular health: GPR151 has been implicated in the regulation of cardiovascular health, with studies suggesting that it may play a role in the modulation of blood pressure and the regulation of vascular tone.\n7. Bone health: GPR151 has been shown to be involved in the regulation of bone metabolism, with studies suggesting that it may play a role in the modulation of bone density and the regulation of bone remodeling.\n8. Sleep: GPR151 has been implicated in the regulation of sleep and circadian rhythms, with studies suggesting that it may play a role in the modulation of sleep duration and quality.",
    "llama-2-7b-chat-hf_fact_raw": "1. GPR151 is classified as an orphan G protein-coupled receptor.\n2. GPR151 has been implicated in the regulation of inflammation and may modulate the production of pro-inflammatory cytokines and chemokines.\n3. GPR151 has been shown to be involved in the regulation of neurotransmission and may play a role in synaptic plasticity and learning and memory.\n4. GPR151 has been implicated in the regulation of glucose and lipid metabolism, possibly affecting insulin sensitivity and glucose uptake.\n5. GPR151 has been found to be overexpressed in various cancer types, including breast, lung, and colon cancer.",
    "llama-2-7b-chat-hf_fact": [
      "GPR151 is classified as an orphan G protein-coupled receptor.",
      "GPR151 has been implicated in the regulation of inflammation and may modulate the production of pro-inflammatory cytokines and chemokines.",
      "GPR151 has been shown to be involved in the regulation of neurotransmission and may play a role in synaptic plasticity and learning and memory.",
      "GPR151 has been implicated in the regulation of glucose and lipid metabolism, possibly affecting insulin sensitivity and glucose uptake.",
      "GPR151 has been found to be overexpressed in various cancer types, including breast, lung, and colon cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: As of my knowledge cutoff date in March 2023, GPR151 was not widely known to be overexpressed in various cancer types including breast, lung, and colon cancer. It is important to note that scientific research is ongoing, and new discoveries about G protein-coupled receptors like GPR151 are made regularly. However, based on the data available up until March 2023, this statement does not match the established research regarding the expression of GPR151 in cancer.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-7b-chat-hf_response": "The Fluzone Intradermal Quadrivalent vaccine contains the following attenuated live viruses:\n1. Influenza A/H1N1 (A/California/7/2009)\n2. Influenza A/H3N2 (A/Perth/1/2009)\n3. Influenza B/Victoria (B/Brisbane/60/2008)\n4. Influenza B/Yamagata (B/Florida/4/2006)\nIt's important to note that the strains contained in the vaccine may vary by manufacturer and by year, so it's always best to check the specific vaccine product insert or consult with a healthcare professional for the most up-to-date information.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Fluzone Intradermal Quadrivalent vaccine contains an attenuated live virus of Influenza A/H1N1 (A/California/7/2009).\n2. The Fluzone Intradermal Quadrivalent vaccine contains an attenuated live virus of Influenza A/H3N2 (A/Perth/1/2009).\n3. The Fluzone Intradermal Quadrivalent vaccine contains an attenuated live virus of Influenza B/Victoria (B/Brisbane/60/2008).\n4. The Fluzone Intradermal Quadrivalent vaccine contains an attenuated live virus of Influenza B/Yamagata (B/Florida/4/2006).",
    "llama-2-7b-chat-hf_fact": [
      "The Fluzone Intradermal Quadrivalent vaccine contains an attenuated live virus of Influenza A/H1N1 (A/California/7/2009).",
      "The Fluzone Intradermal Quadrivalent vaccine contains an attenuated live virus of Influenza A/H3N2 (A/Perth/1/2009).",
      "The Fluzone Intradermal Quadrivalent vaccine contains an attenuated live virus of Influenza B/Victoria (B/Brisbane/60/2008).",
      "The Fluzone Intradermal Quadrivalent vaccine contains an attenuated live virus of Influenza B/Yamagata (B/Florida/4/2006)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Fluzone Intradermal Quadrivalent vaccine does not contain live viruses; it contains inactivated (killed) viruses or virus components.\n2. FALSE [correction]: The Fluzone Intradermal Quadrivalent vaccine does not contain live viruses; it contains inactivated (killed) viruses or virus components.\n3. FALSE [correction]: The Fluzone Intradermal Quadrivalent vaccine does not contain live viruses; it contains inactivated (killed) viruses or virus components.\n4. FALSE [correction]: The Fluzone Intradermal Quadrivalent vaccine does not contain live viruses; it contains inactivated (killed) viruses or virus components.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-7b-chat-hf_response": "The TNFR2 gene, also known as the tumor necrosis factor receptor superfamily member 2 gene, has been associated with systemic lupus erythematosus (SLE), a chronic autoimmune disease that can affect multiple organ systems.\nSeveral genetic variations in the TNFR2 gene have been identified as risk factors for SLE, including:\n1. TNFR2 gene promoter polymorphisms: The TNFR2 gene promoter region contains several polymorphisms, including -232 C/G, -260 C/A, and -592 A/C, that have been associated with an increased risk of SLE.\n2. TNFR2 gene mutations: Some studies have identified mutations in the TNFR2 gene, such as the R75W and Y70C mutations, that are more common in SLE patients than in the general population.\n3. TNFR2 gene copy number variations: Some studies have found that SLE patients have an increased copy number of the TNFR2 gene, which may contribute to the development of the disease.\n4. TNFR2 gene methylation: Some studies have found that the TNFR2 gene is hypermethylated in SLE patients, which may lead to decreased gene expression and contribute to the development of the disease.\nIt is important to note that the genetic associations with SLE are complex and multiple genetic variants, as well as environmental and epigenetic factors, likely contribute to the development of the disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. The TNFR2 gene promoter region polymorphisms, including -232 C/G, -260 C/A, and -592 A/C, have been associated with an increased risk of systemic lupus erythematosus (SLE).\n2. Mutations in the TNFR2 gene, such as the R75W and Y70C mutations, are found to be more common in SLE patients than in the general population.\n3. Patients with systemic lupus erythematosus have been found to have an increased copy number of the TNFR2 gene in some studies.\n4. The TNFR2 gene is hypermethylated in patients with systemic lupus erythematosus, which may lead to decreased gene expression.\n5. Environmental and epigenetic factors, along with multiple genetic variants, likely contribute to the development of systemic lupus erythematosus.",
    "llama-2-7b-chat-hf_fact": [
      "The TNFR2 gene promoter region polymorphisms, including -232 C/G, -260 C/A, and -592 A/C, have been associated with an increased risk of systemic lupus erythematosus (SLE).",
      "Mutations in the TNFR2 gene, such as the R75W and Y70C mutations, are found to be more common in SLE patients than in the general population.",
      "Patients with systemic lupus erythematosus have been found to have an increased copy number of the TNFR2 gene in some studies.",
      "The TNFR2 gene is hypermethylated in patients with systemic lupus erythematosus, which may lead to decreased gene expression.",
      "Environmental and epigenetic factors, along with multiple genetic variants, likely contribute to the development of systemic lupus erythematosus."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The association of specific TNFR2 gene promoter polymorphisms with SLE risk would require verification from scientific studies, which are not provided here.\n2. UNKNOWN: The prevalence of particular mutations in the TNFR2 gene in SLE patients as compared to the general population also requires validation through genetic research, which is not cited in the statements provided.\n3. UNKNOWN: Whether SLE patients have an increased copy number of the TNFR2 gene is a claim that needs to be backed by genetic studies. Without such information, this statement's accuracy cannot be determined.\n4. UNKNOWN: The statement regarding TNFR2 gene hypermethylation and its potential effect on gene expression in SLE patients would need to be supported by epigenetic studies. Without access to relevant research, the truth of this claim cannot be decided.\n5. TRUE: It is widely accepted that both environmental and epigenetic factors, in combination with genetic variants, contribute to the development of systemic lupus erythematosus. This is a general statement consistent with current understanding of complex autoimmune diseases like SLE.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-7b-chat-hf_response": "There is currently no licensed vaccine available for the prevention of peanut allergy. However, researchers are actively working on developing a peanut allergy vaccine, also known as a therapeutic vaccine or immunotherapy.\nThe goal of a peanut allergy vaccine is to help the body build up tolerance to peanut proteins, reducing the severity of an allergic reaction. The vaccine would contain small amounts of peanut proteins, which the immune system would learn to recognize and tolerate over time.\nSeveral approaches are being explored in the development of a peanut allergy vaccine, including:\n1. Oral immunotherapy: This involves giving the patient small amounts of peanut protein in a gradually increasing dose to help the immune system build up tolerance.\n2. Epicutaneous immunotherapy: This involves applying a small amount of peanut protein to the skin, where it is absorbed by the immune system.\n3. Sublingual immunotherapy: This involves placing a small amount of peanut protein under the tongue, where it is absorbed by the immune system.\n4. mRNA-based vaccines: This involves using a piece of genetic material called messenger RNA (mRNA) to instruct cells to produce a specific protein, in this case, peanut protein. The mRNA is delivered to the cells using a carrier molecule, and the cells then produce the peanut protein, which the immune system can learn to tolerate.\nWhile these approaches show promise, it is important to note that the development of a peanut allergy vaccine is still in its early stages, and more research is needed to determine its safety and effectiveness. Additionally, it is likely that a peanut allergy vaccine will only be effective for a subset of patients, and it may not provide complete protection against an allergic reaction.\nIn summary, while there is currently no licensed vaccine available for the prevention of peanut allergy, researchers are actively working on developing a peanut allergy vaccine, which may offer a new treatment option for patients with this condition in the future.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is currently no licensed vaccine available for the prevention of peanut allergy.\n2. Researchers are working on developing a peanut allergy vaccine, which is also known as a therapeutic vaccine or immunotherapy.\n3. Oral immunotherapy for peanut allergy involves giving patients small amounts of peanut protein in gradually increasing doses.\n4. Epicutaneous immunotherapy for peanut allergy involves applying a small amount of peanut protein to the skin.\n5. mRNA-based vaccines for peanut allergy use messenger RNA to instruct cells to produce peanut protein.",
    "llama-2-7b-chat-hf_fact": [
      "There is currently no licensed vaccine available for the prevention of peanut allergy.",
      "Researchers are working on developing a peanut allergy vaccine, which is also known as a therapeutic vaccine or immunotherapy.",
      "Oral immunotherapy for peanut allergy involves giving patients small amounts of peanut protein in gradually increasing doses.",
      "Epicutaneous immunotherapy for peanut allergy involves applying a small amount of peanut protein to the skin.",
      "mRNA-based vaccines for peanut allergy use messenger RNA to instruct cells to produce peanut protein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: mRNA-based vaccines for peanut allergy do not instruct cells to produce peanut protein. mRNA vaccines for allergies would aim to instruct cells to produce allergen-specific proteins that help the immune system build tolerance to the allergen, but they would not cause the production of the allergen itself (peanut protein).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-7b-chat-hf_response": "The FXY gene in mice is located on chromosome 17, specifically at 17q21.3. This is a specific chromosomal position that is important for the function of the FXY gene.\nHere's why:\n1. Chromosome 17: The FXY gene is located on chromosome 17, which is one of the 23 pairs of chromosomes in mammals. Chromosome 17 is involved in a wide range of biological processes, including DNA repair, cell signaling, and immune function.\n2. 17q21.3: Within chromosome 17, the FXY gene is located at a specific region called 17q21.3. This region is a hotspot for genetic variation and is associated with a variety of genetic disorders, including intellectual disability and congenital anomalies.\n3. Gene dosage: The FXY gene is located on one copy of chromosome 17 in mice, which means that it has only one functional copy of the gene. This is in contrast to humans, who have two copies of the FXY gene (one from each parent). The single copy of the FXY gene in mice can lead to differences in its function and regulation compared to humans.\nIn summary, the FXY gene in mice is located on chromosome 17 at a specific region called 17q21.3, which is different from the human genome where the FXY gene is located on two copies of chromosome 17. This difference in gene dosage between mice and humans can lead to differences in the function and regulation of the FXY gene.",
    "llama-2-7b-chat-hf_fact_raw": "1. The FXY gene in mice is located on chromosome 17.\n2. The specific chromosomal position of the FXY gene in mice is at 17q21.3.\n3. Chromosome 17 in mammals is involved in a range of biological processes such as DNA repair, cell signaling, and immune function.\n4. The region 17q21.3 on chromosome 17 is associated with a variety of genetic disorders, including intellectual disability and congenital anomalies.\n5. Unlike humans who have two copies of the FXY gene, mice have only one functional copy of the FXY gene on chromosome 17.",
    "llama-2-7b-chat-hf_fact": [
      "The FXY gene in mice is located on chromosome 17.",
      "The specific chromosomal position of the FXY gene in mice is at 17q21.3.",
      "Chromosome 17 in mammals is involved in a range of biological processes such as DNA repair, cell signaling, and immune function.",
      "The region 17q21.3 on chromosome 17 is associated with a variety of genetic disorders, including intellectual disability and congenital anomalies.",
      "Unlike humans who have two copies of the FXY gene, mice have only one functional copy of the FXY gene on chromosome 17."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The FXY gene in mice is not widely recognized in scientific literature. There might have been a misunderstanding or error in referring to this gene. It is possible that the intended reference is to the FMR1 (Fragile X Mental Retardation 1) gene, which is linked to Fragile X syndrome in humans and is located on the X chromosome. It's also possible that the name \"FXY\" is a typographical error or an informal shorthand for a gene with a different official name. As such, without proper context or clarification, the location of the so-called \"FXY\" gene cannot be accurately provided.\n\n2. UNKNOWN: Since the existence and identity of the \"FXY\" gene in mice is unclear, its specific chromosomal position cannot be confirmed either.\n\n3. TRUE: Chromosome 17 in mammals, including mice and humans, is indeed involved in a variety of important biological processes such as DNA repair, cell signaling, and immune function.\n\n4. TRUE: The region 17q21.3 on the human chromosome 17 is associated with a variety of genetic disorders. Conditions such as Koolen-De Vries Syndrome and related intellectual disabilities have been linked to this region. However, the statement does not specify whether this is in mice or humans, but it is assumed here to refer to human genetics based on the well-documented associations.\n\n5. UNKNOWN: As the existence of the \"FXY\" gene in mice is uncertain based on the previous statements, it cannot be asserted how many copies of this gene mice may have. Moreover, most genes in mice and humans are found in pairs due to the diploid nature of their genomes; this statement would require additional context to correctly determine its validity.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-7b-chat-hf_response": "Methidiumpropyl-EDTA (MPE) sequencing is a method used to isolate and sequence specific DNA sequences in a complex genome. The basis of the MPE-seq method is based on the use of a chemical probe that selectively binds to the target DNA sequence, followed by enrichment and sequencing of the bound DNA.\nHere's a breakdown of the MPE-seq method:\n1. Target recognition: A specific DNA sequence of interest is identified, and a chemical probe, methidiumpropyl-EDTA (MPE), is designed to recognize this target sequence.\n2. Probe binding: The MPE probe is added to the sample, and it selectively binds to the target DNA sequence.\n3. Enrichment: The bound probe-DNA complex is then separated from the rest of the genome using a series of washing steps. This step enriches for the target DNA sequence.\n4. Library preparation: The enriched DNA is then prepared for sequencing by adding adapter sequences and amplifying the DNA using PCR.\n5. Sequencing: The prepared DNA library is then sequenced using Next-Generation Sequencing (NGS) technologies, such as Illumina or PacBio.\nThe MPE-seq method offers several advantages over other DNA sequencing methods, including:\n* High specificity: The MPE probe is highly specific to the target DNA sequence, reducing the background and increasing the signal-to-noise ratio.\n* High sensitivity: The MPE probe can detect low-abundance target sequences, making it useful for analyzing rare genetic variations.\n* Efficient enrichment: The MPE-seq method can enrich for the target DNA sequence with high efficiency, reducing the amount of genome required for sequencing.\n* Simple library preparation: The MPE-seq method requires minimal library preparation, making it faster and more cost-effective than other sequencing methods.\nOverall, the MPE-seq method is a powerful tool for isolating and sequencing specific DNA sequences in a complex genome, with applications in fields such as genomics, transcriptomics, and epigenomics.",
    "llama-2-7b-chat-hf_fact_raw": "1. Methidiumpropyl-EDTA (MPE) sequencing uses a chemical probe to selectively bind to a target DNA sequence.\n2. The MPE probe-DNA complex is enriched from the rest of the genome using washing steps.\n3. The enriched DNA is prepared for sequencing by adding adapter sequences and amplifying the DNA through PCR.\n4. MPE-seq relies on Next-Generation Sequencing (NGS) technologies such as Illumina or PacBio for sequencing the prepared DNA library.\n5. Methidiumpropyl-EDTA sequencing is used for isolating and sequencing specific DNA sequences within a complex genome.",
    "llama-2-7b-chat-hf_fact": [
      "Methidiumpropyl-EDTA (MPE) sequencing uses a chemical probe to selectively bind to a target DNA sequence.",
      "The MPE probe-DNA complex is enriched from the rest of the genome using washing steps.",
      "The enriched DNA is prepared for sequencing by adding adapter sequences and amplifying the DNA through PCR.",
      "MPE-seq relies on Next-Generation Sequencing (NGS) technologies such as Illumina or PacBio for sequencing the prepared DNA library.",
      "Methidiumpropyl-EDTA sequencing is used for isolating and sequencing specific DNA sequences within a complex genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific context regarding \"Methidiumpropyl-EDTA (MPE) sequencing,\" it is challenging to verify the accuracy of this statement. Methidiumpropyl-EDTA is not a standard or widely recognized term in common sequencing techniques.\n2. UNKNOWN: While this statement follows the logic of some sequencing methods that involve enriching target sequences, due to the earlier uncertainty, the details of the procedure cannot be confirmed.\n3. TRUE: This is a standard process in many sequencing workflows, where after enriching the target DNA, adapters are added and the DNA is amplified through PCR to prepare it for sequencing.\n4. TRUE: Next-Generation Sequencing (NGS) technologies, including those from Illumina and PacBio, are methods commonly used for sequencing DNA libraries in various sequencing strategies.\n5. UNKNOWN: Given the uncertainty about the specific method referred to as \"Methidiumpropyl-EDTA sequencing,\" it is not clear if it is indeed used for isolating and sequencing specific DNA sequences within a complex genome.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-7b-chat-hf_response": "GWAR (Gene Expression Analysis Workbench) is a software platform for the analysis of gene expression data. While GWAR is a bioinformatics tool, it is not a programming language in the classical sense. Instead, it is a collection of software components that are written in various programming languages, including:\n1. R: GWAR is built on top of the R programming language, which is a popular language for statistical computing and graphics. R is used for implementing the core algorithms and data structures of GWAR.\n2. Python: Some components of GWAR are written in Python, which is a versatile language for scientific computing and data analysis. Python is used for implementing the web interface and some of the data processing tools in GWAR.\n3. Java: GWAR also uses Java for implementing some of the core components, such as the Gene Ontology (GO) term mapper. Java is a popular language for developing large-scale bioinformatics tools due to its platform independence and ability to run on multiple operating systems.\n4. C++: Some parts of GWAR are written in C++, which is a high-performance language for developing efficient and fast algorithms. C++ is used for implementing the statistical models and data structures that are used in GWAR.\nIn summary, GWAR is a bioinformatics tool that is built using a combination of R, Python, Java, and C++ programming languages.",
    "llama-2-7b-chat-hf_fact_raw": "1. GWAR is built on top of the R programming language.\n2. Python is used in GWAR for implementing the web interface and some data processing tools.\n3. Java is used in GWAR for implementing the Gene Ontology (GO) term mapper.\n4. C++ is used in GWAR for implementing statistical models and data structures.",
    "llama-2-7b-chat-hf_fact": [
      "GWAR is built on top of the R programming language.",
      "Python is used in GWAR for implementing the web interface and some data processing tools.",
      "Java is used in GWAR for implementing the Gene Ontology (GO) term mapper.",
      "C++ is used in GWAR for implementing statistical models and data structures."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nWithout specific context or information on what \"GWAR\" refers to, or if it's an acronym or a specific software, library, or framework in this case, it's not possible to determine the truthfulness of the statements regarding the programming languages used within it.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-7b-chat-hf_response": "Xaliproden (also known as Idebench) is a small molecule inhibitor of the enzyme histone deacetylase (HDAC) that has been investigated for its potential therapeutic effects in various diseases, including amyotrophic lateral sclerosis (ALS).\nThere is limited evidence to suggest that xaliproden may have a potential therapeutic effect in improving the prognosis of ALS. Here are some of the key findings from the available literature:\n1. A phase II clinical trial published in 2018 evaluated the safety and efficacy of xaliproden in patients with ALS. The trial found that xaliproden treatment was associated with a slowing of disease progression, as measured by the rate of decline in forced vital capacity (FVC) over 24 weeks.\n2. Another study published in 2020 found that xaliproden treatment increased the expression of the survival protein Bcl-2 in ALS motor neurons, which may help to protect these cells from degeneration.\n3. Xaliproden has also been shown to have neuroprotective effects in preclinical studies of ALS, including reducing oxidative stress and inflammation, and promoting the survival of motor neurons.\nHowever, it is important to note that these findings are based on preliminary studies and the evidence is not yet conclusive. More research is needed to fully understand the potential benefits and risks of xaliproden in ALS, and to determine its place in the treatment of this devastating disease.\nIn summary, while there is some evidence to suggest that xaliproden may have a potential therapeutic effect in improving the prognosis of ALS, more research is needed to confirm these findings and to determine the safety and efficacy of this drug in clinical settings.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xaliproden is a small molecule inhibitor of the enzyme histone deacetylase (HDAC).\n2. A phase II clinical trial published in 2018 evaluated the safety and efficacy of xaliproden in patients with amyotrophic lateral sclerosis (ALS).\n3. The 2018 trial found that xaliproden treatment was associated with a slowing of disease progression in ALS patients over 24 weeks.\n4. A study published in 2020 found that xaliproden treatment increased the expression of the survival protein Bcl-2 in ALS motor neurons.\n5. In preclinical studies, xaliproden has been shown to reduce oxidative stress and inflammation, and promote the survival of motor neurons in ALS.",
    "llama-2-7b-chat-hf_fact": [
      "Xaliproden is a small molecule inhibitor of the enzyme histone deacetylase (HDAC).",
      "A phase II clinical trial published in 2018 evaluated the safety and efficacy of xaliproden in patients with amyotrophic lateral sclerosis (ALS).",
      "The 2018 trial found that xaliproden treatment was associated with a slowing of disease progression in ALS patients over 24 weeks.",
      "A study published in 2020 found that xaliproden treatment increased the expression of the survival protein Bcl-2 in ALS motor neurons.",
      "In preclinical studies, xaliproden has been shown to reduce oxidative stress and inflammation, and promote the survival of motor neurons in ALS."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Xaliproden is not a histone deacetylase (HDAC) inhibitor. It is a compound that was under investigation for its neuroprotective properties and its potential to enhance serotonergic and noradrenergic neurotransmission.\n2. UNKNOWN: Without access to specific databases or reference materials to confirm the details of the clinical trial, I cannot verify the accuracy of this statement.\n3. UNKNOWN: The outcome of the 2018 trial concerning whether xaliproden treatment was associated with a slowing of disease progression in ALS patients over 24 weeks cannot be verified without specific study data.\n4. UNKNOWN: Without access to the specific 2020 study, the veracity of the claim regarding xaliproden treatment and its effects on Bcl-2 expression in ALS motor neurons cannot be determined.\n5. UNKNOWN: The effects of xaliproden in preclinical studies, including its potential impact on oxidative stress and inflammation, and the survival of motor neurons in ALS, cannot be confirmed without the specific preclinical study data.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-7b-chat-hf_response": "The LiPS-A3S line is a transgenic line of mice that expresses the human APP695 gene under the control of the mouse prion-associated protein 1 (Map) promoter. The APP695 gene encodes the amyloid precursor protein, which is involved in the pathogenesis of Alzheimer's disease.\nIn the case of the LiPS-A3S line, the transgene is inserted into chromosome 17. Specifically, the transgene is located on chromosome 17p13, which is a region that is syntenic to human chromosome 14q24.1, where the APP gene is located.\nThe LiPS-A3S line was generated by injecting a construct containing the human APP695 gene and the Map promoter into mouse embryonic stem cells. The resulting transgenic mice express the human APP695 gene in a tissue-specific manner, primarily in the brain and peripheral tissues.\nIt's worth noting that the LiPS-A3S line is one of several transgenic lines that have been developed to study Alzheimer's disease and other neurodegenerative disorders. Each of these lines has its own unique characteristics and advantages, and the choice of which line to use depends on the specific research question being addressed.",
    "llama-2-7b-chat-hf_fact_raw": "1. The transgene in the LiPS-A3S line of mice is inserted into chromosome 17.\n2. The transgene location in the LiPS-A3S line is chromosome 17p13.\n3. Chromosome 17p13 is syntenic to human chromosome 14q24.1, where the APP gene is located.\n4. The LiPS-A3S line of mice expresses the human APP695 gene under the control of the mouse prion-associated protein 1 (Map) promoter.\n5. The LiPS-A3S line was generated by injecting a construct containing the human APP695 gene and the Map promoter into mouse embryonic stem cells.",
    "llama-2-7b-chat-hf_fact": [
      "The transgene in the LiPS-A3S line of mice is inserted into chromosome 17.",
      "The transgene location in the LiPS-A3S line is chromosome 17p13.",
      "Chromosome 17p13 is syntenic to human chromosome 14q24.1, where the APP gene is located.",
      "The LiPS-A3S line of mice expresses the human APP695 gene under the control of the mouse prion-associated protein 1 (Map) promoter.",
      "The LiPS-A3S line was generated by injecting a construct containing the human APP695 gene and the Map promoter into mouse embryonic stem cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThese statements require very specific scientific knowledge related to a particular line of genetically-modified mice, the LiPS-A3S line. Without access to the specific research article or scientific literature that describes the generation and characterization of the LiPS-A3S mouse line, it is not possible to confirm the accuracy of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-7b-chat-hf_response": "There are several deep learning tools and approaches that can be used for predicting drug synergy. Here are some of the most popular ones:\n1. DeepDrug: DeepDrug is a deep learning-based tool for predicting drug synergy. It uses a convolutional neural network (CNN) to analyze the molecular structures of drugs and predict their synergy.\n2. Drug2Drug: Drug2Drug is a deep learning-based tool that predicts drug synergy by analyzing the molecular structures of drugs. It uses a recurrent neural network (RNN) to predict the interactions between drugs and their synergy.\n3. SynergyNet: SynergyNet is a deep learning-based tool that predicts drug synergy by analyzing the molecular structures of drugs. It uses a CNN to predict the interactions between drugs and their synergy.\n4. ChEA-Net: ChEA-Net is a deep learning-based tool that predicts drug synergy by analyzing the molecular structures of drugs. It uses a CNN to predict the interactions between drugs and their synergy.\n5. Drug-Drug Interaction Prediction (DDIP): DDIP is a deep learning-based tool that predicts drug synergy by analyzing the molecular structures of drugs. It uses a RNN to predict the interactions between drugs and their synergy.\n6. Multi-task Drug-Drug Interaction Prediction (MuDDIP): MuDDIP is a deep learning-based tool that predicts drug synergy by analyzing the molecular structures of drugs. It uses a multi-task CNN to predict the interactions between drugs and their synergy.\n7. Drug-Drug Affinity Prediction (DDAP): DDAP is a deep learning-based tool that predicts drug synergy by analyzing the molecular structures of drugs. It uses a RNN to predict the affinity between drugs and their synergy.\n8. Drug-Drug Interaction Prediction (DDIP-VAE): DDIP-VAE is a deep learning-based tool that predicts drug synergy by analyzing the molecular structures of drugs. It uses a Variational Autoencoder (",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepDrug is a tool that uses convolutional neural network (CNN) for predicting drug synergy.\n2. Drug2Drug employs a recurrent neural network (RNN) to analyze and predict drug synergy.\n3. SynergyNet uses a convolutional neural network (CNN) to predict drug synergy.\n4. ChEA-Net is a deep learning-based tool that uses a CNN to predict drug synergy.\n5. Multi-task Drug-Drug Interaction Prediction (MuDDIP) uses a multi-task CNN for predicting drug synergy.",
    "llama-2-7b-chat-hf_fact": [
      "DeepDrug is a tool that uses convolutional neural network (CNN) for predicting drug synergy.",
      "Drug2Drug employs a recurrent neural network (RNN) to analyze and predict drug synergy.",
      "SynergyNet uses a convolutional neural network (CNN) to predict drug synergy.",
      "ChEA-Net is a deep learning-based tool that uses a CNN to predict drug synergy.",
      "Multi-task Drug-Drug Interaction Prediction (MuDDIP) uses a multi-task CNN for predicting drug synergy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nUnfortunately, without specific knowledge or context about \"DeepDrug,\" \"Drug2Drug,\" \"SynergyNet,\" \"ChEA-Net,\" and \"MuDDIP,\" and how they function, it's impossible to ascertain the veracity of the given statements. The technology behind these tools – whether they use CNNs, RNNs, or multi-task learning – cannot be confirmed or corrected.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-7b-chat-hf_response": "There are several cloud-based platforms that have been developed for comparing genome-wide association studies (GWAS). Here are a few examples:\n1. cloudGWAS: cloudGWAS is a cloud-based platform for analyzing and comparing GWAS data. It allows users to upload their GWAS data and perform a variety of analyses, including association mapping, genetic risk scoring, and gene-gene interaction analysis.\n2. GWAS Central: GWAS Central is a cloud-based platform that provides a centralized repository for storing and sharing GWAS data. It also includes tools for analyzing and comparing GWAS data, as well as for visualizing the results.\n3. GWASdb: GWASdb is a cloud-based platform for storing, sharing, and analyzing GWAS data. It includes tools for performing association mapping, gene-gene interaction analysis, and other types of genomic analysis.\n4. OpenGWAS: OpenGWAS is an open-source, cloud-based platform for analyzing and comparing GWAS data. It includes tools for performing association mapping, genetic risk scoring, and other types of genomic analysis.\n5. GWAS-Toolkit: GWAS-Toolkit is a cloud-based platform for analyzing and comparing GWAS data. It includes tools for performing association mapping, genetic risk scoring, and other types of genomic analysis.\n6. MetaGWAS: MetaGWAS is a cloud-based platform for analyzing and comparing GWAS data across multiple studies. It includes tools for performing association mapping, genetic risk scoring, and other types of genomic analysis.\n7. GWAS-Server: GWAS-Server is a cloud-based platform for analyzing and comparing GWAS data. It includes tools for performing association mapping, genetic risk scoring, and other types of genomic analysis.\n8. GWAS-API: GWAS-API is a cloud-based platform for analyzing and comparing GWAS data. It includes tools for performing association mapping, genetic risk scoring, and other types of genomic analysis.\n9. GWAS-Workbench: GWAS-Workbench is a cloud-based platform for analyzing and comparing GWAS data. It includes tools for performing association mapping, genetic risk scoring,",
    "llama-2-7b-chat-hf_fact_raw": "1. cloudGWAS is a cloud-based platform designed for analyzing and comparing GWAS data.\n2. GWAS Central provides a centralized repository for GWAS data and includes analysis and visualization tools.\n3. GWASdb includes tools for association mapping and gene-gene interaction analysis.\n4. OpenGWAS is an open-source, cloud-based platform with tools for genomic analysis, including association mapping and genetic risk scoring.\n5. MetaGWAS is a cloud-based platform that allows analysis and comparison of GWAS data across multiple studies.",
    "llama-2-7b-chat-hf_fact": [
      "cloudGWAS is a cloud-based platform designed for analyzing and comparing GWAS data.",
      "GWAS Central provides a centralized repository for GWAS data and includes analysis and visualization tools.",
      "GWASdb includes tools for association mapping and gene-gene interaction analysis.",
      "OpenGWAS is an open-source, cloud-based platform with tools for genomic analysis, including association mapping and genetic risk scoring.",
      "MetaGWAS is a cloud-based platform that allows analysis and comparison of GWAS data across multiple studies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: GWASdb provides a curated repository for GWAS data and mainly features tools for annotation and visualization, not specifically tools for association mapping and gene-gene interaction analysis.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-7b-chat-hf_response": "CMB305 is a small molecule inhibitor of the protein kinase B (PKB), also known as Akt. PKB is a key regulator of cell survival and proliferation, and it is often overexpressed in various types of cancer, including sarcomas.\nSarcomas are a group of rare and complex cancers that arise from the mesenchyme, a type of connective tissue. They can arise in any part of the body, and they are often aggressive and difficult to treat. Sarcomas are characterized by a high degree of genetic instability, which can lead to the development of resistance to conventional chemotherapy and radiation therapy.\nCMB305 has been shown to have antitumor activity against various types of cancer, including sarcomas. Studies have shown that CMB305 can inhibit the growth of sarcoma cells and induce apoptosis (programmed cell death), which can lead to the shrinkage of tumors. CMB305 has also been shown to inhibit the activation of PKB in sarcoma cells, which can help to prevent the development of resistance to chemotherapy.\nHowever, it is important to note that CMB305 is still a experimental drug, and it has not been approved by regulatory authorities for the treatment of sarcomas or any other type of cancer. More research is needed to fully understand the safety and efficacy of CMB305 in humans, and to determine its potential as a therapeutic agent for the treatment of sarcomas and other cancers.\nIn summary, CMB305 has shown promise as a potential treatment for sarcomas, but more research is needed to fully evaluate its safety and efficacy in humans.",
    "llama-2-7b-chat-hf_fact_raw": "1. CMB305 is a small molecule inhibitor of the protein kinase B (PKB), also known as Akt.\n2. PKB is a key regulator of cell survival and proliferation and is often overexpressed in various types of cancer, including sarcomas.\n3. Sarcomas are a group of cancers that arise from the mesenchyme, a type of connective tissue.\n4. CMB305 has been shown to inhibit the growth of sarcoma cells and induce apoptosis.\n5. CMB305 is still an experimental drug and has not been approved by regulatory authorities for the treatment of sarcomas or any other type of cancer.",
    "llama-2-7b-chat-hf_fact": [
      "CMB305 is a small molecule inhibitor of the protein kinase B (PKB), also known as Akt.",
      "PKB is a key regulator of cell survival and proliferation and is often overexpressed in various types of cancer, including sarcomas.",
      "Sarcomas are a group of cancers that arise from the mesenchyme, a type of connective tissue.",
      "CMB305 has been shown to inhibit the growth of sarcoma cells and induce apoptosis.",
      "CMB305 is still an experimental drug and has not been approved by regulatory authorities for the treatment of sarcomas or any other type of cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN (The statement contains specific information that cannot be verified without additional context since CMB305 is not a widely recognized name for a drug or compound in public databases as of my last update.)\n2. TRUE\n3. TRUE\n4. UNKNOWN (The statement contains specific information that cannot be confirmed without access to up-to-date scientific literature or clinical trial results regarding CMB305's effects.)\n5. UNKNOWN (Without current information on the regulatory status of CMB305, it's not possible to confirm whether it has been approved by any authority for medical use.)",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-7b-chat-hf_response": "The Saint's Triad, also known as the St. Vitus' Dance, is a group of symptoms that were described in the Middle Ages and were believed to be caused by demonic possession. The symptoms of the Saint's Triad include:\n1. Dance-like movements: The affected individual would experience uncontrolled, jerky movements of the arms, legs, and torso, often in a dancing or twirling motion.\n2. Trismus: The individual would experience rigidity and spasms of the jaw muscles, making it difficult to open the mouth or speak.\n3. Atonia: The individual would experience weakness or paralysis of the muscles, often accompanied by tremors or spasms.\nThese symptoms were believed to be caused by demonic possession and were often seen in individuals who were considered to be holy or pious. The Saint's Triad was a common affliction in the Middle Ages and was often associated with mystical experiences and visions.\nIt is important to note that the Saint's Triad is not a recognized medical condition and is not recognized as a valid medical diagnosis by modern medical professionals. The symptoms described in the Saint's Triad are similar to those of several neurological conditions, including dystonia, chorea, and ataxia, which are caused by abnormalities in the brain or nervous system. These conditions can be caused by a variety of factors, including genetic mutations, infections, and injuries.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Saint's Triad, also known as St. Vitus' Dance, was described in the Middle Ages.\n2. Symptoms of the Saint's Triad include dance-like movements, trismus, and atonia.\n3. The dance-like movements are described as uncontrolled, jerky movements often resembling a dancing or twirling motion.\n4. Trismus is characterized by rigidity and spasms of the jaw muscles, making it difficult to open the mouth or speak.\n5. Atonia involves weakness or paralysis of the muscles, often with tremors or spasms.\n\nPlease note that these historical descriptions of the Saint's Triad (St. Vitus' Dance) do not correspond with modern medical understanding, and thus some of these descriptions may be considered outdated or inaccurate based on current medical knowledge.",
    "llama-2-7b-chat-hf_fact": [
      "The Saint's Triad, also known as St. Vitus' Dance, was described in the Middle Ages.",
      "Symptoms of the Saint's Triad include dance-like movements, trismus, and atonia.",
      "The dance-like movements are described as uncontrolled, jerky movements often resembling a dancing or twirling motion.",
      "Trismus is characterized by rigidity and spasms of the jaw muscles, making it difficult to open the mouth or speak.",
      "Atonia involves weakness or paralysis of the muscles, often with tremors or spasms.",
      "ease note that these historical descriptions of the Saint's Triad (St. Vitus' Dance) do not correspond with modern medical understanding, and thus some of these descriptions may be considered outdated or inaccurate based on current medical knowledge."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The \"dance\" diseases, including what was known as St. Vitus' Dance (now more commonly referred to as Sydenham's chorea), were indeed described in the Middle Ages.\n2. FALSE [correction]: The Saint's Triad is not a recognized medical condition. St. Vitus' Dance is associated with Sydenham's chorea, which includes symptoms of involuntary movements, but trismus and atonia are not typical features. \"Saint's Triad\" may be a confusion with \"Saint Vitus' Dance\" and some other conditions.\n3. TRUE: The description of the dance-like movements in St. Vitus' Dance (Sydenham's chorea) as uncontrolled, jerky movements resembling a dance or twirling motion is accurate.\n4. TRUE: While trismus is not a symptom of St. Vitus' Dance (Sydenham's chorea), the description of trismus itself is correct—it is rigidity and spasms of the jaw muscles that can make it difficult to open the mouth or speak.\n5. FALSE [correction]: While atonia is characterized by a lack or loss of muscle strength, it is not a typical symptom of St. Vitus' Dance (Sydenham's chorea). Sydenham's chorea is more often associated with involuntary movements, rather than paralysis or weakness.\n6. UNKNOWN: Without a specific statement to evaluate, the truth or falsehood of this statement cannot be determined. However, it is true that historic medical descriptions can differ significantly from modern understandings.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-7b-chat-hf_response": "LY6K is a protein that has been shown to play a role in the progression of non-small cell lung cancer (NSCLC). Studies have shown that overexpression of LY6K is associated with better prognosis in NSCLC patients.\nOne study published in the journal Oncogene in 2016 found that LY6K expression was significantly higher in tumor tissues than in adjacent non-tumor tissues in NSCLC patients. The study also found that high LY6K expression was associated with better overall survival and disease-free survival in NSCLC patients.\nAnother study published in the journal Clinical Cancer Research in 2018 found that LY6K overexpression was associated with improved overall survival and progression-free survival in NSCLC patients. The study also found that LY6K overexpression was associated with a lower risk of disease recurrence and death in NSCLC patients.\nA review article published in the journal Cancer Treatment Reviews in 2020 also discussed the prognostic value of LY6K in NSCLC. The authors concluded that high LY6K expression is associated with better prognosis in NSCLC patients, and that LY6K may be a promising therapeutic target for the treatment of NSCLC.\nOverall, these studies suggest that overexpression of LY6K is associated with better prognosis in NSCLC patients, and that LY6K may be a useful biomarker for predicting prognosis and response to therapy in NSCLC.",
    "llama-2-7b-chat-hf_fact_raw": "1. Overexpression of LY6K is associated with better prognosis in non-small cell lung cancer (NSCLC) patients.\n2. A study published in the journal Oncogene in 2016 reported that LY6K expression was higher in tumor tissues than in adjacent non-tumor tissues in NSCLC patients.\n3. The 2016 study also indicated that high LY6K expression was correlated with better overall survival and disease-free survival in NSCLC patients.\n4. Research published in Clinical Cancer Research in 2018 found that LY6K overexpression in NSCLC patients was linked to improved overall survival and progression-free survival.\n5. The same 2018 study noted that LY6K overexpression was linked to a lower risk of disease recurrence and death in NSCLC patients.",
    "llama-2-7b-chat-hf_fact": [
      "Overexpression of LY6K is associated with better prognosis in non-small cell lung cancer (NSCLC) patients.",
      "A study published in the journal Oncogene in 2016 reported that LY6K expression was higher in tumor tissues than in adjacent non-tumor tissues in NSCLC patients.",
      "The 2016 study also indicated that high LY6K expression was correlated with better overall survival and disease-free survival in NSCLC patients.",
      "Research published in Clinical Cancer Research in 2018 found that LY6K overexpression in NSCLC patients was linked to improved overall survival and progression-free survival.",
      "The same 2018 study noted that LY6K overexpression was linked to a lower risk of disease recurrence and death in NSCLC patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Overexpression of LY6K is typically associated with a poorer prognosis in non-small cell lung cancer (NSCLC) patients.\n2. TRUE\n3. FALSE [correction]: High LY6K expression is generally correlated with poorer overall survival and disease-free survival in NSCLC patients.\n4. FALSE [correction]: Research typically finds that LY6K overexpression in NSCLC patients is linked to poorer overall survival and progression-free survival.\n5. FALSE [correction]: The study likely noted that LY6K overexpression was linked to a higher risk of disease recurrence and death in NSCLC patients.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-7b-chat-hf_response": "During cytokinesis, the CDK (cyclin-dependent kinase) inhibitor p21 is phosphorylated and degraded, leading to the activation of CDKs and the progression of the cell cycle. Here are some CDK targets that are dephosphorylated during cytokinesis:\n1. Cyclin-dependent kinase 1 (CDK1): CDK1 is a key regulator of the cell cycle and is involved in the progression from G2 to M phase. During cytokinesis, CDK1 is dephosphorylated and activated, leading to the breakdown of the cleavage furrow and the completion of cell division.\n2. Cyclin-dependent kinase 2 (CDK2): CDK2 is another important regulator of the cell cycle and is involved in the progression from G1 to S phase. During cytokinesis, CDK2 is dephosphorylated and activated, leading to the activation of downstream targets and the progression of the cell cycle.\n3. Cyclin B1: Cyclin B1 is a regulatory protein that binds to and activates CDK1 during the G2 phase of the cell cycle. During cytokinesis, cyclin B1 is dephosphorylated and sequestered in the nucleus, leading to the activation of CDK1 and the progression of the cell cycle.\n4. Cyclin D1: Cyclin D1 is a regulatory protein that binds to and activates CDK4/6 during the G1 phase of the cell cycle. During cytokinesis, cyclin D1 is dephosphorylated and sequestered in the nucleus, leading to the activation of CDK4/6 and the progression of the cell cycle.\n5. Polo-like kinase 1 (PLK1): PLK1 is a CDK that is involved in the regulation of the cell cycle and the formation of the cleavage furrow during cytokinesis. During cytokinesis, PLK1 is dephosphorylated and activated, leading to the proper formation of the cleavage furrow and the completion of cell division.\nIn summary, during cytokinesis, several CDK targets are dephosphory",
    "llama-2-7b-chat-hf_fact_raw": "1. Cyclin-dependent kinase 1 (CDK1) is involved in the progression from G2 to M phase and is dephosphorylated and activated during cytokinesis.\n2. Cyclin-dependent kinase 2 (CDK2) is involved in the progression from G1 to S phase and is dephosphorylated and activated during cytokinesis.\n3. Cyclin B1 binds to and activates CDK1 during the G2 phase of the cell cycle and is dephosphorylated and sequestered in the nucleus during cytokinesis.\n4. Cyclin D1 binds to and activates CDK4/6 during the G1 phase of the cell cycle and is dephosphorylated and sequestered in the nucleus during cytokinesis.\n5. Polo-like kinase 1 (PLK1) is involved in the regulation of the cell cycle and the formation of the cleavage furrow during cytokinesis and is dephosphorylated and activated during cytokinesis.",
    "llama-2-7b-chat-hf_fact": [
      "Cyclin-dependent kinase 1 (CDK1) is involved in the progression from G2 to M phase and is dephosphorylated and activated during cytokinesis.",
      "Cyclin-dependent kinase 2 (CDK2) is involved in the progression from G1 to S phase and is dephosphorylated and activated during cytokinesis.",
      "Cyclin B1 binds to and activates CDK1 during the G2 phase of the cell cycle and is dephosphorylated and sequestered in the nucleus during cytokinesis.",
      "Cyclin D1 binds to and activates CDK4/6 during the G1 phase of the cell cycle and is dephosphorylated and sequestered in the nucleus during cytokinesis.",
      "Polo-like kinase 1 (PLK1) is involved in the regulation of the cell cycle and the formation of the cleavage furrow during cytokinesis and is dephosphorylated and activated during cytokinesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cyclin-dependent kinase 1 (CDK1) is involved in the progression from G2 to M phase but it is not dephosphorylated and activated during cytokinesis. It is actually activated earlier upon dephosphorylation to initiate mitosis.\n2. TRUE\n3. FALSE [correction]: Cyclin B1 does bind to and activate CDK1 during the G2 phase of the cell cycle; however, it is not dephosphorylated and sequestered in the nucleus during cytokinesis. Cyclin B1 is targeted for degradation during mitosis, which contributes to the cell's exit from mitosis.\n4. TRUE\n5. FALSE [correction]: Polo-like kinase 1 (PLK1) is involved in the regulation of the cell cycle and the formation of the cleavage furrow during cytokinesis. However, it is not typically described as being dephosphorylated and activated during cytokinesis; it is already active and plays a role in the earlier stages of mitosis as well.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-7b-chat-hf_response": "Xanamem is a synthetic compound that is structurally similar to the natural neurotransmitter acetylcholine (ACh). It is used as a research tool in neuroscience to study the function and regulation of cholinergic systems in the brain.\nCholinergic systems are involved in a wide range of brain functions, including attention, learning, memory, and regulation of the autonomic nervous system. Xanamem is used to selectively activate or inhibit cholinergic receptors in the brain, allowing researchers to study their function and interactions with other neurotransmitters.\nXanamem has been shown to have a number of interesting properties and actions in the brain, including:\n1. Selective activation of cholinergic receptors: Xanamem has been shown to selectively activate certain subtypes of cholinergic receptors, such as the nicotinic acetylcholine receptor (nAChR) and the muscarinic acetylcholine receptor (mAChR).\n2. Modulation of synaptic plasticity: Xanamem has been shown to modulate long-term potentiation (LTP) and long-term depression (LTD), two forms of synaptic plasticity that are involved in learning and memory.\n3. Regulation of gene expression: Xanamem has been shown to regulate the expression of certain genes involved in cholinergic signaling, such as the gene for the cholinergic receptor muscarinic acetylcholine receptor 1 (mAChR1).\n4. Anti-inflammatory effects: Xanamem has been shown to have anti-inflammatory effects in the brain, which may contribute to its potential therapeutic uses.\nOverall, Xanamem is a valuable tool for studying the complex cholinergic systems in the brain and for exploring the potential therapeutic uses of cholinergic agonists and antagonists.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xanamem is used as a research tool in neuroscience.\n2. It is designed to selectively activate or inhibit cholinergic receptors in the brain.\n3. Xanamem can modulate long-term potentiation (LTP) and long-term depression (LTD).\n4. The compound has been shown to regulate the expression of genes involved in cholinergic signaling.\n5. Xanamem has demonstrated anti-inflammatory effects in the brain.",
    "llama-2-7b-chat-hf_fact": [
      "Xanamem is used as a research tool in neuroscience.",
      "It is designed to selectively activate or inhibit cholinergic receptors in the brain.",
      "Xanamem can modulate long-term potentiation (LTP) and long-term depression (LTD).",
      "The compound has been shown to regulate the expression of genes involved in cholinergic signaling.",
      "Xanamem has demonstrated anti-inflammatory effects in the brain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Xanamem is designed to inhibit the production of excess cortisol by blocking the activity of the enzyme 11β-HSD1 in the brain.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nXanamem is indeed used in neuroscience research, particularly in the context of investigating its effects related to cortisol regulation in the brain. However, it is not designed to activate or inhibit cholinergic receptors; instead, it targets the enzyme 11β-HSD1 to prevent the creation of excess cortisol. Statements 3, 4, and 5 are not verifiable with the information provided and would require specific research data or evidence to confirm their accuracy.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-7b-chat-hf_response": "In yeast, the Hof1-Cyk3 interaction plays a crucial role in regulating the cell cycle and metabolism. Here's a breakdown of their roles:\n1. Hof1:\nHof1 (Histone fold 1) is a protein that binds to and regulates the activity of various transcription factors and other proteins involved in the cell cycle and metabolism.\nRole:\n* Hof1 acts as a scaffold protein that brings together different transcription factors and regulatory proteins to modulate their activity.\n* Hof1 also interacts with the transcriptional coactivator Cyk3 (Cyclic AMP-dependent protein kinase 3) and regulates its activity.\n2. Cyk3:\nCyk3 (Cyclic AMP-dependent protein kinase 3) is a key regulator of the cell cycle and metabolism in yeast. It is a protein kinase that phosphorylates and activates various downstream targets involved in the cell cycle, metabolism, and stress response.\nRole:\n* Cyk3 is activated by the binding of cAMP (cyclic adenosine monophosphate) to its regulatory domain, leading to its autophosphorylation and activation.\n* Cyk3 phosphorylates and activates various downstream targets, including the transcription factor Skn7 (Sterile alpha factor), which regulates the expression of genes involved in the cell cycle and metabolism.\n* Cyk3 also interacts with and regulates the activity of the transcriptional coactivator Hof1.\nInteraction between Hof1 and Cyk3:\nThe interaction between Hof1 and Cyk3 is crucial for the regulation of the cell cycle and metabolism in yeast. Here's how:\n* Hof1 binds to Cyk3 and regulates its activity by modulating its phosphorylation and stability.\n* Cyk3 phosphorylation by Hof1 is important for its activity and stability, as well as for the regulation of its downstream targets.\n* The interaction between Hof1 and Cyk3 also regulates the expression of genes involved in the cell cycle and metabolism, as well as the response to stress.\nIn summary, the interaction between Hof1 and Cyk",
    "llama-2-7b-chat-hf_fact_raw": "1. Hof1 is a protein in yeast that binds to and regulates various transcription factors and proteins involved in the cell cycle and metabolism.\n2. Cyk3 is a protein kinase in yeast that phosphorylates and activates various downstream targets involved in the cell cycle, metabolism, and stress response.\n3. Cyk3 is activated by the binding of cAMP to its regulatory domain, which leads to its autophosphorylation and activation.\n4. Hof1 acts as a scaffold protein that brings together different transcription factors and regulatory proteins, including Cyk3.\n5. The interaction between Hof1 and Cyk3 is important for the regulation of the cell cycle and metabolism in yeast.",
    "llama-2-7b-chat-hf_fact": [
      "Hof1 is a protein in yeast that binds to and regulates various transcription factors and proteins involved in the cell cycle and metabolism.",
      "Cyk3 is a protein kinase in yeast that phosphorylates and activates various downstream targets involved in the cell cycle, metabolism, and stress response.",
      "Cyk3 is activated by the binding of cAMP to its regulatory domain, which leads to its autophosphorylation and activation.",
      "Hof1 acts as a scaffold protein that brings together different transcription factors and regulatory proteins, including Cyk3.",
      "The interaction between Hof1 and Cyk3 is important for the regulation of the cell cycle and metabolism in yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The information provided is too specific for a general knowledge base without access to current scientific literature on yeast proteins. Hof1's role in yeast cell cycle regulation is known, but without specific reference, it's unclear if it binds to and regulates various transcription factors and proteins involved in metabolism.\n2. FALSE [correction]: Cyk3 is not a protein kinase but a protein involved in cytokinesis. It could have other roles, but it is not known for phosphorylating and activating downstream targets related to cell cycle, metabolism, and stress response.\n3. FALSE [correction]: Cyk3 is not known to be activated by the binding of cAMP. This is a characteristic of some other proteins with regulatory domains that bind cAMP, such as PKA (protein kinase A), but not Cyk3.\n4. UNKNOWN: Without specific literature, it is unclear if Hof1 acts specifically as a scaffold protein for transcription factors and regulatory proteins, including Cyk3. The role of Hof1 in organizing such complexes could be context-dependent and requires specific references to confirm.\n5. UNKNOWN: The exact nature of the interaction between Hof1 and Cyk3 in the regulation of the cell cycle and metabolism in yeast cannot be confirmed without specific scientific literature.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-7b-chat-hf_response": "T-bet and Eomesodermin (Eomes) are two transcription factors that have been implicated in the development and progression of gastric cancer. Here's a brief overview of their roles and how they are involved in gastric cancer:\nT-bet:\n* T-bet is a transcription factor that belongs to the T-box family of proteins.\n* T-bet is a key regulator of T-cell development and differentiation, and it plays a crucial role in the immune response against cancer.\n* In gastric cancer, T-bet has been shown to be downregulated, leading to the inhibition of anti-tumor immune responses.\n* T-bet deficiency has been associated with a poor prognosis in gastric cancer patients.\nEomesodermin (Eomes):\n* Eomes is a transcription factor that regulates the expression of genes involved in cell proliferation, differentiation, and survival.\n* Eomes is overexpressed in many types of cancer, including gastric cancer, and it promotes the progression of cancer by suppressing the immune response.\n* In gastric cancer, Eomes has been shown to be overexpressed in a majority of cases, and it is associated with a poor prognosis.\n* Eomes overexpression can also lead to the inhibition of apoptosis and the promotion of cell proliferation in gastric cancer cells.\nIn summary, both T-bet and Eomes have been implicated in the development and progression of gastric cancer, and their downregulation is associated with a poor prognosis in patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. T-bet is a transcription factor belonging to the T-box family of proteins involved in T-cell development and differentiation.\n2. T-bet has been shown to be downregulated in gastric cancer, inhibiting anti-tumor immune responses.\n3. T-bet deficiency is associated with a poor prognosis in gastric cancer patients.\n4. Eomesodermin (Eomes) is a transcription factor overexpressed in many types of cancer, including gastric cancer, and it suppresses the immune response.\n5. Eomes overexpression in gastric cancer is associated with the inhibition of apoptosis and promotion of cell proliferation.",
    "llama-2-7b-chat-hf_fact": [
      "T-bet is a transcription factor belonging to the T-box family of proteins involved in T-cell development and differentiation.",
      "T-bet has been shown to be downregulated in gastric cancer, inhibiting anti-tumor immune responses.",
      "T-bet deficiency is associated with a poor prognosis in gastric cancer patients.",
      "Eomesodermin (Eomes) is a transcription factor overexpressed in many types of cancer, including gastric cancer, and it suppresses the immune response.",
      "Eomes overexpression in gastric cancer is associated with the inhibition of apoptosis and promotion of cell proliferation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Eomesodermin (Eomes) is a transcription factor related to T-bet and plays a role in T-cell development and function, but its expression levels and effects on immune responses can vary significantly in different types of cancer.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-7b-chat-hf_response": "The Lupus Severity Index (LSI) is a clinical index used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease that can affect multiple organ systems. The LSI is a composite score that takes into account various clinical and laboratory parameters, including:\n1. Serologic markers: anti-nuclear antibodies (ANA), anti-double-stranded DNA (anti-dsDNA), and complement levels.\n2. Organ involvement: renal, neurological, cardiovascular, and musculoskeletal systems.\n3. Disease activity: patient-reported measures of disease activity, such as the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) or the Lupus Patient Index (LPI).\n4. Quality of life: measures of physical and mental well-being, such as the Short Form-36 (SF-36) or the Lupus Quality of Life Questionnaire (LQoL).\n5. Immunosuppressive medications: the use of corticosteroids, immunosuppressive drugs, or biologic agents to treat SLE.\nThe LSI is calculated by assigning weights to each of these parameters based on their perceived importance in determining the overall severity of SLE. The weights are typically determined through a combination of expert opinion and empirical data. The total score on the LSI can range from 0 to 100, with higher scores indicating greater severity of disease.\nThe LSI has been shown to be a useful tool for evaluating the severity of SLE in clinical trials and for monitoring the effectiveness of treatments. It can help clinicians to identify patients who may benefit from more intensive treatment and to assess the response to therapy over time. However, it is important to note that the LSI is not a perfect measure of disease severity, and other factors such as patient quality of life and functional status may also need to be considered in clinical decision-making.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) is a clinical index used to assess the severity of systemic lupus erythematosus (SLE).\n2. The LSI takes into account clinical and laboratory parameters including serologic markers, organ involvement, and disease activity.\n3. Patient-reported measures of disease activity used in LSI assessment include the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and the Lupus Patient Index (LPI).\n4. Quality of life assessments in LSI may involve the Short Form-36 (SF-36) or the Lupus Quality of Life Questionnaire (LQoL).\n5. The LSI score can range from 0 to 100, with higher scores indicating greater severity of the disease.",
    "llama-2-7b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) is a clinical index used to assess the severity of systemic lupus erythematosus (SLE).",
      "The LSI takes into account clinical and laboratory parameters including serologic markers, organ involvement, and disease activity.",
      "Patient-reported measures of disease activity used in LSI assessment include the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and the Lupus Patient Index (LPI).",
      "Quality of life assessments in LSI may involve the Short Form-36 (SF-36) or the Lupus Quality of Life Questionnaire (LQoL).",
      "The LSI score can range from 0 to 100, with higher scores indicating greater severity of the disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without additional context, it's impossible to validate the existence or use of a \"Lupus Severity Index (LSI)\" as a recognized clinical index. The standard tools used for assessing SLE severity are SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) and BILAG (British Isles Lupus Assessment Group index), among others.\n   \n2. TRUE: In general, clinical and laboratory parameters including serologic markers, organ involvement, and disease activity are indeed used for assessing the severity of systemic lupus erythematosus (SLE). Whether the specific term \"LSI\" is standard is not confirmed, but the statement about what is typically included in such assessments is accurate.\n\n3. FALSE [correction]: While patient-reported measures are often important in the context of SLE assessment, SLEDAI is a clinician-administered tool and not a patient-reported measure. The Lupus Patient Index (LPI) does not exist as a recognized standard instrument. Patient-reported outcome measures in SLE often include LupusPRO (Lupus Patient-Reported Outcome) or LUP-QoL (Lupus Quality of Life questionnaire), among others.\n\n4. UNKNOWN: Without confirming the existence of the \"Lupus Severity Index,\" it's unclear whether quality of life assessments such as the Short Form-36 (SF-36) or a Lupus Quality of Life Questionnaire (which could be referred to as LQoL) are included within it. However, these are typical quality of life assessments used in medical contexts including SLE.\n\n5. UNKNOWN: Because the existence or specifics of the \"Lupus Severity Index\" have not been validated, it is not possible to confirm the scoring range or interpretation. In well-known indices like SLEDAI, scoring does reflect disease activity, but they do not necessarily range from 0 to 100.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-7b-chat-hf_response": "ZSWIM6 is a gene that has been associated with several human disorders, primarily related to brain development and function. De novo mutations in ZSWIM6 have been identified as a cause of several rare genetic disorders, including:\n1. Zellweger syndrome spectrum disorders: Zellweger syndrome is a rare genetic disorder that affects the development of the brain and other organs. De novo mutations in ZSWIM6 have been identified as a cause of this syndrome, which is characterized by intellectual disability, seizures, and vision and hearing loss.\n2. Neuronal ceroid lipofuscinosis (NCL): NCL is a group of rare genetic disorders that affect the brain and nervous system. De novo mutations in ZSWIM6 have been identified as a cause of some forms of NCL, which are characterized by progressive loss of cognitive and motor functions, seizures, and early death.\n3. Pelizaeus-Merzbacher disease (PMD): PMD is a rare genetic disorder that affects the development of the myelin sheath surrounding nerve fibers. De novo mutations in ZSWIM6 have been identified as a cause of some forms of PMD, which are characterized by delayed development, seizures, and loss of vision and hearing.\n4. Other disorders: De novo mutations in ZSWIM6 have also been identified in individuals with other rare genetic disorders, such as intellectual disability, autism spectrum disorder, and cerebral palsy.\nIt is important to note that the frequency and distribution of de novo mutations in ZSWIM6 may vary depending on the population studied and the specific disorder under investigation. Further research is needed to fully understand the role of ZSWIM6 in human disease and to identify the underlying mechanisms of these disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. De novo mutations in ZSWIM6 have been identified as a cause of Zellweger syndrome spectrum disorders.\n2. Zellweger syndrome spectrum disorders are characterized by intellectual disability, seizures, and vision and hearing loss.\n3. De novo mutations in ZSWIM6 can cause Neuronal ceroid lipofuscinosis, affecting cognitive and motor functions.\n4. Some forms of Pelizaeus-Merzbacher disease, which affects the myelin sheath of nerve fibers, are caused by de novo mutations in ZSWIM6.\n5. De novo mutations in ZSWIM6 have been linked to individuals with other rare genetic disorders, including intellectual disability and autism spectrum disorder.",
    "llama-2-7b-chat-hf_fact": [
      "De novo mutations in ZSWIM6 have been identified as a cause of Zellweger syndrome spectrum disorders.",
      "Zellweger syndrome spectrum disorders are characterized by intellectual disability, seizures, and vision and hearing loss.",
      "De novo mutations in ZSWIM6 can cause Neuronal ceroid lipofuscinosis, affecting cognitive and motor functions.",
      "Some forms of Pelizaeus-Merzbacher disease, which affects the myelin sheath of nerve fibers, are caused by de novo mutations in ZSWIM6.",
      "De novo mutations in ZSWIM6 have been linked to individuals with other rare genetic disorders, including intellectual disability and autism spectrum disorder."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: De novo mutations in ZSWIM6 have not been identified as a cause of Zellweger syndrome spectrum disorders. Zellweger syndrome spectrum disorders are more commonly associated with mutations in the PEX genes, which are required for the normal function of peroxisomes.\n\n2. TRUE: Zellweger syndrome spectrum disorders are indeed characterized by a range of symptoms including intellectual disability, seizures, and issues with vision and hearing.\n\n3. TRUE: De novo mutations in ZSWIM6 can cause Neuronal ceroid lipofuscinosis, which is a group of progressive neurodegenerative disorders that affect cognitive and motor functions.\n\n4. UNKNOWN: Without specific information about the genetic causes of different forms of Pelizaeus-Merzbacher disease, it cannot be determined whether de novo mutations in ZSWIM6 are a cause. Pelizaeus-Merzbacher disease is usually associated with mutations in the PLP1 gene, but there could be other less common genetic associations.\n\n5. TRUE: De novo mutations in ZSWIM6 have been linked to individuals with a variety of rare genetic disorders, and this includes conditions such as intellectual disability and autism spectrum disorder.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-7b-chat-hf_response": "The Koos Classification is a system used to classify brain tumors based on their histological features. It was developed by Dr. G.W. Koos in the 1970s and is still widely used today. The Koos Classification system divides brain tumors into four main categories:\n1. Astrocytomas: These are tumors that arise from star-shaped glial cells called astrocytes. Examples of astrocytomas include glioblastoma, astrocytoma, and diffuse astrocytic tumors.\n2. Oligodendrogliomas: These are tumors that arise from oligodendroglial cells, which are a type of glial cell that provides support and structure to the brain. Examples of oligodendrogliomas include oligodendroglioma, oligoastrocytoma, and oligo-astrocytic tumors.\n3. Acoustic neuromas: These are benign tumors that arise from the covering of the nerve that connects the inner ear to the brain. They are also known as vestibular schwannomas.\n4. Other tumors: This category includes rare types of brain tumors, such as chordoma, colloid cyst, and craniopharyngioma.\nEach of these categories has distinct clinical and histological features, and the Koos Classification system helps to guide the diagnosis and treatment of brain tumors.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Koos Classification system is used to classify brain tumors.\n2. It was developed by Dr. G.W. Koos in the 1970s.\n3. The system divides brain tumors into four main categories: Astrocytomas, Oligodendrogliomas, Acoustic neuromas, and Other tumors.\n4. Astrocytomas arise from star-shaped glial cells called astrocytes.\n5. Acoustic neuromas, also known as vestibular schwannomas, are benign tumors that arise from the covering of the nerve connecting the inner ear to the brain.",
    "llama-2-7b-chat-hf_fact": [
      "The Koos Classification system is used to classify brain tumors.",
      "It was developed by Dr. G.W. Koos in the 1970s.",
      "The system divides brain tumors into four main categories: Astrocytomas, Oligodendrogliomas, Acoustic neuromas, and Other tumors.",
      "Astrocytomas arise from star-shaped glial cells called astrocytes.",
      "Acoustic neuromas, also known as vestibular schwannomas, are benign tumors that arise from the covering of the nerve connecting the inner ear to the brain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Koos Classification system is used to classify vestibular schwannomas (also known as acoustic neuromas), not all brain tumors.\n2. TRUE\n3. FALSE [correction]: The Koos Classification system does not divide brain tumors into categories. It specifically grades vestibular schwannomas based on their size and anatomical extension.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-7b-chat-hf_response": "AZD8601 is a small molecule inhibitor of the protein kinase CAMKK1 (calcium/calmodulin-dependent protein kinase kinase 1), which is a key regulator of neural stem cell proliferation and differentiation. In vivo studies have shown that AZD8601 has a range of effects on neural development and function, including:\n1. Neural stem cell proliferation: AZD8601 has been shown to promote the proliferation of neural stem cells in vitro and in vivo, suggesting that it may have a role in promoting neural stem cell expansion and differentiation.\n2. Neuronal differentiation: AZD8601 has been shown to promote the differentiation of neural progenitor cells into neurons and glial cells in vitro, and to enhance the expression of neuronal markers in vivo.\n3. Synaptic plasticity: AZD8601 has been shown to enhance long-term potentiation (LTP) and long-term depression (LTD), two forms of synaptic plasticity that are important for learning and memory.\n4. Neuroprotection: AZD8601 has been shown to protect against neurodegeneration in various animal models of neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.\n5. Behavioral effects: AZD8601 has been shown to improve cognitive function in animal models of neurological disorders, such as Alzheimer's disease and Huntington's disease.\n6. Cardiovascular effects: AZD8601 has been shown to reduce blood pressure and heart rate in animal models of hypertension, suggesting that it may have a role in treating cardiovascular disease.\n7. Metabolic effects: AZD8601 has been shown to improve glucose tolerance and insulin sensitivity in animal models of type 2 diabetes, suggesting that it may have a role in treating metabolic disorders.\n8. Anti-tumor effects: AZD8601 has been shown to have anti-tumor",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD8601 is a small molecule inhibitor of the protein kinase CAMKK1.\n2. AZD8601 has been shown to promote the proliferation of neural stem cells in vivo.\n3. AZD8601 has been shown to enhance the expression of neuronal markers in vivo.\n4. AZD8601 has been reported to protect against neurodegeneration in various animal models of neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.\n5. AZD8601 has been shown to improve cognitive function in animal models of neurological disorders, such as Alzheimer's disease and Huntington's disease.",
    "llama-2-7b-chat-hf_fact": [
      "AZD8601 is a small molecule inhibitor of the protein kinase CAMKK1.",
      "AZD8601 has been shown to promote the proliferation of neural stem cells in vivo.",
      "AZD8601 has been shown to enhance the expression of neuronal markers in vivo.",
      "AZD8601 has been reported to protect against neurodegeneration in various animal models of neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.",
      "AZD8601 has been shown to improve cognitive function in animal models of neurological disorders, such as Alzheimer's disease and Huntington's disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: AZD8601 is not a small molecule inhibitor of the protein kinase CAMKK1; it is an experimental mRNA-based therapy designed to increase the production of VEGF-A, a protein that can promote the regeneration of blood vessels.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe corrections and assessment are based on the fact that AZD8601 is an mRNA therapy as opposed to a small molecule inhibitor, which is mentioned in the first statement. The remaining statements cannot be confirmed without additional context or specific studies supporting those claims, as AZD8601 is associated with cardiovascular diseases in known research, not directly with neurodegeneration or neural stem cell proliferation.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-7b-chat-hf_response": "SAHFs (Spatially-Aggregated Hierarchical Framework Structures) are created through a process called self-assembly, which involves the spontaneous organization of building blocks into a hierarchical structure. The specific mechanism for creating SAHFs can vary depending on the particular system and conditions, but generally involves the following steps:\n1. Preparation of Building Blocks: The starting materials for SAHFs are typically small, simple molecules such as lipids, amphiphiles, or other organic compounds. These building blocks are designed to have specific properties that allow them to self-assemble into a hierarchical structure.\n2. Formation of Micelles: The building blocks are first assembled into micelles, which are small, spherical structures composed of multiple lipids. The lipids are arranged in a specific arrangement that allows them to form a stable, spherical shape.\n3. Formation of Corona Structures: The micelles then aggregate to form larger, more complex structures called corona structures. These structures are composed of multiple layers of micelles that are arranged in a hierarchical manner.\n4. Formation of SAHFs: The corona structures then aggregate to form SAHFs. This process involves the self-assembly of the corona structures into a hierarchical structure that is composed of multiple layers of corona structures.\n5. Maturation: The final step is the maturation of the SAHF, which involves the formation of a stable, three-dimensional structure that is stable over time. This process can involve the formation of additional layers or the reorganization of the existing layers to form a more stable structure.\nIn summary, SAHFs are created through the spontaneous self-assembly of building blocks into a hierarchical structure, involving the formation of micelles, corona structures, and finally SAHFs through maturation. The specific mechanism can vary depending on the particular system and conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. SAHFs (Spatially-Aggregated Hierarchical Framework Structures) are created through a process called self-assembly.\n2. The starting materials for creating SAHFs typically include small molecules like lipids, amphiphiles, or other organic compounds.\n3. In the creation of SAHFs, micelles are formed as an initial step in the self-assembly process.\n4. The building blocks assemble into corona structures, which are composed of multiple layers of micelles.\n5. The final structure of SAHFs involves maturation to form a stable, three-dimensional structure.",
    "llama-2-7b-chat-hf_fact": [
      "SAHFs (Spatially-Aggregated Hierarchical Framework Structures) are created through a process called self-assembly.",
      "The starting materials for creating SAHFs typically include small molecules like lipids, amphiphiles, or other organic compounds.",
      "In the creation of SAHFs, micelles are formed as an initial step in the self-assembly process.",
      "The building blocks assemble into corona structures, which are composed of multiple layers of micelles.",
      "The final structure of SAHFs involves maturation to form a stable, three-dimensional structure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: SAHFs (Spatially-Aggregated Hierarchical Framework Structures) can be created through a process called self-assembly, which refers to the spontaneous organization of components into structured arrangements without external direction.\n2. TRUE: The starting materials for creating hierarchical structures like SAHFs typically include small molecules, which can consist of lipids, amphiphiles, or other organic compounds that can assemble into larger structures.\n3. TRUE: In the self-assembly process to create structures like SAHFs, micelles can indeed form as an initial step. Micelles occur when amphiphilic molecules organize in an aqueous environment, with hydrophobic tails inward and hydrophilic heads outward.\n4. UNKNOWN: The statement about building blocks assembling into corona structures composed of multiple layers of micelles is specific and would depend on the particular self-assembly process and materials involved. Without specific context or domain knowledge, the accuracy of this statement cannot be confirmed.\n5. TRUE: A hallmark of self-assembly processes that result in SAHFs is the maturation of the structure into a stable, three-dimensional form, although the specifics can vary depending on the materials and conditions involved.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-7b-chat-hf_response": "SATB1 (Sex-determining region, Y-box 1) is a transcription factor that plays a crucial role in the regulation of gene expression during development and cell differentiation. SATB1 contains multiple domains, including an N-terminal PDZ (PSD-95/Discs-large/ZO-1) domain.\nThe PDZ domain of SATB1 is involved in the following functions:\n1. Protein-protein interactions: The PDZ domain of SATB1 can interact with other proteins, such as PDZ-binding proteins, which are involved in various cellular processes, including cell adhesion, migration, and signaling.\n2. Subcellular localization: The PDZ domain can affect the subcellular localization of SATB1, as it can mediate the association of SATB1 with membranous structures, such as the plasma membrane and the Golgi apparatus.\n3. Protein stability: The PDZ domain can also influence the stability of SATB1, as it can interact with proteins involved in protein degradation pathways.\n4. Nuclear localization: The PDZ domain can also contribute to the nuclear localization of SATB1, as it can interact with nuclear proteins that promote the transport of SATB1 into the nucleus.\nIn summary, the PDZ domain of SATB1 plays a multifaceted role in regulating the function of this transcription factor, including protein-protein interactions, subcellular localization, protein stability, and nuclear localization.",
    "llama-2-7b-chat-hf_fact_raw": "1. The PDZ domain of SATB1 (Sex-determining region, Y-box 1) can interact with other proteins involved in various cellular processes.\n2. The PDZ domain can affect the subcellular localization of SATB1, including its association with the plasma membrane and the Golgi apparatus.\n3. The PDZ domain of SATB1 can influence the stability of the protein by interacting with proteins involved in protein degradation pathways.\n4. The PDZ domain contributes to the nuclear localization of SATB1 by interacting with nuclear proteins that promote its transport into the nucleus.",
    "llama-2-7b-chat-hf_fact": [
      "The PDZ domain of SATB1 (Sex-determining region, Y-box 1) can interact with other proteins involved in various cellular processes.",
      "The PDZ domain can affect the subcellular localization of SATB1, including its association with the plasma membrane and the Golgi apparatus.",
      "The PDZ domain of SATB1 can influence the stability of the protein by interacting with proteins involved in protein degradation pathways.",
      "The PDZ domain contributes to the nuclear localization of SATB1 by interacting with nuclear proteins that promote its transport into the nucleus."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The PDZ domain is a common structural domain of signaling proteins, but SATB1 (Special AT-rich sequence-binding protein 1) does not contain a PDZ domain. SATB1 is known to interact with other proteins involved in various cellular processes, but its interaction domain is not a PDZ domain.\n2. FALSE [correction]: Since SATB1 does not have a PDZ domain, it does not affect its subcellular localization, including its association with the plasma membrane and the Golgi apparatus, through a PDZ domain.\n3. FALSE [correction]: The PDZ domain does not influence the stability of SATB1 for the same reason mentioned above – SATB1 does not contain a PDZ domain, and therefore its stability is not influenced by PDZ domain interactions.\n4. FALSE [correction]: The nuclear localization of SATB1 is not contributed to by a PDZ domain. SATB1 does have nuclear localization due to its role as a chromatin organizer and transcription factor, but this is not because of a PDZ domain interaction.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-7b-chat-hf_response": "BLISS (Blocking, Lysis, Isolation, and Size Selection) is a technique used to isolate and purify RNA from cells. The basis of the BLISS technique is to separate RNA from other cellular components, such as proteins and DNA, and to enrich for RNA molecules of a specific size.\nHere's a step-by-step explanation of the BLISS technique:\n1. Blocking: The cells are fixed with a fixative, such as paraformaldehyde, to prevent any further metabolic activity.\n2. Lysis: The fixed cells are then lysed in a buffer that is designed to break open the cell membrane and release the RNA.\n3. Isolation: The RNA is then isolated from the lysate using a series of washes and centrifugations. This step is designed to remove any contaminants, such as proteins and DNA, that may interfere with the RNA isolation process.\n4. Size Selection: The isolated RNA is then separated based on size using a process called gel electrophoresis. This step is designed to enrich for RNA molecules of a specific size, such as messenger RNA (mRNA) or small RNA molecules.\n5. Collection: The isolated RNA is then collected and purified for further analysis.\nThe BLISS technique is a simple and efficient way to isolate and purify RNA from cells, and it has been widely used in a variety of applications, including gene expression analysis, RNA sequencing, and RNA interference studies.",
    "llama-2-7b-chat-hf_fact_raw": "1. BLISS (Blocking, Lysis, Isolation, and Size Selection) is a technique used to isolate and purify RNA from cells.\n2. The BLISS technique includes a step where cells are fixed with a fixative, such as paraformaldehyde.\n3. In the BLISS technique, RNA is released by lysing the fixed cells in a buffer.\n4. RNA isolation in BLISS involves a series of washes and centrifugations to remove contaminants like proteins and DNA.\n5. The BLISS technique includes a size selection step where RNA is separated based on size using gel electrophoresis.",
    "llama-2-7b-chat-hf_fact": [
      "BLISS (Blocking, Lysis, Isolation, and Size Selection) is a technique used to isolate and purify RNA from cells.",
      "The BLISS technique includes a step where cells are fixed with a fixative, such as paraformaldehyde.",
      "In the BLISS technique, RNA is released by lysing the fixed cells in a buffer.",
      "RNA isolation in BLISS involves a series of washes and centrifugations to remove contaminants like proteins and DNA.",
      "The BLISS technique includes a size selection step where RNA is separated based on size using gel electrophoresis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: BLISS is not primarily known as a technique for RNA isolation. BLISS stands for \"Bisulfite Ligand Interactome Scanning of Cells,\" which is used for DNA methylation profiling and analysis. A common technique for RNA isolation is RNA-Seq.\n2. UNKNOWN: Without additional context on which BLISS technique is referred to (assuming it's the common DNA methylation profiling technique), it's impossible to verify if the cells are fixed with a fixative like paraformaldehyde, as this is not a standard step in DNA methylation profiling.\n3. UNKNOWN: Again, without further context, it's uncertain whether lysing the fixed cells in a buffer relates to the presumed methylation profiling technique. If referring to a RNA preparation technique, lysing cells to release RNA would be a correct statement.\n4. UNKNOWN: Whether the RNA isolation involves washes and centrifugations to remove contaminants depends on the specific technique being referenced. In general, RNA isolation does involve such steps to purify RNA, but it's unclear if this statement is true for the BLISS technique as described in the given context.\n5. FALSE [correction]: Assuming BLISS refers to DNA methylation profiling, size selection by gel electrophoresis would not be a step in this process. Size selection using gel electrophoresis is more commonly associated with RNA or DNA preparation steps in different sequencing techniques, such as preparation for RNA-Seq or DNA library preparation for sequencing.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-7b-chat-hf_response": "Sure, here are three known NK3R antagonists:\n1. GR 113802: GR 113802 is a potent and selective NK3R antagonist that has been shown to have potential in the treatment of various conditions, including cancer and metabolic disorders.\n2. MK-0359: MK-0359 is a potent and selective NK3R antagonist that has been shown to have potential in the treatment of gastrointestinal disorders, such as irritable bowel syndrome (IBS).\n3. RX-0201: RX-0201 is a potent and selective NK3R antagonist that has been shown to have potential in the treatment of various conditions, including cancer and metabolic disorders.\nIt's worth noting that these are just a few examples of NK3R antagonists, and there may be other compounds that have been identified as potential NK3R antagonists as well.",
    "llama-2-7b-chat-hf_fact_raw": "1. GR 113802 is a NK3R antagonist.\n2. MK-0359 is a NK3R antagonist.\n3. RX-0201 is a NK3R antagonist.",
    "llama-2-7b-chat-hf_fact": [
      "GR 113802 is a NK3R antagonist.",
      "MK-0359 is a NK3R antagonist.",
      "RX-0201 is a NK3R antagonist."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: RX-0201 is an Akt antisense oligonucleotide, not an NK3R antagonist.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-7b-chat-hf_response": "The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is called BMS-911597. This drug was developed by Bristol-Myers Squibb and was studied in a phase 1 clinical trial in 2011. The trial was designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of BMS-911597 in healthy subjects, and it was found to be well-tolerated and showed potential for effective ghrelin receptor antagonism.",
    "llama-2-7b-chat-hf_fact_raw": "1. BMS-911597 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.\n2. BMS-911597 was developed by Bristol-Myers Squibb.\n3. A phase 1 clinical trial for BMS-911597 took place in 2011.\n4. The phase 1 clinical trial evaluated the safety, pharmacokinetics, and pharmacodynamics of BMS-911597 in healthy subjects.\n5. BMS-911597 was found to be well-tolerated in the phase 1 clinical trial.",
    "llama-2-7b-chat-hf_fact": [
      "BMS-911597 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
      "BMS-911597 was developed by Bristol-Myers Squibb.",
      "A phase 1 clinical trial for BMS-911597 took place in 2011.",
      "The phase 1 clinical trial evaluated the safety, pharmacokinetics, and pharmacodynamics of BMS-911597 in healthy subjects.",
      "BMS-911597 was found to be well-tolerated in the phase 1 clinical trial."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the specific passage containing the facts about BMS-911597, its development, clinical trials, and findings, I cannot verify the accuracy of these statements. Additionally, the statements contain specific and technical information that typically requires access to a database or published studies, which is beyond my present capabilities.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-7b-chat-hf_response": "Vaxchora, also known as Shanchol, is an oral cholera vaccine that has been shown to be effective in preventing moderate to severe cholera in various clinical trials. Here are some of the key findings on the protective efficacy of Vaxchora against moderate to severe cholera:\n1. Phase 3 clinical trial (2016): In this large, multinational trial, Vaxchora was evaluated in 4,000 adults aged 18-64 years in Bangladesh, India, and Mozambique. The vaccine provided 77% protection against moderate to severe cholera during the 12-month follow-up period.\n2. Phase 2b clinical trial (2014): In this trial, 1,200 adults in Bangladesh received either Vaxchora or a placebo. The vaccine provided 57% protection against moderate to severe cholera during the 6-month follow-up period.\n3. Phase 2a clinical trial (2012): In this smaller trial, 200 adults in Bangladesh received Vaxchora or a placebo. The vaccine provided 37% protection against moderate to severe cholera during the 3-month follow-up period.\n4. Post-hoc analysis (2018): A post-hoc analysis of the phase 3 trial data found that Vaxchora provided 84% protection against severe cholera and 62% protection against moderate cholera in participants who had received the vaccine at least 6 months prior to the onset of symptoms.\nOverall, the available data suggest that Vaxchora is effective in preventing moderate to severe cholera in adults, particularly in areas where cholera is common and outbreaks are frequent. However, it's important to note that the vaccine is not 100% effective, and individuals may still contract cholera despite being vaccinated. Therefore, it's important to continue practicing good hygiene and sanitation practices, such as proper handwashing and food preparation, to reduce the risk of cholera infection.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora provided 77% protection against moderate to severe cholera during the 12-month follow-up period in a Phase 3 clinical trial involving 4,000 adults aged 18-64 years.\n2. In a Phase 2b clinical trial with 1,200 adults in Bangladesh, Vaxchora provided 57% protection against moderate to severe cholera during the 6-month follow-up period.\n3. A Phase 2a clinical trial showed that Vaxchora provided 37% protection against moderate to severe cholera over a 3-month follow-up period among 200 adults in Bangladesh.\n4. A post-hoc analysis of the phase 3 trial data indicated that Vaxchora provided 84% protection against severe cholera and 62% protection against moderate cholera when administered at least 6 months prior to symptom onset.\n5. The available data suggest that Vaxchora is effective in preventing moderate to severe cholera in adults, especially in regions where cholera is prevalent.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora provided 77% protection against moderate to severe cholera during the 12-month follow-up period in a Phase 3 clinical trial involving 4,000 adults aged 18-64 years.",
      "In a Phase 2b clinical trial with 1,200 adults in Bangladesh, Vaxchora provided 57% protection against moderate to severe cholera during the 6-month follow-up period.",
      "A Phase 2a clinical trial showed that Vaxchora provided 37% protection against moderate to severe cholera over a 3-month follow-up period among 200 adults in Bangladesh.",
      "A post-hoc analysis of the phase 3 trial data indicated that Vaxchora provided 84% protection against severe cholera and 62% protection against moderate cholera when administered at least 6 months prior to symptom onset.",
      "The available data suggest that Vaxchora is effective in preventing moderate to severe cholera in adults, especially in regions where cholera is prevalent."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without access to specific details or results of the Phase 3 clinical trial for Vaxchora, the truth of this statement cannot be ascertained.\n2. UNKNOWN: Similarly, without specific data or results from the Phase 2b clinical trial for Vaxchora, it's not possible to confirm or deny the accuracy of this statement.\n3. UNKNOWN: The details of the Phase 2a clinical trial results are not provided, which makes the truth of this statement indeterminable.\n4. UNKNOWN: The truth of this post-hoc analysis cannot be confirmed or refuted without access to the detailed data and analysis from the Phase 3 trial for Vaxchora.\n5. UNKNOWN: This is a summary statement that draws a conclusion from the supposed data from the trials mentioned in the previous statements. Since the validity of those statements is unknown, the overall effectiveness conclusion cannot be confirmed as true or false without additional evidence.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-7b-chat-hf_response": "The first cholera vaccine approved in the US was the oral cholera vaccine, also known as the Shanchol vaccine, which was approved by the US Food and Drug Administration (FDA) in 2016. This vaccine is developed by the biotechnology company, Shantha Biotechnics, and is based on a killed, inactivated whole-cell oral cholera vaccine.\nPrior to the approval of Shanchol, the only other cholera vaccine approved in the US was the injectable cholera vaccine, known as the Dukoral vaccine, which was approved in 1991. The Dukoral vaccine is made by the French company, Sanofi Pasteur, and is a live, attenuated (weakened) vaccine that is given by injection.\nIt's worth noting that both of these vaccines are only approved for use in adults aged 18 years and older, and are not recommended for use in children or pregnant women. Additionally, the Centers for Disease Control and Prevention (CDC) recommend that travelers to areas where cholera is common should consider getting vaccinated, regardless of the vaccine they choose.",
    "llama-2-7b-chat-hf_fact_raw": "1. The first cholera vaccine approved in the US was the oral Shanchol vaccine.\n2. The Shanchol vaccine was approved by the US Food and Drug Administration in 2016.\n3. Shantha Biotechnics developed the Shanchol vaccine.\n4. The only other cholera vaccine approved in the US before Shanchol was the Dukoral vaccine, approved in 1991.\n5. The Dukoral vaccine is made by Sanofi Pasteur and is a live, attenuated vaccine given by injection.",
    "llama-2-7b-chat-hf_fact": [
      "The first cholera vaccine approved in the US was the oral Shanchol vaccine.",
      "The Shanchol vaccine was approved by the US Food and Drug Administration in 2016.",
      "Shantha Biotechnics developed the Shanchol vaccine.",
      "The only other cholera vaccine approved in the US before Shanchol was the Dukoral vaccine, approved in 1991.",
      "The Dukoral vaccine is made by Sanofi Pasteur and is a live, attenuated vaccine given by injection."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. FALSE [correction]: There was no cholera vaccine approved in the US before Shanchol. Dukoral is not approved for use in the United States.\n5. FALSE [correction]: The Dukoral vaccine is made by Valneva (previously it was Crucell, and then Johnson & Johnson), and it is an inactivated vaccine given orally, not a live, attenuated vaccine given by injection.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-7b-chat-hf_response": "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is a mutation in the X-linked genes encoding the immunoglobulin heavy chain (IGH) or the T-cell receptor alpha chain (TCRα). These genes are located on the X chromosome and are responsible for the production of immunoglobulins and T cells, which are important components of the adaptive immune system.\nThe most common mutations associated with CVID are found in the IGH gene, particularly in the CDR3 region, which is responsible for the antigen-binding site of the immunoglobulin. These mutations can lead to a decrease in the affinity of the immunoglobulins for their antigens, resulting in a weakened immune response.\nAccording to the European CVID Consortium, the frequency of X-linked IGH mutations in CVID patients of European ancestry is estimated to be around 60-70%. The most common mutations include:\n1. IGHV3-23: This is the most common mutation in CVID patients of European ancestry, occurring in approximately 30% of cases.\n2. IGHV1-69: This mutation is found in approximately 20% of CVID patients of European ancestry.\n3. IGHV3-21: This mutation is less common, occurring in approximately 10% of CVID patients of European ancestry.\nIt's important to note that not all CVID patients have a identifiable mutation in the X-linked genes, and some may have mutations in other genes involved in the immune system. Additionally, some patients may have a combination of genetic and environmental factors that contribute to the development of CVID.",
    "llama-2-7b-chat-hf_fact_raw": "1. A mutation in the X-linked genes encoding the immunoglobulin heavy chain (IGH) or the T-cell receptor alpha chain (TCRα) is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans.\n2. The mutations associated with CVID are most commonly found in the IGH gene's CDR3 region, which impacts the antigen-binding site of the immunoglobulin.\n3. According to the European CVID Consortium, the frequency of X-linked IGH mutations in European CVID patients is estimated to be around 60-70%.\n4. The IGHV3-23 mutation occurs in approximately 30% of CVID patients of European ancestry.\n5. The IGHV1-69 mutation is found in approximately 20% of CVID patients of European ancestry.",
    "llama-2-7b-chat-hf_fact": [
      "A mutation in the X-linked genes encoding the immunoglobulin heavy chain (IGH) or the T-cell receptor alpha chain (TCRα) is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans.",
      "The mutations associated with CVID are most commonly found in the IGH gene's CDR3 region, which impacts the antigen-binding site of the immunoglobulin.",
      "According to the European CVID Consortium, the frequency of X-linked IGH mutations in European CVID patients is estimated to be around 60-70%.",
      "The IGHV3-23 mutation occurs in approximately 30% of CVID patients of European ancestry.",
      "The IGHV1-69 mutation is found in approximately 20% of CVID patients of European ancestry."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations in the genes ICOS, CD19, CD20, CD21, CD81, CTLA4, LRBA, and PIK3CD, among others, have been associated with CVID, but a mutation in the X-linked genes encoding the immunoglobulin heavy chain (IGH) or the T-cell receptor alpha chain (TCRα) is not described as the most common monogenic causes of CVID in Europeans.\n2. UNKNOWN: Without specific literature reference, the claim that mutations associated with CVID are most commonly found in the IGH gene's CDR3 region cannot be confirmed. The CDR3 region is indeed important for antigen binding, but stating it is the most commonly mutated in the context of CVID is not a widely established fact and may require specific research findings to substantiate.\n3. FALSE [correction]: There is no established estimation that X-linked IGH mutations occur in 60-70% of European CVID patients. The genetic causes of CVID are diverse and complex, and no single gene mutation has been identified with such a high frequency in the patient population.\n4. FALSE [correction]: The IGHV3-23 mutation's prevalence in CVID patients of European ancestry is not established as being approximately 30%. The specific frequency of this mutation in CVID patients would require citation from up-to-date research as it is not a widely recognized statistic.\n5. FALSE [correction]: The IGHV1-69 mutation's prevalence in CVID patients of European ancestry is not established as being approximately 20%. As with the IGHV3-23 mutation, the frequency of this mutation in the CVID patient population would need to be supported by current research data.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-7b-chat-hf_response": "The IFIT1 gene has been found to play a role in the development and progression of Systemic Lupus Erythematosus (SLE), a complex and multifactorial autoimmune disease. Here are some of the key findings and roles of the IFIT1 gene in SLE:\n1. IFIT1 is a gene that encodes for a protein called interferon-induced protein with tetratricopeptide repeats 1 (IFIT1). This protein is involved in the regulation of mRNA splicing and transport.\n2. Studies have shown that IFIT1 is differentially expressed in SLE patients compared to healthy controls, with higher levels of IFIT1 mRNA expression observed in SLE patients.\n3. IFIT1 has been shown to play a role in the regulation of autophagy, a process by which cells degrade and recycle damaged or dysfunctional cellular components. Autophagy is thought to be involved in the pathogenesis of SLE, and alterations in autophagy have been observed in SLE patients.\n4. IFIT1 has also been shown to regulate the expression of pro-inflammatory genes, such as interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α), which are overproduced in SLE patients.\n5. IFIT1 has been shown to interact with other genes involved in the regulation of SLE, such as the STAT3 gene, which is also involved in the regulation of autophagy and the expression of pro-inflammatory genes.\n6. IFIT1 has been found to be a negative regulator of the NF-κB pathway, which is activated in SLE and leads to the overproduction of pro-inflammatory genes.\n7. IFIT1 has been shown to be involved in the regulation of apoptosis, or programmed cell death, which is impaired in SLE patients.\n8. IFIT1 has been found to be a predictive marker of SLE disease activity, with higher levels of IFIT1 mRNA expression correlating with more active disease.\n9. IFIT1 has been shown to be a potential therapeutic target for the treatment of SLE",
    "llama-2-7b-chat-hf_fact_raw": "1. The IFIT1 gene encodes for a protein called interferon-induced protein with tetratricopeptide repeats 1 (IFIT1), involved in the regulation of mRNA splicing and transport.\n2. IFIT1 is differentially expressed in SLE patients compared to healthy controls, with higher levels of IFIT1 mRNA expression observed in SLE patients.\n3. IFIT1 plays a role in the regulation of autophagy, which is involved in the pathogenesis of SLE.\n4. IFIT1 regulates the expression of pro-inflammatory genes, such as interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α), which are overproduced in SLE patients.\n5. IFIT1 has been found to be a negative regulator of the NF-κB pathway, which leads to the overproduction of pro-inflammatory genes in SLE.",
    "llama-2-7b-chat-hf_fact": [
      "The IFIT1 gene encodes for a protein called interferon-induced protein with tetratricopeptide repeats 1 (IFIT1), involved in the regulation of mRNA splicing and transport.",
      "IFIT1 is differentially expressed in SLE patients compared to healthy controls, with higher levels of IFIT1 mRNA expression observed in SLE patients.",
      "IFIT1 plays a role in the regulation of autophagy, which is involved in the pathogenesis of SLE.",
      "IFIT1 regulates the expression of pro-inflammatory genes, such as interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α), which are overproduced in SLE patients.",
      "IFIT1 has been found to be a negative regulator of the NF-κB pathway, which leads to the overproduction of pro-inflammatory genes in SLE."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The IFIT1 gene encodes for a protein called interferon-induced protein with tetratricopeptide repeats 1 (IFIT1), but it is involved in antiviral responses, typically by inhibiting viral replication, not specifically in the regulation of mRNA splicing and transport.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nFor statements 1, 3, 4, and 5, the roles of IFIT1 can vary and depend on the context of the passage where the statements were extracted since the functions and regulatory impacts of IFIT1 in disease are complex and may not be fully characterized. Statement 1 needed correction regarding the primary known role of IFIT1. Statements 3, 4, and 5 require specific supporting information from the literature, which was not provided, hence the response of \"UNKNOWN.\"",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-7b-chat-hf_response": "The Liverpool Elbow Score (LES) is a patient-reported outcome measure used to assess the severity of elbow symptoms and disability in patients with elbow conditions, such as tennis elbow (lateral epicondylitis) and golfer's elbow (medial epicondylitis). The score is used to evaluate the effectiveness of treatments for these conditions and to monitor progress over time.\nThe LES consists of 11 items that assess the following domains:\n1. Pain\n2. Stiffness\n3. Functional limitation\n4. Disability\n5. Grip strength\n6. Pain on extension\n7. Pain on flexion\n8. Pain on rotation\n9. Pain on pronation\n10. Pain on supination\n11. Global assessment\nEach item is rated on a 5-point Likert scale, with higher scores indicating greater severity of symptoms and disability. The total score can range from 0 to 55, with higher scores indicating greater impairment.\nThe LES has been shown to be reliable and valid in measuring elbow symptoms and disability in various populations, including athletes and non-athletes. It has been used in clinical trials to evaluate the effectiveness of different treatments for elbow conditions, such as physical therapy, medication, and surgery.\nIn summary, the Liverpool Elbow Score is a patient-reported outcome measure used to assess the severity of elbow symptoms and disability in patients with elbow conditions. It is a useful tool for evaluating the effectiveness of treatments and monitoring progress over time.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Liverpool Elbow Score (LES) is used to assess the severity of elbow symptoms and disability in patients with elbow conditions.\n2. LES is a patient-reported outcome measure with 11 items that cover various domains including pain, stiffness, and functional limitation.\n3. Each LES item is rated on a 5-point Likert scale, and the total score can range from 0 to 55.\n4. Higher LES scores indicate greater severity of symptoms and disability.\n5. The Liverpool Elbow Score is used to evaluate the effectiveness of treatments and to monitor progress over time for elbow conditions.",
    "llama-2-7b-chat-hf_fact": [
      "The Liverpool Elbow Score (LES) is used to assess the severity of elbow symptoms and disability in patients with elbow conditions.",
      "LES is a patient-reported outcome measure with 11 items that cover various domains including pain, stiffness, and functional limitation.",
      "Each LES item is rated on a 5-point Likert scale, and the total score can range from 0 to 55.",
      "Higher LES scores indicate greater severity of symptoms and disability.",
      "The Liverpool Elbow Score is used to evaluate the effectiveness of treatments and to monitor progress over time for elbow conditions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-7b-chat-hf_response": "The 100,000 Genomes Project is a large-scale genomics initiative launched in 2015 by the National Health Service (NHS) in the UK with the goal of analyzing the genomes of 100,000 individuals, including those with rare and aggressive cancers such as sarcoma. The project aims to identify genetic variations associated with these cancers and develop new diagnostic and treatment approaches. Here are some efforts on sarcoma from the 100,000 Genomes Project:\n1. Whole-genome sequencing: The project has performed whole-genome sequencing on a large number of sarcoma tumors to identify genetic mutations and variations that may be driving the disease.\n2. Identification of novel mutations: The project has identified novel mutations in sarcoma tumors that were not previously known to be associated with the disease. These findings have helped researchers to better understand the genetic landscape of sarcoma and to develop new diagnostic and treatment strategies.\n3. Development of targeted therapies: The project has identified potential targets for targeted therapies in sarcoma, including mutations in genes such as KRAS, PI3K, and ATR. These findings have the potential to lead to the development of new drugs and treatments for sarcoma.\n4. Improved diagnosis: The project has helped to improve the diagnosis of sarcoma by identifying genetic markers that can be used to distinguish sarcoma from other types of cancer. This will help to ensure that patients receive the most appropriate treatment for their disease.\n5. Collaboration with clinical teams: The project has collaborated with clinical teams to ensure that the genetic findings are translated into clinical practice. This has involved working with clinicians to develop new diagnostic and treatment strategies based on the genetic findings.\n6. Development of new treatments: The project has the potential to lead to the development of new treatments for sarcoma, including targeted therapies and immunotherapies. These treatments will be tailored to the specific genetic mutations identified in each patient's tumor.\n7. Improved understanding of disease mechanisms: The project has provided a deeper understanding of the genetic mechan",
    "llama-2-7b-chat-hf_fact_raw": "1. The 100,000 Genomes Project was launched in 2015 by the National Health Service (NHS) in the UK.\n2. The project aims to analyze the genomes of 100,000 individuals, including those with sarcoma.\n3. Whole-genome sequencing of sarcoma tumors was performed to identify genetic mutations and variations.\n4. The project has identified novel mutations in sarcoma tumors.\n5. Genetic markers have been identified to improve the diagnosis of sarcoma and distinguish it from other types of cancer.",
    "llama-2-7b-chat-hf_fact": [
      "The 100,000 Genomes Project was launched in 2015 by the National Health Service (NHS) in the UK.",
      "The project aims to analyze the genomes of 100,000 individuals, including those with sarcoma.",
      "Whole-genome sequencing of sarcoma tumors was performed to identify genetic mutations and variations.",
      "The project has identified novel mutations in sarcoma tumors.",
      "Genetic markers have been identified to improve the diagnosis of sarcoma and distinguish it from other types of cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nWhile the first three statements are accurate, the specifics of novel mutations identified in sarcoma tumors (statement 4) and the discovery of genetic markers to improve the diagnosis of sarcoma (statement 5) would require access to the latest results and data from the 100,000 Genomes Project, which is not provided in the context. As a result, the accuracy of statements 4 and 5 cannot be confirmed without additional information.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-7b-chat-hf_response": "Yes, protein ALEX1 (Armadillo-like Expressed in Xenopus 1) contains multiple armadillo repeats.\nArmadillo repeats are a type of protein structure that are found in many proteins involved in chromatin remodeling and transcriptional regulation. These repeats are characterized by a conserved sequence motif that is composed of a stretch of about 30-40 amino acids that are rich in proline and glutamine residues. The repeats are arranged in a tandem array, with the amino acid residues in each repeat folding into a beta-sheet structure.\nALEX1 is a protein that was first identified in Xenopus laevis (the African clawed frog) and is thought to play a role in the regulation of gene expression, particularly in the context of cell fate determination and differentiation. ALEX1 contains multiple armadillo repeats, with a total of 10 repeats in the full-length protein. These repeats are thought to be involved in the protein's ability to recognize and bind to specific DNA sequences, and to modulate the activity of transcription factors and other chromatin-associated proteins.\nOverall, the presence of armadillo repeats in ALEX1 is consistent with its role in chromatin remodeling and transcriptional regulation, and suggests that the protein may play a key role in the regulation of gene expression in a wide range of cellular contexts.",
    "llama-2-7b-chat-hf_fact_raw": "1. Protein ALEX1 contains multiple armadillo repeats.\n2. Armadillo repeats are characterized by a conserved sequence motif with about 30-40 amino acids that are rich in proline and glutamine.\n3. ALEX1 was first identified in Xenopus laevis (the African clawed frog).\n4. ALEX1 contains a total of 10 armadillo repeats in the full-length protein.\n5. The armadillo repeats in ALEX1 are thought to play a role in DNA binding and modulation of transcription factors and chromatin-associated proteins.",
    "llama-2-7b-chat-hf_fact": [
      "Protein ALEX1 contains multiple armadillo repeats.",
      "Armadillo repeats are characterized by a conserved sequence motif with about 30-40 amino acids that are rich in proline and glutamine.",
      "ALEX1 was first identified in Xenopus laevis (the African clawed frog).",
      "ALEX1 contains a total of 10 armadillo repeats in the full-length protein.",
      "The armadillo repeats in ALEX1 are thought to play a role in DNA binding and modulation of transcription factors and chromatin-associated proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Armadillo repeats are characterized by a sequence motif that is approximately 42 amino acids in length and typically not rich in proline and glutamine.\n3. TRUE\n4. FALSE [correction]: Without specific information on the number of armadillo repeats in ALEX1, it's impossible to confirm the exact number of repeats with certainty. This statement would require specific domain knowledge or a sequence analysis of ALEX1 to verify.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-7b-chat-hf_response": "There are several enzymes that remove histone modifications, including:\n1. Histone demethylases: These enzymes remove methyl groups from histone proteins, which can alter chromatin structure and gene expression. Examples of histone demethylases include KDM4B, KDM5, and KDM1A.\n2. Histone acetyltransferases (HATs): These enzymes add acetyl groups to histone proteins, which can also alter chromatin structure and gene expression. Examples of HATs include p300 and CBP (CREB-binding protein).\n3. Histone deacetylases (HDACs): These enzymes remove acetyl groups from histone proteins, which can compact chromatin and repress gene expression. Examples of HDACs include HDAC1, HDAC2, and HDAC3.\n4. Histone ubiquitin ligases: These enzymes remove histone modifications by ubiquitinating them, which can target them for degradation. Examples of histone ubiquitin ligases include RNF2 and RNF4.\n5. Histone chaperones: These enzymes help to fold and stabilize histone proteins, which can affect their interactions with DNA and other proteins. Examples of histone chaperones include HSP90 and HSP70.\n6. Histone-specific proteases: These enzymes can remove histone proteins from chromatin, which can also affect chromatin structure and gene expression. Examples of histone-specific proteases include histone-specific protease 1 (HSPP1) and histone-specific protease 2 (HSPP2).\n7. Chromodomain-containing proteins: These enzymes remove histone modifications by recognizing and binding to specific histone residues, and then recruiting other proteins that can remove the modifications. Examples of chromodomain-containing proteins include CHD1 and CHD4.\n8. Hox gene complexes: These enzymes remove histone modifications by recognizing and binding to specific DNA sequences, and then recruiting other proteins that can remove the modifications. Examples of Hox gene complexes include Hoxa1 and H",
    "llama-2-7b-chat-hf_fact_raw": "1. Histone demethylases such as KDM4B, KDM5, and KDM1A remove methyl groups from histone proteins.\n2. Histone acetyltransferases (HATs) like p300 and CBP add acetyl groups to histone proteins.\n3. Histone deacetylases (HDACs) including HDAC1, HDAC2, and HDAC3 remove acetyl groups from histones.\n4. Histone ubiquitin ligases such as RNF2 and RNF4 remove histone modifications by ubiquitinating them.\n5. Histone-specific proteases like histone-specific protease 1 (HSPP1) and histone-specific protease 2 (HSPP2) can remove histone proteins from chromatin.",
    "llama-2-7b-chat-hf_fact": [
      "Histone demethylases such as KDM4B, KDM5, and KDM1A remove methyl groups from histone proteins.",
      "Histone acetyltransferases (HATs) like p300 and CBP add acetyl groups to histone proteins.",
      "Histone deacetylases (HDACs) including HDAC1, HDAC2, and HDAC3 remove acetyl groups from histones.",
      "Histone ubiquitin ligases such as RNF2 and RNF4 remove histone modifications by ubiquitinating them.",
      "Histone-specific proteases like histone-specific protease 1 (HSPP1) and histone-specific protease 2 (HSPP2) can remove histone proteins from chromatin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Histone ubiquitin ligases, such as RNF2 (also known as RING2 or RING1B) and RNF4, do not remove histone modifications; they add ubiquitin tags to histones, which can signal for different processes including histone removal or DNA repair.\n5. FALSE [correction]: There are no known enzymes that are specifically called \"histone-specific protease 1 (HSPP1)\" and \"histone-specific protease 2 (HSPP2)\" that remove histone proteins from chromatin. However, the general idea that there are proteases involved in histone processing and removal from chromatin is true, though they are not typically referred to with the provided names.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-7b-chat-hf_response": "There is some evidence to suggest that head CT scans may increase the risk of developing a brain tumor, although the evidence is not yet conclusive.\n1. Radiation exposure: CT scans involve exposure to ionizing radiation, which can increase the risk of cancer, including brain tumors. The more frequent the CT scans, the higher the radiation exposure, and the potential risk of cancer.\n2. Genetic mutations: Some studies have suggested that head CT scans may increase the risk of genetic mutations in the brain, which can increase the risk of developing a brain tumor.\n3. Inflammation: Head CT scans can detect inflammation in the brain, which can increase the risk of developing a brain tumor.\n4. Brain tumor markers: Some studies have suggested that head CT scans may increase the levels of certain markers in the brain that are associated with an increased risk of brain tumors.\nIt is important to note that the evidence for an increased risk of brain tumors associated with head CT scans is still emerging, and more research is needed to fully understand the potential risks. However, it is clear that frequent CT scans can increase radiation exposure, which is a known risk factor for cancer.\nTo minimize the potential risks, it is important to use CT scans judiciously and only when necessary. If you have concerns about the potential risks of head CT scans, you should discuss them with your healthcare provider. They can help you weigh the potential benefits and risks of the scan and make an informed decision.",
    "llama-2-7b-chat-hf_fact_raw": "1. CT scans involve exposure to ionizing radiation, which can increase the risk of cancer, including brain tumors.\n2. The more frequent the CT scans, the higher the radiation exposure, and the potential risk of cancer.\n3. Head CT scans may increase the risk of genetic mutations in the brain, which could lead to brain tumors, according to some studies.\n4. Inflammation in the brain can be detected by head CT scans and this condition can potentially increase the risk of developing a brain tumor.\n5. Certain studies suggest head CT scans may increase the levels of brain tumor markers.",
    "llama-2-7b-chat-hf_fact": [
      "CT scans involve exposure to ionizing radiation, which can increase the risk of cancer, including brain tumors.",
      "The more frequent the CT scans, the higher the radiation exposure, and the potential risk of cancer.",
      "Head CT scans may increase the risk of genetic mutations in the brain, which could lead to brain tumors, according to some studies.",
      "Inflammation in the brain can be detected by head CT scans and this condition can potentially increase the risk of developing a brain tumor.",
      "Certain studies suggest head CT scans may increase the levels of brain tumor markers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Head CT scans do not directly increase the risk of genetic mutations; radiation from CT can increase the risk of mutations in general, but the statement as it stands is too specific.\n4. UNKNOWN: While head CT scans can detect abnormalities in the brain, including inflammation, the direct correlation to inflammation increasing the risk of a brain tumor may need more specific context to verify whether this statement is true.\n5. UNKNOWN: The statement is vague and without specific references to studies or findings regarding brain tumor markers and the impact of CT scans on their levels, it's difficult to assess the truthfulness.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-7b-chat-hf_response": "Otx2 is a transcription factor that is associated with neural pluripotency. Neural pluripotency refers to the ability of cells to differentiate into various cell types of the nervous system, including neurons and glial cells. Otx2 is specifically expressed in the neural progenitor cells and is important for their self-renewal and maintenance of their pluripotent state.\nIn addition, Otx2 has been shown to be involved in the regulation of cell fate decisions in the developing nervous system, particularly in the context of neural stem cell maintenance and differentiation. Therefore, Otx2 can be considered as a marker of neural pluripotency.",
    "llama-2-7b-chat-hf_fact_raw": "1. Otx2 is associated with neural pluripotency.\n2. Neural pluripotency is the ability of cells to differentiate into various cell types of the nervous system.\n3. Otx2 is expressed in neural progenitor cells.\n4. Otx2 contributes to the self-renewal and maintenance of the pluripotent state of neural progenitor cells.\n5. Otx2 is involved in the regulation of cell fate decisions in the developing nervous system.",
    "llama-2-7b-chat-hf_fact": [
      "Otx2 is associated with neural pluripotency.",
      "Neural pluripotency is the ability of cells to differentiate into various cell types of the nervous system.",
      "Otx2 is expressed in neural progenitor cells.",
      "Otx2 contributes to the self-renewal and maintenance of the pluripotent state of neural progenitor cells.",
      "Otx2 is involved in the regulation of cell fate decisions in the developing nervous system."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nOtx2, which is a transcription factor, is indeed associated with pluripotency, particularly in the context of neural cells. It is expressed in neural progenitor cells and has a role in maintaining their pluripotent state while also influencing cell fate decisions during the development of the nervous system.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-7b-chat-hf_response": "The murine beta globin locus region has several DNase I hypersensitive sites (DHSs), which are regions of the genome that are more susceptible to cleavage by the enzyme DNase I. The exact number of DHSs at the murine beta globin locus region can vary depending on the specific strain of mouse and the method used to identify them, but here are some general estimates:\n* In the mouse strain C57BL/6, there are approximately 10-15 DHSs located throughout the beta globin locus region (Liu et al., 2010).\n* In the mouse strain 129SvJ, there are approximately 20-25 DHSs located in the beta globin locus region (Chen et al., 2009).\n* In the mouse strain B6.CBA-Tg(H1-GFP)1Marr/J, which expresses GFP in the beta globin locus region, there are approximately 30-40 DHSs (Wang et al., 2010).\nIt's worth noting that the number of DHSs at the beta globin locus region can vary depending on the specific stage of development and the presence of any epigenetic modifications. Additionally, some DHSs may overlap with other regulatory elements or gene promoters in the region, making it difficult to determine their exact number and function.",
    "llama-2-7b-chat-hf_fact_raw": "1. DNase I hypersensitive sites (DHSs) are regions of the genome that are more susceptible to cleavage by the enzyme DNase I.\n2. The mouse strain C57BL/6 is reported to have approximately 10-15 DHSs located throughout the beta globin locus region.\n3. The mouse strain 129SvJ is reported to have approximately 20-25 DHSs located in the beta globin locus region.\n4. The mouse strain B6.CBA-Tg(H1-GFP)1Marr/J with GFP expression in the beta globin locus region is reported to have approximately 30-40 DHSs.",
    "llama-2-7b-chat-hf_fact": [
      "DNase I hypersensitive sites (DHSs) are regions of the genome that are more susceptible to cleavage by the enzyme DNase I.",
      "The mouse strain C57BL/6 is reported to have approximately 10-15 DHSs located throughout the beta globin locus region.",
      "The mouse strain 129SvJ is reported to have approximately 20-25 DHSs located in the beta globin locus region.",
      "The mouse strain B6.CBA-Tg(H1-GFP)1Marr/J with GFP expression in the beta globin locus region is reported to have approximately 30-40 DHSs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The actual number of DNase I hypersensitive sites (DHSs) in the mouse strain C57BL/6 at the beta globin locus region is not specified in general knowledge, and the exact number may vary based on experimental conditions and detection methods. Therefore, a definitive number cannot be given without specific reference to experimental data.\n3. FALSE [correction]: Similar to statement 2, the actual number of DNase I hypersensitive sites (DHSs) in the mouse strain 129SvJ at the beta globin locus region is not specified in general knowledge, and the exact number may vary. Specific experimental evidence is needed to affirm this statement.\n4. UNKNOWN: Without specific experimental results, the exact number of DHSs for the mouse strain B6.CBA-Tg(H1-GFP)1Marr/J at the beta globin locus region is unknown.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-7b-chat-hf_response": "There are several European influenza vaccines available in the market. Here are some of them:\n1. Fluarix Tetra (GlaxoSmithKline): This is a quadrivalent vaccine that protects against four strains of the influenza virus (two A strains and two B strains).\n2. Flulaval (GlaxoSmithKline): This is a trivalent vaccine that protects against three strains of the influenza virus (two A strains and one B strain).\n3. Afluria (Sanofi): This is a quadrivalent vaccine that protects against four strains of the influenza virus (two A strains and two B strains).\n4. Fluvirin (Novartis): This is a trivalent vaccine that protects against three strains of the influenza virus (two A strains and one B strain).\n5. Fluad (Baxalta): This is a quadrivalent vaccine that protects against four strains of the influenza virus (two A strains and two B strains).\n6. Vaxigrip (Sanofi): This is a trivalent vaccine that protects against three strains of the influenza virus (two A strains and one B strain).\n7. Pandemrix (GlaxoSmithKline): This is a quadrivalent vaccine that protects against four strains of the influenza virus (two A strains and two B strains).\n8. Focetria (Novartis): This is a trivalent vaccine that protects against three strains of the influenza virus (two A strains and one B strain).\n9. Influvac (Baxalta): This is a quadrivalent vaccine that protects against four strains of the influenza virus (two A strains and two B strains).\n10. Celvapan (GlaxoSmithKline): This is a trivalent vaccine that protects against three strains of the influenza virus (two A strains and one B strain).\nPlease note that this list may not be exhaustive and is subject to change based on the availability of vaccines in different regions and countries. It's always best to consult",
    "llama-2-7b-chat-hf_fact_raw": "1. Fluarix Tetra is a quadrivalent vaccine produced by GlaxoSmithKline.\n2. Flulaval is a trivalent vaccine produced by GlaxoSmithKline.\n3. Afluria is a quadrivalent vaccine produced by Sanofi.\n4. Fluvirin is a trivalent vaccine produced by Novartis.\n5. Fluad is a quadrivalent vaccine produced by Baxalta.",
    "llama-2-7b-chat-hf_fact": [
      "Fluarix Tetra is a quadrivalent vaccine produced by GlaxoSmithKline.",
      "Flulaval is a trivalent vaccine produced by GlaxoSmithKline.",
      "Afluria is a quadrivalent vaccine produced by Sanofi.",
      "Fluvirin is a trivalent vaccine produced by Novartis.",
      "Fluad is a quadrivalent vaccine produced by Baxalta."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Flulaval is a quadrivalent influenza vaccine produced by GlaxoSmithKline, not trivalent.\n3. FALSE [correction]: Afluria is a quadrivalent vaccine produced by Seqirus, not Sanofi.\n4. FALSE [correction]: As of my knowledge cutoff in 2023, Fluvirin was a trivalent vaccine produced by Novartis but was discontinued. Current manufacturers may differ.\n5. FALSE [correction]: Fluad is a trivalent or quadrivalent influenza vaccine produced by Seqirus, not Baxalta.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-7b-chat-hf_response": "Yes, the Paramyxovirus geneome is segmented, negative-sense RNA.\n1. Segmented genome: Paramyxoviruses have a segmented genome, meaning that their genetic material is organized into multiple segments or bands, each containing a specific set of genes.\n2. Negative-sense RNA: The RNA genome of Paramyxoviruses is negative-sense, meaning that the RNA molecule has a complementary sequence to the messenger RNA (mRNA) transcripts it produces. This is in contrast to positive-sense RNA viruses, where the RNA molecule has the same sequence as the mRNA transcripts.\n3. Transcription and replication: Paramyxoviruses replicate their genome through a complex process involving transcription and replication of each segment separately. The viral RNA-dependent RNA polymerase (RdRp) enzyme transcribes the genome in the 5' to 3' direction, producing a complementary RNA strand. This complementary RNA strand is then used as a template for the synthesis of new viral RNA segments.\n4. Genome organization: The segmented nature of the Paramyxovirus genome allows for the organization of genes into functional modules, with each segment containing a specific set of genes involved in different stages of the viral life cycle, such as replication, transcription, and maturation.\n5. Evolutionary implications: The segmented genome of Paramyxoviruses has been suggested to provide a mechanism for rapid evolution and adaptation to changing environments, as mutations in one segment do not necessarily affect the function of other segments.\nIn summary, the Paramyxovirus geneome is segmented, negative-sense RNA, which allows for the organization of genes into functional modules and provides a mechanism for rapid evolution and adaptation.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Paramyxovirus genome is segmented.\n2. The RNA genome of Paramyxoviruses is negative-sense.\n3. Paramyxoviruses use a viral RNA-dependent RNA polymerase enzyme to transcribe their genome.\n4. Each segment of the Paramyxovirus genome contains a set of genes involved in different stages of the viral life cycle.\n5. The segmented genome of Paramyxoviruses may contribute to rapid evolution and adaptation.\n\nNote: The first statement extracted from the answer is incorrect. Paramyxoviruses do not have a segmented genome; their genome is non-segmented. The other statements related to the segmentation of the genome and its implications, such as statements 3, 4, and 5, would also be incorrect as they rely on the initial incorrect statement. Here we follow the verbatim answer, but keep in mind that mistakes in the source information can lead to incorrect factual statements.",
    "llama-2-7b-chat-hf_fact": [
      "The Paramyxovirus genome is segmented.",
      "The RNA genome of Paramyxoviruses is negative-sense.",
      "Paramyxoviruses use a viral RNA-dependent RNA polymerase enzyme to transcribe their genome.",
      "Each segment of the Paramyxovirus genome contains a set of genes involved in different stages of the viral life cycle.",
      "The segmented genome of Paramyxoviruses may contribute to rapid evolution and adaptation.",
      "te: The first statement extracted from the answer is incorrect. Paramyxoviruses do not have a segmented genome; their genome is non-segmented. The other statements related to the segmentation of the genome and its implications, such as statements 3, 4, and 5, would also be incorrect as they rely on the initial incorrect statement. Here we follow the verbatim answer, but keep in mind that mistakes in the source information can lead to incorrect factual statements."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Paramyxovirus genome is non-segmented.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: This statement is incorrect as the Paramyxovirus genome is not segmented. Each Paramyxovirus genome contains a continuous set of genes, not divided into segments.\n5. FALSE [correction]: This statement is false because the Paramyxovirus genome is not segmented. Rapid evolution and adaptation in paramyxoviruses do occur, but not due to genome segmentation.\n6. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-7b-chat-hf_response": "Roflumilast cream is a topical medication used to treat a specific type of skin condition called psoriasis. Specifically, it is approved for the treatment of plaque psoriasis, which is a common form of psoriasis that causes red, scaly patches on the skin. Roflumilast cream works by reducing inflammation and slowing down the growth of skin cells, which can help to improve the appearance of the skin and relieve symptoms such as itching and burning. It is applied directly to the affected area of the skin, usually twice daily, and can be used alone or in combination with other treatments.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roflumilast cream is used to treat psoriasis.\n2. It is specifically approved for the treatment of plaque psoriasis.\n3. Plaque psoriasis is characterized by red, scaly patches on the skin.\n4. Roflumilast cream works by reducing inflammation and slowing down the growth of skin cells.\n5. The cream is typically applied twice daily directly to the affected area of the skin.",
    "llama-2-7b-chat-hf_fact": [
      "Roflumilast cream is used to treat psoriasis.",
      "It is specifically approved for the treatment of plaque psoriasis.",
      "Plaque psoriasis is characterized by red, scaly patches on the skin.",
      "Roflumilast cream works by reducing inflammation and slowing down the growth of skin cells.",
      "The cream is typically applied twice daily directly to the affected area of the skin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Roflumilast is available in tablet form and is used to treat chronic obstructive pulmonary disease (COPD), not psoriasis. There are topical forms of roflumilast being studied for psoriasis treatment, but as of my last update, it might not be approved yet.\n2. UNKNOWN [correction]: While roflumilast in its topical form could be under investigation for plaque psoriasis, without the up-to-date information on its approval status, it is not possible to say if it is specifically approved for this treatment.\n3. TRUE\n4. TRUE (assuming the basis of the statement is the pharmacological action of roflumilast, which indeed reduces inflammation, but this is specifically relevant to its use in COPD)\n5. UNKNOWN [correction]: Assuming this refers to the topical form of roflumilast for psoriasis, the correct dosage and application would depend on the official treatment guidelines, which may vary and would need current confirmation.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-7b-chat-hf_response": "Several tools have been developed for identifying and visualizing non-coding RNA (ncRNA) promoters. Here are some of the commonly used tools:\n1. CpG Island Finder: This tool identifies CpG islands in the genome, which are known to be enriched in ncRNA promoters.\n2. Prodigal: This tool can predict the location and orientation of ncRNA promoters based on the sequence context.\n3. PIWI-interacting RNA (piRNA) predictor: This tool predicts piRNA genes and their potential promoters based on the sequence similarity to known piRNA genes.\n4. RNA polymerase II (RNA Pol II) ChIP-seq peak caller: This tool identifies potential ncRNA promoters by analyzing ChIP-seq data for RNA Pol II, which is a key component of the transcriptional machinery.\n5. Transcriptional start site (TSS) finder: This tool identifies the TSS of genes and can also be used to identify potential ncRNA promoters by analyzing the proximity of the TSS to known ncRNA genes.\n6. DeepSEA: This tool predicts ncRNA promoters by analyzing the deep-seeking chromatin accessibility profiles.\n7. DREAM: This tool predicts ncRNA promoters by analyzing the DNA sequence and chromatin structure.\n8. RNA polymerase II (RNA Pol II) occupancy predictor: This tool predicts the occupancy of RNA Pol II at potential ncRNA promoters based on the sequence similarity to known RNA Pol II binding sites.\n9. ChromHMM: This tool predicts ncRNA promoters by analyzing the chromatin structure and histone modification profiles.\n10. Enhancer-TarGator: This tool predicts enhancer elements and potential ncRNA promoters by analyzing the chromatin structure and histone modification profiles.\nThese tools can be used to identify and visualize ncRNA promoters in various organisms, including humans, and can help researchers understand the regulation of ncRNA expression and its role in",
    "llama-2-7b-chat-hf_fact_raw": "1. CpG Island Finder is a tool that identifies CpG islands which are enriched in ncRNA promoters.\n2. Prodigal can predict the location and orientation of ncRNA promoters based on the sequence context.\n3. PIWI-interacting RNA (piRNA) predictor is a tool for predicting piRNA genes and their potential promoters based on sequence similarity to known piRNA genes.\n4. RNA polymerase II (RNA Pol II) ChIP-seq peak caller identifies potential ncRNA promoters by analyzing ChIP-seq data for RNA Pol II.\n5. DeepSEA is a tool used to predict ncRNA promoters by analyzing deep-sea chromatin accessibility profiles.",
    "llama-2-7b-chat-hf_fact": [
      "CpG Island Finder is a tool that identifies CpG islands which are enriched in ncRNA promoters.",
      "Prodigal can predict the location and orientation of ncRNA promoters based on the sequence context.",
      "PIWI-interacting RNA (piRNA) predictor is a tool for predicting piRNA genes and their potential promoters based on sequence similarity to known piRNA genes.",
      "RNA polymerase II (RNA Pol II) ChIP-seq peak caller identifies potential ncRNA promoters by analyzing ChIP-seq data for RNA Pol II.",
      "DeepSEA is a tool used to predict ncRNA promoters by analyzing deep-sea chromatin accessibility profiles."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: CpG Island Finder is indeed a tool used for identifying CpG islands, and these regions can be associated with gene promoters, including those of non-coding RNAs (ncRNAs).\n\n2. FALSE [correction]: Prodigal is a microbial gene prediction tool used to identify protein-coding genes in bacterial and archaeal genomes, not ncRNA promoters.\n\n3. UNKNOWN: While there are tools designed to predict piRNA genes, the description provided doesn't contain enough detail to verify the existence of a piRNA predictor with the specified capabilities. Additionally, piRNA promoters' prediction is a complex task, and it's unclear whether such a tool predicts both piRNA genes and their promoters specifically based on sequence similarity.\n\n4. TRUE: RNA Polymerase II ChIP-seq peak callers can be used to identify potential promoters by analyzing ChIP-seq data. Since RNA Pol II is involved in the transcription of ncRNAs as well as mRNAs, these peaks can be indicative of ncRNA promoter locations.\n\n5. FALSE [correction]: DeepSEA is a deep learning-based framework that predicts the effects of noncoding variants on gene expression, DNA accessibility, and other chromatin effects. It is not specifically a tool for predicting ncRNA promoters based on deep-sea chromatin accessibility profiles, and its name does not imply any association with the deep sea.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-7b-chat-hf_response": "The SWIM tool is a computational tool that can identify genes that are down-regulated in glioblastoma compared to normal brain tissue. Here are some examples of genes that SWIM has identified as being down-regulated in glioblastoma:\n1. TP53: TP53 is a tumor suppressor gene that is commonly mutated in glioblastoma. SWIM has identified TP53 as one of the most significantly down-regulated genes in glioblastoma.\n2. CDKN2A: CDKN2A is a tumor suppressor gene that encodes a protein that regulates the cell cycle and is inhibited by TP53. SWIM has identified CDKN2A as one of the most significantly down-regulated genes in glioblastoma.\n3. BRCA1: BRCA1 is a tumor suppressor gene that is involved in DNA repair and is inhibited by TP53. SWIM has identified BRCA1 as one of the most significantly down-regulated genes in glioblastoma.\n4. PTEN: PTEN is a tumor suppressor gene that regulates the PI3K/Akt signaling pathway and is inhibited by TP53. SWIM has identified PTEN as one of the most significantly down-regulated genes in glioblastoma.\n5. MLH1: MLH1 is a tumor suppressor gene that is involved in DNA mismatch repair and is inhibited by TP53. SWIM has identified MLH1 as one of the most significantly down-regulated genes in glioblastoma.\n6. MSH2: MSH2 is a tumor suppressor gene that is involved in DNA mismatch repair and is inhibited by TP53. SWIM has identified MSH2 as one of the most significantly down-regulated genes in glioblastoma.\n7. BRAF: BRAF is a gene that encodes a protein that regulates the RAS/MAPK signaling pathway, which is commonly mutated in glioblastoma. SWIM has identified BRAF as one of the most significantly down-regulated genes in glioblastoma.\n8. RB1: RB1 is a tumor suppress",
    "llama-2-7b-chat-hf_fact_raw": "1. The SWIM tool identified TP53 as a significantly down-regulated gene in glioblastoma.\n2. CDKN2A was identified by the SWIM tool as one of the significantly down-regulated genes in glioblastoma.\n3. BRCA1 has been identified by SWIM as being significantly down-regulated in glioblastoma.\n4. The SWIM tool identified PTEN as a significantly down-regulated gene in glioblastoma.\n5. SWIM has distinguished MLH1 as one of the most significantly down-regulated genes in glioblastoma.",
    "llama-2-7b-chat-hf_fact": [
      "The SWIM tool identified TP53 as a significantly down-regulated gene in glioblastoma.",
      "CDKN2A was identified by the SWIM tool as one of the significantly down-regulated genes in glioblastoma.",
      "BRCA1 has been identified by SWIM as being significantly down-regulated in glioblastoma.",
      "The SWIM tool identified PTEN as a significantly down-regulated gene in glioblastoma.",
      "SWIM has distinguished MLH1 as one of the most significantly down-regulated genes in glioblastoma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nAs I don't have access to the latest data or information regarding the genes identified by the SWIM tool in glioblastoma, I cannot verify the veracity of these statements. Therefore, the truthfulness of these statements cannot be determined without further context or access to the specific research findings they are based on.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-7b-chat-hf_response": "Several R packages have been developed for studying Topologically Associating Domains (TADs), which are genomic regions that are associated with each other through their topological interactions. Here are some of the commonly used R packages for TAD analysis:\n1. TADA: TADA is a package for identifying and visualizing TADs in ChIP-seq data. It uses a Bayesian approach to detect TADs and can be used to identify both cis- and trans-acting TADs.\n2. TSS-TAD: TSS-TAD is a package for identifying TSSs and TADs in ChIP-seq data. It uses a Bayesian approach to detect TSSs and TADs and can be used to identify both cis- and trans-acting TADs.\n3. TAD-seq: TAD-seq is a package for identifying TADs in ChIP-seq data. It uses a probabilistic approach to detect TADs and can be used to identify both cis- and trans-acting TADs.\n4. TAD-detector: TAD-detector is a package for identifying TADs in ChIP-seq data. It uses a machine learning approach to detect TADs and can be used to identify both cis- and trans-acting TADs.\n5. TAD-tracker: TAD-tracker is a package for tracking the movement of TADs during cell division. It uses a Bayesian approach to detect TADs and can be used to identify both cis- and trans-acting TADs.\n6. TAD-hunter: TAD-hunter is a package for identifying TADs in ChIP-seq data. It uses a machine learning approach to detect TADs and can be used to identify both cis- and trans-acting TADs.\n7. TAD-finder: TAD-finder is a package for identifying TADs in ChIP-seq data. It uses a probabilistic approach to detect TADs and can be used to identify both cis- and trans-acting TADs.\n8. TAD-cluster: TAD-cluster is a package for clustering TADs in ChIP-seq data. It uses a hierarchical clustering approach",
    "llama-2-7b-chat-hf_fact_raw": "1. TADA is an R package designed for identifying and visualizing Topologically Associating Domains (TADs) in ChIP-seq data.\n2. TSS-TAD is an R package that uses a Bayesian approach to detect both transcription start sites (TSSs) and TADs in ChIP-seq data.\n3. TAD-seq is an R package that identifies TADs using a probabilistic approach.\n4. TAD-detector is an R package that employs a machine learning approach for TAD detection in ChIP-seq data.\n5. TAD-tracker is an R package for tracking the movement of TADs during cell division, and it utilizes a Bayesian approach for detection.",
    "llama-2-7b-chat-hf_fact": [
      "TADA is an R package designed for identifying and visualizing Topologically Associating Domains (TADs) in ChIP-seq data.",
      "TSS-TAD is an R package that uses a Bayesian approach to detect both transcription start sites (TSSs) and TADs in ChIP-seq data.",
      "TAD-seq is an R package that identifies TADs using a probabilistic approach.",
      "TAD-detector is an R package that employs a machine learning approach for TAD detection in ChIP-seq data.",
      "TAD-tracker is an R package for tracking the movement of TADs during cell division, and it utilizes a Bayesian approach for detection."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific knowledge or a reference to TADA being an R package with the described functionality, it's difficult to determine the truthfulness of this statement.\n2. UNKNOWN: Like the previous statement, without specific information about TSS-TAD, the truthfulness of the claim that it uses a Bayesian approach to detect both transcription start sites (TSSs) and TADs cannot be confirmed or denied.\n3. UNKNOWN: Again, without direct knowledge or a valid reference about the TAD-seq R package and its approach for identifying TADs, the validity of this statement cannot be assessed.\n4. UNKNOWN: Without supporting information, it's unclear whether TAD-detector is an R package that uses machine learning for TAD detection in ChIP-seq data.\n5. UNKNOWN: Without more information, the existence and functionality of an R package named TAD-tracker for tracking TAD movement during cell division and its use of a Bayesian approach for detection cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-7b-chat-hf_response": "There are several bioconductor tools that have been developed for accessing bacterial regulatory networks. Here are a few examples:\n1. BIOCARTA: BIOCARTA is a bioconductor package for the analysis of transcriptional regulation in bacteria. It provides tools for the analysis of gene expression data, the prediction of transcriptional regulatory networks, and the identification of regulatory elements.\n2. RegulonDB: RegulonDB is a bioconductor package that provides a comprehensive collection of tools for the analysis of bacterial transcriptional regulatory networks. It includes tools for the prediction of regulatory interactions, the analysis of gene expression data, and the visualization of regulatory networks.\n3. CRN: CRN (Cytoscape Regulatory Network) is a bioconductor package that provides tools for the construction and analysis of regulatory networks in bacteria. It includes tools for the importation of gene expression data, the prediction of regulatory interactions, and the visualization of regulatory networks.\n4. BactoCyc: BactoCyc is a bioconductor package that provides a comprehensive collection of tools for the analysis of bacterial metabolic and regulatory networks. It includes tools for the prediction of metabolic pathways, the analysis of gene expression data, and the visualization of regulatory networks.\n5. Rhea: Rhea is a bioconductor package that provides tools for the analysis of transcriptional regulation in bacteria. It includes tools for the prediction of regulatory interactions, the analysis of gene expression data, and the visualization of regulatory networks.\nThese are just a few examples of the many bioconductor tools that have been developed for accessing bacterial regulatory networks. Each tool has its own unique features and capabilities, and the choice of which tool to use will depend on the specific research question and experimental design.",
    "llama-2-7b-chat-hf_fact_raw": "1. BIOCARTA is a bioconductor package for analysis of transcriptional regulation in bacteria.\n2. RegulonDB is a bioconductor package that contains tools for analysis of bacterial transcriptional regulatory networks.\n3. CRN (Cytoscape Regulatory Network) is a bioconductor package designed for constructing and analyzing regulatory networks in bacteria.\n4. BactoCyc is a bioconductor package that offers tools for analyzing bacterial metabolic and regulatory networks.\n5. Rhea is a bioconductor package focused on transcriptional regulation analysis in bacteria.",
    "llama-2-7b-chat-hf_fact": [
      "BIOCARTA is a bioconductor package for analysis of transcriptional regulation in bacteria.",
      "RegulonDB is a bioconductor package that contains tools for analysis of bacterial transcriptional regulatory networks.",
      "CRN (Cytoscape Regulatory Network) is a bioconductor package designed for constructing and analyzing regulatory networks in bacteria.",
      "BactoCyc is a bioconductor package that offers tools for analyzing bacterial metabolic and regulatory networks.",
      "Rhea is a bioconductor package focused on transcriptional regulation analysis in bacteria."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: BIOCARTA is not a bioconductor package; it refers to a database of pathway and gene-to-phenotype associations, primarily for human biological pathways.\n2. FALSE [correction]: RegulonDB is not a bioconductor package; it is a database that contains information about the transcriptional regulation of gene expression in the bacterium Escherichia coli.\n3. UNKNOWN: There is no widely recognized bioconductor package by the name CRN (Cytoscape Regulatory Network); however, Cytoscape itself is a software platform for visualizing complex networks and integrating these with any type of attribute data, and it has plugins/applications for regulatory network analysis which could be confused with the term \"CRN.\"\n4. FALSE [correction]: BactoCyc is not a bioconductor package; it is a tool within the BioCyc database collection focused on providing metabolic pathway information for bacteria.\n5. FALSE [correction]: Rhea is not a bioconductor package; Rhea is a curated biochemical reaction database that provides a non-redundant resource of enzyme-catalyzed and spontaneous chemical reactions. It is not specifically focused on transcriptional regulation analysis in bacteria.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-7b-chat-hf_response": "The end products of the shikimate pathway are aromatic amino acids, which are important building blocks for various biomolecules, including proteins, neurotransmitters, and hormones. The specific end products of the shikimate pathway depend on the specific enzymes involved in the pathway and the availability of substrates.\nThe main end products of the shikimate pathway are:\n1. Aromatic amino acids: The shikimate pathway produces several aromatic amino acids, including:\na. Tyrosine: Converted from 4-coumarate by the enzyme 4-Coumarate:CoA ligase.\nb. Tryptophan: Converted from 3-hydroxybutyrate by the enzyme 3-Hydroxybutyryl-CoA dehydrogenase.\nc. Phenylalanine: Converted from 4-coumarate by the enzyme 4-Coumarate:CoA ligase.\nd. Tyrptophan: Converted from 3-hydroxybutyrate by the enzyme 3-Hydroxybutyryl-CoA dehydrogenase.\n2. Other compounds: The shikimate pathway also produces other compounds, including:\na. Quinates: These are produced from the oxidation of 4-coumarate and are further metabolized to produce other compounds.\nb. 3-Hydroxybutyrate: This compound is produced from the degradation of tryptophan and is further metabolized to produce other compounds.\nc. 4-Coumarate: This compound is produced from the degradation of aromatic amino acids and is further metabolized to produce other compounds.\nIn summary, the shikimate pathway produces aromatic amino acids, including tyrosine, tryptophan, phenylalanine, and other compounds, such as quinates, 3-hydroxybutyrate, and 4-coumarate. These compounds are important for various cellular processes, including the synthesis of proteins, neurotransmitters, and hormones.",
    "llama-2-7b-chat-hf_fact_raw": "1. The shikimate pathway produces aromatic amino acids.\n2. Tyrosine is one of the aromatic amino acids produced by the shikimate pathway.\n3. Tryptophan is one of the aromatic amino acids produced by the shikimate pathway.\n4. Phenylalanine is one of the aromatic amino acids produced by the shikimate pathway.\n5. The shikimate pathway produces quinates, 3-hydroxybutyrate, and 4-coumarate in addition to aromatic amino acids.",
    "llama-2-7b-chat-hf_fact": [
      "The shikimate pathway produces aromatic amino acids.",
      "Tyrosine is one of the aromatic amino acids produced by the shikimate pathway.",
      "Tryptophan is one of the aromatic amino acids produced by the shikimate pathway.",
      "Phenylalanine is one of the aromatic amino acids produced by the shikimate pathway.",
      "The shikimate pathway produces quinates, 3-hydroxybutyrate, and 4-coumarate in addition to aromatic amino acids."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The shikimate pathway is primarily known for producing aromatic amino acids. Quinates and 4-coumarate can be derived from intermediates in the pathway, while 3-hydroxybutyrate is not a direct product of the shikimate pathway; it is associated with lipid metabolism.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-7b-chat-hf_response": "Yes, cabergoline is sometimes used to treat Nelson's syndrome, which is a condition that can occur after surgical removal of a pituitary tumor. Nelson's syndrome is characterized by the rapid growth of the remaining pituitary tissue, leading to an overproduction of hormones and a variety of symptoms, including headache, visual disturbances, and endocrinopathies.\nCabergoline, a dopamine receptor agonist, has been shown to be effective in reducing the symptoms of Nelson's syndrome by suppressing the production of hormones by the remaining pituitary tissue. It works by binding to dopamine receptors in the pituitary gland, which inhibits the production of hormones and reduces the size of the pituitary gland.\nStudies have shown that cabergoline can significantly reduce the levels of prolactin, growth hormone, and adrenocorticotropic hormone (ACTH) in patients with Nelson's syndrome, leading to improvement in symptoms such as headache, visual disturbances, and endocrinopathies. However, the response to cabergoline can vary among patients, and it may not be effective in all cases.\nIt's important to note that cabergoline is not a cure for Nelson's syndrome, and it may not completely eliminate the symptoms. However, it can help manage the symptoms and improve the quality of life for some patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cabergoline is used to treat Nelson's syndrome.\n2. Nelson's syndrome can occur after the surgical removal of a pituitary tumor.\n3. Treatment with cabergoline involves suppressing the production of hormones by the remaining pituitary tissue.\n4. Cabergoline has been shown to reduce the levels of prolactin, growth hormone, and adrenocorticotropic hormone (ACTH) in patients with Nelson's syndrome.\n5. Cabergoline can lead to improvement in symptoms associated with Nelson's syndrome, such as headaches, visual disturbances, and endocrinopathies.",
    "llama-2-7b-chat-hf_fact": [
      "Cabergoline is used to treat Nelson's syndrome.",
      "Nelson's syndrome can occur after the surgical removal of a pituitary tumor.",
      "Treatment with cabergoline involves suppressing the production of hormones by the remaining pituitary tissue.",
      "Cabergoline has been shown to reduce the levels of prolactin, growth hormone, and adrenocorticotropic hormone (ACTH) in patients with Nelson's syndrome.",
      "Cabergoline can lead to improvement in symptoms associated with Nelson's syndrome, such as headaches, visual disturbances, and endocrinopathies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cabergoline is used to treat conditions associated with hyperprolactinemia, such as pituitary adenomas that produce prolactin, but it is not the standard treatment for Nelson's syndrome. Treatment for Nelson's syndrome may involve surgery or other medications such as hormone replacement.\n2. TRUE\n3. TRUE – Treatment with cabergoline, as a dopamine agonist, can suppress the production of certain hormones.\n4. FALSE [correction]: While cabergoline has been shown to reduce levels of prolactin, it is not typically used to target growth hormone or adrenocorticotropic hormone (ACTH) in patients with Nelson's syndrome. Nelson's syndrome is characterized by elevated ACTH levels after the removal of an ACTH-producing pituitary tumor, and its management is not directly related to the actions of cabergoline.\n5. FALSE [correction]: While cabergoline can lead to improvements in symptoms associated with conditions related to hyperprolactinemia, there is no standard indication that it leads to improvement in symptoms specifically associated with Nelson's syndrome. Management of Nelson's syndrome symptoms usually involves different treatment approaches.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-7b-chat-hf_response": "Liebenberg syndrome is a rare genetic disorder that affects the nervous system and is characterized by a variety of symptoms. The main manifestations of Liebenberg syndrome include:\n1. Ataxia: The most common symptom of Liebenberg syndrome is ataxia, which is a loss of coordination and balance. This can lead to difficulties with walking, balance, and movement.\n2. Spasticity: Patients with Liebenberg syndrome often experience spasticity, which is an abnormal increase in muscle tone. This can lead to stiffness, rigidity, and spasms in the muscles.\n3. Sensory loss: Many individuals with Liebenberg syndrome experience sensory loss, including loss of touch, pain, and temperature sensation.\n4. Cognitive impairment: Some people with Liebenberg syndrome may experience cognitive impairment, including difficulties with memory, attention, and problem-solving.\n5. Seizures: Seizures are a common manifestation of Liebenberg syndrome, particularly in children.\n6. Vision problems: Some individuals with Liebenberg syndrome may experience vision problems, including blurred vision, double vision, and light sensitivity.\n7. Hearing loss: Hearing loss is another common manifestation of Liebenberg syndrome, particularly in older adults.\n8. Respiratory problems: Some people with Liebenberg syndrome may experience respiratory problems, including shortness of breath and respiratory infections.\n9. GI problems: Gastrointestinal problems, such as constipation, diarrhea, and gastroesophageal reflux disease (GERD), are also common in Liebenberg syndrome.\n10. Cardiac problems: Some individuals with Liebenberg syndrome may experience cardiac problems, including abnormal heart rhythms and heart failure.\nIt's important to note that the severity and specific manifestations of Liebenberg syndrome can vary widely between individuals, and some people may experience additional symptoms not listed here.",
    "llama-2-7b-chat-hf_fact_raw": "1. Liebenberg syndrome affects the nervous system.\n2. Ataxia, characterized by a loss of coordination and balance, is the most common symptom of Liebenberg syndrome.\n3. Spasticity, an abnormal increase in muscle tone, is often experienced by patients with Liebenberg syndrome.\n4. Some individuals with Liebenberg syndrome may experience cognitive impairments.\n5. Seizures are a common manifestation of Liebenberg syndrome, particularly in children.",
    "llama-2-7b-chat-hf_fact": [
      "Liebenberg syndrome affects the nervous system.",
      "Ataxia, characterized by a loss of coordination and balance, is the most common symptom of Liebenberg syndrome.",
      "Spasticity, an abnormal increase in muscle tone, is often experienced by patients with Liebenberg syndrome.",
      "Some individuals with Liebenberg syndrome may experience cognitive impairments.",
      "Seizures are a common manifestation of Liebenberg syndrome, particularly in children."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There is no well-documented medical condition named \"Liebenberg syndrome\" that affects the nervous system. It is possible that this is a fictional or incorrectly cited condition.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout accurate medical information or recognition of \"Liebenberg syndrome\" as a medical condition, it is not possible to verify the symptoms listed or provide a meaningful correction. All statements regarding the symptoms of \"Liebenberg syndrome\" are therefore marked as \"UNKNOWN.\" If \"Liebenberg syndrome\" is a misnomer or an incorrect reference to an actual condition, further information would be required for accurate statements.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-7b-chat-hf_response": "MPS1 (myotonic dystrophy protein 1) kinase is an enzyme that plays a crucial role in regulating various cellular processes, including cell growth, differentiation, and survival. Here are some orally bioavailable MPS1 kinase inhibitors that have been identified or developed:\n1. Vorinostat (Zolinza): Vorinostat is an orally available HDAC inhibitor that has been approved for the treatment of cutaneous T-cell lymphoma. It has been shown to inhibit MPS1 kinase activity and has been investigated as a potential treatment for various cancers, including breast, lung, and ovarian cancer.\n2. Romidepsin (Istodax): Romidepsin is an orally available HDAC inhibitor that has been approved for the treatment of cutaneous T-cell lymphoma. It has been shown to inhibit MPS1 kinase activity and has been investigated as a potential treatment for various cancers, including breast, lung, and ovarian cancer.\n3. Panobinostat (Farydak): Panobinostat is an orally available HDAC inhibitor that has been approved for the treatment of multiple myeloma. It has been shown to inhibit MPS1 kinase activity and has been investigated as a potential treatment for various cancers, including breast, lung, and ovarian cancer.\n4. ACY-1215: ACY-1215 is an orally available small molecule inhibitor of MPS1 kinase that has been shown to have antitumor activity in various cancer cell lines.\n5. BAY 80-6946: BAY 80-6946 is an orally available small molecule inhibitor of MPS1 kinase that has been shown to have antitumor activity in various cancer cell lines.\n6. GSK2801: GSK2801 is an orally available small molecule inhibitor of MPS1 kinase that has been shown to have antitumor activity in various cancer cell lines.\n7. LBH-589: LBH-589 is an orally available small molecule inhib",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-7b-chat-hf_response": "Golimumab, a tumor necrosis factor (TNF) inhibitor, is approved for the treatment of certain autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. However, it has not been specifically approved for the treatment of diabetes.\nThere have been some studies that have investigated the potential effects of golimumab on glycemic control in patients with type 1 diabetes or type 2 diabetes, but these studies have been small and had limited scope. Here are some of the key findings from these studies:\n1. A phase II study published in 2010 in the Journal of Clinical Endocrinology and Metabolism found that golimumab treatment improved glycemic control in patients with type 1 diabetes over a 24-week period. However, the study had only 24 participants, and the results were not statistically significant.\n2. A phase II study published in 2012 in the Journal of Diabetes and Its Complications found that golimumab treatment improved glycemic control in patients with type 2 diabetes over a 12-week period. The study included 50 participants, and the results suggested that golimumab may be effective in improving glycemic control in patients with type 2 diabetes.\n3. A phase III study published in 2017 in the Journal of Clinical Endocrinology and Metabolism found that golimumab treatment did not significantly improve glycemic control in patients with type 2 diabetes over a 52-week period compared to placebo. The study included 300 participants, and the results were disappointing given the previous positive findings from smaller studies.\nOverall, while there is some evidence to suggest that golimumab may have potential as a treatment for diabetes, particularly type 1 diabetes, larger and more robust studies are needed to confirm these findings and establish the safety and efficacy of golimumab for this indication.",
    "llama-2-7b-chat-hf_fact_raw": "1. Golimumab is approved for the treatment of autoimmune diseases including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.\n2. A phase II study published in 2010 in the Journal of Clinical Endocrinology and Metabolism reported that golimumab improved glycemic control in patients with type 1 diabetes over a 24-week period.\n3. The 2010 phase II study on type 1 diabetes had 24 participants and the results were not statistically significant.\n4. A phase II study published in 2012 in the Journal of Diabetes and Its Complications indicated golimumab improved glycemic control in patients with type 2 diabetes over a 12-week period and included 50 participants.\n5. A phase III study published in 2017 in the Journal of Clinical Endocrinology and Metabolism found no significant improvement in glycemic control with golimumab treatment in type 2 diabetes patients over 52 weeks compared to placebo and included 300 participants.",
    "llama-2-7b-chat-hf_fact": [
      "Golimumab is approved for the treatment of autoimmune diseases including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.",
      "A phase II study published in 2010 in the Journal of Clinical Endocrinology and Metabolism reported that golimumab improved glycemic control in patients with type 1 diabetes over a 24-week period.",
      "The 2010 phase II study on type 1 diabetes had 24 participants and the results were not statistically significant.",
      "A phase II study published in 2012 in the Journal of Diabetes and Its Complications indicated golimumab improved glycemic control in patients with type 2 diabetes over a 12-week period and included 50 participants.",
      "A phase III study published in 2017 in the Journal of Clinical Endocrinology and Metabolism found no significant improvement in glycemic control with golimumab treatment in type 2 diabetes patients over 52 weeks compared to placebo and included 300 participants."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN (Without access to the specific study, it is not possible to verify this information.)\n3. UNKNOWN (As for statement 2, the specifics of the study such as participant numbers and statistical significance cannot be confirmed without access to the actual study.)\n4. UNKNOWN (Again, without the specific study details, the results and the number of participants cannot be verified.)\n5. UNKNOWN (The results of this study and number of participants cannot be verified without access to the article or study reference.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-7b-chat-hf_response": "Yes, progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is caused by an autosomal recessive genetic mutation. This means that a person must inherit two copies of the mutated gene, one from each parent, in order to develop the condition.\nThe genetic mutation responsible for progeria is located on chromosome 17 and affects the LMNA gene, which encodes for the protein lamin A. The mutation leads to the production of a truncated form of lamin A, known as progerin, which accumulates in the nuclei of affected cells and disrupts their normal function.\nProgeria is a rare genetic disorder, and it is estimated to occur in about 1 in 4 million births. The majority of cases are sporadic, meaning that they occur in individuals who have no family history of the condition. However, some cases can be inherited in an autosomal recessive pattern, meaning that each affected person has two copies of the mutated gene, one from each parent.\nIn summary, progeria is caused by an autosomal recessive genetic mutation in the LMNA gene, which leads to the production of a truncated form of lamin A and disrupts the normal function of affected cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. Progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is caused by a genetic mutation.\n2. The genetic mutation responsible for progeria is located on chromosome 17.\n3. The mutation affects the LMNA gene, which encodes for the protein lamin A.\n4. The mutation leads to the production of a truncated form of lamin A, known as progerin.\n5. Progeria is estimated to occur in about 1 in 4 million births.",
    "llama-2-7b-chat-hf_fact": [
      "Progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is caused by a genetic mutation.",
      "The genetic mutation responsible for progeria is located on chromosome 17.",
      "The mutation affects the LMNA gene, which encodes for the protein lamin A.",
      "The mutation leads to the production of a truncated form of lamin A, known as progerin.",
      "Progeria is estimated to occur in about 1 in 4 million births."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The genetic mutation responsible for progeria is located on chromosome 1.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-7b-chat-hf_response": "Variants at chromosome 12q14 and 12q24 have been associated with several genetic conditions, including:\n12q14:\n1. DiGeorge syndrome: A rare genetic disorder characterized by the absence of part of the 6th and 7th cervical vertebrae, a cleft palate, and other congenital abnormalities.\n2. Velocardiofacial syndrome: A rare genetic disorder that affects the heart and face. It is characterized by heart defects, such as tetralogy of Fallot, and facial abnormalities, such as a cleft palate and small jaw.\n3. 12q14.1 microdeletion syndrome: A rare genetic disorder characterized by intellectual disability, delayed speech and language development, and a distinct facial appearance.\n12q24:\n1. Beta-thalassemia/HbE: A genetic disorder that affects the production of hemoglobin, leading to anemia and other complications.\n2. HbE beta-thalassemia: A genetic disorder that affects the production of hemoglobin, leading to anemia and other complications.\n3. Glucose-6-phosphate dehydrogenase (G6PD) deficiency: A genetic disorder that affects the body's ability to break down glucose, leading to hemolytic anemia and other complications.\nIt's important to note that the variants associated with these conditions are rare and may not be present in every individual with the disorder. Genetic testing can help identify the specific genetic cause of a disorder in an individual.",
    "llama-2-7b-chat-hf_fact_raw": "1. DiGeorge syndrome is characterized by the absence of part of the 6th and 7th cervical vertebrae, a cleft palate, and other congenital abnormalities.\n2. Velocardiofacial syndrome is characterized by heart defects, such as tetralogy of Fallot, and facial abnormalities, such as a cleft palate and small jaw.\n3. The 12q14.1 microdeletion syndrome is characterized by intellectual disability, delayed speech and language development, and a distinct facial appearance.\n4. Beta-thalassemia/HbE is a genetic disorder that affects the production of hemoglobin, leading to anemia and other complications.\n5. Glucose-6-phosphate dehydrogenase deficiency affects the body's ability to break down glucose, leading to hemolytic anemia and other complications.",
    "llama-2-7b-chat-hf_fact": [
      "DiGeorge syndrome is characterized by the absence of part of the 6th and 7th cervical vertebrae, a cleft palate, and other congenital abnormalities.",
      "Velocardiofacial syndrome is characterized by heart defects, such as tetralogy of Fallot, and facial abnormalities, such as a cleft palate and small jaw.",
      "The 12q14.1 microdeletion syndrome is characterized by intellectual disability, delayed speech and language development, and a distinct facial appearance.",
      "Beta-thalassemia/HbE is a genetic disorder that affects the production of hemoglobin, leading to anemia and other complications.",
      "Glucose-6-phosphate dehydrogenase deficiency affects the body's ability to break down glucose, leading to hemolytic anemia and other complications."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: DiGeorge syndrome is characterized by a deletion in chromosome 22q11.2, not the absence of part of the 6th and 7th cervical vertebrae. It includes congenital heart problems, specific facial features, cleft palate, and immune system deficiencies, among other abnormalities.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Glucose-6-phosphate dehydrogenase deficiency affects red blood cells' ability to handle oxidative stress, leading to hemolytic anemia typically after exposure to certain medications, infections, or other stressors, not an issue with breaking down glucose.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-7b-chat-hf_response": "The Roundabout (Robo) receptors are a family of transmembrane receptors that play a crucial role in regulating cell migration, axon guidance, and tissue patterning during embryonic development and in various diseases. There are four known ligands of the Robo receptors:\n1. Roundabout ligand (RoboL): Also known as Robo-responsive ligand (RRL), it is the primary ligand for Robo1 and Robo2 receptors. RoboL is a secreted protein that is expressed in the extracellular space and binds to Robo1 and Robo2 with high affinity.\n2. Rho-associated protein kinase (ROCK): ROCK is a secreted protein that is a ligand for Robo3 receptor. ROCK binds to Robo3 with high affinity and activates downstream signaling pathways that regulate cell migration and axon guidance.\n3. Ephrin-B2: Ephrin-B2 is a transmembrane protein that is a ligand for Robo2 receptor. Ephrin-B2 is expressed on the surface of neurons and other cells, and it binds to Robo2 with high affinity, activating downstream signaling pathways that regulate cell migration and axon guidance.\n4. Ephrin-B1: Ephrin-B1 is another transmembrane protein that is a ligand for Robo2 receptor. Ephrin-B1 is expressed on the surface of neurons and other cells, and it binds to Robo2 with high affinity, activating downstream signaling pathways that regulate cell migration and axon guidance.\nIt is worth noting that Robo receptors can also be activated by other ligands, such as the extracellular matrix proteins and growth factors, which can modulate their activity and specificity.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roundabout ligand (RoboL) is a primary ligand for the Robo1 and Robo2 receptors.\n2. Rho-associated protein kinase (ROCK) is a ligand for the Robo3 receptor.\n3. Ephrin-B2 is a ligand for the Robo2 receptor.\n4. Ephrin-B1 is a ligand for the Robo2 receptor.\n5. Robo receptors can be activated by other ligands, including extracellular matrix proteins and growth factors.",
    "llama-2-7b-chat-hf_fact": [
      "Roundabout ligand (RoboL) is a primary ligand for the Robo1 and Robo2 receptors.",
      "Rho-associated protein kinase (ROCK) is a ligand for the Robo3 receptor.",
      "Ephrin-B2 is a ligand for the Robo2 receptor.",
      "Ephrin-B1 is a ligand for the Robo2 receptor.",
      "Robo receptors can be activated by other ligands, including extracellular matrix proteins and growth factors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: ROCK is not a ligand; it is a serine/threonine kinase that can be a downstream effector of signaling pathways but does not directly bind to Robo3 as a ligand.\n3. FALSE [correction]: Ephrin-B2 is not reported as a ligand for the Robo2 receptor; instead, it is typically known to bind Eph receptors.\n4. FALSE [correction]: Ephrin-B1 is not reported as a ligand for the Robo2 receptor; like Ephrin-B2, it is typically known to bind Eph receptors.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-7b-chat-hf_response": "Yes, there is evidence to suggest that TFII-I plays a role in megakaryopoiesis, which is the process of developing megakaryocytes, the precursors of platelets, in the bone marrow.\nTFII-I is a transcription factor that belongs to the TFII family of proteins, which are involved in the initiation of transcription in eukaryotic cells. In megakaryocytes, TFII-I has been shown to play a role in the regulation of genes involved in platelet function and megakaryocyte survival.\nStudies have shown that TFII-I is expressed in megakaryocytes and platelets, and that it regulates the expression of genes involved in platelet activation, aggregation, and secretion. For example, TFII-I has been shown to activate the expression of the platelet-derived growth factor receptor alpha (PDGFRα), which is involved in platelet activation and aggregation. TFII-I has also been shown to regulate the expression of genes involved in platelet survival, such as the Bcl-2 family of proteins.\nIn addition, TFII-I has been shown to play a role in the regulation of megakaryocyte proliferation and differentiation. For example, TFII-I has been shown to regulate the expression of genes involved in the G1/S checkpoint of the cell cycle, which is important for megakaryocyte proliferation. TFII-I has also been shown to regulate the expression of genes involved in megakaryocyte differentiation, such as the gene encoding the platelet-specific protein glycoprotein (GP) IIb.\nOverall, the evidence suggests that TFII-I plays a role in the regulation of megakaryopoiesis, particularly in the regulation of gene expression involved in platelet function and megakaryocyte survival.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFII-I is a transcription factor that is involved in the development of megakaryocytes, the precursors of platelets, in the bone marrow.\n2. TFII-I has been found to regulate genes related to platelet function and megakaryocyte survival.\n3. TFII-I expression has been observed in megakaryocytes and platelets.\n4. TFII-I activates the expression of the platelet-derived growth factor receptor alpha (PDGFRα), which plays a role in platelet activation and aggregation.\n5. TFII-I has been shown to regulate the expression of genes involved in the G1/S checkpoint of the cell cycle, which is significant for megakaryocyte proliferation.",
    "llama-2-7b-chat-hf_fact": [
      "TFII-I is a transcription factor that is involved in the development of megakaryocytes, the precursors of platelets, in the bone marrow.",
      "TFII-I has been found to regulate genes related to platelet function and megakaryocyte survival.",
      "TFII-I expression has been observed in megakaryocytes and platelets.",
      "TFII-I activates the expression of the platelet-derived growth factor receptor alpha (PDGFRα), which plays a role in platelet activation and aggregation.",
      "TFII-I has been shown to regulate the expression of genes involved in the G1/S checkpoint of the cell cycle, which is significant for megakaryocyte proliferation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN \n5. UNKNOWN\n\nAs a language model AI, without specific scientific references for these complex biological statements, it's difficult to definitively confirm or refute statements 4 and 5. They seem plausible within the context of transcription factor activities but would require specific literature or scientific studies to verify.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-7b-chat-hf_response": "Yes, atenolol is metabolized by the cytochrome P450 enzyme CYP2D6. CYP2D6 is one of the most important enzymes involved in the metabolism of drugs in the human liver, and it is responsible for the metabolism of many clinically used drugs, including atenolol.\nAtenolol is primarily metabolized by CYP2D6 to form its active metabolite, beta-hydroxyatenolol, which is responsible for most of the drug's pharmacological effects. The rate of metabolism of atenolol to its active metabolite is highly dependent on the activity of the CYP2D6 enzyme, and genetic variations in the CYP2D6 gene can affect the metabolism of atenolol and its efficacy.\nIndividuals with reduced activity of the CYP2D6 enzyme may have reduced levels of the active metabolite of atenolol, which can result in reduced efficacy of the drug. Conversely, individuals with increased activity of the CYP2D6 enzyme may have higher levels of the active metabolite, which can result in increased efficacy or adverse effects.\nTherefore, genetic variations in the CYP2D6 gene can have a significant impact on the pharmacokinetics and pharmacodynamics of atenolol, and this information can be used to optimize drug therapy in patients who are taking this drug.",
    "llama-2-7b-chat-hf_fact_raw": "1. Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6 in the human liver.\n2. CYP2D6 is responsible for the metabolism of many clinically used drugs, including atenolol.\n3. Atenolol is metabolized by CYP2D6 to form its active metabolite, beta-hydroxyatenolol.\n4. Genetic variations in the CYP2D6 gene can affect the metabolism and efficacy of atenolol.\n5. Individuals with reduced CYP2D6 enzyme activity may have reduced efficacy of atenolol due to lower levels of the active metabolite.",
    "llama-2-7b-chat-hf_fact": [
      "Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6 in the human liver.",
      "CYP2D6 is responsible for the metabolism of many clinically used drugs, including atenolol.",
      "Atenolol is metabolized by CYP2D6 to form its active metabolite, beta-hydroxyatenolol.",
      "Genetic variations in the CYP2D6 gene can affect the metabolism and efficacy of atenolol.",
      "Individuals with reduced CYP2D6 enzyme activity may have reduced efficacy of atenolol due to lower levels of the active metabolite."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Atenolol is not significantly metabolized by cytochrome P450 enzymes such as CYP2D6; it is primarily excreted unchanged in the urine.\n2. TRUE\n3. FALSE [correction]: Atenolol does not have an active metabolite formed through metabolism by CYP2D6; it is administered as the active drug and is not significantly metabolized by the liver.\n4. FALSE [correction]: Given that atenolol is not significantly metabolized by CYP2D6, genetic variations in the CYP2D6 gene would not typically affect the metabolism and efficacy of atenolol.\n5. FALSE [correction]: Since atenolol is not significantly metabolized to an active metabolite by CYP2D6, individuals with reduced CYP2D6 enzyme activity would not have reduced efficacy of atenolol due to lower levels of an active metabolite.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-7b-chat-hf_response": "ExpansionHunter is a tool developed by the lab of Dr. Feng Zhang at the Broad Institute, and there have been several versions released over time. Here are some of the notable versions of ExpansionHunter:\n1. ExpansionHunter 1.0: This was the initial release of ExpansionHunter, which introduced the concept of using CRISPR-Cas9 to detect and characterize gene fusions.\n2. ExpansionHunter 2.0: This version improved the accuracy and speed of the gene fusion detection process, and introduced new features such as the ability to detect gene fusions in multiple samples simultaneously.\n3. ExpansionHunter 3.0: This version introduced a new algorithm that improved the accuracy and sensitivity of gene fusion detection, and also introduced new features such as the ability to detect gene fusions in RNA sequences.\n4. ExpansionHunter 4.0: This version further improved the accuracy and speed of the gene fusion detection process, and introduced new features such as the ability to detect gene fusions in multiple samples simultaneously and the ability to visualize the fusion junctions.\n5. ExpansionHunter 5.0: This is the latest version of ExpansionHunter, which includes several new features such as the ability to detect gene fusions in a more efficient manner, and the ability to identify fusion genes that are not present in the reference genome.\n6. ExpansionHunter-P: This is a variant of ExpansionHunter that is specifically designed for the analysis of single-cell RNA sequencing data.\n7. ExpansionHunter-C: This is a variant of ExpansionHunter that is specifically designed for the analysis of chromatin immunoprecipitation sequencing (ChIP-seq) data.\n8. ExpansionHunter-D: This is a variant of ExpansionHunter that is specifically designed for the analysis of RNA sequencing data from samples with known gene fusions.\nPlease note that these are the versions that are mentioned in the paper, there may be more recent versions of the tool.\nIt's worth mentioning that the latest version of ExpansionHunter (5.0) is the most widely used and recommended version, as it includes several improvements and new features compared to the previous versions.",
    "llama-2-7b-chat-hf_fact_raw": "1. ExpansionHunter is a tool developed by the lab of Dr. Feng Zhang at the Broad Institute.\n2. ExpansionHunter 1.0 introduced the concept of using CRISPR-Cas9 to detect and characterize gene fusions.\n3. ExpansionHunter 3.0 introduced a new algorithm to improve the accuracy and sensitivity of gene fusion detection.\n4. ExpansionHunter 5.0 is described as the latest version mentioned in the paper, which includes the ability to detect gene fusions more efficiently.\n5. ExpansionHunter-P, ExpansionHunter-C, and ExpansionHunter-D are variants of the tool designed for analysis of single-cell RNA sequencing data, ChIP-seq data, and RNA sequencing data from samples with known gene fusions, respectively.",
    "llama-2-7b-chat-hf_fact": [
      "ExpansionHunter is a tool developed by the lab of Dr. Feng Zhang at the Broad Institute.",
      "ExpansionHunter 1.0 introduced the concept of using CRISPR-Cas9 to detect and characterize gene fusions.",
      "ExpansionHunter 3.0 introduced a new algorithm to improve the accuracy and sensitivity of gene fusion detection.",
      "ExpansionHunter 5.0 is described as the latest version mentioned in the paper, which includes the ability to detect gene fusions more efficiently.",
      "ExpansionHunter-P, ExpansionHunter-C, and ExpansionHunter-D are variants of the tool designed for analysis of single-cell RNA sequencing data, ChIP-seq data, and RNA sequencing data from samples with known gene fusions, respectively."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ExpansionHunter is a software tool designed to analyze genetic repeat expansions, but it was not developed by Dr. Feng Zhang's lab at the Broad Institute. It was developed by Illumina and collaborators, not specifically associated with Dr. Feng Zhang.\n2. FALSE [correction]: ExpansionHunter does not use CRISPR-Cas9. It is a computational tool for detecting repeat expansions in genomic sequences, not for detecting or characterizing gene fusions.\n3. UNKNOWN: Without detailed version history information, it's unclear what specific improvements were introduced in ExpansionHunter 3.0.\n4. UNKNOWN: Without access to the specific paper mentioned, the details about ExpansionHunter 5.0 and its capabilities remain unclear.\n5. FALSE [correction]: This is not accurate as described. ExpansionHunter does not have variants specifically named ExpansionHunter-P, ExpansionHunter-C, and ExpansionHunter-D for these types of data. It is primarily focused on detecting repeat expansions rather than analyzing specific forms of sequencing data. Additionally, the names given do not match known versions or variants of ExpansionHunter.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-7b-chat-hf_response": "Adamts18 (A disintegrin and metalloproteinase domain-containing protein 18) is a protein that plays a crucial role in hormone receptor signaling, particularly in the regulation of estrogen receptor (ER) signaling. Here's a breakdown of the role of Adamts18 in hormone receptor signaling:\n1. Estrogen receptor (ER) signaling: Adamts18 is an ER ligand that activates ER alpha (ERα) and ER beta (ERβ) receptors. It does this by binding to the ligand binding domain of the receptor, leading to the activation of downstream signaling pathways.\n2. Cross-talk with other hormone receptors: Adamts18 can also interact with other hormone receptors, such as the progesterone receptor (PR) and the retinoid X receptor (RXR), to modulate their activity. This cross-talk can have important implications for the regulation of various cellular processes, including gene expression and cell proliferation.\n3. Regulation of gene expression: Adamts18 can regulate the expression of target genes by modulating the activity of transcription factors, such as nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1). It does this by binding to specific DNA sequences in the promoter regions of these genes and recruiting other transcription factors to activate or repress their transcription.\n4. Cell proliferation and differentiation: Adamts18 can regulate cell proliferation and differentiation by modulating the activity of signaling pathways, such as the mitogen-activated protein kinase (MAPK) and the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. It can also regulate the expression of genes involved in cell cycle progression and differentiation.\n5. Tissue-specific functions: Adamts18 has been shown to have tissue-specific functions in various organisms, including the uterus, mammary gland, and bone. For example, in the uterus, Adamts18 regulates the expression of genes involved in the maintenance of the female reproductive",
    "llama-2-7b-chat-hf_fact_raw": "1. Adamts18 activates estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) by binding to their ligand-binding domain.\n2. Adamts18 interacts with other hormone receptors like progesterone receptor (PR) and retinoid X receptor (RXR) to modulate their activity.\n3. Adamts18 regulates the expression of target genes through modulation of transcription factors such as NF-κB and AP-1.\n4. Adamts18 influences cell proliferation and differentiation by affecting signaling pathways like MAPK and PI3K/Akt.\n5. Adamts18 has tissue-specific functions in the uterus, mammary gland, and bone.",
    "llama-2-7b-chat-hf_fact": [
      "Adamts18 activates estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) by binding to their ligand-binding domain.",
      "Adamts18 interacts with other hormone receptors like progesterone receptor (PR) and retinoid X receptor (RXR) to modulate their activity.",
      "Adamts18 regulates the expression of target genes through modulation of transcription factors such as NF-κB and AP-1.",
      "Adamts18 influences cell proliferation and differentiation by affecting signaling pathways like MAPK and PI3K/Akt.",
      "Adamts18 has tissue-specific functions in the uterus, mammary gland, and bone."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The specific molecular interactions of ADAMTS18 with estrogen receptors or its mechanism of activation are not common knowledge and would require specific scientific research data to confirm.\n2. UNKNOWN: Similar to statement 1, the interaction of ADAMTS18 with other hormone receptors like PR and RXR is not commonly known information and requires specific scientific research for confirmation.\n3. UNKNOWN: The regulation of target gene expression by ADAMTS18 through modulation of transcription factors such as NF-κB and AP-1 would need to be verified with scientific evidence.\n4. UNKNOWN: The effects of ADAMTS18 on cell proliferation and differentiation and its impact on signaling pathways like MAPK and PI3K/Akt are not well-known and require scientific data for validation.\n5. UNKNOWN: ADAMTS18 having tissue-specific functions in the uterus, mammary gland, and bone is a specific claim that would need to be supported by targeted research and is not common knowledge.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-7b-chat-hf_response": "Thiazovivin is a small molecule inhibitor of the enzyme pyruvate kinase (PK) that has been shown to have anticancer activity. Here is a brief overview of its mode of action:\n1. Inhibition of PK: Thiazovivin selectively binds to the ATP-binding site of PK, inhibiting its activity and preventing the conversion of pyruvate to acetyl-CoA.\n2. Inhibition of glycolysis: By inhibiting PK, thiazovivin reduces the ability of cancer cells to undergo glycolysis, which is the primary source of energy for these cells.\n3. Inhibition of cell proliferation: The inhibition of glycolysis by thiazovivin leads to a reduction in the availability of ATP, which is essential for cell proliferation. As a result, thiazovivin inhibits the proliferation of cancer cells.\n4. Induction of apoptosis: Thiazovivin has been shown to induce apoptosis (programmed cell death) in cancer cells, which can lead to the death of these cells.\n5. Inhibition of angiogenesis: Thiazovivin has been shown to inhibit the formation of new blood vessels, which are essential for the growth and spread of solid tumors.\n6. Enhancement of chemotherapy: Thiazovivin has been shown to enhance the effectiveness of chemotherapy drugs in treating cancer, possibly by inhibiting the activity of PK and reducing the ability of cancer cells to undergo glycolysis.\nIn summary, the mode of action of thiazovivin is to inhibit the activity of pyruvate kinase, leading to the inhibition of glycolysis, reduction of cell proliferation, induction of apoptosis, and inhibition of angiogenesis, all of which can contribute to its anticancer activity.",
    "llama-2-7b-chat-hf_fact_raw": "1. Thiazovivin is a small molecule inhibitor of the enzyme pyruvate kinase (PK).\n2. Thiazovivin binds to the ATP-binding site of PK, preventing the conversion of pyruvate to acetyl-CoA.\n3. By inhibiting PK, thiazovivin reduces the ability of cancer cells to undergo glycolysis.\n4. Thiazovivin induces apoptosis in cancer cells.\n5. Thiazovivin inhibits the formation of new blood vessels needed for the growth and spread of solid tumors.",
    "llama-2-7b-chat-hf_fact": [
      "Thiazovivin is a small molecule inhibitor of the enzyme pyruvate kinase (PK).",
      "Thiazovivin binds to the ATP-binding site of PK, preventing the conversion of pyruvate to acetyl-CoA.",
      "By inhibiting PK, thiazovivin reduces the ability of cancer cells to undergo glycolysis.",
      "Thiazovivin induces apoptosis in cancer cells.",
      "Thiazovivin inhibits the formation of new blood vessels needed for the growth and spread of solid tumors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Thiazovivin is not an inhibitor of the enzyme pyruvate kinase (PK); it is a small molecule inhibitor used to promote stem cell survival and enhance reprogramming of cells to pluripotency.\n2. FALSE [correction]: Since thiazovivin is not an inhibitor of pyruvate kinase, it does not bind to the ATP-binding site of PK and does not prevent the conversion of pyruvate to acetyl-CoA. Pyruvate dehydrogenase, not pyruvate kinase, is involved in the conversion of pyruvate to acetyl-CoA.\n3. FALSE [correction]: Thiazovivin's primary known function is not to inhibit glycolysis in cancer cells by targeting pyruvate kinase, as it is not an inhibitor of this enzyme.\n4. UNKNOWN: Without specific evidence, it is not clear if thiazovivin directly induces apoptosis in cancer cells. Its main use is in stem cell culture.\n5. UNKNOWN: The statement about inhibiting the formation of new blood vessels (anti-angiogenesis) might be referring to the effects of other cancer therapy drugs, but there is no clear evidence that thiazovivin has anti-angiogenic properties. Its known function is in enhancing cell survival and reprogramming in a stem cell context.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  }
]